Psychonaut Bookworm

“The mushroom spoke, and our symbiotic relationship with it is what has given us souls.”

Terence McKenna's most famous hypothesis — that psilocybin mushrooms catalyzed the evolution of human consciousness, that they sit at the origin of language and culture and the doubled brain — is almost certainly wrong in its mechanism and possibly right in its direction.

The specific claim is this: as hominids migrated out of the forest into the grasslands of Africa roughly two million years ago, they began following herds of cattle. The cattle grazed. The cattle produced dung. In the dung, particularly in the tropical lowland conditions that pertained along migration routes, grew Psilocybe cubensis mushrooms. Hominids who ate the dung — as many primates will opportunistically eat the dung of other animals for nutritional and microbiological reasons — encountered the mushrooms. At low doses, the psilocybin improved visual acuity, potentially providing an advantage in hunting. At higher doses, it produced the states of visual, auditory, and conceptual richness that McKenna associates with the origins of religious experience, language, and art.

McKenna supported this argument with data on human brain expansion: the hominin brain doubled in size over approximately two million years, from around 530 cubic centimeters in Homo habilis to around 1450 in anatomically modern humans. This expansion is real. It is one of the most dramatic brain size increases in evolutionary history. McKenna argued that psilocybin, by stimulating synaptic density and the growth of new neural connections, could plausibly have contributed to this expansion.

The problem is that this argument has two levels, and only one of them can be evaluated with current science.

The evolutionary claim — that mushroom consumption drove the doubling of the hominin brain — lacks fossil evidence and genetic confirmation. We have no mushroom residue in early hominin coprolites. We have no genetic signature of psilocybin exposure in ancient DNA. We do not have the kind of evidence that would allow us to distinguish McKenna's hypothesis from dozens of competing explanations for human brain expansion, including increased caloric density from cooking, social complexity and its cognitive demands, the selective advantages of symbolic thinking, or simple sexual selection for intelligence.

The neuroscientific claim — that psilocybin increases synaptic density and promotes the growth of new neural connections — is supported. David Nichols's 2016 Pharmacological Reviews comprehensive survey of psychedelic science documents the mechanism: psilocybin acts as an agonist at 5-HT2A receptors, with secondary effects on glutamate signaling, and produces measurable changes in cortical connectivity. More recently, research from Washington University (Shao et al., 2021) and other groups has shown that psilocybin promotes dendritic spine growth in mouse frontal cortex — the structural substrate of new synaptic connections — and that this effect persists for weeks after a single exposure. The neuroplasticity claim, in other words, is real. The evolutionary timeline it implies is speculative.

What McKenna was most right about was something more diffuse than the specific mechanism. He was right that the relationship between human beings and psychoactive plants is ancient, ubiquitous, and poorly understood. He was right that the standard scientific framework for thinking about drug use — as pathology, as addiction, as a behavior to be explained in terms of reward circuits hijacked by foreign molecules — does not begin to account for the role these substances have played in human cultural history. The ethnobotanist Richard Evans Schultes, whose 1967 NIMH symposium paper documented the extraordinary depth and sophistication of indigenous psychopharmacological knowledge, estimated that the relationship between humans and psychoactive plants predates recorded history by orders of magnitude. Seventy plant species used for intoxication globally, each with its own cultural context, ceremonial tradition, and accumulated empirical knowledge — this is not the behavior of a species stumbling accidentally into drugs. It is the behavior of a species that has organized major portions of its cultural life around these substances.

McKenna was right about that pattern. His error was in the specificity of the causal claim. He wanted to identify the exact molecule that made us human — as if there were such a thing — rather than describing the broader truth that our relationship with plant medicines is woven into what we are. The stoned ape hypothesis fails as a specific scientific claim and succeeds as a rhetorical provocation: it forces you to take seriously the possibility that something important happened at the intersection of human evolution and psychoactive plants, even if what exactly happened cannot yet be specified.

The mushroom spoke. McKenna was confident about that. What it said, and when, and what exactly it did to the brains of the creatures who ate it — those questions remain open, waiting for the kind of evidence that the fossil record may never provide.

Sources

• McKenna, T. Food of the Gods (1992)
• Nichols, D.E. Psychedelics. Pharmacological Reviews, 68(2) (2016)
• Medical History of Psychedelic Drugs. Cambridge HPS dissertation (2007)

“Something in nature knows more chemistry than we do.”

N,N-dimethyltryptamine — DMT — is present in your body right now. It has been found in human blood, urine, cerebrospinal fluid, and brain tissue. It is structurally related to serotonin and melatonin. It is produced by the same biochemical pathway that produces serotonin. It is, in the technical sense, an endogenous compound: your body makes it.

What your body makes it for remains almost entirely unknown.

This is one of the most interesting unsolved questions in psychopharmacology, and it sits at the intersection of neuroscience, pharmacology, and the phenomenology of altered states in a way that makes it genuinely consequential rather than merely strange. The three-tier framework for evaluating claims in this area is essential: what is confirmed, what is plausible but unproven, and what is speculative.

Confirmed: DMT is present in human tissue. This was established definitively in the 1970s and has been replicated repeatedly. David Nichols's 2016 Pharmacological Reviews comprehensive review confirms the presence of endogenous DMT and documents its structural relationship to serotonin and the shared biosynthetic pathway. When administered exogenously — injected intravenously in Rick Strassman's FDA-approved studies at the University of New Mexico in the 1990s, or smoked, or consumed as part of ayahuasca — DMT produces dramatic alterations in consciousness that typically last between five and fifteen minutes (when smoked) or several hours (in ayahuasca, where MAO inhibitors from Banisteriopsis caapi prevent its rapid metabolism).

Plausible but unproven: the pineal gland as primary DMT production site. Serena Roney-Dougal, writing in the 2011 issue of Paranthropology dedicated to psi and psychedelic experience, presents the most detailed version of this hypothesis. The pineal gland — a small endocrine structure in the center of the brain — has been proposed by Strassman and others as the likely site of endogenous DMT synthesis, based on several converging lines of evidence: the pineal contains the enzyme machinery required for DMT synthesis, it is anatomically positioned in ways that might allow DMT to reach the brain's receptor systems without being metabolized before arrival, and the timing of certain peak pineal activity (near birth, near death, during REM sleep) correlates with the conditions under which people most commonly report spontaneous experiences resembling DMT states — near-death experiences, birth recall, and vivid dreams.

The hypothesis is physiologically plausible. It has not been confirmed. The specific claim that the pineal produces DMT in sufficient quantities to produce psychedelic effects in the brain requires measurement data that does not yet exist. It is not impossible. It is simply undemonstrated.

Speculative: the broader McKenna-Strassman framework in which endogenous DMT mediates naturally occurring mystical states, death experiences, and potentially psi phenomena. Terence McKenna and his brother Dennis, in True Hallucinations and its companion scientific paper, proposed that the La Chorrera experiment produced a catalysis of the brain's own DMT system — that what happened in the Amazon in 1971 was not simply the effect of externally administered tryptamines but an unlocking of an endogenous capacity. The psi and psychedelic experience literature, as documented by David Luke in Paranthropology's special issue, notes that psychedelics and psi phenomena show consistent co-occurrence across multiple cultural and experimental contexts, and proposes the shared neurochemical mechanism as a possible explanation.

This is genuinely interesting. It is not, by current evidence, more than that.

What the ayahuasca literature — the two Labate and Cavnar volumes published by Springer — adds to this picture is the therapeutic dimension. The beta-carbolines in Banisteriopsis caapi are MAO-A inhibitors, which is why orally administered DMT in ayahuasca produces a much longer experience than smoked DMT: the MAO enzymes that would otherwise metabolize DMT in the gut are blocked, allowing it to reach the brain. But harmine, one of those beta-carbolines, has an additional effect that has nothing to do with the DMT pathway: it inhibits DYRK1A, an enzyme involved in neurogenesis, and this inhibition promotes the growth of new neurons and new synaptic connections. The therapeutic effects of ayahuasca for depression, addiction, and trauma may therefore involve two parallel mechanisms: the DMT-mediated experiential component and the harmine-mediated neuroplasticity component, operating through different pathways simultaneously.

The Changa literature documents the practical consequence of this pharmacology: the addition of MAOI-containing herbs to smoked DMT extends the experience from five to fifteen minutes to thirty to forty-five minutes, and participants report qualitative differences in the character of the experience — more sustained, more integrated, with greater narrative coherence. Changa exists precisely because the DMT experience alone is too brief for the kind of processing that therapeutic benefit requires.

DMT is in your body. What it is doing there, and what it might be doing during your dreams and your deepest experiences and possibly your approach to death, remains genuinely unknown. The questions are specific enough to be scientific. The answers are not yet in. In the meantime, the most precise thing that can be said is what Terence McKenna said about the Amazon itself: something in nature knows more chemistry than we do.

Sources

• Nichols, D.E. Psychedelics. Pharmacological Reviews, 68(2) (2016)
• Roney-Dougal, S. in Hunter, J. (ed.) Psi and the Psychedelic Experience. Paranthropology, Vol. 2 No. 2 (2011)
• McKenna, T. True Hallucinations (1993)
• Labate, B. & Cavnar, C. (eds.) Ayahuasca Healing and Science. Springer (2021)

“Stay away from Schultes, a Harvard colleague warned a graduate student in the 1970s. He spent a decade alone in the Amazon. He's a dinosaur. The student ignored the advice. His name was Wade Davis.”

In December 1941, a twenty-six-year-old Harvard botanist received orders that would transform his life and, eventually, the history of pharmacology. Richard Evans Schultes had come to the Amazon on a one-year grant to study indigenous arrow poisons. The Japanese had just attacked Pearl Harbor. His government needed rubber — the Japanese had taken Southeast Asia and with it the world's supply. Schultes was told to stay, help revive Amazonian rubber production, and then come back when it was done.

He stayed for twelve years.

When Schultes finally returned to Harvard in 1953, he carried something more valuable than rubber statistics: a comprehensive record of the psychoactive plant practices of dozens of Amazonian indigenous groups, the largest single collection of such documentation ever assembled by a Western scientist. He brought herbarium specimens — over 24,000 plant species, 300 previously unknown to science. He brought photographs, field notes, and chemical samples. And he brought a question that would occupy the rest of his life: how do indigenous peoples know what they know?

The question was not rhetorical. Schultes had documented practices of staggering pharmacological sophistication. The Amazonian preparation of ayahuasca combined two plants — Banisteriopsis caapi and Psychotria viridis — whose interaction was not obvious from their separate properties. The vine contained MAO inhibitors; the leaf contained DMT. Without the combination, DMT is metabolically inactive when taken orally. In an Amazon of 80,000 plant species, indigenous people had identified these two specific plants and discovered their pharmacological synergy. Schultes watched this knowledge in practice and could not account for its origin through any model Western science offered.

His answer was not mystical. Schultes was constitutionally incapable of mysticism. He wore a suit in the jungle. He called his indigenous hosts 'native peoples' with unfashionable precision when the anthropological literature oscillated between condescension and romanticism. His answer was empirical and uncomfortable: he didn't know. The knowledge was real — he could verify its pharmacological accuracy — and its origin was unexplained. He catalogued it and moved on.

At Harvard, Schultes ran the Botanical Museum for decades and became the most influential ethnobotanist of the twentieth century without ever becoming famous. His students became famous: Wade Davis, whose One River is partly a portrait of Schultes; Mark Plotkin, who founded the Amazon Conservation Team; Tim Plowman, who led the definitive botanical study of coca. They became famous partly because Schultes taught them that the story was in the field, not the institution, and partly because he never bothered to become famous himself.

Plants of the Gods, co-authored with Albert Hofmann and published in 1979, was Schultes's only popular book. It was not written for popular audiences — it was written for the record. Ninety-one psychoactive plant species, organized by chemistry and culture, with descriptions of ritual use, botanical classification, and chemical analysis. A catalogue of what was being lost.

Because that was what Schultes knew, with increasing urgency as the decades passed: it was being lost. The aspirin pill. The mission school. The road. These were destroying in years what had taken millennia to accumulate. In 1967, at a government symposium, he said: 'In the search for new hallucinogens, we have much to do and little time in which to do it.' That was fifty years ago. The time has continued to run.

What Schultes documented — the pharmacological intelligence embedded in Amazonian plant practice — was not primitive knowledge that happened to work. It was a research tradition more ancient and in some respects more sophisticated than anything Western science could produce from the same materials in the same time. The ayahuasca preparation is the example that makes this plain: no laboratory starting from scratch in an Amazon rainforest could have identified that specific combination from among 80,000 candidate species in any foreseeable timeframe.

Schultes never speculated about how it was discovered. He documented that it existed. That may have been the more important contribution — the refusal to explain away what he could not explain, and the insistence on keeping the record straight.

Sources

• Schultes & Hofmann, Plants of the Gods (1979)
• Davis, Wade. One River: Explorations and Discoveries in the Amazon Rain Forest (1996)
• Plotkin, Mark. Tales of a Shaman's Apprentice (1993)
• Harvard Magazine, Richard Evans Schultes obituary (2001)
• Wikipedia, Richard Evans Schultes
• Academy of Achievement, Richard Evans Schultes interview

“For Aldous Huxley it was the next step in human evolution. For the CIA it was a potential tool for mind control. For Timothy Leary it was the liberator of humankind. The molecule was the same. The theories were not.”

On April 19, 1943, Albert Hofmann rode his bicycle home from a Sandoz laboratory in Basel, Switzerland, and arrived at a different world than the one he'd left. He had deliberately ingested 250 micrograms of a compound he'd synthesized five years earlier and then filed away when the animal tests showed nothing interesting. Now it showed something. The neighbor who brought him milk looked like a malevolent witch. The furniture attacked him. He thought he was dying.

By the following morning he was fine, and the world had a new problem.

Jay Stevens's Storming Heaven (1987) is the history of what happened to that problem over the next twenty-five years, from Hofmann's bicycle to the US government's Schedule I classification in 1968. It is one of the essential books of American cultural history, written with novelistic precision and documented with the kind of archival rigor that makes its most improbable claims verifiable. The story it tells is simultaneously a tragedy of institutional failure, a portrait of an era, and a cautionary tale whose moral has never stopped being relevant.

The structure of the story is a collision. On one side: a clinical and philosophical tradition — Osmond, Huxley, Hoffer, and eventually Grof — that understood LSD as a tool for consciousness research, with applications in treating alcoholism, depression, and end-of-life anxiety. On the other: two forces that couldn't have been more different in ideology but were identical in their interest in scale. The CIA wanted to weaponize it; the counterculture wanted to democratize it. Both succeeded in transforming a controlled clinical substance into a cultural symbol, and the clinical tradition was destroyed in the crossfire.

The CIA chapter is the one that reads most like fiction. Operation Midnight Climax was the program in which CIA operative George White dosed unwitting subjects in San Francisco safe houses while watching through one-way mirrors. White's retrospective assessment of his career, preserved in his private diary and quoted by Stevens: 'Where else could a red-blooded American boy lie, kill, cheat, steal, rape and pillage with the sanction and blessing of the All-Highest?' The program produced nothing useful in intelligence terms. What it produced, in at least one case, was a death — Frank Olson, the Army researcher who was secretly dosed by Sidney Gottlieb and fell from a New York hotel window in November 1953.

The counterculture chapter is the one that reads like elegy. Leary and Kesey were not villains. Stevens is fair enough to show that Leary's Harvard psilocybin project produced genuine results and that his early framing of the experience — careful, concerned with set and setting, grounded in serious psychological theory — was not wrong. What was wrong, or at least what was fatal, was the decision to go public with a mass advocacy campaign at exactly the moment when the clinical evidence was most promising. 'Tune in, turn on, drop out' was not a research protocol. It was a declaration of war on the social order, and the social order won.

The 1968 Schedule I designation was not a scientific conclusion. No evidence of harm was presented that exceeded what was already known, and the clinical trial record — over a thousand scientific papers, forty thousand patients, fifteen years of accumulated practice — was simply set aside. The scheduling was political: a response to the counterculture, to race panic (the drug war's racial targeting would be confirmed by Ehrlichman's 2016 admission), and to the institutional desire to control what could not be controlled.

Fifty years elapsed before the clinical research program resumed. That gap — from 1968 to approximately 2018 when the Johns Hopkins and NYU trials began producing publishable results — is what Storming Heaven mourns. The research wasn't destroyed because it failed. It was destroyed because it succeeded in reaching people the establishment didn't want illuminated.

Stevens ended his book in 1968. He could not have known that the story would resume. As of 2025, psilocybin is in Phase 3 clinical trials in the US and Europe, LSD-assisted therapy is in Phase 2 in Switzerland and Canada, and MDMA-assisted therapy for PTSD has completed Phase 3. The interruption lasted fifty-five years. The curious molecule waited.

Sources

• Stevens, Jay. Storming Heaven: LSD and the American Dream (1987)
• Marks, John. The Search for the Manchurian Candidate (1979)
• Church Committee Hearings, US Senate (1975)
• Ehrlichman, John, quoted in Dan Baum, Harper's Magazine (April 2016)
• Hofmann, Albert. LSD: My Problem Child (1979)
• ACLU, A Tale of Two Countries (2020)

“The first time an Ashaninca man told me that he had learned the medicinal properties of plants by drinking a hallucinogenic brew, I thought he was joking. But he was not smiling.”

The combinatorial problem is this: in an Amazon containing approximately 80,000 plant species, indigenous peoples identified two specific plants whose combination creates oral DMT activity. The vine, Banisteriopsis caapi, contributes beta-carboline compounds that inhibit monoamine oxidase. The leaf, Psychotria viridis, contributes dimethyltryptamine. Neither plant alone produces the sustained visionary state that the combination produces, because DMT is ordinarily metabolized before it can cross the blood-brain barrier. The combination defeats this metabolism. This requires knowing both plants and knowing their interaction.

How was this discovered? Richard Evans Schultes spent twelve years in the Amazon and never answered the question satisfactorily. When Jeremy Narby asked his Ashaninca hosts in the Peruvian Amazon in 1984, they answered without hesitation: the plants told us.

The Cosmic Serpent (1998) is Narby's decade-long investigation of what that answer might mean. It is not a credulous book, despite what its critics suggest. Narby is a Stanford-trained anthropologist who spent years trying to dismiss the answer and eventually found he couldn't. The evidence he assembled — from molecular biology, from cross-cultural mythology, from the pharmacology of DMT, from the history of scientific discovery — doesn't prove the shamanic claim. But it makes the Western dismissal of that claim look increasingly like willful blindness.

Narby's central argument operates on two tracks. The first is epistemological: Western science has two built-in assumptions that prevent engagement with the shamanic knowledge claim. First, that hallucinations are internal productions of the mind — projections, not perceptions. Second, that plants cannot communicate with humans through imagery or language. Both assumptions are cultural, not empirical. Both foreclose exactly the investigation that would be needed to evaluate the shamanic claim.

The second track is structural: the serpent. In shamanic traditions across all inhabited continents — including Siberia, where there are no serpents — the primary visionary entity is a snake or pair of snakes. Mircea Eliade documented this pattern across his life's work; Narby extended it. The double helix of DNA — visualized by Francis Crick in a structural model that resembles, in striking ways, the twin-serpent image that appears in shamanic iconography, in the caduceus of Western medicine, in creation myths from Sumer to the Pacific — is Narby's proposed referent. The shamans are seeing DNA, he suggests. Not metaphorically. Literally, at some level he cannot specify but cannot dismiss.

The critics are not wrong that this is a difficult hypothesis to test. Jacques Dubochet, a biophysicist who later won a Nobel Prize, criticized Narby for not designing an experimental test. Publishers Weekly accused him of mistaking enthusiasm for evidence. The accusation has merit: Narby's argument frequently proceeds by analogy and parallel rather than demonstration. A hexagonal pattern in an indigenous artwork does not prove knowledge of benzene rings.

But the dismissal also has a problem: the knowledge is real. Indigenous Amazonian pharmacology has produced compounds now used in Western medicine — tubocurarine from curare, which Schultes studied, is a standard surgical muscle relaxant. The pharmacological accuracy of hundreds of plant preparations has been verified by laboratory analysis. Whatever the mechanism of the knowledge, the knowledge itself is not in question. Narby is asking a question that the dismissal doesn't answer: how did they know?

Ten years after publication, Narby organized an expedition of three molecular biologists to the Peruvian Amazon to undergo ayahuasca sessions under shamanic guidance. The biologists, skeptical and methodologically rigorous, found themselves inside experiences they could not explain by their existing frameworks. The documentary Night of the Liana captures what happened. It doesn't resolve Narby's hypothesis. It demonstrates why the hypothesis is harder to dismiss than its critics suggest.

The combinatorial problem remains. The knowledge is there. The mechanism is not explained. Narby's contribution is to have held that space open — insisting that the unexplained does not become explained by being ignored — while documenting the pressures of biopiracy, deforestation, and cultural erosion that are eliminating the knowledge faster than any research program can document it. The snake is real. What it represents is the question.

Sources

• Narby, Jeremy. The Cosmic Serpent: DNA and the Origins of Knowledge (1998)
• Schultes, R.E. & Hofmann, A. Plants of the Gods (1979)
• Wikipedia, Jeremy Narby
• Publishers Weekly review, The Cosmic Serpent (1998)
• Newswise, The Cosmic Serpent press release (1998)

“Because I am either an unsung Newton or completely nuts, there is very little room to maneuver between these two positions.”

In February 1971, five young Americans flew to Colombia, took a series of boats up the Putumayo River, and walked into a fog-bound jungle mission station called La Chorrera in search of a rare indigenous hallucinogen. They were looking for oo-koo-he, a DMT preparation used by the Witoto to communicate with 'little men.' They had brought their academic credentials (Terence McKenna was reading Chinese at Berkeley, his brother Dennis was studying botany), their sleeping bags, and an ambitious theory about the relationship between tryptamine chemistry and human consciousness.

What they found instead was a cow pasture full of psilocybin mushrooms.

True Hallucinations (1993) is Terence McKenna's account of what happened next — written twenty years after the fact, in a voice that holds together self-deprecating irony and genuine cosmic astonishment without letting either one win. It is the most honest book McKenna ever wrote, partly because he could not quite decide whether the events at La Chorrera represented a breakthrough or a breakdown, and he left that ambiguity in.

The experiment itself was Dennis's idea. He proposed that it was possible, through a specific vocalization technique during a mushroom session, to bond the DMT in the psilocybin into the body's endogenous harmala compounds — effectively creating a permanent psychedelic state in which the boundary between self and the collective unconscious would dissolve. Whether this theory was pharmacologically coherent is a question Terence left studiously open. He noted that it was either genius or madness and that the margin between the two was not visible from inside the experience.

Dennis underwent the more dramatic episode — a weeks-long altered state that his brother watched with a mixture of terror and fascination, attempting to determine whether what was happening was dissolution or evolution. Dennis was calm, voluble, and apparently in contact with something Terence couldn't access. He spoke in complex patterns. He made predictions. He was eventually fine. He went on to become one of the most rigorous neuropharmacologists working on tryptamines, and he has spent decades being carefully honest about what he does and does not believe happened at La Chorrera.

Terence's experience was different. During a late-night mushroom session in the forest, he began receiving what he described as a sustained monologue — the mushroom speaking, in his internal voice, on the nature of time, consciousness, and the relationship between human beings and the rest of the universe. He wrote it down. He called it 'the mushroom's claims.' He published them.

From this experience came the Timewave Zero theory — an attempt to map the I Ching's sixty-four hexagrams onto a mathematical model of time's qualitative structure, predicting that novelty would reach a maximum singularity on December 21, 2012. The prediction was falsified. McKenna had acknowledged it was falsifiable, which was one of his more intellectually honest positions. The broader intuition — that time has qualitative structure, that some moments are more 'novel' than others — is a philosophical claim independent of the specific mapping and remains interesting on its own terms.

What persists from La Chorrera beyond the failed prediction is the description. McKenna's account of the machine elves — 'merry elfin, self-transforming, machine creatures, looking like self-dribbling Fabergé eggs on the rebound' — has become the most reproduced phenomenological report in the DMT literature. In a 2020 Johns Hopkins survey (Davis et al., J. Psychopharmacol. 34(9):1008-1020) of 2,561 people who had already had a DMT entity encounter, McKenna's basic description was corroborated across thousands of independent accounts. It documents the phenomenology in detail but sets no prevalence rate, because every respondent was recruited for having had an encounter; the 97% figure often attached to it appears in no published paper. What he saw at Berkeley in 1965 and at La Chorrera in 1971 has since been seen by tens of thousands of people who had never read his description. The consistency of the report is a genuine scientific puzzle, regardless of what it means.

True Hallucinations does not answer the question of what happened at La Chorrera. It documents the question precisely. The book's most valuable quality is its epistemological honesty: Terence McKenna, who spent thirty years speaking with enormous confidence about the nature of reality, spent twenty years uncertain about whether the most important experience of his life was revelation or psychosis. He chose to publish the uncertainty. That is the book.

Sources

• McKenna, Terence. True Hallucinations: Being an Account of the Author's Extraordinary Adventures in the Devil's Paradise (1993)
• McKenna, Dennis. The Brotherhood of the Screaming Abyss (2012)
• Wikipedia, Terence McKenna
• Timmermann et al., PNAS 120(13) (2023)
• Sexton et al., J. Psychopharmacol. 33(9) (2019)
• Davis et al., J. Psychopharmacol. 34(9):1008-1020 (2020)

“Thirty years separated them. In Brave New World, the drug was the problem. In Island, the drug was the solution. Huxley was the same man. The difference was May 4, 1953.”

Aldous Huxley invented two fictional drugs. The first was soma — Brave New World's instrument of social control, a substance that produced pleasant numbness and kept the population docile and productive. The second was moksha — Island's instrument of liberation, a yellow mushroom that brought Palanese citizens into direct contact with the structure of existence.

Thirty years separated them. In 1931, when Brave New World was published, Huxley had never taken a psychedelic drug. He had no direct experience of what consciousness-alteration could be. Soma was an extrapolation from what he'd observed — the way alcohol, propaganda, and entertainment kept people comfortable inside systems that served their rulers' interests rather than their own.

In 1953, Humphry Osmond gave him four-tenths of a gram of mescaline in a glass of water. The world he'd been describing from the outside became, briefly, accessible from within. The Doors of Perception was the immediate result. Island, which took nine years to complete, was the deeper consequence.

The difference between the two drugs tracks exactly the difference between the two books. Soma operates on the pleasure centers — it produces happiness without content, satiety without fulfillment, peace without truth. It is a sophisticated conditioning technology. Moksha operates on the perception centers — it removes the filters that make ordinary experience tolerable and bearable and safe, and leaves the user confronting reality at a density they cannot manage through their usual cognitive shortcuts.

The political implications diverge accordingly. Soma maintains the social order by ensuring that citizens don't notice what's wrong with it. Moksha threatens the social order by ensuring that citizens cannot unsee what's wrong with it — which is why Island ends with Pala's military invasion. A society organized around genuine perception is not compatible with the interests of the oil companies that want Pala's mineral resources.

Huxley knew this. He'd spent three decades documenting how power uses consciousness-alteration as a tool of social control. What he discovered in 1953 was that the same technology — substances that alter perception — could point in the opposite direction. The question was never whether consciousness could be altered. The question was in whose interest the alteration was designed.

Sources

• Huxley, The Doors of Perception (1954)
• Huxley, Island (1962)
• MIT Press Reader, When Aldous Huxley Opened the Doors of Perception (2021)
• Wikipedia, Island (Huxley novel)

“Huxley borrowed the reducing valve from Bergson, borrowed the C.D. Broad citation to give it academic credibility, and built the central neuroscientific argument of his era without any neuroscience.”

Henri Bergson proposed in 1896 that the brain's primary function was not to produce consciousness but to filter it. Most of what the mind could perceive is suppressed in the interests of practical action — what makes it through is the small portion relevant to survival and social functioning. The rest is excluded.

Aldous Huxley read this proposition and recognized it as the theoretical foundation for something he'd experienced in a Los Angeles living room in May 1953. He quoted C.D. Broad's sympathetic commentary on Bergson's argument, gave the mechanism a name — the reducing valve — and built The Doors of Perception's central claim: that mescaline works by impairing the brain's filtering function, allowing more of Mind at Large into awareness.

Huxley had no neuroscience to support this. The tools didn't exist. Brain imaging was decades away. What he had was philosophical precision and the quality of the experience itself — which felt exactly like what the reducing valve model predicted it should feel like.

Sixty-five years later, neuroscientist Robin Carhart-Harris and mathematician Karl Friston published the REBUS model: Relaxed Beliefs Under Psychedelics. Their proposal, derived from predictive coding theory and supported by fMRI data, describes psychedelics as reducing the 'precision weighting' of top-down priors — the brain's predictions about what it's about to perceive. When those predictions are weighted less heavily, bottom-up sensory information enters awareness in greater abundance and with less pre-processing.

This is Bergson's reducing valve, translated into the vocabulary of computational neuroscience. The mechanism Huxley described intuitively in 1954 — impairment of the brain's filtering function, resulting in richer but less practically organized perceptual experience — maps precisely onto what contemporary neuroscience has verified experimentally.

Huxley borrowed the reducing valve from Bergson, borrowed the C.D. Broad citation to give it academic credibility, and built the central neuroscientific argument of the psychedelic literature without any neuroscience. The argument was correct. That's either very good philosophy or very good luck.

Sources

• Huxley, The Doors of Perception (1954)
• Carhart-Harris & Friston, Nature Reviews Neuroscience (2019)
• Bergson, Matter and Memory (1896)

“The Owl Drug Company was known as the World's Biggest Drugstore. Huxley examined its art books while under mescaline and concluded that Botticelli had stood where he was standing.”

At some point during the eight hours, after the flowers and the folds of grey flannel trousers and the Vermeer thought, Aldous Huxley and Humphry Osmond and Maria Huxley made a seven-block walk through West Hollywood to a pharmacy called the Owl Drug Company, known locally as the World's Biggest Drugstore.

This is the strangest passage in The Doors of Perception — stranger, even, than the flowers. Huxley, under mescaline, in a pharmacy. He browsed art books in the magazine section. He turned pages. He looked at Botticelli's Judith and observed, in the purple silk of her pleated bodice, the same 'is-ness' he had been finding all morning in his living room. He concluded that Botticelli had looked at drapery with the same eyes he was currently using. He looked at Van Gogh and found him insufficient — Van Gogh's flowers were symbols of flowers, not flowers. He returned the Van Gogh to its rack.

The episode is routinely skipped over by commentators who focus on the flowers and the philosophy. But it contains Huxley's most specific claim about art: that certain painters had access, constitutionally or momentarily, to the same perceptual register that mescaline temporarily opened. The claim is not that art is inferior to the direct experience — though he says that too — but that the best art is the record of this register, and that it can be identified from within the experience.

Standing in the World's Biggest Drugstore, surrounded by aspirin and cosmetics and pop magazines, Aldous Huxley was conducting what amounted to a quality-assurance review of Western art history. Botticelli passed. Van Gogh did not. Vermeer, consulted earlier from memory, was the standard. The setting — fluorescent lights, commercial pharmacy, the mundane hum of Los Angeles in 1953 — only sharpens the absurdity and the precision of the observation.

He turned the pages. He made his assessments. He walked the seven blocks back.

Sources

• Huxley, The Doors of Perception (1954)
• Wikipedia, The Doors of Perception
• MAPS edition, The Doors of Perception PDF

“Cary Grant said he had been born again. He said this publicly, in 1959, to journalist Joe Hyams. The LSD sessions, he said, had cured him of everything he had been.”

In the late 1950s, before the counterculture existed, before Timothy Leary had been fired from Harvard, before the word 'psychedelic' was widely known, there was a brief period in Los Angeles when LSD-assisted therapy was simply a promising psychiatric tool used by respectable clinicians on willing patients.

Cary Grant was one of those patients. He underwent LSD sessions with psychiatrist Mortimer Hartman — not experimentally, not recreationally, but in formal clinical psychotherapy, using the drug the way Osmond and Huxley had proposed it should be used: with preparation, with a qualified guide, with intention, in a proper setting. He went repeatedly. He found it transformative.

In 1959, he told journalist Joe Hyams exactly what had happened. The resulting article — published in This Week magazine under the headline 'Cary Grant's Bizarre Experiments' — was one of the first mainstream accounts of LSD therapy. Grant described being reborn. He described crying for the first time in years. He described understanding, finally, why his four marriages had failed. He said the sessions had done for him what years of conventional therapy had not.

Huxley's Doors of Perception had created the conceptual framework for taking this kind of experience seriously — the argument that direct perceptual transformation was not hallucination but revelation, not pathology but insight. Grant's testimony was the famous-person evidence that the framework wasn't just intellectual fancy. Here was one of the most guarded men in Hollywood, describing a softening, an opening, a change that he was willing to put his name on in a national magazine.

The article was received with bewilderment more than scandal. The scandal would come later, when the counterculture made LSD a symbol of social disruption. In 1959, it was strange but not threatening — a movie star trying something odd in a psychiatrist's office and finding it useful. The small window when that was possible opened in 1953 with Huxley's book and closed around 1967 when Leary's public advocacy made any clinical framing politically untenable. Grant's sessions happened in the middle of that window, and his testimony is one of the documents that shows how different psychedelic history could have been.

Sources

• Stevens, Jay. Storming Heaven (1987)
• Hyams, Joe. 'Cary Grant's Bizarre Experiments,' This Week magazine (1959)
• Huxley, The Doors of Perception (1954)

“Huxley's education argument is the passage most people never reach, buried in the final pages. It is also the passage that has aged best.”

The Doors of Perception is remembered as a book about mescaline. It was written as a book about education.

The final pages — past the flowers, past Botticelli, past the philosophy of the reducing valve — contain Huxley's sharpest argument, and his most practical one. We teach children to reason verbally. We give them no training in direct perception. We have no techniques for transcending the merely conceptual. What mescaline showed him was that the verbal-conceptual mode of experience was not a baseline but a choice — and a costly one. The part of experience that language couldn't carry, that words couldn't reach, that the educational system had spent twelve years teaching him not to notice, turned out to contain a great deal.

The argument has several layers. First, that verbal education confirms the reduced awareness as the only awareness — students graduate believing that what language can describe is what exists, and that what language can't describe probably doesn't. Second, that this belief actively impedes perception: it trains people to look through experience at the concept, rather than at the experience itself. Third, that the cost is not merely aesthetic but practical: a civilization that can't perceive directly is a civilization operating on an impoverished data set.

Huxley's proposed remedy was not that everyone should take mescaline — he was careful about this, repeating that it was 'a gratuitous grace' not 'a necessity.' He argued for what we would now call contemplative education: training in direct perception alongside training in verbal reasoning, with neither privileged over the other.

Sixty years later, 'contemplative education' has entered the curriculum at hundreds of institutions. Mindfulness practices derived from Buddhist meditation traditions are taught in US public schools under secular names. Johns Hopkins now trains clinical researchers through guided psychedelic sessions, on the explicit logic that the experience is part of the professional formation. Huxley's education argument — the most ignored part of his most-read book — has quietly been implemented, piecemeal, in exactly the institutional settings he would have chosen.

Sources

• Huxley, The Doors of Perception (1954)
• MIT Press Reader, When Aldous Huxley Opened the Doors of Perception (2021)
• Davis et al., J. Psychopharmacol. (2021)

“Huxley had spent two decades arguing that all genuine mystical traditions converge on the same truth. Mescaline gave him the experiential evidence for a thesis he had previously argued only from texts.”

In 1945, Aldous Huxley published The Perennial Philosophy — a 300-page anthology of mystical writings from across traditions, organized by his argument that all genuine mystical experience converges on the same recognition: that an impersonal divine ground underlies all particular things, and that the purpose of spiritual practice is to bring this recognition into ordinary awareness.

He had argued this entirely from texts. He had read Eckhart, the Upanishads, the Tao Te Ching, the Desert Fathers, Sufi poetry. He had not, at the time of writing, had a mystical experience himself.

In 1953, the experience arrived chemically. The flowers were not flowers in the ordinary sense. The Suchness Meister Eckhart wrote about was not a philosophical concept but a perceptual quality that the flowers had and he was witnessing. The 'direct, total awareness from the inside of Love as the primary and fundamental cosmic fact' that he described in a letter to Osmond after a later LSD session was not Vedanta as a doctrine but Vedanta as a report.

The Doors of Perception is, among other things, the story of a perennial philosopher getting evidence for his own thesis. This shapes the book's confident tone, which critics found frustrating — Huxley seemed to know what the experience meant before he had it, because he had spent twenty years studying what others who had it had said about it. He came to mescaline pre-theorized.

This is both the book's strength and its weakness. The strength: Huxley could articulate what he experienced in philosophical terms that placed it in a tradition, making it legible to readers who might otherwise dismiss it as individual hallucination. The weakness: the pre-existing framework may have shaped the experience itself — what you expect to find in altered states partially determines what you find, and Huxley arrived expecting Suchness.

The current clinical literature navigates this problem by using standardized measures — the Mystical Experience Questionnaire, the Challenging Experience Questionnaire — that assess experience before the subject has been told what to expect. The evidence they generate is, in a sense, more controlled than Huxley's. It is also, inevitably, less eloquent.

Sources

• Huxley, The Perennial Philosophy (1945)
• Huxley, The Doors of Perception (1954)
• Yaden & Griffiths, Perspect. Psychol. Sci. (2021)

“Osmond's winning couplet beat Huxley's losing one. The word 'psychedelic' won over 'phanerothyme' because it was easier to say. The history of a field turned on a rhyming competition.”

In the spring of 1956, Aldous Huxley and Humphry Osmond were corresponding about a problem neither had solved: what to call these substances. The existing vocabulary was bad. 'Hallucinogen' was pejorative and inaccurate — the experiences were not primarily hallucinatory, and framing them as such imported the clinical assumption that what was seen wasn't there. 'Psychotomimetic' was more accurate but clinically catastrophic — it described the substances as schizophrenia simulators, which guaranteed that the only people who'd investigate them would be looking for applications in interrogation or combat psychiatry.

They needed a new word. Both submitted a proposal, each in the form of a couplet — a gentleman's bet on which would prove more durable.

Huxley's entry: 'To make this trivial world sublime, / take half a gram of phanerothyme.' Phanerothyme, from the Greek for 'making the spirit visible.' Precise, philosophical, and completely unpronounceable.

Osmond's entry: 'To fathom Hell or soar angelic, / just take a pinch of psychedelic.' Psychedelic, from psyche (soul, mind) and delos (to manifest, to reveal). Less philosophically precise but catchier, and containing a recognition that the territory was bipolar — hell was possible alongside the angelic.

Osmond's won. He introduced it formally in a 1957 paper in the Annals of the New York Academy of Sciences, and the word entered the scientific literature. It entered the cultural vocabulary via Leary and the counterculture, acquiring associations that Osmond hadn't intended and eventually becoming so culturally contaminated that researchers now regularly use 'classical serotonergic psychedelics' to avoid it.

But the word survives because the definition was good. Mind-manifesting: not adding something foreign to the mind but revealing what was already there. The dispute about whether psychedelics reveal or distort — whether Huxley's 'Mind at Large' is real or hallucinatory — is still the central dispute in the field. The word that described one side of that debate was coined in a rhyming competition in 1956.

Sources

• Osmond, Ann. N.Y. Acad. Sci. (1957)
• Huxley & Osmond, in Moksha (1977)
• Nichols, Pharmacol. Rev. (2016)

“Osmond thought the most important thing a psychiatrist could do was take mescaline. Not to get high — to understand what their patients were experiencing.”

Humphry Osmond's first insight about psychedelics was clinical and it was simple: they gave him access to what his schizophrenic patients were experiencing.

At Weyburn Mental Hospital in Saskatchewan in the early 1950s, Osmond was working with patients whose subjective experience was, by definition, inaccessible to him. They reported visions, heard voices, experienced the texture of reality differently from how he experienced it. He could observe the behavioral consequences; he could adjust the medications; he could not know what it was actually like to be where they were. The gap between clinician and patient was experiential. No amount of training or empathy could bridge it without some access to the territory.

Mescaline provided that access. Not perfectly, not identically — the comparison between mescaline intoxication and schizophrenia is inexact in ways that subsequent research has documented at length. But sufficiently: what Osmond experienced under mescaline was enough to make him understand what his patients meant when they said the world had become strange and terrible and significant in ways that ordinary language couldn't carry.

He began having his clinical staff take mescaline and LSD for the same reason. This was standard practice at Weyburn before it became controversial everywhere else. The idea was not that clinicians needed the experience to function, but that they needed it to understand — to reduce the experiential gap between the person who administered the treatment and the person who needed it.

Huxley formalized this insight in Doors, writing that the mescaline experience provided a 'gratuitous grace' of understanding that was 'of inestimable value to everyone and especially to the intellectual.' But the origin of the insight was clinical, not philosophical. It came from Osmond watching his patients and realizing that the thing they most needed — to be understood rather than merely managed — required him to go somewhere he'd never been.

The contemporary movement to have clinical researchers undergo psychedelic sessions as part of their training is this same insight, sixty years later. Johns Hopkins and NYU now include guided psilocybin sessions in their clinical psychedelic research programs. The rationale: knowing the territory is part of professional formation. Osmond understood this in 1951.

Sources

• Osmond, H. A Review of the Clinical Effects of Psychotomimetic Agents, Ann. NY Acad. Sci. (1957)
• Huxley, The Doors of Perception (1954)
• Vollenweider & Preller, Dialogues Clin. Neurosci. (2020)

“Al Hubbard gave LSD to Aldous Huxley, Gerald Heard, and a remarkable number of Hollywood figures. His methods were Osmond's; his ambition was larger. He called himself the Johnny Appleseed of LSD.”

Alfred Matthew Hubbard defies clean description. He was, depending on who was reporting and when: a bootlegger, a rumrunner, a government informant, an inventor who held early patents on radio navigation, a uranium entrepreneur, and — most relevantly for this story — the man who gave LSD to Aldous Huxley.

Hubbard encountered LSD in 1951 through a connection with Sandoz and became convinced, with the evangelical certainty he brought to everything, that it was the most important substance in human history. He bought large quantities from Sandoz, obtained credentials from a Uruguayan diplomatic service that allowed him to travel with controlled substances, and began administering sessions to everyone he thought could handle and benefit from the experience.

His contact with Osmond was through the clinical network; his contact with Huxley was through the Los Angeles intellectual circle. He turned Huxley on to LSD in 1955 — two years after Osmond's mescaline session, in a setting that reflected Hubbard's characteristic approach: music, art on the walls, careful attention to atmosphere, an implicit faith that the substance itself would do what it needed to do if the environment supported it.

Huxley found the LSD session profoundly different from mescaline — less visually intense, more emotionally transparent. He wrote to Osmond about it, comparing the experiences in the careful phenomenological language they'd developed together.

The correspondence that runs through Moksha includes references to Hubbard, always slightly at arm's length. He was useful — his distribution of LSD to cultural and intellectual figures created the milieu in which Doors of Perception was received — but he wasn't Huxley and Osmond's kind of careful. He self-titled himself the 'Johnny Appleseed of LSD,' which suggested an enthusiasm for scale that made Huxley nervous. Huxley was always worried about scale. He was right to be.

Sources

• Stevens, Jay. Storming Heaven (1987)
• Lattin, Don. The Harvard Psychedelic Club (2010)
• Huxley & Osmond, in Moksha (1977)

“Osmond coined the words 'sociofugal' and 'sociopetal' to describe spaces that push people apart or pull them together. The vocabulary came from his experience with psychedelics revealing how environment shapes experience.”

Humphry Osmond's contribution to the psychedelic literature is well-known — the word 'psychedelic,' the Weyburn clinical trials, the partnership with Huxley. Less known is his contribution to architecture.

At Weyburn Mental Hospital, Osmond became preoccupied with a question that his LSD sessions had made urgent: how does physical space shape psychological experience? The standard psychiatric ward of the 1950s — long corridors, institutional furniture arranged in rows, minimal natural light — seemed designed to reinforce the worst features of the conditions it was supposed to treat. Schizophrenia already made the world feel hostile and isolating; an institutional ward made it more so.

Osmond began studying how furniture arrangement and spatial design affected the behavior and reported experience of patients. He collaborated with architect Kiyoshi Izumi, who also underwent LSD sessions at Osmond's invitation, specifically to understand the spatial experience of altered states. The resulting hospital design — built in Saskatchewan in the 1960s — was the first psychiatric facility explicitly designed using experiential evidence from psychedelic research.

From this work came two words Osmond coined that entered standard design vocabulary: 'sociofugal' and 'sociopetal.' Sociofugal spaces push people apart — the standard airport lounge, rows of chairs facing the same direction, maximum individual isolation. Sociopetal spaces pull people together — the kitchen table, the campfire, circular seating. Osmond argued that most institutional spaces, including hospitals, were sociofugal by design and that this made treatment harder.

The correspondence in Moksha contains threads of this thinking, woven through the letters on consciousness and mescaline. Osmond was not a man who separated his ideas. The substance that revealed how environment shaped experience was the same substance whose clinical use was shaped by environment. The letters carry both.

Sources

• Wikipedia, Humphry Osmond
• Sommer, Robert. In Memoriam: Humphry Osmond. J. Environmental Psychology (2004)
• Huxley & Osmond, in Moksha (1977)

“Huxley believed Leary's mass advocacy would destroy the clinical program. He said so in his letters to Osmond. He was right, and he couldn't stop it.”

By 1960, Aldous Huxley was concerned. He had spent seven years building, through Doors of Perception and through the letters and the lectures and the careful philosophical framing, a case that mescaline and LSD were tools for genuine psychological and spiritual development — tools that required preparation, proper setting, experienced guidance, and the kind of sustained intellectual engagement he and Osmond had brought to their own sessions.

Then Timothy Leary had his psilocybin experience in Cuernavaca in 1960, and the trajectory changed.

Huxley and Leary had met. Huxley respected Leary's intelligence and found his energy useful. But in the letters to Osmond, the concern deepens. Leary's approach — mass advocacy, public spectacle, the insistence on democratizing the experience regardless of preparation or context — was the wrong strategy for a substance that required the right conditions to work safely and well. The counterculture's enthusiasm for LSD was not the problem; the problem was that the enthusiasm was disconnecting the experience from everything Huxley thought made it meaningful.

Huxley wrote to Osmond that he was afraid Leary would provoke a crackdown. He worried that the clinical program — the careful work of Hoffer and Osmond and the hundred researchers following their methods — would be destroyed by the association with mass recreational use. He was right about the mechanism. He was right about the timeline. The crackdown came in 1968, three years after his death.

The letters in Moksha are not a record of this in detail — the most direct evidence is in Stevens's Storming Heaven, which draws on the full correspondence. But the texture is there in the published letters: Huxley in his last years, watching the wave he had helped start break in the wrong direction, unable to redirect it, still writing carefully, still arguing for the gratuitous grace rather than the political program.

Sources

• Stevens, Jay. Storming Heaven (1987)
• Lattin, Don. The Harvard Psychedelic Club (2010)
• Huxley & Osmond, in Moksha (1977)

“Ergot had been trying to get Hofmann's attention for years. It was the fungus that stopped postpartum hemorrhage, caused the Dancing Plague of 1374, and eventually, through his hands, became LSD.”

Albert Hofmann joined Sandoz Laboratories in Basel in 1929 and was assigned to study ergot — the fungus Claviceps purpurea, which grows on rye and other grains and had been known since antiquity for two completely opposite properties.

The first: it caused uterine contractions, making it useful for stopping postpartum hemorrhage. Midwives in medieval Europe had used ergot-contaminated rye for this purpose, passing the knowledge through generations without understanding the mechanism.

The second: it caused what medieval observers called St. Anthony's Fire — a syndrome combining hallucinations, convulsions, burning sensations in the extremities, and sometimes gangrene. The Paris epidemic of 1418 killed fifty thousand people. The Dancing Plague of 1374, in which hundreds of people danced uncontrollably for days, is now attributed to ergot in the grain supply. The Salem witch trials may have been ergot poisoning.

Hofmann's task at Sandoz was to isolate the medically useful alkaloids from ergot and develop pharmaceutical derivatives. He succeeded with ergotamine and ergobasine, both of which became important drugs. In 1938, pursuing the pharmaceutical potential further, he synthesized a derivative of lysergic acid — the backbone structure common to all ergot alkaloids — and called it LSD-25. It was the twenty-fifth compound in the lysergic acid series. The animal tests showed nothing interesting. He filed it and moved on.

Five years later — for reasons he described as a 'peculiar presentiment' — he returned to LSD-25. In the final stages of the synthesis, he absorbed a small amount through his skin. The rest is what we know.

What connects ergot's two properties — the obstetrical and the hallucinogenic — is the chemistry of the ergot alkaloids and their action on serotonin receptors. The same receptor family that controls uterine muscle contraction is implicated in the perceptual effects of LSD. Hofmann, working at the boundary between these two pharmacological territories, accidentally synthesized the most potent psychoactive compound known. The fungus had been hiding it in plain sight for millennia.

Sources

• Hofmann, LSD: My Problem Child (1979)
• The Lancet, Albert Hofmann obituary (2008)
• Wacker et al., Cell (2017)

“In 1953, the CIA purchased the entire world supply of LSD from Sandoz — approximately 10 kilograms, enough for 100 million doses. Sandoz was relieved to sell it. They had no idea what to do with it.”

Albert Hofmann's problem child became the world's problem almost immediately after it left the laboratory.

Sandoz Laboratories had been distributing LSD-25 since 1947 under the trade name Delysid, primarily to psychiatric researchers studying schizophrenia and alcoholism. By 1953, word had spread beyond the academic psychiatric community. The CIA's Technical Services Division, which was running MK-Ultra under Sidney Gottlieb, learned about LSD's extreme potency and psychological effects and decided it needed to control the supply.

They bought it all. Approximately 10 kilograms — the entire global stock — for an amount Sandoz considered reasonable. This was enough for roughly 100 million doses of 100 micrograms each. Gottlieb's goal was to determine whether LSD could be used as a truth serum, an interrogation tool, a method for temporarily incapacitating enemies, or a vector for inducing psychiatric disorders in targets.

The answers, after a decade of human experimentation including MK-Ultra's various subprojects, were: no, no, no, and unreliably. The CIA's LSD program produced no usable intelligence techniques. It produced a death (Frank Olson in 1953), extensive psychological damage to unwitting subjects, and eventually a political scandal when the Church Committee exposed the program in 1975.

Hofmann, describing this period in My Problem Child, is characteristically measured. He understood that Sandoz had no means to control what happened to LSD once it left the laboratory — the chemistry was publishable, the synthesis was reproducible, and the demand created by the drug's effects was not something a pharmaceutical company could manage. The CIA's purchase was one symptom. Leary's mass distribution was another. The street market that emerged in the 1960s was a third.

What Sandoz could control — and eventually did — was its own production. In 1965, as the counterculture's use of LSD became impossible to ignore, Sandoz stopped making it. By then, illicit synthesis labs had been running for years. The problem child had left home.

Sources

• Stevens, Jay. Storming Heaven (1987)
• Marks, John. The Search for the Manchurian Candidate (1979)
• Hofmann, LSD: My Problem Child (1979)

“Hofmann trekked to Huautla de Jiménez and met Maria Sabina. He gave her tablets of psilocybin — the compound he'd isolated from her mushrooms. She took them. She said they were the same.”

The connection between Hofmann's LSD research and the psilocybin mushrooms of Mexico was not accidental. It was the same man.

In 1957, Gordon Wasson published his account of participating in a Mazatec mushroom ceremony with the curandera Maria Sabina in Huautla de Jiménez in the mountains of Oaxaca. The article, published in Life magazine under the headline 'Seeking the Magic Mushroom,' was the first mainstream Western account of teonanácatl — the flesh of the gods — and it reached exactly the people who were already thinking about consciousness, plants, and the relationship between them.

Wasson sent Hofmann a sample of the mushrooms. Hofmann analyzed them. In 1958 he isolated two new indole alkaloids — psilocybin and psilocin — and determined their chemical structures. The relationship to LSD was immediately visible: both compounds acted on the serotonin system, though through different mechanisms and with different duration profiles.

Two years later, Hofmann traveled to Mexico with his wife and colleagues to see the ceremony in its context. In Huautla, he met Maria Sabina and provided her with pills containing synthetic psilocybin that he had brought from the laboratory. She took them in a ceremony, without knowing exactly what was in them, and afterward reported that their power was the same as that of the mushrooms — she could work with the spirits equally well.

This exchange — the chemist with his tablets, the curandera with her centuries-old tradition, the confirmation that the molecule captured the spirit — is one of the most quietly significant moments in Hofmann's story. It grounded his lifelong argument: that what he had synthesized was not a foreign substance imposed on human chemistry but a compound that human cultures had been working with, in one form or another, for as long as there had been human cultures. The problem child had ancestors.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Wasson, Gordon. Seeking the Magic Mushroom, Life magazine (1957)
• Wikipedia, Maria Sabina

“Hofmann lived to 102. He took LSD on his hundredth birthday. He said the experience restored something he had felt as a child in the Swiss countryside — a quality of luminous presence in ordinary things.”

Albert Hofmann was born in 1906 and died in 2008. Between these dates, he synthesized LSD, isolated psilocybin and psilocin, studied the chemistry of morning glory seeds, wrote My Problem Child, attended the 2006 Basel symposium on LSD's medical potential, and gave his last major interview at 101.

He took LSD at 100. He was not performing nostalgia or staging a statement. He took it the way he'd always taken it — carefully, in appropriate surroundings, with people he trusted — because the experience still did for him what he had discovered it could do in 1943: restore the quality of perception he had first known as a child.

Hofmann returned throughout his life to a specific memory: a morning walk in the Swiss countryside as a young boy, when the world had appeared luminous and saturated with presence, each thing exactly itself and impossibly significant. This quality had gradually faded with education and maturity, replaced by the ordinary adult perception of objects in terms of their usefulness and category. LSD had not introduced something foreign — it had recovered something that had been there before and been trained away.

This is the deepest claim in My Problem Child, and it is not pharmacological but autobiographical: that the state LSD produces is not aberrant but prior. The drug does not add content to consciousness; it removes the learned suppressions that make ordinary adult perception feel normal. What is revealed is not the drug's creation but consciousness's original condition.

Hofmann died on April 29, 2008 — a Tuesday, four months after his hundred-and-second birthday. He had lived long enough to see the research program he'd hoped for begin again: MAPS-sponsored clinical trials of LSD for anxiety, the first in decades. He did not live to see the clinical results published, but he knew the direction.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Various interviews, Albert Hofmann, 2006-2008
• MAPS obituary, Albert Hofmann (2008)

“In 2017, scientists solved the crystal structure of LSD bound to its receptor. The lid that traps the drug in place — explaining its 12-hour duration — was a protein loop nobody had anticipated.”

For most of the century since Hofmann's bicycle ride, the mechanism of LSD's action was understood in general terms — it bound to serotonin receptors, particularly 5-HT2A — but the precise structural explanation for two of its most distinctive features remained unknown: its extreme potency and its unusual duration.

A standard psychedelic dose of LSD is 100 micrograms. A dose of mescaline producing comparable effects requires 200-400 milligrams — roughly 2,000 to 4,000 times more by weight. And where most drugs' effects follow their pharmacological half-life and clear when the drug clears, LSD's effects persist for 8-12 hours even though the drug itself metabolizes faster.

In 2017, a team led by Bryan Roth at UNC Chapel Hill published the crystal structure of LSD bound to the 5-HT2A receptor in Cell. The structure explained both mysteries at once.

On potency: LSD's molecular shape allows near-perfect complementarity with the receptor's binding pocket. The fit is so precise that even tiny amounts occupy the receptor almost completely.

On duration: a protein loop — an 'extracellular lid' formed by the receptor's second extracellular loop — closes over the LSD molecule after binding and traps it inside. The drug cannot leave until the lid opens. This explains why blocking the receptor with ketanserin before the LSD stops the effects but administering ketanserin afterward does not — the drug is locked in, and even the blocker can't reach it.

Hofmann described the intensity and duration of Bicycle Day's experience as a source of bewilderment. He'd expected the compound to metabolize more normally. The lid is why it didn't. The molecular explanation for the most famous accidental dose in pharmacological history was solved in a University of North Carolina laboratory seventy-four years after it happened.

Sources

• Wacker et al., Cell (2017)
• Hofmann, LSD: My Problem Child (1979)
• Preller & Vollenweider, Brain Stimul. (2019)

“McKenna studied history at Berkeley, not pharmacology. The intellectual formation behind Food of the Gods was humanistic — he came to the plants through the library, then through the forest.”

Terence Kemp McKenna was born on November 16, 1946, in Paonia, Colorado — a small coal-mining town in the western part of the state — and grew up reading science fiction and collecting butterflies. He was not a child prodigy in any institutional sense. He was a reader.

At Berkeley in the mid-1960s, he studied history and ecology. The intellectual formation behind Food of the Gods was humanistic before it was pharmacological: he encountered the ideas of Marshall McLuhan, Buckminster Fuller, Carl Jung, and Alfred North Whitehead in the library before he encountered psilocybin in a Californian apartment. He came to the plants through the books, and then let the plants revise the books.

His first serious psychedelic experience was in Berkeley in 1965, with psilocybin mushrooms obtained through the network that preceded the counterculture's full public emergence. He described it, in various interviews, as the most significant intellectual event of his life — not because of what he saw but because of what he understood: that the categories he had been accumulating through five years of serious reading were provisional, that ordinary consciousness was a constrained subset of what was available, and that this had implications for everything.

He left Berkeley without completing his degree and spent several years traveling — across Asia, through India, Nepal, and Southeast Asia, studying shamanism, the I Ching, and the ethnobotanical literature that Schultes had been building at Harvard. He returned to the United States in 1971 having read almost everything available on psychoactive plants in the academic literature and having developed the hypothesis that would become Food of the Gods: that the relationship between human consciousness and psychoactive plants was not peripheral but foundational to what humans were.

The book took twenty years to write, in the sense that La Chorrera in 1971 was the experiential foundation and the 1992 publication was the intellectual elaboration. In between, McKenna became a lecturer, a radio presence, and eventually, in the 1990s, an internet figure whose audio recordings circulated among the early communities of what would become the psychedelic renaissance. Food of the Gods was the argument. The lectures were the argument in performance.

Sources

• Wikipedia, Terence McKenna
• Grokipedia, Terence McKenna
• Lucid News, Genius and Delusion in Terence McKenna's Life (2025)

“In 1985, McKenna and his then-wife Kathleen Harrison founded Botanical Dimensions on the Big Island of Hawaii — a living archive of ethnobotanically significant plants, many of them psychoactive.”

Food of the Gods argues that the relationship between humans and psychoactive plants is fundamental — not a curiosity but a constitutive feature of what humans are and have been for most of their evolutionary history. Botanical Dimensions was McKenna's attempt to act on this argument materially.

In 1985, McKenna and his then-wife Kathleen Harrison founded Botanical Dimensions on the Big Island of Hawaii. It was a nonprofit ethnobotanical preserve with a specific mandate: to collect, protect, propagate, and study plants of ethnomedical significance — with an emphasis on the plants that appeared in the psychoactive plant literature Schultes and Hofmann had assembled.

The preserve grew plants that were, in some cases, rarely cultivated outside their native regions. It maintained living specimens of species that were being lost to deforestation and agricultural displacement in their original habitats. It served as a research resource, a conservation site, and a demonstration that the ethnobotanical relationship McKenna described in his writing could be maintained physically as well as conceptually.

Harrison, who remained involved with Botanical Dimensions after the couple's separation, is herself a botanist and ethnobotanist whose work has focused on the cultural contexts of plant medicine use. Her approach — more patient and more careful about cultural appropriation than McKenna's — represents a complementary strand of the same project: the argument that the plants deserve serious attention, sustained relationship, and proper context.

McKenna lived on the Big Island intermittently through the 1990s. He was diagnosed with a brain tumor in 1999 and died on April 3, 2000, in San Rafael, California. Botanical Dimensions continues to operate. The garden he built outlasted the lectures, which is probably what he intended.

Sources

• Wikipedia, Terence McKenna
• Grokipedia, Terence McKenna
• McKenna, Food of the Gods (1992)

“Published in 1975, The Invisible Landscape was the theoretical foundation for everything McKenna would argue for the next twenty-five years. Almost nobody read it.”

Food of the Gods (1992) was Terence McKenna's third book and his first to reach a wide audience. It was also the most accessible articulation of ideas he had been developing since 1975, when he and his brother Dennis published The Invisible Landscape: Mind, Hallucinogens, and the I Ching.

The Invisible Landscape is a stranger, harder book than Food of the Gods — closer to the raw experience of La Chorrera and less processed through the narrative skills McKenna would develop over the following fifteen years. It attempts to construct a mathematical model of time's qualitative structure, based on the I Ching's sixty-four hexagrams, in which novelty is not uniformly distributed but has specific topological features that can be mapped. This became Timewave Zero.

It also contains the first formal presentation of the tryptamine hypothesis: that psilocybin and related compounds are not simply consciousness-altering drugs but represent a class of molecules with special relationships to human cognitive evolution, to the structure of the nervous system, and to what McKenna called 'the Other' — the alien intelligence that consistently presented itself in high-dose tryptamine experience.

The book sold modestly and was largely ignored by academic reviewers. Dennis McKenna went on to complete a doctorate in neuropharmacology and to pursue the underlying questions through conventional scientific channels. Terence went on the lecture circuit.

Food of the Gods distills and translates the Invisible Landscape argument for a general audience: the evolutionary hypothesis becomes the stoned ape; the mathematical model of time becomes the Archaic Revival; the tryptamine entities become the Transcendent Other. The underlying claims are the same. What changed was McKenna's ability to present them in language that reached people who had no reason to work through the I Ching mathematics.

The Invisible Landscape is, in retrospect, the intellectual foundation and Food of the Gods is the cultural intervention. Understanding both is the only way to assess either.

Sources

• McKenna, D. & McKenna, T. The Invisible Landscape (1975)
• Wikipedia, Terence McKenna
• Lucid News, Genius and Delusion (2025)

“Published under pseudonyms in 1976, Psilocybin: Magic Mushroom Grower's Guide sold 100,000 copies by the 1980s. McKenna and his brother democratized access to psilocybin mushrooms a decade before Food of the Gods made the theoretical argument.”

Before Food of the Gods, before the lectures, before the term 'archaic revival' had entered anyone's vocabulary, Terence McKenna made his most consequential practical contribution to psychedelic culture: a 63-page cultivation manual.

Published in 1976 under the pseudonyms O.T. Oss and O.N. Oeric, Psilocybin: Magic Mushroom Grower's Guide described in clear, reproducible terms how to cultivate Psilocybe cubensis — the same species the McKennas had found in abundance in the cattle pastures around La Chorrera. The guide covered substrate preparation, inoculation, fruiting conditions, and spore collection. It required no laboratory equipment and no specialized knowledge. A reasonably careful person with a mason jar and a pressure cooker could follow it successfully.

The book sold more than 100,000 copies before the 1980s were over. Terence was, by his own account, personally responsible for many of the psilocybin mushrooms circulating in the San Francisco Bay Area during the 1970s. The Grower's Guide created a supply chain that preceded and enabled much of what came later — the broader cultural engagement with psilocybin that the psychedelic renaissance of the 2000s and 2010s eventually institutionalized.

The pseudonyms were not purely commercial strategy — they were legal protection, since psilocybin was Schedule I. But they also reflect a McKenna quality that the later lecture performances sometimes obscured: a practical intelligence, a willingness to do the unglamorous technical work of making something actually available rather than merely talking about why it mattered.

Food of the Gods provided the theoretical framework. The Grower's Guide, published sixteen years earlier, had already done the distribution.

Sources

• Wikipedia, Terence McKenna
• Lucid News, Genius and Delusion (2025)
• Grokipedia, Terence McKenna

“McKenna was diagnosed with glioblastoma in 1999. He was 52. He said the diagnosis was the most interesting thing that had ever happened to him. He spent his final year thinking about death.”

In mid-1999, Terence McKenna had a grand mal seizure while giving a lecture in Hawaii. The diagnosis was glioblastoma multiforme — the most aggressive form of primary brain cancer. He was 52 years old.

In the months between the diagnosis and his death on April 3, 2000, McKenna conducted himself in a way that his closest observers found characteristic: he was genuinely curious about what was happening. He described the diagnosis as the most interesting thing that had ever happened to him — not a performance of equanimity but an actual intellectual engagement with the phenomenon of dying, viewed from the perspective of someone who had spent thirty years thinking about consciousness, the nature of the self, and what lay on the other side of ordinary awareness.

He gave several long interviews in his final months, accessible through the various audio archives of his work. They contain some of his most unguarded thinking — about the limits of the timewave theory, about what he was uncertain of, about the relationship between the psychedelic experience and death. He had long argued that high-dose psilocybin and DMT were rehearsals for the dissolution of the self. The brain tumor was making that argument testable in a way he hadn't anticipated.

He stopped giving lectures but continued corresponding. He remained interested in language, in mathematical structures, in the question of what the entities were. He did not, as far as any record shows, resolve these questions. He maintained what had always been his most admirable intellectual quality: the willingness to hold uncertainty without collapsing it into either certainty or despair.

Food of the Gods was published eight years before the diagnosis. The argument in it — that psychedelic plants represent a necessary reconnection with a relationship humans had severed — McKenna pursued to the end with the same energy, which was characteristic. What changed in the last year was only that the stakes became personal in a way they hadn't previously been.

Sources

• Wikipedia, Terence McKenna
• Lucid News, Genius and Delusion (2025)
• Various interviews, Terence McKenna, 1999-2000

“The most sustained critique of McKenna is not that he was wrong about everything — it's that his certainty exceeded his evidence, and that the performance of intellectual bravado made critical evaluation harder than it should have been.”

Terence McKenna's most famous hypothesis — that psilocybin mushrooms catalyzed human cognitive evolution — is not supported by direct evidence. No archaeological record confirms psilocybin use by early hominids at the scale the hypothesis requires. The genetic argument about 5-HT2A receptor divergence from primate baseline is speculative. The specific mechanisms by which psilocybin would have caused the cognitive changes McKenna described have not been demonstrated.

The broader critique of McKenna runs deeper than the stoned ape. His critics — including his brother Dennis, who has been consistently honest about this — argue that McKenna's rhetorical skill and the genuine phenomenological novelty of what he was describing made it easy to mistake confidence for evidence. He spoke as if he had solved problems that remained open. He used the language of conclusion when he was practicing intuition.

A 2025 biography by Graham St John, published by MIT Press, attempts a serious assessment of McKenna's intellectual legacy. St John's conclusion is nuanced: McKenna was a genuine original whose phenomenological reporting on the DMT and psilocybin experience was accurate in ways that subsequent clinical research has confirmed, and whose cultural diagnosis of Western civilization's estrangement from plant intelligence was substantially correct. His specific theoretical claims — the timewave, the stoned ape in its strong form, the 2012 singularity — were not.

The honest account of McKenna is that he was a brilliant popularizer of questions that deserved serious attention, whose certainty sometimes outran his evidence, and who contributed to psychedelic culture both the permission to take the experience seriously and the bad habit of treating compelling narrative as proof.

The questions Food of the Gods raises — about the evolutionary relationship between humans and plants, about the epistemic status of the entity encounter, about what the drug war is really suppressing — are genuine and important. The answers McKenna offered should be held more lightly than he held them.

Sources

• Grokipedia, Terence McKenna
• Lucid News, Genius and Delusion (2025)
• Wikipedia, Stoned Ape Theory

“McKenna believed that visible language — language that could be seen, not just heard — was what psilocybin unlocked. He called this 'the alien tongue' and spent decades trying to describe it.”

Running through Food of the Gods, and more explicitly through McKenna's lectures, is an argument about language that is distinct from and more interesting than the stoned ape hypothesis.

McKenna proposed that high-dose psilocybin unlocked a form of experience he called 'visible language' — a mode of communication in which language is not heard but seen, in which meaning takes visual form. He described the entities he encountered as 'offering objects' — producing visible, physical manifestations of meaning that existed independent of any verbal code. He called the mode of experience 'glossolalia with access to the visual field.'

This is not the hallucination description that most popular accounts of psilocybin offer. McKenna was not describing patterns and colors. He was describing a different epistemic mode: one in which the gap between symbol and referent collapses, in which meaning becomes directly perceptible rather than inferred from signs.

The linguistic argument in Food of the Gods connects to the broader cultural argument: the dominator culture's reliance on verbal-conceptual representation is, in his view, a limitation that psychedelics expose. Verbal language is representational — it points at things. What psilocybin opens, in McKenna's account, is something more direct: meaning without the mediation of sign.

This argument is speculative but not empty. Current neuroscience of psychedelics confirms that they produce unusual cross-modal integration — sounds can be seen, shapes can carry emotional meaning, the usual segregation of sensory modalities loosens. Whether this constitutes 'visible language' in McKenna's sense is unclear. That something corresponding to his description occurs is supported by the consistency of the report across independent subjects.

McKenna was, among other things, a theorist of language. Food of the Gods is partly a book about what language costs us, and what the plants restore.

Sources

• McKenna, Food of the Gods (1992)
• McKenna, various lectures 1984-2000
• Wikipedia, Terence McKenna

“In the early 1990s, McKenna began describing the internet as a psychedelic technology — a system for the collective exteriorization of human imagination. Food of the Gods was published the year the World Wide Web was invented.”

Food of the Gods was published in 1992 — the same year Tim Berners-Lee made the World Wide Web publicly available. McKenna did not know this was happening, but he anticipated something like it.

In the lectures he gave through the early 1990s, McKenna described a coming technological transformation that he framed in psychedelic terms: the exteriorization of the human imagination into shared space. Virtual reality, which was then a laboratory concept rather than a consumer product, seemed to him like a technology for making visible the content that psychedelics revealed internally — a way of creating the 'visible language' he had been describing for twenty years.

His engagement with the early internet, documented in lectures from 1993-1995, was enthusiastic and prescient in some ways. He saw in networked communication the possibility of the kind of collective consciousness that the psychedelic experience gestures toward — a space in which individual minds could pool their contents and where the usual isolation of the ego might be partially dissolved.

He also saw the risks. The same technological substrate that could serve genuine collective intelligence could serve the dominator culture's purposes just as well — a more efficient version of the television he'd criticized in Food of the Gods, optimized for the same purpose: keeping people passive, consuming content rather than producing experience.

McKenna died in April 2000 — eight months before Wikipedia launched, thirteen years before smartphones became ubiquitous. He didn't see social media. His prediction about the internet's dual nature — liberation engine and attention capture machine — has been validated more fully than he knew.

Sources

• McKenna, Food of the Gods (1992)
• Wikipedia, Terence McKenna
• Edge.org, Terence McKenna biography

“Sagan thought the cosmos was empty except for matter arranged in various patterns of complexity. McKenna thought the cosmos was saturated with intent. They both had beautiful prose. They could not both be right.”

Carl Sagan and Terence McKenna were exact contemporaries in American intellectual culture — both born in the 1930s and 1940s, both gifted popularizers, both deeply interested in the question of what humans are and where they fit in the cosmos. They represented opposing epistemologies so cleanly that their confrontation, had it happened explicitly, would have illuminated something essential about what the psychedelic question is really asking.

Sagan's cosmos was magnificent and empty. The billions of galaxies he described in Cosmos were not saturated with intent — they were matter undergoing processes according to laws. Intelligence was rare, precious, and probably local to Earth and a handful of other planets. The DMT entities that McKenna described encountering were, from Sagan's perspective, products of a brain under chemical stress — vivid, phenomenologically real, and without external referent.

McKenna's cosmos was saturated with intent. The DMT entities were not brain productions — they were inhabitants of a territory that human consciousness could access under specific conditions. The relationship between humans and psilocybin mushrooms was not accidental chemistry but something close to dialogue. The universe was not indifferent; it was communicating, and the plants were the medium.

Food of the Gods is, among other things, an argument for McKenna's cosmos against Sagan's. The argument is not primarily scientific — it is phenomenological and historical. The evidence he offers is the consistency of the entity report across cultures and centuries, the sophistication of indigenous pharmacological knowledge, and his own direct experience.

Sagan's The Demon-Haunted World was published in 1995, three years after Food of the Gods. It addressed, directly and critically, the kind of experiential claims McKenna was making — not by name, but by type. The two books represent, in their disagreement, the most fundamental open question in the psychedelic literature: what is the experience evidence of?

Sources

• McKenna, Food of the Gods (1992)
• Sagan, The Demon-Haunted World (1995)
• Various interviews

“Anslinger arrived at the Federal Bureau of Narcotics in 1930 as a pragmatist, not a zealot. He became a zealot when he discovered that cannabis was more politically useful than heroin.”

Harry Jacob Anslinger was appointed the first commissioner of the Federal Bureau of Narcotics in September 1930. He was thirty-eight years old, had spent his career in Prohibition enforcement, and had been noticed by Treasury Secretary Andrew Mellon — whose wife's family was related to Anslinger's wife — as honest, effective, and politically reliable.

What the historical record shows, and what Chasing the Scream simplifies, is that Anslinger's transformation into a cannabis crusader was not ideological from the beginning. For his first four years at the FBN, he actively downplayed cannabis as a minor regional concern, telling Congress it didn't warrant federal attention. His bureau was focused on heroin and cocaine — the genuine pharmaceutical problems of the era.

What changed in 1934 was not the drug but the political landscape. Prohibition had been repealed in December 1933, eliminating the FBN's largest mandate. The bureau needed a new enemy to justify its existence and budget. Cannabis, associated with Mexican immigrants in the Southwest and with Black jazz musicians in northern cities, was politically available in ways that opiates — used by a much broader demographic — were not.

Anslinger pivoted. He began collecting what the HistoryOfCannabis.org timeline calls 'the gore files' — newspaper clippings of crimes allegedly committed under cannabis influence, many unverified and some fabricated — and deploying them in testimony and press releases. His 1937 Marijuana article titled 'Assassin of Youth' in The American Magazine established the public framework that drove the Marihuana Tax Act.

By the time he testified before Congress in 1937, the approach had been refined through three years of public campaign. The testimony was theatrical, the evidence was thin, and the legislation passed in two hours. Anslinger had learned, from Prohibition, that effective law enforcement requires public fear. He manufactured the fear where the evidence didn't provide it.

Sources

• Wikipedia, Harry J. Anslinger
• HistoryOfCannabis.org, Anslinger profile
• Hari, Chasing the Scream (2015)
• CBS News, The Man Behind the Marijuana Ban (2016)

“Hari's account of Anslinger targeting Holiday because of Strange Fruit has been disputed by jazz historians. The racial targeting is documented; the specific Strange Fruit trigger is not.”

Johann Hari's Chasing the Scream contains one of its most vivid claims in the account of Harry Anslinger targeting Billie Holiday: that the federal narcotics commissioner personally hunted Holiday because she performed 'Strange Fruit,' the anti-lynching song, and that suppressing her voice was the goal while her heroin addiction was merely the tool.

Jazz historian Lewis Porter, among others, has contested this specific claim. Porter found no evidence in the FBN archives of any campaign targeting Holiday in connection with 'Strange Fruit.' The historical record shows that the FBN targeted Holiday for her heroin addiction — which was documented and genuine — rather than as a deliberate political suppression of anti-racist art.

Hari acknowledged some of these criticisms on a corrections page on his website after the book was published. He maintained that the racial targeting of Holiday's treatment, as compared to how white artists with similar addictions were handled, remained documented and real. The Mob Museum's account confirms that Anslinger's fixation on Holiday was real and that his motivations included racial bias and a view that celebrities should model 'societal standards.'

The distinction matters: Hari's broader argument — that the drug war was racially targeted from its inception, that Black artists were prosecuted while white artists were counseled, and that the enforcement was not about pharmacology but about social control — is well-supported. The specific 'Strange Fruit' narrative may be compression of a more complex causality into a more compelling story.

The factual debate does not invalidate the book's central claims. Anslinger's own words — his internal memos, his congressional testimony, his published writings — are explicit about the racial associations he was making. What the Holiday case shows, with or without the 'Strange Fruit' trigger, is a federal enforcement system that applied its power differentially by race, to devastating individual effect.

Sources

• Wikipedia, Harry J. Anslinger
• Hari, Chasing the Scream (2015) and corrections
• Mob Museum, Anslinger profile
• Szwed, Billie Holiday: The Musician and the Myth (2015)

“Alexander's Rat Park showed something real. It also showed less than Hari claimed. The nuance matters for policy — if environment modulates but doesn't determine addiction, the treatment implications shift.”

Bruce Alexander's Rat Park experiment (1978-1981) is the empirical foundation of Chasing the Scream's central argument: that social environment, not pharmacological dependence, is the primary driver of addiction.

In the original experiment, isolated rats chose morphine-laced water heavily. Rats in the Rat Park environment — with space, companions, and stimulation — chose plain water by a wide margin, even when they had previously been exposed to morphine. The difference in consumption was dramatic: isolated rats used up to 25 milligrams per day; socially enriched rats rarely exceeded 5 milligrams.

Alex's subsequent papers extended the argument: rats that had become dependent while isolated would voluntarily reduce their morphine consumption when moved to Rat Park, even enduring withdrawal to do so. Social environment, he concluded, was more powerful than pharmacological addiction.

The controversy is in the replication. A 1996 study by Petrie did not reproduce Alexander's specific results using comparable methods. A 2020 review by Gage and Sumnall in Addiction found that the 'conceptual but not direct' replication pattern: social enrichment reliably reduces drug-seeking across many experimental paradigms, but not always through the specific mechanisms Alexander proposed, and the magnitude of the environmental effect varies considerably across studies.

What this means for Chasing the Scream's argument: the core claim — that disconnection and isolation are major drivers of addiction, and that policy should address social conditions rather than only pharmacology — is supported. The strong version of the claim — that environment almost entirely overrides pharmacological dependence — exceeds the evidence.

For drug policy, the nuance matters. If environment modulates but doesn't determine, then harm reduction, social services, and community building are necessary but not sufficient. Pharmacological treatment remains important. Portugal's model, which combined decriminalization with investment in jobs, housing, and services, is a more accurate embodiment of the evidence than the simple slogan 'the opposite of addiction is connection.'

Sources

• Hari, Chasing the Scream (2015)
• Gage & Sumnall, Addiction (2020)
• Koob & Volkow, Neuropsychopharmacol. (2010)
• Alexander, B. The Globalization of Addiction (2008)

“In 1971, Nixon's White House commissioned a study on heroin use in Vietnam. What Lee Robins found challenged every assumption the drug war was built on.”

In 1971, reports reached Congress that approximately 20 percent of US soldiers in Vietnam were addicted to heroin — easily available, cheap, and more potent than what was available at home. The White House commissioned Lee Robins, a sociologist at Washington University, to study the situation.

What Robins found upended the standard model of addiction. She tracked soldiers after their return to the United States and found that of those who had been addicted in Vietnam, approximately 95 percent stopped using heroin after they came home — without treatment, without rehabilitation programs, without formal support. Most simply stopped.

This was not supposed to be possible. The standard model of heroin addiction, which informed drug policy, held that the drug created a pharmacological dependency that the body could not simply discontinue — that withdrawal was a physical process requiring medical management and that relapse was the default outcome of exposure. Robins's data showed something different: that the vast majority of people who had become dependent on heroin in one environmental context did not continue that dependence when the environmental context changed radically.

Johann Hari uses the Vietnam study as one of his strongest empirical arguments for the connection model. The soldiers didn't stop because they received treatment — they stopped because they returned to environments that offered alternatives. The drug was the same. The context was different.

The study's implications are significant and contested. Critics note that heroin in Vietnam was different in purity and administration route from street heroin in the US, and that the cultural context of returning home itself is a complex variable. Robins acknowledged these complications in her later work. The study remains the most dramatic natural experiment available on the relationship between environment and addiction — and its conclusion, that context shapes pharmacological dependence more powerfully than the model predicted, is supported by the data regardless of how the mechanism is interpreted.

Sources

• Hari, Chasing the Scream (2015)
• Robins, L. Vietnam Veterans Three Years After Vietnam: How Our Study Changed Our View of Heroin (1993)
• Wikipedia, Lee Robins

“Portugal decriminalized all drugs in 2001. By 2015 when Hari reported it, the results were remarkable. By 2024, they were more mixed. The model works when the social investment matches the policy.”

In 1999, Portugal had one of the worst drug problems in Western Europe: approximately one percent of the population was addicted to heroin, and HIV transmission among injecting drug users was among the highest in Europe. The government commissioned a panel of experts to recommend a response.

The panel's 2000 report was radical: decriminalize personal possession of all drugs, including heroin and cocaine, and redirect the enforcement savings into treatment, housing, and employment for addicts. The Dissuasion Commission system replaced criminal courts with panels of counselors, lawyers, and social workers who could assign treatment, community service, or fines — but not prison.

Johann Hari reported the 2001-2015 results in Chasing the Scream as a vindication of the connection model: drug-related HIV transmission fell dramatically, overdose deaths fell, drug use among young people did not increase, and the money saved on imprisonment was redirected to services. The Portuguese model became the most-cited international example of successful drug decriminalization.

The longer view, available by 2024, is more complicated. Portugal faced a fentanyl and synthetic opioid crisis through the late 2010s and early 2020s that drove drug-related deaths upward. Austerity measures following the 2008 financial crisis cut many of the social programs that had made the model work — the housing, the employment, the treatment capacity. When the social investment declined, so did the outcomes.

This is not a refutation of Portugal's approach but a specification of it: decriminalization alone produces modest results. Decriminalization combined with substantial investment in social services produces the dramatic results Hari documented. The lesson is not that punishment is unnecessary — it's that the social support must accompany the policy reform, or the policy reform works much less well.

Sources

• Hari, Chasing the Scream (2015)
• EMCDDA, Portugal Country Drug Report (2023)
• Hughes & Stevens, Drug Alcohol Rev. (2010)

“Harry Anslinger spent thirty-two years destroying the lives of people dependent on opiates. He spent his final years dependent on morphine for angina. He never publicly acknowledged the irony.”

Harry Anslinger retired from the Federal Bureau of Narcotics in 1962 after thirty-two years. He spent two more years as US Representative to the United Nations Narcotics Commission, continuing to shape international drug policy toward prohibition and criminalization. He died on November 14, 1975.

In the final years of his life, Anslinger developed angina — a heart condition managed with opiates. He used morphine for pain relief. He was, pharmacologically, dependent on the same class of drugs whose users he had spent his career criminalizing, shaming, imprisoning, and in some cases destroying.

An acute version of this irony might suggest that Anslinger was a hypocrite who understood, privately, that opiate dependency was a medical condition and chose to treat it as a crime in others while treating it as an illness in himself. The historical record does not support this clean interpretation. His morphine use was legal and prescribed, and he almost certainly categorized it — as the culture of his time categorized it — as categorically different from 'drug addiction.'

But this categorical distinction is precisely what Chasing the Scream challenges. The pharmacology of dependence does not recognize the distinction between legitimate and illegitimate use. The body that becomes dependent on prescribed morphine and the body that becomes dependent on street heroin are going through the same process. What differs is the social framing, the price, the purity, and the legal status — not the underlying biology.

Anslinger's morphine use is, in Hari's account, the compressed argument of the entire book: the disease does not respect the ideology of the person who has it. The policy that treated addiction as a moral failure deserving punishment was maintained by a man who, in his final years, was medically dependent on the class of drugs he had spent a career condemning. He never made this connection public. It seems he never made it privately either.

Sources

• Hari, Chasing the Scream (2015)
• Wikipedia, Harry J. Anslinger

“The harm reduction movement didn't argue that drugs were good. It argued that people who use drugs don't deserve to die from preventable causes, and that the state has an obligation to prevent that.”

Harm reduction is the set of policies and practices that aim to reduce the negative consequences of drug use without requiring abstinence as the goal. Safe injection sites allow users to inject drugs under medical supervision, with naloxone available and clean equipment provided. Needle exchanges distribute sterile syringes to prevent HIV and hepatitis transmission. Heroin maintenance programs provide pharmaceutical-grade heroin to users who have not responded to other treatment, in a clinical setting with medical oversight.

These programs do not require drug users to stop using drugs. They require, instead, that drug users not die from preventable causes while they remain users — either from overdose, from infected equipment, or from contaminated supply.

Chasing the Scream documents the political resistance to harm reduction as a feature of the drug war's moral logic: if addiction is a moral failure, reducing the harm of addiction without requiring cessation is complicity in that failure. The abstinence-only model — which informed US drug treatment policy through at least the 1990s — treated harm reduction as sending the wrong message.

The evidence accumulated against this position. Safe injection sites in Vancouver, Sydney, and Amsterdam documented reductions in overdose deaths and HIV transmission without documented increases in drug use in surrounding communities. The Frankfurt model, documented in Chasing the Scream, produced dramatic reductions in street crime as users no longer needed to steal to afford their drugs. The Swiss heroin maintenance program produced the outcomes Hari summarizes: crime down 60 percent, employment doubled, program cost less than imprisonment.

As of 2025, the first sanctioned safe injection site in the United States — OnPoint NYC, opened in November 2021 — had reversed over 1,200 overdoses without a single death on-site. US harm reduction policy has shifted substantially since Hari wrote. The resistance to it, in some political quarters, remains essentially unchanged.

Sources

• Hari, Chasing the Scream (2015)
• EMCDDA, European Drug Reports (2020-2024)
• Wikipedia, Harm Reduction

“The Telesterion was not a theater. It was a hall for standing in darkness, for waiting, and for seeing. The distinction is the architectural argument for the pharmacological hypothesis.”

The Telesterion — the Hall of Initiation at Eleusis — was architecturally unusual in the ancient world. Unlike the great temples of Greece, which were designed for public ritual visible from outside, the Telesterion was an enclosed hall designed for interior experience. Its final form, completed in the fourth century BCE, could hold approximately 3,000 initiates simultaneously. They stood, or sat on stone benches around the walls, in near-total darkness.

At the center was the anaktoron — the sacred precinct from which the hierophant emerged to show the sacred objects (the hiera) at the moment of revelation. The classical sources are unanimously silent about what the hiera were. Initiates were bound by the most serious oath in the ancient world to say nothing of what they had experienced.

The architectural distinction between theater and telesterion is central to the Road to Eleusis argument. A theatrical production — lights, stage, performance — requires an architectural environment that supports visibility and attention to a focal point. What ancient accounts describe happening in the Telesterion does not require this. What they describe is individual experience: fear, trembling, vision, a sense of direct encounter with the divine.

This individual, phenomenological quality — each initiate having their own experience in the darkness rather than watching a shared performance — is what the pharmacological hypothesis explains most naturally. A drug, taken as part of the kykeon before entering the hall, would produce individual experience with broadly shared phenomenological features. A theatrical performance would produce a shared external spectacle with individually varied emotional responses.

The distinction is not definitive — some classical scholars argue that skilled theatrical presentation could produce the described effects without drugs. But the architecture, the darkness, and the uniformity of the 'vision' reports across two thousand years of accounts make the theatrical explanation harder to sustain than the pharmacological one.

Sources

• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Mylonas, Eleusis and the Eleusinian Mysteries (1961)
• Muraresku, The Immortality Key (2020)

“Gordon Wasson published his account of the Mazatec mushroom ceremony in Life magazine in 1957. It reached 3.5 million readers. Maria Sabina said afterward that she wished he had never come.”

R. Gordon Wasson was a vice president at J.P. Morgan and an amateur mycologist — a combination that gave him the financial resources to pursue his interest in mushrooms across cultures and the social standing to publish his findings in major venues.

In 1955, Wasson and his photographer Allan Richardson traveled to Huautla de Jiménez in Oaxaca, Mexico, and participated in a nighttime mushroom ceremony — a velada — conducted by the Mazatec curandera Maria Sabina. They were the first Westerners documented to have participated in this ceremony. Wasson took the mushrooms, experienced the visionary state, and returned to New York to write about it.

The resulting article, 'Seeking the Magic Mushroom,' was published in Life magazine on May 13, 1957. It reached approximately 3.5 million subscribers. It described, in careful detail, the ceremony, the mushrooms, the experience, and Wasson's conclusion that the 'magic mushrooms' of Mexico were the key to understanding the religious use of psychoactive plants across ancient cultures.

The article changed everything. Within months, Huautla was receiving a stream of foreign visitors. Within years, Timothy Leary had obtained mushrooms through Wasson's academic network and had his transformative Cuernavaca experience. The article directly enabled the chain of events that led to the counterculture's engagement with psilocybin.

Maria Sabina's comment, recorded years later, was blunt: she wished Wasson had never come. The flood of visitors disrupted the ceremonial practice, exposed her community to outside pressure, and ultimately led to her house being burned down by neighbors who blamed her for the disruption. Wasson's documentation preserved a practice for the world and simultaneously helped destroy it. The tension between preservation and disruption has no resolution that the archive can provide.

Sources

• Wasson, R.G. Seeking the Magic Mushroom, Life magazine (1957)
• Wikipedia, R. Gordon Wasson
• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)

“Classical scholars Walter Burkert and Albert Henrichs rejected the ergot hypothesis. Their alternative — that the Mysteries worked through theater and suggestion — requires explaining evidence that the pharmacological theory explains more simply.”

The Road to Eleusis was published in 1978 by Harcourt Brace Jovanovich. The scholarly reception from classicists was largely hostile.

Walter Burkert, the most eminent classical scholar of ancient Greek religion, addressed the hypothesis in his 1987 book Ancient Mystery Cults. His objection was methodological and hermeneutic: the ancient accounts of the Mysteries could be explained by theatrical performance, psychological suggestion, and the powerful context of the ritual without invoking pharmacology. The darkness, the months of preparation, the collective atmosphere, the hierophant's ceremonial revelations — these were sufficient, in Burkert's view, to produce the transformative experiences described.

Albert Henrichs made a similar argument: that the initiates' accounts were culturally conditioned — shaped by what they expected to experience — and that the consistency of their reports reflected shared expectation rather than shared pharmacology.

Carl Ruck responded in subsequent publications that the alternative explanations required explaining why the Mysteries were specifically described as producing a 'vision' — not an 'insight,' not a 'realization,' but a direct visual encounter. Theater could produce emotional impact; it could not reliably produce the individual visionary experience that the ancient sources consistently describe across two thousand years.

The debate was unresolved when the 2020 Mas Castellar de Pontós archaeological finding — ergot alkaloids in a ritual vessel at an Eleusinian cult site in Catalonia — provided the first direct physical evidence that Wasson, Hofmann, and Ruck's hypothesis was chemically feasible and historically evidenced. Burkert died in 2015 and did not see this finding. The scholarly debate has not fully processed it. Brian Muraresku's The Immortality Key (2020) brought the finding to a popular audience and extended the hypothesis with additional archaeological evidence.

Sources

• Burkert, Ancient Mystery Cults (1987)
• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Muraresku, The Immortality Key (2020)

“The early Church Fathers wrote about the Mysteries — mostly to condemn them. Their condemnations preserve the most detailed surviving descriptions of what happened.”

One of the richest sources of information about the Eleusinian Mysteries is the early Christian literature written to condemn them.

The Church Fathers — Clement of Alexandria, Hippolytus of Rome, and others — wrote detailed accounts of pagan religious practices specifically to demonstrate their error. In doing so, they preserved descriptions that the initiates themselves were forbidden by oath to provide. Clement of Alexandria's Protrepticus (ca. 190 CE) contains some of the most specific surviving material about the Eleusinian ritual sequence, including descriptions of the kykeon, the procession, and what was revealed in the Telesterion — preserved precisely because Clement wanted to show that the Mysteries were shameful.

This is the documentary irony of the Road to Eleusis: the institution that eventually suppressed the Mysteries — which Theodosius formally prohibited in 392 CE — is also the institution that most thoroughly documented them, through the same polemical literature that sought their destruction.

The relationship between early Christianity and the Eleusinian Mysteries is more complex than simple displacement. Some scholars — following in the tradition of the comparative religion literature that Wasson knew well — have argued that early Christianity incorporated elements of mystery religion practice into its own rituals. The Eucharist, with its transformation of bread and cup into the divine, has formal similarities to the kykeon and its claimed transformative properties. Whether this is historical influence, parallel development, or coincidental resemblance is one of the questions Brian Muraresku pursues in The Immortality Key (2020).

The Road to Eleusis leaves this question largely to one side, focusing on the pharmacological hypothesis. But the early Christian documentation of the Mysteries is one of its crucial sources — a reminder that the most thorough records of what was being suppressed were kept by the institution doing the suppressing.

Sources

• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Clement of Alexandria, Protrepticus (ca. 190 CE)
• Mylonas, Eleusis and the Eleusinian Mysteries (1961)

“The Homeric Hymn to Demeter describes the kykeon's ingredients precisely: barley, water, and pennyroyal. It does not mention ergot. Wasson, Hofmann, and Ruck argue it doesn't need to — ergot was a natural contaminant of ancient grain.”

The Homeric Hymn to Demeter, one of the earliest surviving examples of Greek literature (ca. seventh century BCE), describes the moment Demeter accepts the kykeon at Eleusis. The drink is prepared by Metaneira's daughter Iambe from barley, water, and pennyroyal (Mentha pulegium). Demeter had been refusing all food and drink in her grief over Persephone's abduction. The kykeon was what finally broke her fast.

The mythological narrative is understood by Wasson, Hofmann, and Ruck as containing, in encoded form, the actual preparation of the sacramental drink. Barley and water are the documented ingredients. Pennyroyal, a mint with medicinal properties, served as flavoring and possibly as a mild additional pharmacological agent. The fourth ingredient — unmentioned in the Hymn because it was not added deliberately but was a natural feature of the grain — was ergot.

The argument depends on the agricultural reality of ancient grain production. Claviceps purpurea, the ergot fungus, was endemic to rye and barley fields across the Mediterranean world. Ancient grain was not inspected for contamination in any modern sense. The barley harvested at Eleusis in September — the time of the Mysteries — would have carried ergot as a matter of ordinary agricultural probability.

Hofmann's contribution was demonstrating that water-soluble ergot alkaloids (ergine, ergonovine) could be extracted from the fungus through the kind of cold-water preparation that ancient kykeon processing would have involved. The 2026 Scientific Reports paper by Antonopoulos and Dadiotis extended this by showing experimentally that lye — available as wood ash in antiquity — could convert toxic ergopeptides into the water-soluble psychoactive forms at doses achievable through ancient preparation.

The recipe in the Hymn is not a pharmacological specification. It is a mythological preservation of what the kykeon actually contained — minus the one ingredient that didn't need to be added because it was already there.

Sources

• Homeric Hymn to Demeter, trans. Helene Foley (1994)
• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Antonopoulos & Dadiotis, Scientific Reports (2026)

“The site of the most important religious institution in Western civilization for two thousand years is a UNESCO-monitored archaeological zone adjacent to an operating oil refinery. The irony is not subtle.”

Eleusis is a municipality on the Saronic Gulf, approximately thirty kilometers west of Athens. Its ancient sanctuary — the site of the Mysteries that Cicero called the best thing Athens ever gave the world, that Pindar and Sophocles and Plato had called transformative and essential — is an archaeological zone containing excavated ruins of the Telesterion, the Propylaia, the Sacred Way, and various ancillary structures.

The ruins are real and worth visiting. They are also located adjacent to an operating industrial complex — until recently a cement factory, and before that and still operating, an oil refinery. The visual juxtaposition of the excavated base of the ancient sacred hall against petrochemical infrastructure is one of those historical ironies that description cannot improve.

In 2023, Eleusis was designated a European Capital of Culture — part of an EU funding initiative that supported archaeological, artistic, and cultural programming at the site. The initiative brought international attention and investment. Several documentary and investigative projects connected to the Road to Eleusis hypothesis were active at the site during the 2023 programming year.

A major excavation program begun in 2015 by the Hellenic Ministry of Culture has continued through 2025. As of June 2026, no ergot residue has been confirmed at the Eleusis Telesterion site itself — the most decisive possible physical confirmation of the Wasson-Hofmann-Ruck hypothesis remains outstanding. Chemical residue analysis of excavated vessel fragments is under active discussion among researchers, according to the 2026 Scientific Reports paper.

The site is open to visitors. The Telesterion's stone benches are visible among the ruins. The Sacred Way to Athens — down which initiates walked in September for two thousand years — is archaeologically documented if not continuously passable. The ergot is long gone from the grain. What it did remains the question.

Sources

• Hellenic Ministry of Culture, Eleusis Archaeological Site
• Eleusis 2023, European Capital of Culture documentation
• Muraresku, The Immortality Key (2020)

“The initiates were forbidden to say what happened. But they kept saying how it felt. Fear. Trembling. A vision. Death understood. Everything changed. Two thousand years of consistent testimony.”

The initiates of the Eleusinian Mysteries were bound by the most serious oath in the ancient world: to say nothing of what they had experienced in the Telesterion. The penalty for violation was death. The secrecy held for nearly two thousand years.

And yet they kept saying things. Not what they had seen — but what seeing it had done to them.

Pindar: 'Blessed is he who has seen these rites before he goes beneath the hollow earth; for he understands the end of mortal life, and the beginning of a new life given of God.'

Sophocles: 'Thrice blessed are those mortals who have seen these rites and thus enter into Hades; for them alone there is life, while all others have misery.'

Cicero: 'Among the many exceptional and divine things your Athens has produced, nothing is better than those mysteries.'

Aristophanes: In The Frogs, a chorus of blessed initiates describes their posthumous state with imagery drawn from the festival itself — torchlight, meadows, dancing.

The consistency of the testimony across five centuries of Greek and Roman literature is the literary evidence that the Road to Eleusis examines. What it shows is not what happened — the oath prevented that — but what the initiates consistently said happened to them: a direct encounter with the reality of death and what lay beyond it, experienced not as information but as transformation.

This is the phenomenological category that the pharmacological hypothesis is designed to explain. 'Understanding the end of mortal life' is not an intellectual conclusion — it is an experiential one. Something was experienced, not merely thought. The consistency of the description across unrelated authors, centuries apart, in different literary forms, is the most compelling evidence in the Road to Eleusis argument — not the ergot chemistry, not the archaeology, but two thousand years of people saying, in different words, that something happened that changed how they understood dying.

Sources

• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Foley, The Homeric Hymn to Demeter (1994)
• Mylonas, Eleusis and the Eleusinian Mysteries (1961)

“Brian Muraresku spent a decade extending the Road to Eleusis hypothesis into early Christianity, bioarchaeology, and ancient wine production. His 2020 book is both the most ambitious and the most controversial extension of the argument.”

The Road to Eleusis (1978) proposed that the Eleusinian Mysteries involved a psychedelic sacrament derived from ergot-contaminated grain. It was a careful, bounded argument: three specific authors, a specific hypothesis, a specific site.

In 2020, attorney and religious scholar Brian Muraresku published The Immortality Key, which extended the hypothesis across forty years of subsequent scholarship and several new directions the original authors had not explored.

Muraresku's most significant contribution was connecting the Eleusinian hypothesis to early Christianity through the lens of a specific recent finding: the 2019-2020 archaeological work at Mas Castellar de Pontós in Catalonia, an ancient settlement associated with the Demeter cult. Bioarchaeologist Jordi Juan-Tresserras had found, in dental calculus from a woman buried at the site in the third to second century BCE, what appeared to be ergot alkaloids — direct physical evidence of ergot consumption at an Eleusinian-affiliated site.

From this, Muraresku argued that the psychedelic sacrament of the Mysteries survived the formal suppression of 392 CE through underground transmission — through early Christian communities in Greece and Spain that maintained the practice of a spiked wine within Eucharistic ritual. He supported this with analysis of ancient wine vessels from Christian sites in the Mediterranean basin showing traces of psychoactive plant additives.

The evidence is suggestive rather than definitive. The ergot in dental calculus is persuasive; the early Christian psychedelic Eucharist hypothesis is more speculative. Muraresku presents it carefully, acknowledging what is evidenced and what is inferred.

What The Immortality Key demonstrates most clearly is that the Road to Eleusis has remained productive as a research framework for forty years — generating new archaeological questions, new analyses, and new connections. Whether the hypothesis is ultimately confirmed, its heuristic value has already been demonstrated.

Sources

• Muraresku, The Immortality Key (2020)
• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Mas Castellar de Pontós archaeological reports (2019-2020)

“In 1973, Jack Herer's friend Captain Ed Adair told him to start keeping notes. Twelve years later, those notes became The Emperor Wears No Clothes. It has sold over 800,000 copies without ever appearing on a bestseller list.”

Jack Herer was born in New York City on June 18, 1939, served in the Army in Korea, and by the early 1970s was working on the California Marijuana Initiative when his friend — a man he called 'Captain' Ed Adair — gave him an assignment: start keeping notes about everything he learned about hemp and cannabis.

Herer was not an academic. He was not a scientist or a librarian. He was, by most accounts, a passionate autodidact with enormous energy and limited formal methodology, which is both the strength and the limitation of the book he eventually produced.

For twelve years, beginning in 1973, he visited government archives, requested documents through the precursors to FOIA, clipped newspapers, read trade publications, and assembled a file of primary documents that constituted the most comprehensive lay research project in the history of cannabis advocacy. The USDA's own records. Congressional testimony. Popular Mechanics. The DEA's seizure statistics. The USPTO patent filings.

The first edition appeared in 1985, self-published. It sold through cannabis-adjacent bookstores, head shops, and mail order. By the time the twelfth edition was published in November 2010 — shortly after Herer's death — the book had sold over 800,000 copies. It had never appeared on a mainstream bestseller list. It had never been reviewed by the New York Times. It didn't need to be. The audience that needed it found it.

Herer's genius was not analytical — it was archival and rhetorical. He assembled government documents that contradicted the government's stated position and made the contradiction vivid. The USDA's 1942 'Hemp for Victory' film. The Popular Mechanics 1938 'billion dollar crop' article. The Congressional testimony from 1937 in which no medical expert testified and the legislation passed in two hours. He did not need to construct an argument from these documents. The documents made the argument themselves.

He dubbed himself the 'Emperor of Hemp' and traveled the country staffing information booths and giving speeches. The persona was deliberate: if the emperor wore no clothes, the person saying so needed to be willing to be loud about it.

Sources

• Wikipedia, The Emperor Wears No Clothes
• Jetty Extracts, Jack Herer Legacy (2026)
• Herer, The Emperor Wears No Clothes (1985)

“In 1942, the USDA produced a film urging American farmers to grow hemp for the war effort. By the 1980s, the government denied the film had ever existed. Two activists found copies in the Library of Congress.”

In 1942, with the Japanese occupation of the Philippines having cut off the United States' primary supply of Manila hemp — a critical material for military rope, rigging, and parachute webbing — the USDA produced a thirteen-minute documentary film titled Hemp for Victory. It urged American farmers to grow cannabis hemp as a patriotic duty. It explained cultivation methods, harvesting techniques, and fiber processing. It showed footage of hemp fields and processing facilities. It distributed 400,000 pounds of cannabis seed to farmers across the Midwest.

By the 1980s, when Jack Herer began citing the film in Emperor, the government denied it had ever been made. USDA archivists told researchers there was no such film. Library of Congress records did not list it. The official position was that Hemp for Victory did not exist.

Two cannabis activists — Maria Farrow and Carl Packard — spent considerable time searching the Library of Congress holdings. They found copies of the film, registered to the USDA, in 1989. Herer announced the discovery at a press conference. The Library of Congress was subsequently pressured to acknowledge the film's existence and enter it into its publicly accessible catalog.

The film is now publicly available. It runs thirteen minutes. It shows American government officials enthusiastically promoting the cultivation of the same plant that was classified as a Schedule I narcotic with no legitimate use five years after the film was made.

This is the temporal paradox at the center of Herer's argument: not that hemp was always suppressed but that it was suppressed selectively — prohibited in 1937, promoted in 1942 for the war effort, prohibited again in 1946 when the war ended. The scheduling decision, when placed alongside this history, becomes harder to justify as a pharmacological judgment. Whatever drove the 1937 legislation, it was not the same motivation as the 1942 urgency, and the 1946 return to prohibition followed neither pharmacological nor agricultural logic.

Sources

• Herer, The Emperor Wears No Clothes (1985)
• Wikipedia, Hemp for Victory
• USDA Film Archives

“In February 1938, Popular Mechanics called hemp 'the new billion-dollar crop.' The Marihuana Tax Act had been signed into law six months earlier, in October 1937. The article never mentioned the connection.”

The February 1938 issue of Popular Mechanics contained an article titled 'New Billion-Dollar Crop' describing the commercial potential of mechanized hemp processing. The decorticator — a machine that could strip hemp fiber at industrial scale — had recently become commercially available. The article described hemp's potential to produce paper, fiber, and industrial products more cheaply and efficiently than wood pulp and synthetic alternatives.

The Marihuana Tax Act had been signed into law by President Roosevelt on October 1, 1937 — four months before the article appeared.

Herer uses this timing as the most concrete evidence for his conspiracy argument: the industrial potential of hemp was being recognized in mainstream publications at the exact moment that the legislation eliminating that potential was becoming law. The decorticator that Popular Mechanics was celebrating would have made hemp economically competitive with DuPont's newly patented nylon and with the timber industry's wood pulp paper. The Tax Act, which drove hemp off the market, protected both industries from that competition.

Whether this constitutes conspiracy or coincidence is the interpretive question the book leaves open — or rather, the question Herer answers as conspiracy while the documentary record supports only correlation. What the record does show is that the industrial potential was real, that the mechanization was new, that the legislation was enacted with minimal deliberation, and that the beneficiaries of hemp's elimination were the industries that DuPont, Hearst, and their financial backers represented.

The Popular Mechanics article is available in the magazine's archives. It is one of Herer's strongest exhibits because it is neither fabricated nor politically motivated — it is a mainstream trade publication's assessment of hemp's commercial potential, published in the shadow of legislation that made that potential unrealizable.

Sources

• Popular Mechanics, New Billion-Dollar Crop (February 1938)
• Herer, The Emperor Wears No Clothes (1985)
• Wikipedia, Marihuana Tax Act of 1937

“In 1994, Sensi Seeds in the Netherlands named a cannabis cultivar after Jack Herer. It won multiple Cannabis Cup awards. It is now one of the most widely cultivated named strains in the legal cannabis industry.”

In 1994, the Sensi Seeds seed bank in Amsterdam introduced a new cannabis cultivar and named it Jack Herer. The strain was bred to emphasize the sativa-dominant characteristics associated with cerebral, energetic effects — a deliberate contrast to the indica-dominant strains that had dominated the Dutch market through the 1980s.

The Jack Herer strain won nine Cannabis Cup awards at the High Times Cannabis Cup in Amsterdam and became one of the most decorated and widely distributed named cultivars in cannabis breeding history. It served as a genetic foundation for subsequent strains that now appear in dispensaries across the legal US market.

For Herer, the strain was both an honor and a source of amusement. He was a cannabis advocate but not primarily a consumer — his activism was focused on hemp's industrial and medicinal applications, not on the recreational use that the strain represented. He accepted the recognition with characteristic enthusiasm and made the strain a fixture of his public persona.

The Jack Herer strain is now available in most states with legal cannabis markets. Dispensary menus in California, Colorado, Oregon, and elsewhere list it alongside detailed terpene and cannabinoid profiles — a form of product specification that would have seemed fantastical when Herer was running information booths in the 1980s, trying to explain to skeptical audiences that the government had manufactured the case against a plant with genuine medical and industrial applications.

The strain's existence is a small piece of evidence for the vindication he lived to see beginning: a legal industry, generating tax revenue and providing employment, built around the plant whose prohibition he spent his life documenting as an injustice.

Sources

• Jetty Extracts, Jack Herer Legacy (2026)
• Sensi Seeds, Jack Herer strain history
• Wikipedia, Jack Herer (cannabis)

“Chapter 6 of The Emperor Wears No Clothes compiled the medical literature on cannabis from peer-reviewed journals. In 1985, this was radical. By 2025, the FDA had approved multiple cannabinoid-based pharmaceuticals.”

When Jack Herer published The Emperor Wears No Clothes in 1985, cannabis was classified as Schedule I — no accepted medical use, high potential for abuse, cannot be prescribed. The classification was maintained by the Drug Enforcement Administration despite accumulating peer-reviewed evidence for cannabis's therapeutic applications.

Chapter 6 of the book, titled 'Medical Literature on Cannabis Medicine,' compiled this evidence. It drew on published research going back to the nineteenth century — pharmaceutical companies had been producing cannabis-based medications until 1937 — and on contemporaneous research that was accumulating despite the prohibition on clinical trials.

Herer's compilation of medical evidence was not systematic by academic standards. He did not distinguish between different qualities of evidence, between case reports and controlled trials, between animal and human studies. But the underlying point — that a substantial peer-reviewed literature supported cannabis's medical applications, and that the Schedule I classification contradicted that literature — was accurate.

By 2025, the FDA had approved Epidiolex (CBD for epilepsy), Syndros and Marinol (synthetic THC for chemotherapy-induced nausea and AIDS-related weight loss), and Cesamet (nabilone for chemotherapy nausea). The endocannabinoid system — the receptor network through which cannabis compounds act — had been identified in the 1990s and was now a target of active pharmaceutical research. The medical argument Herer made from compiled literature in 1985 had been substantially validated by a pharmaceutical industry that was now racing to develop proprietary cannabinoid compounds.

The irony was not lost on cannabis advocates: the same Schedule I status that prevented legitimate cannabis medical research was now being used to create patent-protected pharmaceutical alternatives. What was illegal as a plant could be profitable as a pill.

Sources

• Herer, The Emperor Wears No Clothes (1985)
• FDA, Approved Cannabis-Derived Pharmaceuticals (2024)
• Russo, Cannabis and Cannabinoids (2013)

“Herer died in April 2010. He had lived to see medical cannabis legalized in thirteen states, the USDA's 'Hemp for Victory' film officially acknowledged, and the Jack Herer strain win nine Cannabis Cups.”

Jack Herer suffered a massive stroke at a cannabis rally in Portland, Oregon in September 2009. He died on April 15, 2010, in Eugene. He was 70 years old.

In the last years of his life, he had seen the beginning of what he had spent three decades working toward. The 1996 California Compassionate Use Act — Proposition 215 — was the first state medical cannabis law, and Herer had campaigned for it. By the time of his stroke, thirteen states had medical cannabis programs. The 2009 Ogden Memo from the Obama Justice Department had directed federal prosecutors not to prioritize cases against state-legal medical cannabis operations.

He did not live to see: the 2012 Colorado and Washington recreational legalization votes, the first in US history; the 2018 Farm Bill legalizing industrial hemp; the 24 states with legal recreational cannabis as of 2025; the proposed federal rescheduling from Schedule I to Schedule III announced by the DOJ in May 2024; the thriving legal hemp industry producing hempcrete, hemp textiles, and CBD products.

The changes he saw beginning were substantial. The changes that came after his death would have seemed, in 1985, almost impossibly optimistic.

What his book contributed to this trajectory is difficult to quantify but easy to characterize: it was the foundational document of the modern cannabis legalization movement. It gave activists a primary-source argument — rooted in government documents — that could withstand the 'just say no' framework because it was not about personal freedom or drug enjoyment but about historical fact, industrial potential, and documented injustice. It changed the terms of the argument.

Herer's name appears on dispensary menus across North America. It appears on hemp farms, on CBD products, on activist websites. The emperor's clothes have been removed. The process he started is still unfinished.

Sources

• Wikipedia, Jack Herer
• NORML, Cannabis Legalization Tracker (2025)
• Jetty Extracts, Jack Herer Legacy (2026)

“Herer's most expansive historical claim: that the War of 1812 was primarily fought over access to Russian hemp, and that Napoleon's invasion of Russia had the same commercial motivation. The argument is colorful and not completely wrong.”

Chapter 11 of The Emperor Wears No Clothes is titled 'The Hemp War of 1812 and Napoleon Invades Russia.' It is one of Herer's most sweeping historical claims: that the War of 1812, fought by the United States against Britain, was primarily motivated by American need for access to Russian cannabis hemp — the primary material for naval rope, rigging, and sail canvas — which Britain's naval blockade had cut off.

The historical evidence for hemp's economic importance in this period is real. The Royal Navy's demand for hemp was enormous — a single warship required dozens of tons of hemp rope — and hemp's primary source was Russia. British control of the seas threatened American access to this supply. The Congress of 1812 debated commercial grievances alongside the impressment of American sailors that was the stated cause.

Whether hemp was the primary cause of the war, as Herer claims, is a different question. Military historians have generally concluded that the war had multiple causes — trade rights, impressment, British support for Native American resistance to American expansion, Canadian territorial ambitions — and that reducing it to any single commercial motive overstates the case.

But Herer's broader point — that hemp was so commercially essential in the pre-industrial era that wars were fought over its supply — is documented in the naval and commercial records. The British Navy's dependence on Russian hemp, the Russian hemp trade's importance in European diplomacy, and the American colonies' early hemp cultivation as both commercial and strategic activity are all historical facts.

The War of 1812 chapter is Herer doing what he does throughout the book: assembling real historical evidence for a conclusion that the evidence supports but doesn't exclusively determine. Hemp mattered enormously to the early industrial world. The leap from 'mattered' to 'was the cause' is where his argument exceeds what the documents can bear.

Sources

• Herer, The Emperor Wears No Clothes (1985)
• Wikipedia, War of 1812
• Herer, Hemp for Victory chapter

“Kesey had written two acclaimed novels by thirty. Then he stopped writing novels and started organizing events at which thousands of people took LSD. Stevens documents this as a tragedy of a particular American kind.”

Ken Kesey published One Flew Over the Cuckoo's Nest in 1962 and Sometimes a Great Notion in 1964. Both were praised; the first became a cultural touchstone. He was thirty years old and had produced, by most measures, a body of work that justified a literary career of sustained attention to craft.

Instead, he organized the Acid Tests.

Kesey had encountered LSD in 1960 as a paid volunteer in a government-sponsored drug study at the Veterans Administration hospital in Menlo Park — the same program, funded ultimately by MK-Ultra money, that was supposed to be testing substances for potential military use. What Kesey experienced was, in his account, the most important perceptual event of his life. He obtained LSD through the same channels and began distributing it to the people around him, initially the circle that became the Merry Pranksters.

The Acid Tests were multimedia events at which LSD was freely available and the goal was collective dissolution of ordinary consciousness boundaries. The largest, the Trips Festival of January 1966 in San Francisco, drew ten thousand people. Tom Wolfe documented the Pranksters in The Electric Kool-Aid Acid Test. Jay Stevens, in Storming Heaven, documents them with less romance: as the moment when the clinical tradition that Osmond and Huxley had built over thirteen years was overwhelmed by the spectacle.

Stevens's assessment is not that Kesey was wrong about LSD's significance. It is that the Acid Tests were structurally incompatible with what LSD actually required: preparation, intention, experienced guidance, a supportive setting, a framework for integrating what happened. A sound stage with strobe lights and two thousand strangers was precisely the worst possible version of all these things.

Kesey continued writing, eventually. He moved to a farm in Oregon. He lived to 2001. He never explained, to Stevens's or anyone's complete satisfaction, why he stopped writing novels after two excellent ones and spent a decade on parties that helped destroy the clinical program that might have justified everything.

Sources

• Stevens, Storming Heaven (1987)
• Perry, Tom. On the Bus: The Complete Guide to the Legendary Trip of Ken Kesey (1990)
• Wolfe, Tom. The Electric Kool-Aid Acid Test (1968)

“Grof conducted over 4,000 LSD sessions before prohibition ended his clinical work. He spent the rest of his life developing breathwork as a non-pharmacological method for the same territory.”

Stanislav Grof arrived in Baltimore from Czechoslovakia in 1967 as a research fellow at the Maryland Psychiatric Research Center — one of the last active centers of LSD psychotherapy in the United States. By the time the 1970 Controlled Substances Act fully closed the door on clinical LSD work, he had conducted or supervised over four thousand sessions.

From this unprecedented clinical database, Grof developed a systematic cartography of what he called the 'holotropic' state — consciousness oriented toward wholeness. He identified recurring features: the recapitulation of birth trauma, the encounter with death, the entry into transpersonal realms that seemed to extend beyond individual biography. He proposed a model of the psyche that included both the biographical (what conventional therapy addressed) and the perinatal and transpersonal (what LSD consistently revealed).

Jay Stevens devotes substantial attention to Grof in Storming Heaven because Grof represents what was being lost to prohibition: not recreational enthusiasm but clinical science. His cartography was based on systematic observation across thousands of sessions with patients diagnosed with neurosis, depression, and terminal illness. The reliability of his observations — the perinatal stages, the transpersonal phenomena — derived from their consistency across unrelated subjects in controlled settings.

After prohibition ended his clinical work, Grof developed Holotropic Breathwork as a method for reaching comparable states through hyperventilation and music rather than pharmacology. The technique has been practiced by tens of thousands of people globally and represents Grof's attempt to make the territory he had mapped accessible without the legal restrictions on its most efficient vehicle.

In the current psychedelic renaissance, Grof's cartography — developed from LSD sessions in the 1960s — has been adopted as a theoretical framework by a new generation of clinical researchers who cite it alongside current neuroscience. What Stevens mourned as lost in 1987 has, in this lineage, survived the interruption.

Sources

• Stevens, Storming Heaven (1987)
• Grof, LSD: Doorway to the Numinous (2009)
• Wikipedia, Stanislav Grof

“Psychiatrist Oscar Janiger gave LSD to over 900 subjects in the 1950s and 1960s, including painters, writers, and actors. His aesthetic research showed that artists produced work they considered superior during sessions.”

While Osmond and Hoffer were treating alcoholics in Saskatchewan and the CIA was dosing unwitting subjects in San Francisco safe houses, the psychiatrist Oscar Janiger was running a very different program in Los Angeles: he was giving LSD to artists.

Janiger conducted what amounted to an informal aesthetic research project from 1954 to 1962, administering LSD to over 900 subjects — an unusually large number for any single clinical researcher — with a specific interest in what happened to creative work during and after sessions. His subjects included painters, writers, musicians, and actors. He collected artwork produced during sessions alongside conventional psychological assessments.

The results were consistent enough to be interesting: subjects who considered themselves artists generally rated their session-period work as superior to their ordinary production, and independent judges rated it as more original in formal terms (compositional risk, color use, departure from habitual approach). The effect was not uniform — some subjects found the experience blocked or disrupted their work — but the majority reported that the session had altered their relationship to their craft in ways they valued.

Janiger's subjects included Cary Grant — the most famous person to publicly discuss his LSD sessions in the 1950s — as well as the painters who have since been identified as part of what scholars call the Los Angeles LSD aesthetic movement of the late 1950s and early 1960s.

Stevens documents Janiger as part of the clinical ecosystem that prohibition destroyed: not a headline figure like Leary or a theorist like Huxley, but a working psychiatrist conducting systematic observation and accumulating a dataset that would have been invaluable to subsequent research. His archives were donated to the Library of Congress. His findings, published in 2003, arrived too late to matter to the clinical program that might have been built on them.

Sources

• Stevens, Storming Heaven (1987)
• Wikipedia, Oscar Janiger
• Janiger, O. & Dobkin de Rios, M. LSD, Spirituality, and the Creative Process (2003)

“On October 6, 1968, the Staggers-Dodd Act made LSD possession a federal crime. Stevens ends his book here. The research program that had produced over a thousand scientific papers stopped.”

Jay Stevens ends Storming Heaven with the legislative death of American psychedelic research. The Staggers-Dodd bill, signed into law on October 6, 1968, made possession of LSD a federal misdemeanor for the first time. The Controlled Substances Act of 1970 completed the classification: Schedule I, alongside heroin, no accepted medical use.

The research program that the scheduling ended had, by 1968, produced over one thousand published scientific papers. Thousands of patients had received LSD-assisted therapy for alcoholism, depression, end-of-life anxiety, and other conditions. International conferences had been held. Journals had published systematic outcome data. The clinical evidence was not the reason for the scheduling — the reason was political, and Stevens documents its components precisely: the counterculture's appropriation of LSD as a symbol, the racial politics of the Nixon administration, the institutional desire to control what could not be controlled.

The irony Stevens leaves with the reader is that the counterculture and the government that suppressed it were, in a sense, collaborating: the counterculture's insistence on using LSD as a political symbol made it impossible for the clinical tradition to maintain its separation from the spectacle. Leary told a generation to drop out; the government told a generation they'd go to jail for it; and the psychiatrists who had spent fifteen years building a careful clinical program watched both forces converge on the thing they'd built.

Stevens wrote in 1987. He did not know that fifty-five years after October 6, 1968, Johns Hopkins University would be running Phase 3 clinical trials of psilocybin for major depressive disorder, that MDMA-assisted therapy would have completed Phase 3 for PTSD, or that Oregon would have a licensed psilocybin services program. The story he ended at 1968 turned out to have a second chapter. He documented the interruption. The resumption was still being written.

Sources

• Stevens, Storming Heaven (1987)
• Controlled Substances Act legislative history (1970)
• Davis et al., JAMA Psychiatry (2021)

“When Osmond and Huxley presented mescaline research to the American Psychiatric Association in Atlantic City in 1955, the reception was cold. The men with the electric shock machines were not interested.”

In 1955, Humphry Osmond was invited to present his research on mescaline and LSD at an American Psychiatric Association roundtable in Atlantic City. He and Aldous Huxley had collaborated on the presentation. They were optimistic. They believed the APA would see, as they had seen, that these substances offered a genuine window into altered states of consciousness with profound clinical implications for the treatment of schizophrenia and alcoholism.

The reception was what Huxley, in a letter to Osmond written immediately after, described with his characteristic precision. He enumerated the 'electric shock boys, the Chlorpromaziners, and the 57 Varieties of Psychotherapists — all equally certain that their methods were the best.' The roundtable audience was not hostile so much as disinterested. The prevailing framework of mid-1950s psychiatry had no conceptual slot for what Osmond was describing.

Jay Stevens uses this episode in Storming Heaven to locate the clinical program in its institutional context: a period when psychiatry was reorganizing around pharmacological management (chlorpromazine had been approved in 1954) and behavioral modification. The question of what the patient was experiencing — which was central to Osmond's approach — was becoming less relevant to a field that was increasingly focused on symptom suppression rather than experiential transformation.

Osmond continued his clinical work at Weyburn regardless. The Saskatchewan provincial government was more receptive than the national psychiatric establishment, and the distance from New York allowed him to build without needing the APA's blessing. The work he did at Weyburn between 1952 and 1961 — over a thousand alcoholic patients, roughly half achieving lasting sobriety — was the most significant body of clinical psychedelic research of the era. It was conducted largely in isolation from the mainstream institutions that would have given it wider impact.

Sources

• Stevens, Storming Heaven (1987)
• Huxley letter to Osmond, in Moksha (1977)
• Wikipedia, Humphry Osmond

“Alan Watts was perhaps the most philosophically sophisticated observer of the psychedelic experience in the 1950s and 1960s. He also drank himself to death. Stevens is careful about what this means.”

Alan Watts appears in Storming Heaven as a counterpoint and a caution. He was the most intellectually rigorous popularizer of the psychedelic experience in the early era — his 1962 book The Joyous Cosmology provided the philosophical framework that made psychedelic experience legible in terms of Eastern philosophy, process philosophy, and phenomenology. He understood, better than almost anyone, what the experiences were pointing toward.

He also drank heavily, struggled with his personal relationships throughout his life, and died in 1973 at 58 of heart failure — an outcome his biographers have associated with his alcoholism.

Stevens includes Watts because the juxtaposition is honest and important: intellectual understanding of what the psychedelic experience reveals is not the same as living that understanding. Watts articulated, with great precision, the insight that the self is not a separate entity but a pattern in a process — that the ego's isolation is a kind of cognitive error that the psychedelic experience corrects. He articulated it in books, in lectures, on the radio. In his personal life, the insight was evidently harder to maintain.

This is the integration problem that runs through the clinical literature of the era and through the current psychedelic renaissance: the experience can reveal something. What it reveals is not automatically incorporated into how a person lives. The work of integration — of taking the insight from the session into ordinary life and habit — is a separate project from having the insight.

Watts knew this. He wrote about it. He did not, by the available evidence, fully solve it. His presence in Storming Heaven is a reminder that the philosophical understanding of the psychedelic experience and the practical incorporation of that understanding are different achievements, requiring different kinds of work.

Sources

• Stevens, Storming Heaven (1987)
• Watts, Alan. The Joyous Cosmology (1962)
• Wikipedia, Alan Watts

“Ten years after publishing The Cosmic Serpent, Narby brought three molecular biologists to the Peruvian Amazon for ayahuasca sessions under shamanic guidance. The resulting documentary captures what happened when skeptical scientists encountered what the book described.”

The Cosmic Serpent was published in 1998 and was criticized, most systematically, for failing to test its central hypothesis. Jacques Dubochet — who would later receive the Nobel Prize in Chemistry — wrote that Narby had not designed any experimental protocol for determining whether shamans actually access molecular-level information through ayahuasca.

Narby's response was, in effect, to run an experiment. Not a controlled clinical trial — that was not available to him — but an observational expedition with trained scientists as participants.

In 2000, Narby organized a journey to the Peruvian Amazon that included three molecular biologists — researchers working in fields directly relevant to the DNA hypothesis. They participated in ayahuasca sessions under the guidance of Shipibo-Conibo shamans, then discussed what they had experienced in relation to their scientific knowledge.

The resulting documentary, Night of the Liana, directed by Jan Kounen, was released in 2011. It shows scientists experiencing visionary states that included imagery they described as consistent with molecular and cellular structures — though they were careful about what claims they would make about what this meant.

Narby published a follow-up book, Intelligence in Nature (2005), which extended the DNA communication hypothesis into a broader argument: that intelligence — the capacity to solve problems, to communicate, to adapt — is not uniquely human but is distributed across the natural world at multiple scales. The argument drew on research into plant signaling, fungal networks, and bacterial communication.

The Night of the Liana expedition didn't prove The Cosmic Serpent's hypothesis. But it demonstrated the seriousness with which credentialed scientists could engage with it, and produced a documentary record of what the encounter between shamanic ayahuasca tradition and Western molecular biology actually looked like when it happened.

Sources

• Wikipedia, Jeremy Narby
• Night of the Liana documentary (2011)
• Narby, Intelligence in Nature (2005)

“Narby's 2005 follow-up extended the Cosmic Serpent hypothesis into plant intelligence, fungal networks, and bacterial communication. By 2025, the science of plant sentience had moved from fringe to mainstream research program.”

Intelligence in Nature (2005) was Jeremy Narby's follow-up to The Cosmic Serpent — less autobiographical, more scientific, and focused on a specific question that the DNA hypothesis had generated: if plants communicate information through chemical and electrical signals, what is the nature of that communication, and can it be called intelligent?

Narby interviewed biologists working on plant signaling, mycelial networks, and bacterial quorum sensing. He was attempting to document what professional scientists were finding at the research frontier of plant and microbial intelligence — to show that the question The Cosmic Serpent had raised (whether plants can 'communicate' with humans through ayahuasca) was related to questions that mainstream science was actively pursuing through conventional methods.

In 2005, this was still fairly marginal territory. By 2025, it had become a significant research field. Suzanne Simard's work on mycorrhizal networks — published in Nature in 1997 and popularized in Finding the Mother Tree (2021) — showed that trees communicate, share resources, and respond to each other's distress through underground fungal networks in ways that parallel nervous system function. Monica Gagliano's research on plant learning and memory published in mainstream peer-reviewed journals showed plant species modifying their behavior in response to experience.

The field that Narby surveyed in 2005 as an emerging and contested area of research had by 2025 produced textbooks, university programs, and a heated philosophical debate about what 'intelligence' and 'communication' mean when applied to organisms without neurons.

The Cosmic Serpent's central question — whether the plants have something to communicate and whether humans can receive it — has not been definitively answered. But the subsidiary question — whether plants have information to communicate at all — has been answered affirmatively by mainstream science.

Sources

• Narby, Intelligence in Nature (2005)
• Wikipedia, Jeremy Narby
• Simard, Finding the Mother Tree (2021)

“For thirty-five years, Narby worked as Amazonian projects director for the Swiss NGO Nouvelle Planète — backing indigenous land rights, education, health, and botanical preservation projects in Peru and Brazil.”

Jeremy Narby is sometimes discussed primarily as the author of The Cosmic Serpent — the DNA hypothesis, the ayahuasca visions, the anthropologist who went native in the theoretical sense. The practical work that grounded the book and occupied most of his professional life is less well known.

From 1989 to 2024 — thirty-five years — Narby served as Amazonian projects director for Nouvelle Planète, a Swiss NGO. The work was not theoretical. It involved land rights negotiations for indigenous communities whose territories were threatened by oil, timber, and agricultural development. It involved primary education projects. It involved village health programs. It involved fish farms, tree nurseries, and botanical documentation.

This practical work is the foundation that makes The Cosmic Serpent's arguments credible rather than merely interesting. Narby was not a theorist visiting the Amazon — he was a working development professional with sustained relationships in specific communities, who happened to encounter something in those communities that his training had not prepared him for.

The combination — rigorous field presence, institutional accountability, and a willingness to report what he actually observed rather than what his framework could accommodate — distinguishes his work from the more credulous ayahuasca literature that has proliferated since 1998.

His departure from Nouvelle Planète in 2024, after thirty-five years, marked the end of what is probably the most sustained engagement between a Western anthropologist and specific Amazonian communities in the context of plant medicine knowledge. The network he built and the documentation he created represent a resource that the communities themselves, as much as Western researchers, will determine how to use.

Sources

• Wikipedia, Jeremy Narby
• Nouvelle Planète organization records
• Narby, The Cosmic Serpent (1998)

“In 1986, a US patent was granted for the ayahuasca vine — a plant sacred to Amazonian peoples who had cultivated knowledge of it for millennia. It was eventually cancelled. The patent race since then has only accelerated.”

One of The Cosmic Serpent's sharpest political arguments concerns the ethics of how Western science engages with indigenous botanical knowledge. Narby frames it as a rule embedded in shamanic tradition: the sacred is not for sale. The accumulation of personal power from spiritual knowledge is, in indigenous frameworks, the definition of black magic.

Western pharmaceutical and biotechnology industries operate by different rules. The drug discovery pipeline depends on identifying active compounds, isolating them, synthesizing modifications, and patenting the resulting intellectual property. Indigenous knowledge has served as a map for this process: which plants to study, which combinations to investigate, which compounds to isolate. The knowledge guides the research; the patent captures the value.

In 1986, US Patent 5,751,559 was granted to Loren Miller for a variety of the ayahuasca vine (Banisteriopsis caapi) he claimed to have discovered. The grant outraged indigenous organizations across the Amazon, who submitted a legal challenge arguing that the vine had been known and cultivated by their communities for millennia and could not constitute a novel invention. After a decade of legal proceedings, the patent was cancelled in 2003 on the grounds that prior art existed — the plant's use was documented in scientific literature before Miller's application.

The ayahuasca patent case is the clearest example of what critics call biopiracy: the appropriation of indigenous knowledge and genetic resources for commercial benefit without consent, benefit-sharing, or acknowledgment. The Nagoya Protocol on Access and Benefit-Sharing, which entered into force in 2014, created a legal framework for addressing this. As of 2024, 138 countries have ratified it. Enforcement remains weak.

The psychedelic patent race accelerated after 2020, with pharmaceutical companies filing patents on therapeutic protocols, dosing regimens, and molecular derivatives of classical psychedelics. The defensive patent movement, initiated by researchers at Johns Hopkins and others, attempts to prevent any single entity from monopolizing psychedelic therapy.

Sources

• Narby, The Cosmic Serpent (1998)
• WIPO, Intergovernmental Committee on GR (2024)
• Tupper, J. Psychoactive Drugs (2009)

“The Cosmic Serpent's critics were not wrong that Narby confuses his enthusiasm for evidence. The book's value survives this criticism — but the criticism should be held alongside the value.”

The Cosmic Serpent attracted serious critical attention from scientists who engaged with its argument rather than dismissing it. The most pointed came from biophysicist Jacques Dubochet, who would receive the Nobel Prize in Chemistry in 2017, and from the reviewer at Publishers Weekly.

Dubochet's criticism was methodological: Narby had proposed a hypothesis — that shamans access molecular-level information through ayahuasca visions — but had not designed any test for it. The hypothesis is falsifiable in principle, but Narby had not attempted to falsify it.

Publishers Weekly's criticism was epistemological: Narby 'confuses his own enthusiasm for evidence' and takes 'similarities of form' — any helical pattern, any double structure, any serpentine shape — as 'proof of identity or causal connection.' A Goodreads reviewer who identified as a geneticist made a similar point: the hypothesis is scientifically framed but poorly executed as science. The visual similarity between the DNA double helix and shamanic serpent imagery is suggestive but not probative.

These criticisms are fair. Narby does make analogical leaps that the evidence doesn't fully support. He does take resemblance as more significant than resemblance alone can bear. His defense — that 'the presuppositions of science are too narrow to permit the test' — is the kind of argument that, if unchecked, can immunize any hypothesis from falsification.

The appropriate response to these criticisms is not to dismiss the book but to read it with them in mind. The combinatorial problem — how did indigenous peoples discover the ayahuasca combination? — is real and unresolved by any alternative explanation. The pragmatic reliability of indigenous pharmacological knowledge is documented and impressive. The question Narby poses is genuine. The answer he proposes is speculative. Both things are true, and both matter.

Sources

• Publishers Weekly review, The Cosmic Serpent (1998)
• Wikipedia, Jeremy Narby
• Goodreads review by geneticist, The Cosmic Serpent

“Dennis McKenna became one of the most rigorous neuropharmacologists working on tryptamines. His assessment of what happened at La Chorrera — calibrated, affectionate, skeptical — is the other side of True Hallucinations.”

Dennis McKenna's memoir, The Brotherhood of the Screaming Abyss (2012), provides the other account of La Chorrera — written by the person who, by all evidence, went furthest into the altered state and came back most intact.

Dennis recalls the episode with clarity that his brother's True Hallucinations does not always provide. His assessment is careful: something happened at La Chorrera that was extraordinary. The nature of what happened — whether it was a genuine encounter with plant intelligence, a pharmacologically induced psychosis, or something between — he does not definitively resolve. What he has said in interviews is that he does not believe the specific claims Terence made (the Timewave, the alien mushroom intelligence) but that he cannot fully dismiss the experiential reality of what they both went through.

Dennis completed a doctorate in neuropharmacology at the University of British Columbia and spent decades doing rigorous scientific research on tryptamines, ayahuasca pharmacology, and the interaction between psychedelic compounds and human neurobiology. His scientific work is careful and precise. It coexists with his account of La Chorrera in ways he navigates openly: he doesn't let the experience override his scientific judgment, and he doesn't let his scientific training negate the experience.

He has spoken about Terence's brain tumor — the glioblastoma that killed Terence in 2000 — with a speculation that he acknowledges is unverifiable: that the decades of high-dose psychedelic use may have had a relationship to the tumor. He does not state this as fact. He states it as something he wonders about, as a neuropharmacologist who loves his brother.

The relationship between the two brothers is the human center of True Hallucinations — more interesting, finally, than the theories. Dennis's ongoing presence as a scientist, commentator, and advocate for rigorous psychedelic research is the most concrete evidence that La Chorrera produced something real, whatever that something was.

Sources

• D. McKenna, The Brotherhood of the Screaming Abyss (2012)
• D. McKenna, various interviews 2010-2025
• Wikipedia, Dennis McKenna

“The Timewave was a mathematical model of time's qualitative structure. McKenna derived it from the I Ching. The mathematics was criticized by professional mathematicians. The underlying philosophical claim — that time is textured — remains interesting.”

The Timewave Zero theory began as an attempt to make a specific phenomenological observation mathematically rigorous: that some periods of time feel more 'novel' — more full of unexpected connections, more generative of new forms — than others.

McKenna's starting point was the I Ching — the Chinese system of sixty-four hexagrams used for divination since antiquity. He observed that the sequence of hexagrams, when treated as a numerical series, had a structure that could be interpreted as a wave function. He mapped this wave function onto historical time, aligning it so that its predicted 'singularity' — the point of maximum novelty — coincided with December 21, 2012.

Professional mathematicians who examined the theory raised multiple objections. The derivation from the I Ching was arbitrary — McKenna had chosen a particular mapping of hexagrams to numbers that produced the desired wave, but other mappings were equally justifiable and produced different results. The theory was not derived from empirical data about historical events but was fitted to historical data post hoc, which violates basic principles of predictive modeling.

McKenna acknowledged some of these criticisms and adjusted his mapping of the I Ching values at least once in response. He never fully resolved the mathematical objections, and the 2012 endpoint was falsified without drama when nothing of particular significance occurred.

What remains from the Timewave is the philosophical claim McKenna derived from the I Ching insight: that time has qualitative structure, that novelty is not uniformly distributed, that history has what he called 'attractor basins' — periods toward which events seem to converge. This claim, stripped of the specific mathematical apparatus and the 2012 prediction, is a genuine philosophical proposition. Whether it is true is a question that the available evidence neither confirms nor refutes. It is the kind of question that the Timewave was supposed to answer and instead preserved as a question.

Sources

• McKenna & McKenna, The Invisible Landscape (1975)
• Wikipedia, Novelty Theory (McKenna)
• Various mathematical critiques of the Timewave, 1990s

“In a 2020 Johns Hopkins survey (Davis et al., J. Psychopharmacol. 34(9):1008-1020) of 2,561 people who had already had a DMT entity encounter, McKenna's description was corroborated in detail. A 2023 Imperial College EEG-fMRI study (Timmermann et al., PNAS 120(13)) mapped DMT's global brain effects but did not isolate entity contact. The phenomenological report has held up; the neuroscience has not caught up.”

When Terence McKenna first described encountering 'merry elfin, self-transforming, machine creatures' during his DMT experiments in Berkeley in the early 1970s, he had no way of knowing whether the experience was idiosyncratic. He was, as far as he knew, one of very few Westerners who had smoked synthesized DMT.

The subsequent decades revealed that the entity report was not idiosyncratic at all.

Rick Strassman's clinical DMT study at the University of New Mexico (1990-1995) — the first human DMT research in decades — found that a majority of his sixty volunteer subjects reported entity contact. Many described the entities in terms strikingly similar to McKenna's: small, playful, insectoid or elfin, engaged in the production of objects or language.

In a 2020 Johns Hopkins survey (Davis et al., J. Psychopharmacol. 34(9):1008-1020) of 2,561 people who had already had a DMT entity encounter, respondents described the encounter in detail. It documents the phenomenology in detail but sets no prevalence rate, because every respondent was recruited for having had an encounter; the 97% figure often attached to it appears in no published paper. The most common entity types were humanoid beings, gods or supernatural figures, and what respondents described as aliens or interdimensional beings. The emotional tone of the encounters was predominantly positive; most respondents described entities as benevolent and the encounter as meaningful.

A 2023 Imperial College London fMRI study (Timmermann et al., PNAS 120(13)) mapped DMT's global brain effects — large increases in global functional connectivity, network disintegration and desegregation, and compression of the principal cortical gradient. It did not isolate entity contact as a distinct neural signature, and no published imaging study yet has: the phenomenology is well documented, the neural specificity is not.

McKenna's phenomenological report has survived into the era of neuroscience intact as description. What it describes — whether external entities, projections of the unconscious, or something else — the neuroscience has not resolved. What it has confirmed is that the consistency of the report across fifty years and thousands of independent subjects is not random. Something consistent is being encountered. McKenna described it first and most vividly. What it is remains open.

Sources

• Sexton et al., J. Psychopharmacol. 33(9) (2019)
• Timmermann et al., PNAS 120(13) (2023)
• Strassman, DMT: The Spirit Molecule (2001)
• McKenna, True Hallucinations (1993)
• Davis et al., J. Psychopharmacol. 34(9):1008-1020 (2020)

“The McKennas went to La Chorrera specifically to find oo-koo-he, a Witoto plant preparation that produced effects described as similar to orally active DMT. They never found it. They found psilocybin mushrooms instead.”

True Hallucinations does not begin with the mushrooms. It begins with oo-koo-he.

Oo-koo-he was the Witoto name for a plant preparation described in the ethnobotanical literature as producing effects similar to ayahuasca — oral DMT activity through some combination of beta-carboline inhibitors and tryptamine-containing admixture plants. Schultes had documented its use in the Colombian Amazon. The McKenna brothers went to La Chorrera specifically to find it, study it, and attempt to synthesize an orally active DMT compound that could extend the brief experience of smoked DMT into something more sustained.

The expedition was scholarly in intention if adventurous in execution. Dennis was studying botanical pharmacology. Terence had read extensively in the ethnobotanical literature. They brought field guides, laboratory equipment, and a level of prior knowledge about Amazonian plant pharmacology that distinguished them from simple psychedelic tourists.

They never found oo-koo-he. The Witoto population in the La Chorrera area had been devastated by the rubber boom — reduced from forty thousand to five thousand in the preceding sixty years — and the ceremonial practices that Schultes had documented were no longer intact in the community they reached.

What they found instead, growing abundantly in the cattle pastures of the mission station in the fog and rain, were Psilocybe cubensis mushrooms — the same species they had encountered in California, growing wild in equatorial abundance. The expedition that had traveled thousands of miles to find one psychoactive plant found a completely different one.

The way science actually works, sometimes, is that you go looking for one thing and come back with something else. True Hallucinations is the account of what happened when the McKennas accepted the substitution.

Sources

• McKenna, True Hallucinations (1993)
• Schultes & Hofmann, Plants of the Gods (1979)
• Wikipedia, Terence McKenna

“Schultes wore a suit and tie in the field. Not from vanity — from respect. He treated the people and their knowledge with the same formality he would have brought to any scientific collaboration.”

The image of Richard Evans Schultes in a suit and tie, deep in the Colombian Amazon in the 1940s, is the central image of Wade Davis's portrait of his mentor in One River. It was not affectation. It was methodology.

Schultes spent twelve years in the Amazon at a time when the dominant attitude of Western scientists toward indigenous knowledge was either condescension or romanticism — either the native practices were superstition to be corrected, or they were evidence of a lost paradise to be mourned. Schultes brought a third attitude: rigorous empiricism. He wanted to know what the plants did and how the people used them, and he approached both questions with the same objectivity he brought to his laboratory work.

The suit was part of this. He treated the communities he worked with as professional collaborators — as sources of systematic knowledge accumulated over generations — rather than as subjects of study or objects of rescue. The formality communicated respect. The respect communicated seriousness. Seriousness was what allowed the knowledge transfer that produced his herbarium.

His students — Davis most memorably, but also Mark Plotkin, Tim Plowman, and dozens of others — describe Schultes as a demanding teacher who showed his students the Amazon the way it had to be understood: on foot, by canoe, in rain, in seasons, with the people who knew it from birth. He didn't lecture about plants in classrooms — he took his students to where the plants grew and introduced them to the people who used them.

The Harvard faculty colleague quoted in the Peabody Museum lecture video — 'whatever you do, stay away from Schultes; he's a dinosaur who spent a decade in the Amazon alone' — missed the point entirely. The decade alone in the Amazon was not an eccentricity. It was the research.

Sources

• Harvard Magazine, Schultes obituary (2001)
• Davis, Wade. One River (1996)
• Wikipedia, Richard Evans Schultes

“Schultes went to the Amazon to study arrow poisons. What he learned — the chemistry of curare and its derivatives — became essential to modern surgery. It was not what he went looking for.”

Richard Evans Schultes's original 1941 Amazon grant was to study curare — the arrow poison used by Amazonian indigenous groups. The substance had fascinated Western pharmacologists since the sixteenth century, when European explorers reported indigenous hunters using darts dipped in a dark paste that paralyzed prey. The mechanism was unknown and the compound had obvious potential medical applications.

Schultes's contribution to curare research was botanical and taxonomic: he identified the plant species that produced it (primarily Chondrodendron tomentosum), documented regional variation in preparation methods, and collected specimens that allowed systematic chemical analysis. The alkaloid tubocurarine, isolated from the specimens he collected, became the prototype for modern neuromuscular blocking agents used in surgery.

Anesthesiologists use curare derivatives in virtually every general anesthetic today. The muscle relaxation that allows surgeons to operate without the patient's reflexes interfering, and that allows intubation for mechanical ventilation, derives from a class of compounds whose botanical identification was largely the work of Schultes and his collaborators.

This is the model that Plants of the Gods argues for applying to other Amazonian plant knowledge: not the selective appropriation of individual compounds for pharmaceutical development, but the systematic documentation of the full pharmacopoeia — what plants are used, for what conditions, in what preparations, by which communities.

Curare became a surgical tool because Schultes could identify the plants and researchers could isolate the chemistry. Schultes's argument was that this should happen with the full range of psychoactive plants before the knowledge and the plants themselves disappeared — that the Amazon represented a pharmacological database that had already produced one surgical revolution and might produce others.

The aspirin pill was destroying that database faster than any political force could. And the time Schultes had was running out.

Sources

• Academy of Achievement, Schultes interview
• Wikipedia, Richard Evans Schultes
• Schultes & Hofmann, Plants of the Gods (1979)

“Among Schultes's discoveries was the tepui plateau Chiribiquete — now the world's largest rainforest national park — containing the largest known repository of pre-Columbian rock paintings. He found it in the 1940s. It was declared a UNESCO World Heritage Site in 2018.”

In the early 1940s, while traveling through the Colombian Amazon on his rubber-tapping assignment, Richard Evans Schultes encountered a massive sandstone plateau that rose from the jungle floor like a fortress. The Chiribiquete tepui — a table mountain in the style of the Guyana Highlands — was unknown to Western science and was home to extraordinary biodiversity and extraordinary archaeology: thousands of years of rock paintings in ochre and red, covering exposed cliff faces with images of animals, humans, rituals, and what appeared to be shamanic vision content.

Schultes documented what he found and moved on. He had rubber to track and plants to catalog. The Chiribiquete plateau was one discovery among many.

The plateau's significance took decades to fully emerge. Colombian archaeologist Gaspar Morcote-Ríos has spent years studying the rock paintings, which extend across hundreds of sites and represent one of the most extensive archives of pre-Columbian visual culture in South America. Some of the oldest paintings may date to 20,000 years before present — among the oldest rock art in the Americas.

In 2018, UNESCO designated Chiribiquete a World Heritage Site. The park is now the world's largest rainforest national park, covering more than four million hectares. It protects three groups of uncontacted indigenous peoples and extraordinary levels of biodiversity — including plant species that Schultes documented and that have never been fully analyzed pharmacologically.

The Harvard Magazine obituary of Schultes in 2022 used Chiribiquete as the emblem of his legacy: a place he found in the 1940s that became, seventy years later, a globally recognized conservation priority. His presence in the Amazon was not destructive tourism — it was discovery that eventually enabled protection.

Sources

• Harvard Magazine, Schultes obituary (2022)
• UNESCO, Chiribiquete National Park designation (2018)
• Wikipedia, Chiribiquete National Park

“Schultes testified on behalf of the Native American Church's right to use peyote in religious practice. He described it as a sacrament, not a drug. His testimony helped establish the scientific and ethnographic record that eventually supported legal protection.”

The Native American Church's peyote sacrament is one of the oldest and most continuously practiced religious uses of a psychoactive plant in North America. The Huichol and other indigenous groups in Mexico have used peyote ceremonially for at least five centuries; the pan-tribal peyote ceremony that became the Native American Church in the early twentieth century extended this tradition across dozens of nations.

Schultes was one of the most important scientific voices defending this practice against legal challenge. In testimony, in published writing, and in the direct authority of his field research, he consistently described peyote use within the Native American Church as a sacramental practice — not drug use in the sense that warranted criminal sanction, but religious practice warranting First Amendment protection.

His argument was both ethnographic (the practice was ancient, embedded in ceremonial tradition, and pharmacologically managed through cultural knowledge) and pharmacological (peyote's safety profile in the sacramental context — low doses, controlled setting, experienced guidance — was fundamentally different from the abuse scenarios that motivated federal drug law).

The American Indian Religious Freedom Act of 1978 formally protected indigenous religious practices, but court decisions in subsequent decades threatened peyote use. The Employment Division v. Smith decision (1990) held that the AIRF Act did not protect peyote use from prosecution under neutral drug laws. The American Indian Religious Freedom Act Amendments of 1994 specifically exempted Native American Church peyote use from the Controlled Substances Act.

Schultes's testimony and published work contributed to the evidentiary record that supported these legal protections. The distinction he made consistently — between sacramental use embedded in cultural tradition and recreational or experimental use — was the distinction that legal frameworks eventually codified.

Sources

• Schultes & Hofmann, Plants of the Gods (1979)
• Wikipedia, Native American Church
• American Indian Religious Freedom Act (1978)

“The collaboration between Schultes and Hofmann was the collaboration between field knowledge and laboratory analysis — between knowing which plants indigenous peoples used and knowing what the plants contained. Neither alone was sufficient.”

Richard Evans Schultes and Albert Hofmann were the ideal collaborators for Plants of the Gods because they represented complementary forms of knowledge that were, individually, incomplete.

Schultes's knowledge was ecological, ethnographic, and taxonomic. He knew which plants indigenous communities used, in which preparations, for what purposes, within what ceremonial contexts. He had watched curanderos prepare ayahuasca, attended peyote ceremonies, and collected specimens of the sacred mushrooms that Wasson's publications had brought to Western attention. What he lacked was the chemistry: he was a botanist, not a pharmacologist.

Hofmann's knowledge was chemical. He had synthesized LSD from ergot alkaloids, isolated psilocybin and psilocin from Schultes's mushroom specimens, and analyzed the chemistry of morning glory seeds. He understood how these compounds interacted with human physiology. What he lacked was the field context: the knowledge of how the plants were used, who used them, in what forms and quantities and ceremonial frameworks.

Plants of the Gods combined these two forms of knowledge in a way that neither could have produced independently. The botanical and ethnographic descriptions are Schultes's. The chemical structures and pharmacological notes are Hofmann's. The book argues, by its structure, that both are necessary for understanding what these plants are and why they matter.

This argument has institutional implications. The current psychedelic renaissance tends to separate the clinical and the cultural: researchers at Johns Hopkins study psilocybin in controlled trials; anthropologists study ayahuasca in indigenous contexts; they rarely read each other. Plants of the Gods was written by two people who talked to each other across the laboratory/field divide and produced something neither could have produced alone. The model is still the right one.

Sources

• Schultes & Hofmann, Plants of the Gods (1979)
• Wikipedia, Albert Hofmann
• Wikipedia, Richard Evans Schultes

“Huxley proposed a mechanism in 1954. Carhart-Harris and Friston named it in 2019. The interval between them was sixty-five years of neuroscience arriving at the same place.”

In May 1953, Aldous Huxley took four-tenths of a gram of mescaline under Humphry Osmond's supervision and spent eight hours observing the world with an attention he had not previously been able to bring to it. The flowers on his table were not simply flowers — they were flowers as flowers actually were, without the filtering by biological utility and social convention that ordinarily reduced them to objects with names and functions.

To explain this, Huxley reached for Henri Bergson's 1896 proposal that the brain's primary function is not to produce consciousness but to restrict it. The brain, Bergson argued, is a reducing valve — it filters out most of what could be perceived, allowing through only what is relevant to survival and action. Huxley borrowed C.D. Broad's elaboration of this hypothesis and gave it the name it has carried since: the reducing valve.

Mescaline, in his account, impaired the valve. More of Mind at Large — the field of consciousness that the valve ordinarily suppressed — was allowed through. The result was not hallucination but perception: not the addition of something foreign but the removal of a filter that had been eliminating most of what was there.

For sixty-five years, this remained philosophy and phenomenology — coherent, intuitively compelling, and without rigorous neuroscientific support. The tools to test it didn't exist.

In 2019, Robin Carhart-Harris and Karl Friston published a paper in Nature Reviews Neuroscience proposing the REBUS model — Relaxed Beliefs Under Psychedelics. Their framework, derived from the predictive coding theory of brain function, proposes that the brain operates as a hierarchical inference machine: it generates predictions about what it expects to perceive (top-down priors) and compares them against incoming sensory signals (bottom-up prediction errors). When predictions are accurate, sensory signals are suppressed — they don't need to reach higher processing because they match what the brain already predicted.

Psychedelic compounds, in the REBUS model, reduce the 'precision weighting' of these top-down priors. The predictions become less certain, less heavily weighted, which means they suppress incoming sensory information less aggressively. More bottom-up signal reaches awareness. The brain's filtering function is relaxed.

This is Bergson's reducing valve, formalized in the vocabulary of computational neuroscience, derived from fMRI studies of psilocybin and LSD, and expressed as a falsifiable hypothesis rather than a philosophical intuition.

The convergence between Huxley's 1954 proposal and the 2019 neuroscience is not coincidental — Huxley was describing a real phenomenological event, and his philosophical framework was an attempt to capture something that was genuinely happening in the brain. But the specificity of the confirmation is remarkable. Carhart-Harris and Friston are not simply saying that Huxley was approximately right. They are saying that the mechanism he described — impairment of the brain's filtering function, resulting in richer but less organized perceptual experience — is precisely what the neuroimaging evidence shows.

The default mode network (DMN) is the system most associated with self-referential processing, mind-wandering, and what neuroscientists call 'top-down' modulation of sensory experience. It is, in functional terms, the neural correlate of Huxley's reducing valve — the system that normally constrains perception within the boundaries of what is already known and expected. Under psychedelics, the DMN shows systematic suppression in fMRI studies. Its internal connectivity decreases. Its ability to modulate other networks is compromised.

The result, as Huxley described and as the clinical literature consistently confirms, is not chaos — it is a different kind of order. Subjects do not report random sensory noise; they report heightened salience of specific features of experience, a quality of direct presence with ordinary objects, and an inability to maintain the usual narrative framing that filters experience through its relevance to the self.

The self, in Huxley's phenomenological terms and in the REBUS framework's technical terms, is a product of the filtering process — the prediction-generating system's attempt to maintain a stable model of what things are in relation to the organism. When the filter relaxes, the self relaxes with it. Ego dissolution is not a bizarre drug effect. It is what happens to the self-model when the system that maintains it is temporarily suspended.

For clinicians, this has direct implications. Depression, in the predictive coding framework, has been proposed to involve over-rigid top-down priors — the system is too certain about negative predictions, and bottom-up signals that contradict them are discounted. Psilocybin-assisted therapy, by temporarily relaxing these priors, may create a window in which the predictions can be revised — in which the certainty that the world is hostile, that the self is defective, that recovery is impossible, can be loosened sufficiently to allow new experience to register.

This is what the clinical evidence suggests, and it is what Huxley's philosophical framework, worked out in an afternoon with mescaline and Bergson, predicted. The neuroscience has arrived at a more detailed account of the same territory he mapped with a metaphor. The metaphor was accurate.

Sources

• Huxley, The Doors of Perception (1954)
• Carhart-Harris & Friston, Relaxed Beliefs Under Psychedelics (REBUS), Nature Reviews Neuroscience (2019)
• Millière & Metzinger, Front. Hum. Neurosci. (2020)
• Carhart-Harris et al., Default Mode Network Modulation by Psychedelics (2022)
• Bergson, Matter and Memory (1896)

“The MEQ30 measures six features: unity, noetic quality, sacredness, deeply felt positive mood, transcendence of time and space, and ineffability. These are Huxley's criteria, operationalized seventy years later.”

Aldous Huxley called the mescaline experience a 'gratuitous grace' — not necessary to salvation but potentially helpful, to be accepted thankfully if made available. He located it within the category of mystical experience as defined by the philosophical and theological literature: a direct encounter with what he called 'the divine Ground,' characterized by unity, noetic quality (a sense of having received genuine knowledge), and a quality of sacredness that he distinguished from ordinary religious feeling.

In 2006, Roland Griffiths and colleagues at Johns Hopkins published the first rigorous modern trial of psilocybin's ability to occasion mystical experience. They used the Mystical Experience Questionnaire (MEQ30), derived from the philosopher Walter Stace's phenomenological analysis of mystical states. The MEQ30 measures six features: unity, noetic quality, sacredness, deeply felt positive mood, transcendence of time and space, and ineffability.

These are Huxley's criteria, operationalized. Not quite in his language — Stace and Griffiths use the vocabulary of phenomenology and psychology rather than Vedantic philosophy — but the underlying structure is identical. The MEQ30 is measuring what Huxley described as the 'gratuitous grace': the direct encounter with what the reducing valve ordinarily prevents.

The Griffiths 2006 trial found that psilocybin could reliably occasion complete mystical experiences (MEQ30 score above 60 percent of maximum) in a significant proportion of participants in appropriate conditions. At fourteen-month follow-up, the majority of those who had complete mystical experiences rated them among the most meaningful of their lives. The finding has been replicated multiple times since.

What has been more significant for clinical practice is the subsequent finding that mystical experience quality predicts therapeutic outcomes better than drug dose alone. In studies of psilocybin for depression, end-of-life anxiety, and alcohol use disorder, MEQ30 scores correlate with treatment response at follow-up. Participants who have complete mystical experiences are more likely to show sustained therapeutic benefit than those who have sub-threshold experiences, even when the dose is the same.

This finding has profound implications. It suggests that the therapeutic mechanism of psychedelic-assisted therapy is not simply pharmacological — not just the drug acting on receptors to produce symptomatic relief. It suggests that the quality of the experience — whether it reaches the threshold of genuine transformation — is what drives the outcome. The medicine is not the molecule but what the molecule occasions.

Huxley articulated this distinction in 1954: the drug is a vehicle, not a destination. What it delivers is not itself the healing; what it delivers is a quality of experience that the person must then bring into their life. The letters to Osmond contain his worry that people who focused on the drug rather than the experience it opened would miss the point entirely.

The COMP005 and COMP006 Phase 3 trials by COMPASS Pathways, reporting in June 2025 and February 2026 respectively, showed statistically significant reductions in MADRS (Montgomery-Åsberg Depression Rating Scale) scores in treatment-resistant depression patients who received a single 25mg dose of synthetic psilocybin alongside psychotherapeutic support. Twenty-five percent of participants achieved clinically meaningful reduction at six weeks, with durability through twenty-six weeks. The NDA submission is targeted for Q4 2026.

These are modest numbers by the standards of antidepressant trials — but the comparison is inexact. Standard antidepressants require daily dosing indefinitely; COMP360 is one or two doses. Standard antidepressants produce response rates that cluster around 40-50 percent in treatment-naive patients and fall sharply in treatment-resistant patients; COMP360 is being tested in patients who have already failed at least two antidepressants.

What the trials are measuring, beneath the MADRS scores and the Phase 3 endpoints, is what Huxley proposed in 1954: that direct perceptual encounter with something beyond the ordinary reducing valve's output can produce lasting change in how a person relates to their experience. The clinical infrastructure for testing this claim did not exist in 1954. It now does, and what it is finding is that the claim was substantially correct.

The EPISODE trial, published in JAMA Psychiatry in May 2026, found that 25mg psilocybin produced treatment response (defined as ≥50% reduction in Hamilton Depression Rating Scale) in significantly more participants than active placebo at six weeks, in a German multicenter Phase 2b trial. The effect sizes are clinically meaningful and the safety profile is well-characterized. Huxley's 'gratuitous grace' is being measured in milligrams and clinical endpoints. The measurement doesn't reduce what it measures.

Sources

• Huxley, The Doors of Perception (1954)
• Griffiths et al., Psilocybin can occasion mystical-type experiences, Psychopharmacology (2006)
• Yaden & Griffiths, The Varieties of Self-Transcendent Experience, Perspect. Psychol. Sci. (2021)
• Barrett & Griffiths, Classic Hallucinogens and Mystical Experiences, Pharmacol. Biochem. Behav. (2018)
• COMPASS Pathways Phase 3 Trial Results (2025-2026)

“Hofmann spent sixty years watching his discovery be used in ways he had not intended. He remained remarkably clear about what those ways were and what would have been right instead.”

Albert Hofmann died on April 29, 2008, at the age of 102 — having lived long enough to see the clinical research program he had hoped for begin again, but not long enough to see it produce a regulatory approval. He had been waiting for sixty-five years.

The patience required for this waiting, and the clarity of mind with which he sustained it, are what make My Problem Child more than a memoir. It is a sustained meditation on the relationship between a discovery and the world that receives it — on what it means when what you create goes somewhere you did not intend, is used in ways you did not design, and becomes, for a generation, the symbol of something you neither endorsed nor recognized.

Hofmann's account of LSD's history has a specific shape: a decade of legitimate clinical research (1947-1957), a period of controlled dissemination through psychiatric and philosophical communities (1957-1963), and then a collapse — Leary's public advocacy, the counterculture appropriation, the Sandoz withdrawal in 1965, the Schedule I designation in 1968. From the discovery's perspective, this is a history of progressive misuse followed by catastrophic over-correction.

But Hofmann's account of this history is not primarily a lament. It is an analysis. He identified, with precision, what the right use would have been: careful preparation of the person, careful attention to setting, experienced guidance, integration of what happened afterward, and a framework that situated the experience within a larger context of human development — religious, philosophical, or therapeutic, but not recreational. These conditions, in his view, were sufficient to make LSD safe and beneficial. Their absence was what made it dangerous.

The crystal structure of LSD published in Cell in 2017 confirmed what Hofmann had observed empirically: the drug binds to the 5-HT2A serotonin receptor with unusual duration because a protein 'lid' in the receptor traps it inside. The twelve-hour experience he had not anticipated on Bicycle Day now had a molecular explanation. The extraordinary potency that meant the drug was active at doses too small to see also had a structural explanation: the molecular fit between LSD and its receptor is nearly perfect.

Hofmann was 100 when this crystal structure was solved; he had died two years before it was published. He knew the mechanism only in pharmacological outline. But the specificity of the confirmation — that the chemistry he had studied for decades was as precise and elegant as he had intuited — would have gratified him.

His legacy as a pharmacologist is secure. The discovery of LSD, the isolation of psilocybin and psilocin, the analysis of morning glory alkaloids — these are substantial achievements in natural product chemistry that would have built a distinguished career even without LSD's cultural significance. But what he cared about, in the final decades of his life, was not the pharmacology. It was whether the discovery would eventually be used correctly.

As of 2026, the evidence suggests: partially. The COMPASS Pathways trials have demonstrated, in Phase 3, that a single high dose of synthetic psilocybin (structurally analogous to LSD in its receptor activity) alongside psychotherapeutic support produces significant and durable antidepressant effects. The conditions of the trial — preparation, guided session, integration — approximate what Hofmann prescribed. The therapeutic framework Stanislav Grof built from 4,000 LSD sessions at the Maryland Psychiatric Research Center, and which is now being applied to psilocybin therapy, is Hofmann's model implemented at clinical scale.

What has not happened is the religious and philosophical use Hofmann considered most important. No Western institution has created the context he envisioned — what he called 'the integration of LSD into a cultural framework that would allow it to serve genuine human development.' The therapeutic framework exists. The philosophical framework does not yet.

Hofmann's word for this — the purpose for which LSD was, in his view, best suited — was 'sacred drug.' He used the phrase deliberately and never retracted it. Not a psychiatric tool, not a recreational substance, not an intelligence weapon, but a sacred drug: something that opened access to an experience that human beings have recognized, across traditions and millennia, as the most important class of experience available.

He was 102 when he died. He took LSD on his hundredth birthday. He said it restored the quality of perception he had known as a child. He waited sixty-five years for the rest of the world to figure out what it was.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Wacker et al., Crystal Structure of LSD and Serotonin 5-HT2B Receptor, Cell (2017)
• Grof, LSD: Doorway to the Numinous (2009)
• Carhart-Harris et al., Nature Reviews Neuroscience (2022)
• COMPASS Pathways, Phase 3 Results (2026)

“On the day Hofmann rode his bicycle home from Sandoz, Germany was fighting on the eastern front, the Holocaust was at its peak, and the Allies had not yet landed in Europe. The world LSD was born into was not the world it would transform.”

Albert Hofmann synthesized LSD for the second time and accidentally absorbed a small amount through his fingertips on April 16, 1943. He rode his bicycle home from the Sandoz laboratory in Basel on April 19, 1943 — now celebrated annually as Bicycle Day.

April 19, 1943 was also the day the Warsaw Ghetto Uprising began — the largest single act of armed Jewish resistance to the Nazi genocide. The coincidence is not meaningless. The world in which LSD was discovered was a world in which the most extreme expressions of human cruelty were operating at industrial scale, a world in which the Enlightenment's confidence in reason's ability to produce better institutions and better people had been catastrophically tested.

Hofmann knew nothing of this context on his bicycle ride. He was experiencing the most dramatic perceptual event of his life and trying to stay on his bicycle while doing so. He reached home. His neighbor brought him milk. She looked like a witch. By morning the world was luminous and ordinary.

What he had discovered would spend the next thirty years being used by people who were partly responding to the world the war had left: a world in which the confidence in Western civilization's adequacy had been shattered, in which the administrative machinery of the rational state had been used for mass murder, in which existentialism and pessimism about the human condition had displaced the Progressive Era's optimism. The countercultural use of LSD in the 1960s was not only about pleasure or rebellion — it was about the search for a different basis for human life than the one that had produced the concentration camps.

Huxley, who first took mescaline in 1953, was a man who had watched the twentieth century's catastrophes from a position of intelligence and literary achievement and found them evidence that Western civilization's confident project was failing. The Doors of Perception was written by someone who had read Huxley's dystopia in Brave New World and then found, in a living room in Los Angeles, what he thought might be a correction.

Hofmann, in My Problem Child, places his discovery in this broader context more gently than Huxley did. He argues that the mystical experience LSD occasions is one of the few things that reliably produces the quality of consciousness that ecological and ethical crisis requires: a sense of connection to the natural world, a reduction in the ego's monopoly on significance, a direct encounter with the sacred that religion was increasingly failing to deliver to secular minds.

The 2017 crystal structure of LSD bound to its receptor — solved at the University of North Carolina — shows a molecule that fits its receptor with nearly perfect complementarity, held in place by a protein lid that explains its twelve-hour duration. The chemistry is elegant in ways that feel intentional, though intention is not something molecules have. Hofmann would have found this structural confirmation satisfying: it shows that what he synthesized was not a crude blunt instrument but a pharmacologically precise key that fits a specific receptor architecture shaped by evolution.

The receptor it fits — the 5-HT2A serotonin receptor — is found in the prefrontal cortex, the anterior cingulate cortex, and the regions of the brain most associated with self-referential processing. Activating it with a molecule of LSD's precision disrupts the default mode network's ability to maintain its ordinary filtering function. The result is what Hofmann described on the morning after Bicycle Day: a world that seemed newly created, luminous, more itself than it ordinarily was.

He had discovered this on April 19, 1943, in the middle of the worst war in human history, in a pharmaceutical laboratory in Switzerland, while trying to make a drug for postpartum hemorrhage. The discovery was not intended. The discovery was not planned. The discovery was, as he always said, something that came to him — a presentiment, a hunch, a return to a compound he had filed away five years before because the animal tests showed nothing.

The world it entered was a world in desperate need of something it could not name. The problem child spent the next eighty years being what the world needed and what the world, repeatedly, refused to use correctly.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Stevens, Jay. Storming Heaven (1987)
• Wacker et al., Cell (2017)
• Wikipedia, History of LSD

“The stoned ape hypothesis is neither proven nor falsified. It is something rarer: a genuinely interesting question that the available evidence neither confirms nor eliminates.”

The stoned ape hypothesis, in its strongest form, proposes that Homo sapiens' distinctive cognitive capacities — language, abstract thinking, religious consciousness, tool innovation — were catalyzed by the regular consumption of psilocybin-containing mushrooms during a critical phase of human evolution in East Africa, approximately 200,000 years ago.

Terence McKenna's version, articulated in Food of the Gods, is specific: as African grasslands expanded and the forests contracted following climatic changes, ancestral hominids followed large herbivores across open savannahs. Psilocybe cubensis, which grows in the dung of cattle and similar herbivores, would have been abundant in this environment. McKenna proposed three mechanisms by which psilocybin consumption at low, medium, and high doses could have conferred evolutionary advantages: enhanced visual acuity (useful for hunting), increased sexual arousal and group bonding, and at high doses, the dissolution of ego boundaries and expansion of social and symbolic consciousness.

The hypothesis has been criticized on multiple grounds. No archaeological evidence of psilocybin use by early hominids has been found — the time scale is too remote and the evidence too fragile. The proposed mechanism is speculative: it assumes that the selective advantages of psilocybin-enhanced cognition were sufficient to produce significant evolutionary change, and that early hominids were encountering mushrooms at the right frequency and in the right quantities to produce that change. Both assumptions are untestable with current methods.

Most importantly for the specific McKenna claim: Psilocybe cubensis is not native to East Africa and probably was not present during the critical period of human cognitive evolution. The mushroom's range has expanded with cattle domestication; its presence in East Africa as early hominid habitat is not documented.

What the hypothesis gets right, or at least what it points at correctly, is the broader question: what role did psychoactive plants play in human evolution and cognitive development? This is a real question, and the evidence that human cultures have consistently used psychoactive plants — that no known culture lacks plant medicine practices — is itself significant. The relationship between humans and these plants is ancient and universal enough to suggest it is not accidental.

A 2021 Science paper by Shao et al. at Yale provides the most relevant recent data: psilocybin induces rapid and persistent growth of dendritic spines in the prefrontal cortex of mice, suggesting that it promotes synaptic plasticity — the mechanism underlying learning and memory formation. The growth was detectable within 24 hours of a single dose and persisted for at least a month. This is a neuroplasticity mechanism that could, in principle, provide cognitive advantages — though the leap from mice to hominids to evolutionary selection is large.

Dennis McKenna, who has done rigorous neuropharmacological research on tryptamines for decades, has said that the general hypothesis — that psychoactive plants were part of the hominid ecological niche and may have had effects on cognition — is plausible. The specific mechanism Terence proposed is not something the evidence currently supports. Dennis is comfortable with this distinction. He has described the experience at La Chorrera as real, the mushroom monologue as real in some sense he cannot fully specify, and the stoned ape hypothesis as an interesting story that may contain truth without being literally true.

This is perhaps the most honest relationship available to the hypothesis: not proof, not dismissal, but residence in a category that McKenna himself inhabited — the genuinely interesting question that the available evidence neither confirms nor eliminates, that calls for more research without promising what that research will find.

What Food of the Gods contributes to this question, regardless of the hypothesis's truth value, is the framework: the idea that the human relationship with psychoactive plants is not a deviation from some drug-free baseline but a consistent and possibly constitutive feature of human culture. Every known traditional society has plant medicine practices. The current pharmacological environment — which excludes most traditional psychoactive plants from legal use — is the historical anomaly, not the norm.

Whether psilocybin shaped the hominid brain or merely reflects what that brain already was, the relationship between the two is real. McKenna's contribution was to take that relationship seriously as a subject of inquiry when taking it seriously was not academically respectable. Whether the specific hypothesis survives is less important than whether the question does.

Sources

• McKenna, Food of the Gods (1992)
• Shao et al., Psilocybin Induces Rapid and Persistent Growth of Dendritic Spines, Science (2021)
• Wikipedia, Stoned Ape Theory
• Grokipedia, Terence McKenna
• D. McKenna, The Brotherhood of the Screaming Abyss (2012)

“McKenna wrote his television critique in 1992. He did not live to see TikTok. Every sentence has gotten more accurate.”

In Food of the Gods, Terence McKenna devoted a chapter to television as a drug — arguing not metaphorically but pharmacologically that passive screen consumption alters brain states in ways that serve the dominator culture's interests. His specific claims: that television is by nature a tool of coercion because it controls content, enforces content uniformity, and makes content repeatable; that it produces passivity rather than agency; and that it replaces direct experience with mediated representation.

He wrote this in 1992. The internet was a research network. The World Wide Web had just been opened to the public. Smartphones did not exist. TikTok did not exist. The algorithmic feed did not exist.

By 2024, what McKenna described as television's dominator properties had been implemented at incomparably greater precision and scale. Variable-ratio reinforcement schedules — the mechanism that makes slot machines compulsive — were engineered into social media feeds. Sean Parker, founding president of Facebook, acknowledged in a 2017 interview that the platform had been deliberately designed to exploit psychological vulnerabilities for engagement. Jonathan Haidt's 2024 book The Anxious Generation documented the epidemiological consequences: dramatic increases in depression, anxiety, and self-harm among adolescents correlating with the adoption of smartphone-mediated social media from 2012 onward.

McKenna's critique of television was correct and insufficient. He diagnosed the mechanism — control of content, uniformity, passivity — but the 2024 version of the problem is worse on every dimension. The algorithmic feed does not merely offer passive content; it actively optimizes content selection for maximum emotional engagement, which in practice means maximum emotional provocation. The uniformity is statistical rather than explicit — not a single channel but an individually tailored stream that nonetheless converges people toward content that increases cortisol and outrage. The passivity is not the passivity of watching; it is the pseudo-activity of scrolling, liking, and sharing — actions that feel like agency but are responses to an optimization system.

McKenna's proposed corrective was also correct but insufficient: 'Stop consuming images and start producing them.' The argument for active creation over passive consumption, for direct experience over mediated representation, for psychedelic attention over screen-induced dissociation, was right. But in 1992, the tools for passive consumption were limited to television schedules and video rental. The tools available in 2024 are incomparably more effective at producing exactly what he warned against.

What connects the television critique to the larger argument of Food of the Gods is the claim that the dominator culture systematically prefers intoxicants that produce compliance over intoxicants that produce questioning. Alcohol sedates; television sedates; social media — in its effect on attention and critical thinking — sedates. Psilocybin disrupts sedation. The drug war, in McKenna's framework, is a war against a specific kind of consciousness: the kind that notices what's wrong with the system.

The current psychedelic renaissance exists partly in tension with this critique. The therapeutic framing of psychedelic research — psilocybin as antidepressant, MDMA as PTSD treatment — is entirely compatible with the existing healthcare system and represents no threat to the attention economy. A drug that makes you a better compliant consumer of the social order is not the drug McKenna was describing.

Huxley drew the same distinction: soma versus moksha. The dominator drug produces happiness without liberation. The liberation drug produces questioning without comfort. What McKenna diagnosed as the television problem — the systematic substitution of sedating spectacle for consciousness-expanding experience — has not been addressed by the psychedelic renaissance. It has gotten worse while the renaissance proceeded.

Sources

• McKenna, Food of the Gods (1992)
• Parker, Sean. Interview, Axios (2017)
• Haidt, Jonathan. The Anxious Generation (2024)
• Various psychedelic ecology literature

“A hundred years. Forty billion dollars annually. The highest incarceration rate in the world. Drug overdose deaths at record highs. The policy has been both very expensive and counterproductive by its own stated measure.”

The Harrison Narcotics Tax Act became law on December 17, 1914. One hundred and twelve years later, the United States is spending approximately forty billion dollars annually on drug enforcement and incarceration, has the highest rate of drug overdose deaths in its history, and maintains the world's largest incarcerated population, with drug offenses accounting for a substantial portion of those sentences.

By the policy's own stated measure — reducing drug use, reducing addiction, reducing the social harm of psychoactive substances — it has not worked. Drug use rates in the United States are not lower than they were in 1914. Addiction rates in the United States are not lower than they were in 1914. The specific harms that prohibition generates — adulterated drug supply, violence over market control, criminal records that perpetuate the social conditions that drive addiction — did not exist before the policy created them.

Chasing the Scream was published as the centenary of the Harrison Act approached, and Hari structured it as a reckoning with what a century of this policy had produced. The evidence he assembled — following the war from Anslinger's appointment in 1930 to Portugal's decriminalization in 2001, from Billie Holiday's persecution to the Vancouver safe injection rooms — is not primarily an argument about drugs. It is an argument about what happens when a society organizes its response to suffering around punishment rather than treatment.

The racial targeting that John Ehrlichman confirmed in 2016 was not a flaw in the drug war's design — it was, in Nixon's administration's explicit framing, part of the design. The drugs were the pretext; the communities were the target. This is the darkest part of Hari's argument, and the one most solidly supported by primary documentation: the Harrison Act, the Marihuana Tax Act, the Controlled Substances Act, and the mandatory minimums of the 1980s and 1990s were all applied with systematic racial disparity that cannot be explained by differential use rates because use rates across racial groups are broadly similar.

The ACLU documented in 2020 that Black Americans are 3.73 times more likely than white Americans to be arrested for marijuana possession despite similar use rates. The disparity is not a statistical artifact. It is a policy outcome.

What has changed since Hari wrote in 2015 is significant but incomplete. Recreational cannabis is now legal in 24 US states. The DOJ proposed rescheduling cannabis from Schedule I to Schedule III in May 2024. The Biden administration issued mass pardons for federal cannabis convictions in October 2022. Oregon decriminalized personal possession of all drugs in 2020 — then partially reversed course in 2024 as implementation challenges mounted. The harm reduction infrastructure has grown: the first sanctioned safe injection site in the US (OnPoint NYC) opened in November 2021 and had reversed over 1,200 overdoses by 2025 without a single on-site death.

And yet: overdose deaths reached a record 107,500 in 2023, primarily from fentanyl and synthetic opioids that entered the supply chain as a consequence of prohibition-driven quality uncertainty. The drug supply is more dangerous, not less, after a century of enforcement.

The Portugal model that Hari cited as the strongest evidence for decriminalization has shown mixed results over twenty years — strong on HIV transmission, weaker on overdose rates when the social investment in treatment and services has been insufficient. The lesson is not that decriminalization fails but that decriminalization alone is insufficient. What works, when it works, is decriminalization combined with substantial investment in the social conditions that drive addiction: housing, employment, community, treatment capacity.

Hari summarized the alternative in the book's final pages: what if the money currently spent on enforcement and incarceration were redirected to the conditions that determine whether people reach for drugs in the first place? This remains the unimplemented proposal. A century of data supports it. The political will to implement it has not yet materialized at federal scale.

Sources

• Hari, Chasing the Scream (2015)
• CDC, Drug Overdose Deaths 2023
• ACLU, A Tale of Two Countries (2020)
• Ehrlichman, John, quoted in Dan Baum, Harper's Magazine (2016)
• Hughes & Stevens, Drug Alcohol Rev. (2010)
• DOJ NPRM, Cannabis Rescheduling (May 2024)

“If Wasson, Hofmann, and Ruck are correct, Western philosophy did not emerge from pure reason. It emerged from a psychedelic sacrament that Plato, Aristotle, Sophocles, and Cicero all received.”

Western philosophy begins, in the standard account, with the pre-Socratic speculation of the sixth and fifth centuries BCE: Thales proposing that everything is water, Heraclitus insisting on universal flux, Pythagoras discovering the mathematical structure of music. Plato synthesizes these into the theory of Forms — the claim that the material world is a shadow of a higher reality that reason can apprehend. Aristotle systematizes Plato's intuitions into the categories of logic and natural science. These are the foundations.

The Road to Eleusis, published in 1978 by three scholars who had spent lifetimes studying mycology, chemistry, and classical philology respectively, proposes a supplement to this account: that the direct encounter with 'higher reality' that Platonic philosophy describes did not arise purely from rational speculation. It arose from a specific experience — the experience of the kykeon, the ritual drink at the center of the Eleusinian Mysteries, which Wasson, Hofmann, and Ruck argue was psychoactive through ergot alkaloids contaminating the barley.

The initiates of the Eleusinian Mysteries included, by historical record, virtually the entire intellectual and cultural leadership of classical Greece and Rome. Plato participated. So did Aristotle, Sophocles, Pindar, Aeschylus, and Cicero. The Mysteries lasted from approximately the seventh century BCE to 395 CE — nearly a thousand years. They were, as Cicero wrote, 'the best thing Athens ever gave the world.'

If the kykeon was psychedelic — if it produced, in the Telesterion's darkness, a direct encounter with something beyond ordinary consciousness — then Platonic philosophy has a phenomenological source that the standard account omits. The theory of Forms — the claim that this visible world is a shadow of a more real, more permanent, more meaningful world apprehensible through a higher faculty than ordinary sense perception — is precisely what you would construct if you had experienced, in the Telesterion, something that made ordinary reality feel like a shadow.

The experience initiates described: fear and trembling in the limbs, nausea, vertigo, and then a vision — a direct encounter with the divine that transformed their understanding of death and what lay beyond it. This phenomenological pattern is not consistent with theatrical presentation. It is consistent with the ingestion of a psychoactive substance in appropriate conditions.

Critical classicists — most notably Walter Burkert, the preeminent scholar of Greek religion — have argued that the Mysteries worked through theater, suggestion, and the powerful context of the ritual without pharmacology. Burkert died in 2015 and did not see the finding from Mas Castellar de Pontós published in 2019-2020: ergot alkaloids in a ritual vessel associated with the Demeter cult in ancient Catalonia. The 2026 Scientific Reports paper by Antonopoulos and Dadiotis demonstrated experimentally that lye — available as wood ash in antiquity — converts toxic ergopeptides into water-soluble psychoactive forms at doses achievable through ancient preparation.

The hypothesis has moved from speculative to experimentally feasible and archaeologically evidenced. The direct confirmation — ergot residue at Eleusis itself — has not yet been found, though excavation and analysis are ongoing.

If the hypothesis is correct, the implications for intellectual history are significant. Western philosophy's most foundational distinction — between the apparent world and the real world, between the cave's shadows and the sunlit reality outside — is not a purely rational construction. It is a philosophical articulation of an experienced reality: the reality that initiates encountered in the Telesterion and that Plato, having encountered it himself, spent his life trying to describe in the vocabulary of reason.

This does not undermine the philosophy. The theory of Forms is either true or false regardless of whether it arose from a psychedelic experience or a purely rational argument. But it changes the intellectual history: the beginning of Western philosophy may not be reason alone but reason encountering a specific quality of experience and trying to account for it.

Brian Muraresku's The Immortality Key (2020) extended the argument into early Christianity, proposing that the psychedelic sacrament of the Mysteries survived its formal prohibition in 392 CE through underground transmission into Christian Eucharistic practice. The evidence for this extension is more suggestive than for the Eleusinian hypothesis itself, but the trajectory is clear: if the foundation of Western philosophy is psychedelic, the question of whether the foundation of Western religion is psychedelic becomes unavoidable.

Sources

• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Burkert, Ancient Mystery Cults (1987)
• Muraresku, The Immortality Key (2020)
• Antonopoulos & Dadiotis, Scientific Reports (February 2026)
• Mylonas, Eleusis and the Eleusinian Mysteries (1961)

“Over a thousand published papers. Forty thousand patients. Roughly fifty percent of treated alcoholics achieving lasting sobriety. The program was not stopped because it failed.”

When the Schedule I designation for LSD took effect with the 1970 Controlled Substances Act, it ended a clinical research program that had been running for twenty-three years and had produced results that no subsequent psychiatric intervention has matched in several key areas.

The program began in 1947 when Sandoz first distributed LSD to psychiatric researchers under the trade name Delysid. The accompanying package insert described two potential research applications: as a model of psychosis (for training clinicians in the phenomenology of schizophrenia), and as a treatment for various neurotic conditions by facilitating the surfacing and processing of psychological material.

By 1965, when Sandoz withdrew Delysid in response to the counterculture controversy, the clinical literature encompassed over one thousand published papers and reports from dozens of research centers. The patient population was heterogeneous: alcoholics, end-of-life anxiety patients, treatment-resistant depressives, and patients with neurotic disorders of various kinds.

The most robust results came from the alcoholism trials. Hoffer and Osmond's work at Weyburn Mental Hospital in Saskatchewan, running from 1952 to approximately 1961, treated over a thousand alcoholic patients with LSD-assisted therapy and documented response rates of approximately 40-50 percent achieving lasting sobriety — rates that were superior to any available alternative treatment. Their methodology was not by modern standards rigorous — the trials were not randomized and controlled by current criteria — but the consistency of the result across variations in method was sufficient for serious clinical attention.

A 2012 meta-analysis by Krebs and Johansen (Journal of Psychopharmacology) examined all available randomized controlled trials of LSD for alcoholism conducted between 1966 and 1970 and found a statistically significant positive effect on drinking behavior, with effects persisting at six to twelve months follow-up. The meta-analysis was limited by the quality of the original trials, but its conclusion — that the effect was real and clinically meaningful — was consistent with the broader clinical record.

The end-of-life anxiety results were comparable. Early trials by Walter Pahnke, Sidney Cohen, and others found that LSD-assisted therapy significantly reduced death anxiety in terminal cancer patients and was associated with reported acceptance of death rather than dread. The mechanism, in Pahnke's account, was the mystical experience: patients who had complete mystical experiences during sessions showed the greatest reduction in anxiety.

This finding — that mystical experience quality predicts therapeutic outcome — has been confirmed in the current psilocybin research (Barrett & Griffiths, 2018; Yaden & Griffiths, 2021) and is one of the most consistent findings across the fifty-year interruption. What was established in the LSD trials of the 1950s and 1960s, lost in the prohibition, and reestablished in the psilocybin trials of the 2010s and 2020s, is: the mechanism of psychedelic-assisted therapy is the quality of the consciousness it occasions, not only the pharmacology.

What was stopped in 1968-1970 was not a research program that had reached its natural conclusion. It was a research program in full development, accumulating positive results, refining its methodology, and approaching the stage at which it might have produced regulatory submissions for specific indications.

The COMPASS Pathways Phase 3 trials of COMP360 psilocybin, reporting in 2025 and 2026, are the research program that the 1970 Controlled Substances Act would have produced forty years earlier if it had not been halted. The clinical evidence for psychedelic-assisted therapy for depression and end-of-life anxiety is now, as of 2026, at Phase 3 quality. This evidence would have existed by approximately 1985 if the program had continued uninterrupted.

Hofmann knew what was being lost in 1968. He had watched the clinical program from Sandoz, contributed to it through his pharmacological analysis, and understood its potential. My Problem Child is partly a document of grief: grief for a research program that was working, for patients who needed it, for a medical opportunity that political decisions eliminated.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Krebs & Johansen, Lysergic acid diethylamide and psilocybin for Major Mood Disorders (2012)
• Hoffer & Osmond, J. Mental Sci. (1961)
• Stevens, Storming Heaven (1987)
• Medical History of Psychedelic Drugs, Cambridge HPS dissertation (2007)

“The connection model is not a refutation of pharmacology. It is a correction of the pharmacological-only model. Both things are true: addiction has chemical dimensions and social dimensions, and the policy implication is that you have to address both.”

The central claim of Chasing the Scream — 'the opposite of addiction is connection' — is a formulation that clarifies and overstates simultaneously. It clarifies because it redirects attention from the drug to the person and the person's environment. It overstates because pharmacological dependence is real, withdrawal is a physiological process, and social connection, however necessary, is not sufficient to reverse all forms of addiction.

Bruce Alexander's Rat Park experiments showed that social enrichment dramatically reduced drug consumption in rats who had been isolated and dependent. The finding was significant and has held up in a general sense across subsequent animal research: social context modulates drug-seeking behavior reliably. The specific Rat Park results have not been directly replicated, and some studies have found the effect less dramatic than Alexander's original data suggested. But the conceptual point — that environment shapes pharmacological behavior in important ways — is now well-established.

The Vietnam natural experiment provides the strongest human data. Lee Robins's 1993 analysis of Vietnam veterans who had been addicted to heroin in the field found that approximately 95 percent stopped using after returning home, without formal treatment. The most important variable was not pharmacological — it was the radical change in environment. The drug was the same; the context was different; the behavior changed.

This finding, combined with the Rat Park data, supports the general claim that social disconnection is a major driver of addiction. But the phrase 'the opposite of addiction is connection' obscures an important nuance: the Vietnam veterans were not simply getting more connection at home. They were getting a different set of environmental affordances — work, family, housing, purpose — that made drug use both less necessary and less available. 'Connection' is a partial description of a richer social ecology.

The pharmacological critique of Hari's strong formulation is that opioid withdrawal is a genuine physiological process that does not reverse simply because a person feels more connected. George Koob and Nora Volkow's framework — which emphasizes the neuroadaptive changes that chronic drug use produces in reward, stress, and executive function circuits — shows that the brain changes measurably with sustained use, and that these changes persist after environmental improvement. The social context model and the neurobiological model are not contradictory; they are complementary accounts of different aspects of the same phenomenon.

The policy implication of this more nuanced picture is: both. Treatment for opioid use disorder needs both medication-assisted treatment (buprenorphine, methadone) and social support (housing, employment, community). Portugal's model, which Hari cites as the strongest evidence for the connection approach, actually implements both: decriminalization removes the legal barrier to treatment-seeking, and the social investment provides the environmental conditions that support recovery.

Where Portugal's results have been weaker — particularly through the 2015-2023 period, when austerity cut social service budgets — the model has underperformed. Not because decriminalization failed but because the social investment was insufficient. The lesson is not that connection is the opposite of addiction; it is that connection is necessary but not sufficient, and that the pharmacological and the social interventions work best in combination.

Hari's formulation, for all its incompleteness, accomplished something the more nuanced version would not have: it made the argument accessible and memorable, it redirected public attention from moral failure to social conditions, and it built the political case for harm reduction and decriminalization that the evidence supports even if the slogan overstates. The compression of a complex finding into a memorable formulation is not always wrong. Sometimes it is the thing that moves policy when the nuanced version would not.

Sources

• Hari, Chasing the Scream (2015)
• Alexander, The Globalization of Addiction (2008)
• Gage & Sumnall, Addiction (2020)
• Koob & Volkow, Neuropsychopharmacology (2016)
• Robins, Vietnam Veterans Three Years After Vietnam (1993)

“Forty-eight years after publication, the Road to Eleusis hypothesis has moved from speculative to experimentally feasible and archaeologically evidenced. The direct confirmation — ergot at Eleusis — has not yet arrived. The search is active.”

The Road to Eleusis was published in 1978 as a proposition: that the most revered religious institution of classical antiquity derived its transformative power from a psychedelic sacrament. Wasson provided the mycological and ethnomycological argument, Hofmann provided the pharmacological analysis, and Ruck provided the classical scholarship. Together they proposed that the kykeon — the ritual drink prepared from barley, water, and mint according to the Homeric Hymn to Demeter — contained ergot alkaloids that produced the visions initiates described.

For the first four decades after publication, the hypothesis remained in the category of interesting speculation: suggestive, internally consistent, supported by the ancient testimonies and by Hofmann's pharmacological experiments with water-soluble ergot alkaloids, but without direct archaeological confirmation. Classical scholars were largely hostile; the Eleusis site itself had not produced chemical residue evidence.

In 2019-2020, that changed.

The excavation at Mas Castellar de Pontós — an ancient settlement in Catalonia associated with the Demeter cult — produced two significant findings. In dental calculus from a woman buried at the site (third to second century BCE), bioarchaeologist Jordi Juan-Tresserras found apparent traces of ergot alkaloids alongside phytoplankton associated with the cultivation of cereal grains. In a sealed ritual vessel from the same site, further analysis found ergot spores and residues in direct association with beer-making equipment.

The Catalonia site is not Eleusis. It is an Eleusinian-affiliated sanctuary in the western Mediterranean — evidence that the cult of Demeter, wherever it established itself, used grain-based preparations contaminated with or incorporating ergot. The finding cannot prove that the Eleusinian sanctuary in Greece used the same preparation, but it demonstrates that the preparation was used in cultic contexts associated with the Eleusinian tradition.

The February 2026 Scientific Reports paper by Antonopoulos and Dadiotis at the National Kapodistrian University of Athens provided the chemical mechanism that Hofmann had proposed but not fully demonstrated. They showed experimentally that lye — readily available in antiquity as wood ash solution — converts the toxic ergotamine and ergotoxine alkaloids in ergot into water-soluble lysergic acid amide (LSA) derivatives at doses that would be achievable through ancient preparation methods. This is the specific transformation that would have made ergot psychoactive in the kykeon without producing the dangerous ergotism that ergot had caused in European grain crops.

The Antonopoulos-Dadiotis paper also called explicitly for chemical residue analysis of vessels excavated at the Eleusis site itself — the analysis that would be the most direct test of the hypothesis. As of June 2026, this analysis has not been completed. The Hellenic Ministry of Culture's ongoing excavation program, combined with the attention brought by Eleusis's designation as a European Capital of Culture in 2023, has raised both the research interest and the political complexity of pursuing invasive analysis on one of Greece's most important archaeological sites.

The hypothesis stands in 2026 in a condition its authors in 1978 would have found encouraging: experimentally demonstrated as feasible (the Antonopoulos-Dadiotis chemistry), archaeologically supported in an affiliated site (the Catalonia findings), and directly testable at Eleusis if the political and institutional conditions allow the analysis.

The scholarly resistance has softened. Burkert's generation of classicists who dismissed the hypothesis has retired or died. Brian Muraresku's popular treatment in The Immortality Key reached an audience far larger than the original scholarly edition, and the 2019-2020 archaeological findings gave his argument a stronger evidentiary base than he had when the book went to press.

The question Wasson, Hofmann, and Ruck posed — whether Western civilization's most important religious institution was founded on a psychedelic sacrament — remains open. The evidence that would answer it definitively is in the soil at Eleusis, waiting for the right analysis to reach it.

Sources

• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Antonopoulos & Dadiotis, Scientific Reports (February 2026)
• Mas Castellar de Pontós excavation reports (2019-2020)
• Muraresku, The Immortality Key (2020)
• Eleusis 2023 European Capital of Culture documentation

“The phrase 'set and setting' is attributed to Timothy Leary, but the concept was built by Osmond and Huxley, letter by letter, between 1953 and 1963. Leary named it. They invented it.”

The concept of set and setting is now so fundamental to psychedelic research that it appears in the safety guidelines of every clinical trial, in the training materials of every facilitator program, and in the published recommendations of every professional organization working in the field. Set — the mindset, expectations, and psychological state of the person taking the substance. Setting — the physical environment, social context, and relational conditions in which the experience occurs. The two variables together, clinicians now understand, predict a substantial proportion of the variance in psychedelic experience quality and therapeutic outcome.

The phrase is attributed to Timothy Leary, who used it in lectures during the Harvard psilocybin project in the early 1960s. But the concept was developed by Humphry Osmond and Aldous Huxley through a decade of correspondence, beginning with Osmond's May 1953 mescaline session with Huxley in Los Angeles and elaborated across hundreds of letters.

Osmond's clinical contribution was the observation that the same dose of the same substance produced dramatically different experiences in different people and in different contexts. He had seen this at Weyburn: patients who received LSD in the same protocol reported experiences ranging from peaceful insight to terror. The variable was not the drug. The variable was the person and the situation.

Huxley's contribution was the philosophical framework: the drug did not add content to consciousness but removed filters. What was revealed when the filters were removed depended enormously on what was already there — the person's beliefs, anxieties, hopes, and emotional state — and on what the environment provided — whether it was frightening or safe, chaotic or structured, cold or warm. The drug was an amplifier, not a specific producer. What it amplified was everything.

The correspondence worked out the practical implications of this framework over years of reflection. Huxley described his own sessions — the first mescaline session with Osmond, subsequent LSD sessions, his wife's use of psychedelics — with systematic attention to what conditions had contributed to positive outcomes: familiar surroundings, trusted companions, beautiful art, carefully chosen music, freedom from interruption, absence of time pressure. He was building, empirically, a list of set and setting variables based on direct experience.

Osmond was doing the same thing clinically. The Weyburn LSD protocol that produced 40-50 percent sobriety rates in alcoholic patients was not simply 'give LSD.' It was preparation (discussing the experience in advance, establishing trust), dosing (in a carefully prepared room with meaningful objects and music), and integration (follow-up sessions to process what had happened). These three phases — preparation, session, integration — are now the standard clinical model for psychedelic-assisted therapy, formalized in Johnson et al.'s 2008 safety guidelines and mandated by the protocols of every current clinical trial.

A 2024 systematic review published in Expert Review of Clinical Pharmacology (Borkel et al.) confirmed what Huxley and Osmond had established empirically seventy years earlier: set and setting variables predict psychopathology, wellbeing, and meaningfulness of psychedelic experiences across independent samples. A 2024 review of integration session frameworks (Thal & Lommen, Clinical Psychology & Psychotherapy) synthesized 75 clinical trials and found that the therapeutic alliance and the quality of preparation and integration sessions were significant predictors of outcome across conditions.

The letters in Moksha are not simply historical documents. They are the first systematic working-out of what is now the foundational clinical infrastructure of the psychedelic renaissance. When a clinical trial at Johns Hopkins or Imperial College specifies preparation requirements, therapist training, session environment, and integration follow-up, it is implementing the framework that Huxley and Osmond developed letter by letter between 1953 and 1963.

Leary named it. He condensed a decade of careful clinical and philosophical development into a slogan — 'set and setting' — that was both accurate and easily misunderstood. The slogan suggested that you could control the experience by controlling the variables, which was true in a general sense and false in a specific sense: set and setting shape the experience, they do not determine it. The difference between shaping and determining is the difference between a clinical framework and a guarantee, and Leary's promotional style often presented it as the latter.

Huxley and Osmond's letters are the guarantee-free version: two careful people working out, from direct experience and clinical observation, what conditions most reliably support positive outcomes while acknowledging that the experience remains fundamentally unpredictable. This is the epistemic posture that current clinical research is recovering — the posture that Leary's showmanship temporarily obscured.

Sources

• Huxley & Osmond, in Moksha (1977)
• Hartogsohn, Constructing drug effects: a history of set and setting, Drug Sci Policy Law (2017)
• Borkel et al., Set and setting predict psychopathology, wellbeing and meaningfulness, Expert Rev Clin Pharmacol (2024)
• Thal & Lommen, Therapeutic frameworks in integration sessions, Clin Psychol Psychother (2024)
• Johnson et al., Human hallucinogen research guidelines for safety, J Psychopharmacol (2008)

“Huxley died with LSD. The clinical program he helped create is now treating the same anxiety — cancer, dying, the dissolution of the self — that he faced in November 1963.”

On November 22, 1963 — the day John F. Kennedy was assassinated, though neither Aldous Huxley nor his wife Laura knew this — Huxley was dying of laryngeal cancer. He had lost the ability to speak. He wrote a note asking Laura to administer LSD. She gave him 100 micrograms at 11:20 AM and another 100 micrograms at 1:00 PM, speaking to him softly as he died: 'You are doing this willingly and consciously, and you are doing this beautifully.'

The nurses who were present said they had never seen such a peaceful death.

This event — which Laura Huxley described in a letter to Osmond written shortly after, published in This Timeless Moment — was not an improvisation. It was the culmination of a decade of thinking about what psychedelics could do at the end of life, a decade that began with the Huxley-Osmond correspondence and found its fullest fictional expression in Island (1962), where the moksha-medicine was explicitly integrated into the community's approach to dying.

Huxley had written about death as one of the three or four things that psychedelics could transform. Not prevent, not deny — transform. The moksha experience, in his account, was particularly relevant to dying because what dying required — a release of the ego's grip on its own continuity, an opening to whatever lay on the other side of the known — was precisely what the psychedelic experience trained. The person who had genuinely dissolved the ego's boundaries in a guided session had, in some sense, rehearsed dying.

Osmond, as a psychiatrist who worked regularly with seriously ill patients, had thought about this from the clinical side. He had observed that the LSD sessions with terminal patients produced responses unlike those in other populations: a quality of peace, acceptance, and even gratitude that was not explicable by any pharmacological action on disease symptoms. Whatever was happening was happening to the relationship between the person and their situation, not to the situation itself.

The clinical program that tested this systematically did not begin until after Huxley's death. Walter Pahnke's work at the Maryland Psychiatric Research Center in the 1960s and 1970s established that LSD-assisted therapy significantly reduced anxiety and depression in terminal cancer patients. The research was stopped by prohibition in 1970.

The program resumed, with psilocybin rather than LSD, in 2016, with two landmark studies published simultaneously. Griffiths et al. at Johns Hopkins and Ross et al. at NYU found, in separate double-blind trials, that a single session of psilocybin-assisted therapy produced rapid and sustained reductions in end-of-life anxiety and depression in cancer patients, with effects persisting at six-month follow-up. The mechanism, consistent across both studies, was mystical experience quality: patients who had complete mystical experiences showed the greatest therapeutic benefit.

Australia's Therapeutic Goods Administration approved psilocybin for treatment-resistant depression and MDMA for PTSD in February 2023 — the first regulatory approvals for psychedelic-assisted therapy in any country outside of a trial setting. The approval includes provisions for palliative care contexts.

Huxley wrote Laura's words at the end of life into Island: 'Willingly and consciously and beautifully — you're doing it willingly and consciously and beautifully.' He wrote them into his novel two years before he died; Laura used them at his bedside because they were the right words, because he had worked out what the right words were in decades of thinking about how the mind met its own dissolution.

The clinical program that now provides this to dying patients in clinical trials is the institutionalized version of what Huxley worked out in his letters to Osmond. The language has changed — outcomes, endpoints, MADRS scores — but the underlying event, and the reason it helps, is what the correspondence described.

Sources

• Huxley & Osmond, in Moksha (1977)
• Griffiths et al., Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer, J Psychopharmacol (2016)
• Ross et al., Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer, J Psychopharmacol (2016)
• TGA Australia, Psilocybin clinical approval (February 2023)

“The people building the current psychedelic renaissance have read Storming Heaven. They are explicitly trying not to repeat 1968. Whether they will succeed is the open question.”

Jay Stevens ended Storming Heaven in 1968. Fifty-five years later, the research program he mourned has resumed. The question Storming Heaven's history now poses is not historical but prospective: will the current psychedelic renaissance avoid the collapse that ended the first one?

The people building the current renaissance have read Stevens's book — or something equivalent. The explicit institutional memory of what went wrong in the 1960s is present in every major clinical psychedelic research organization. Matthew Johnson's 2008 safety guidelines for human psychedelic research, which have become the baseline protocol for clinical trials, were written with the specific goal of preventing the kind of adverse events and public credibility damage that enabled the 1968 prohibition. The guidelines specify: screening for contraindicated conditions, therapeutic alliance established before dosing, trained monitors present during sessions, post-session integration, careful management of public communication.

This is the clinical tradition Osmond and Huxley built, formalized into something that can survive its most charismatic exponents. The problem in the 1960s was that the clinical tradition depended on individual practitioners — Osmond, Hoffer, Grof, Pahnke — and the moment it was disrupted by public controversy, the institutional infrastructure that might have sustained it did not exist. The current infrastructure — the Society for Psychedelic Outreach, Reform and Education, the Multidisciplinary Association for Psychedelic Studies, the academic centers at Hopkins, NYU, Imperial, and elsewhere — is designed to be more durable.

The specific risks that Stevens documented are also more visible now. The Leary risk — mass public advocacy that overtaxes the regulatory goodwill needed for clinical approval — has materialized in the ayahuasca retreat industry, in the ketamine wellness clinic proliferation, and in the general 'psychedelic renaissance' media coverage that sometimes outruns the evidence. The FDA's August 2024 rejection of Lykos Therapeutics' MDMA-assisted therapy application for PTSD was partly a response to this problem: not a rejection of the underlying science, but a finding that the trial design had insufficient safeguards against expectation effects and therapeutic boundary violations. The FDA's concern was not that MDMA doesn't work — it was that the trial design couldn't prove it works in a way that would survive commercialization at scale.

This is the 1968 problem in new form: the substance is promising, the evidence is promising, and the enthusiasm of advocates is threatening to outrun the methodological rigor needed to make the evidence stick.

The COMPASS Pathways Phase 3 trials for psilocybin in treatment-resistant depression — reporting in June 2025 and February 2026 — represent the methodologically rigorous approach: double-blind design, active placebo comparison, pre-registered primary endpoints, independent data monitoring, and a trial population (treatment-resistant patients) where the effect size is most meaningful. The results met primary endpoints with high statistical significance. The NDA submission is targeted for Q4 2026.

If approved — and the current trajectory suggests approval in late 2026 or early 2027 — COMP360 will be the first psychedelic-assisted therapy with full FDA approval. This is not what the 1960s research was close to producing; the 1960s research would have taken another decade of refinement to reach this point. The fifty-five-year interruption is ending, and it is ending with better methodology than what was interrupted.

But Stevens's other warning — about the co-optation of the clinical tradition by commercial and cultural forces that transform it into something it wasn't designed to be — is still live. The economic incentives in the legal psychedelic market are substantial. The distance between a rigorous clinical protocol and a commercial psychedelic retreat is the distance between Osmond's Weyburn and Kesey's Trips Festival. That distance exists regardless of whether COMP360 gets approved.

What Storming Heaven shows, and what the current renaissance has to reckon with, is that the clinical and the cultural cannot be cleanly separated. They were not separable in the 1960s, and they are not separable now. The question is not whether to manage the relationship but how.

Sources

• Stevens, Storming Heaven (1987)
• Johnson et al., Human hallucinogen research guidelines for safety, J Psychopharmacol (2008)
• Lykos Therapeutics, FDA rejection of MDMA for PTSD (August 2024)
• COMPASS Pathways Phase 3 Results (2025-2026)
• Davis et al., Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder, JAMA Psychiatry (2021)

“McKenna's central intellectual virtue was the willingness to hold unresolved the question of what the entities were. He neither proved they were real nor dismissed them as hallucination. He reported them.”

The entity contact problem is, as of 2026, the most philosophically interesting open question in psychedelic science. It has been reported consistently since the first accounts of DMT use in the 1950s, documented in Strassman's clinical study, documented in detail in a 2020 Johns Hopkins survey of 2,561 people who had had such an encounter (Davis et al., J. Psychopharmacol. 34(9)). Imaging has not yet isolated it: the 2023 Imperial College EEG-fMRI study (Timmermann et al., PNAS 120(13)) mapped DMT's global brain effects, not entity contact specifically. The consistency of the report is established. The explanation is not.

Terence McKenna encountered the entities in Berkeley in 1965. He described them — merry, elfin, self-transforming, fractal, offering visible objects made of language — with a specificity that subsequent independent reporters have consistently corroborated without having read his description. He spent the next thirty-five years neither claiming that they were objectively real in the naive sense nor dismissing them as mere hallucination. He held the question open.

This epistemological position — call it principled uncertainty — is what distinguishes True Hallucinations from both the credulous and the dismissive traditions in psychedelic literature. McKenna was not a simple believer. He acknowledged, consistently, that the entities might be products of his own mind: unconscious material given dramatic form by DMT's action on the brain. He acknowledged that the Timewave was either revolutionary or delusional and that he could not determine which from the inside. He acknowledged that what happened at La Chorrera might have been a psychosis rather than a revelation.

He continued to report what he had experienced. Not as proven fact. As experience.

The philosophical distinction matters enormously. The scientific establishment's refusal to engage seriously with entity contact reports has not been based on evidence that they are mere hallucinations — it has been based on an a priori assumption that if something is produced under the influence of a drug, it cannot be genuinely informative about external reality. This assumption is itself a philosophical position, not an empirical finding, and it is one that the consistency of entity contact reports makes harder to sustain.

The standard materialist account — entities are projections of the unconscious, elaborate productions of a brain temporarily released from its filtering function — is a coherent explanation that fits the available evidence. It is not, however, the only coherent explanation that fits the available evidence. The question of whether DMT entities have any reality beyond the brain that produces them is not currently answerable by available methods.

Researcher Andrew Gallimore has proposed a more rigorous version of McKenna's basic position: that DMT may allow access to a genuine alternative reality — not by taking the brain outside itself, but by reconfiguring the brain's perceptual apparatus to receive signals from a state space that ordinary consciousness excludes. This is Huxley's reducing valve argument, applied to entities rather than flowers: what is usually filtered out is allowed through.

Gallimore's position is speculative but scientifically articulated. It makes predictions: that the entity environment should show internal consistency across users that exceeds what could be explained by shared cultural expectations (the survey data suggests this is true); that entity-contact neural signatures should differ from those of ordinary hallucination (the 2023 Timmermann fMRI data suggests this is true); and that specific features of the entity environment should be reproducible across independent subjects in conditions that control for cultural priming (not yet tested).

Dennis McKenna — the most rigorous neuropharmacologist in the family — has said, in various interviews, that he believes something real happened at La Chorrera, while being careful about what 'real' means. His scientific training makes him unwilling to assert objective external entities. His direct experience makes him unwilling to dismiss what happened as simply drug-induced brain noise.

This is the position True Hallucinations occupies. Not the position of the believer. Not the position of the skeptic. The position of the careful reporter who has experienced something that current frameworks cannot accommodate and refuses either to force it into a framework or to deny that it happened.

The entity contact problem will be resolved, if it is resolved, by better science than currently exists. McKenna's contribution was to keep the question open — to insist on the rigor of accurate phenomenological reporting even when the phenomenon reported was epistemologically inconvenient. That is the book's lasting value: not the answer but the quality of the question.

Sources

• McKenna, True Hallucinations (1993)
• Strassman, DMT: The Spirit Molecule (2001)
• Sexton et al., J. Psychopharmacol. 33(9) (2019)
• Timmermann et al., PNAS 120(13) (2023)
• D. McKenna, The Brotherhood of the Screaming Abyss (2012)
• Davis et al., J. Psychopharmacol. 34(9):1008-1020 (2020)

“Mescaline has been Schedule I since 1970. Huxley's mescaline session was legal. The book describing it is legal. The experience it describes is a federal crime.”

When Humphry Osmond administered four-tenths of a gram of mescaline to Aldous Huxley in May 1953, the act was entirely legal. Mescaline had been a pharmaceutical curiosity and occasional clinical tool since the 1890s. The Controlled Substances Act of 1970 placed mescaline in Schedule I — alongside heroin and LSD — not driven by evidence of harm but by the political context of the Nixon drug war, which was, as Ehrlichman later confirmed, explicitly targeted at political enemies and minority communities.

Mescaline's Schedule I status has remained unchanged for fifty-five years despite the absence of documented harm from clinical or ceremonial use. The Native American Church's peyote ceremonies — which involve mescaline as the active compound — received a specific religious exemption in the 1994 American Indian Religious Freedom Act Amendments, making NAC members the only legal mescaline users in the United States.

Colorado's Proposition 122 (November 2022) decriminalized personal possession of mescaline (excluding peyote) alongside psilocybin, ibogaine, and DMT. No other state has followed. The federal Schedule I status remains.

Huxley's book is taught in universities. The experience it describes is illegal. The plant providing the experience has grown in the Chihuahuan Desert for millions of years. The law making it illegal is fifty-five years old and has produced no documented reduction in mescaline use.

Sources

• Huxley, The Doors of Perception (1954)
• Controlled Substances Act (1970)
• Wikipedia, Mescaline

“Oregon's Measure 109 created the first regulated psilocybin services program in the US. Over 100 service centers were licensed by 2026. The model is imperfect, instructive, and being revised in real time.”

Huxley's vision in The Doors of Perception was not unlimited access to mescaline but legitimate pathways for people who had the preparation, intention, and support to use psychedelics well. Oregon's Measure 109 is the closest existing policy implementation: adults 21+ can access psilocybin at licensed service centers under licensed facilitators — without prescription, but within a regulated framework.

As of 2026, over 100 service centers are licensed in Oregon. The program has already required significant revision: HB 2387 (signed May 2025) corrected an absurd provision preventing licensed medical professionals from using their professional skills while facilitating sessions. Further modifications were signed in March 2026.

Colorado's Proposition 122 went further: it combined licensed healing center access with broader decriminalization of personal possession and social sharing of psilocybin, ibogaine, DMT, and mescaline (excluding peyote). Colorado's first healing center opened in July 2025. Governor Polis pardoned people convicted of state possession charges.

Both models produce data that will inform the next generation of state and eventually federal policy. What the programs demonstrate is that Huxley's fundamental premise was correct: structured, supported access to psychedelic experience is feasible within a regulatory framework. What remains unresolved is how to design that framework to serve those who most need it — people without $300-2000 per-session access fees, people in rural areas, people whose mental health conditions create clinical need.

Sources

• Oregon Health Authority Psilocybin Services (2023)
• Reason Foundation State Psychedelics Policy Roundup (2025)
• High Times Psychedelic Reform (April 2026)

“Four organizations now have federal DEA exemptions for ayahuasca. The Church of Gaia received the first-ever non-litigation DEA approval in May 2025. Huxley called the experience a sacrament. The law is slowly catching up.”

Huxley framed the mescaline experience in explicitly religious terms: a 'gratuitous grace,' a 'sacrament.' The Religious Freedom Restoration Act (1993) created the federal framework for this argument: it prohibits the government from substantially burdening a person's exercise of religion unless the government demonstrates a compelling interest by least restrictive means.

The Supreme Court applied RFRA to psychedelic religion in Gonzales v. O Centro (2006), unanimously holding the government could not prohibit the União do Vegetal's ayahuasca ceremonies. Four US organizations now hold confirmed federal DEA exemptions: the União do Vegetal (SCOTUS 2006), Santo Daime (9th Circuit 2009), the Iowaska Church of Healing (DEA settlement 2024), and the Church of Gaia — the first-ever non-litigation DEA approval, granted in May 2025.

Colorado's Proposition 122 addressed the limits of the religious institution model by allowing payment for 'spiritual and harm-reduction services' outside licensed healing centers — protecting indigenous ceremonial practice and access modalities that don't fit clinical or commercial frameworks.

The tension between institutional religious exemption and broader spiritual access remains the central unresolved question of psychedelic religious law. Huxley's 'gratuitous grace' was available, in his argument, regardless of denominational affiliation. The legal framework for psychedelic access that requires institutional religious structure creates exactly the kind of gatekeeping his democratic impulse resisted.

Sources

• RFRA (1993)
• Gonzales v. O Centro (2006)
• Mindmedicinelaw.com Psychedelic Legal Status (2026)

“Huxley called the experience 'of inestimable value to everyone.' Oregon sessions cost $300-$2,000 out of pocket. These facts are in tension.”

In The Doors of Perception, Huxley argued that the experience of direct perception was 'of inestimable value to everyone.' The qualitative democracy of the claim is deliberate: not everyone who wants mescaline should have it, but the benefit of opening the reducing valve is not restricted to any class or education level.

The psychedelic therapy market as actually developed is not structurally democratic. In Oregon, a psilocybin session costs between $300 and $2,000 out of pocket, with no insurance coverage as of 2026. Clinical trials require specific diagnoses and geographic proximity. Ketamine infusion clinics cost $400-$800 per session, also typically without insurance.

The MAPS Policy Guidebook (2026) explicitly acknowledges this equity gap, noting the historical invisibility and exploitation of Indigenous people in the American narrative.

The racial equity dimension is sharpest in the cannabis parallel: communities most heavily criminalized under cannabis prohibition have not received commensurate benefit from legalization. Oregon's Measure 109 required an underserved community access program; Colorado's Proposition 122 included equity licensing provisions. Whether these provisions translate into meaningful equitable access or primarily function as symbolic concessions is the open empirical question.

Sources

• Huxley, The Doors of Perception (1954)
• Oregon Health Authority Psilocybin Services (2024)
• MAPS Policy Guidebook (2026)

“Hoffer and Osmond's 1961 paper showed roughly 50% sobriety rates in treated alcoholics. COMPASS Pathways' NDA is targeted for Q4 2026. The interrupted clinical program is completing its interrupted work.”

When Osmond and Hoffer published their LSD alcoholism results in 1961, they were presenting a landmark finding: roughly half of treated alcoholic patients achieved lasting sobriety. The result exceeded anything available in 1961 psychiatry for alcohol use disorder. The finding did not lead to clinical approval — the Controlled Substances Act of 1970 ended the program.

The clinical research now reaching regulatory maturity uses psilocybin rather than LSD — structurally similar, pharmacologically analogous. COMPASS Pathways' COMP360 has completed two Phase 3 trials: COMP005 (June 2025) and COMP006 (February 2026), both hitting primary endpoints for treatment-resistant depression. The NDA submission is targeted for Q4 2026, with potential FDA approval in late 2026 or early 2027.

FDA's Breakthrough Therapy Designation for COMP360 (2018) provides intensive FDA guidance and rolling review eligibility. The DEA increased its 2026 psilocybin production quota to 50,000 grams — up from 30,000 in 2025 — citing expanded research and clinical trial needs. The Usona Institute's IPR001 program, testing psilocybin for major depressive disorder, received a National Priority Voucher accelerating FDA review.

What approval means: COMP360, if approved, would be the first FDA-approved psychedelic-assisted therapy. It would require certified clinical settings with trained therapists. The clinical model the FDA is approving is structurally what Osmond proposed in the 1950s: preparation, guided session, integration. The regulatory infrastructure for what Huxley called 'proper use' is, sixty-five years after the letters began, approaching completion.

Sources

• Hoffer & Osmond, J. Mental Sci. (1961)
• COMPASS Pathways Phase 3 (2025-2026)
• FDA Breakthrough Therapy Designation (2018)
• Psychedelic Beacon FDA Approval Tracker (April 2026)

“The evidence for psilocybin in end-of-life anxiety is among the strongest in all of psychedelic medicine. The policy response has been among the slowest.”

The 2016 Johns Hopkins and NYU studies of psilocybin for end-of-life anxiety in terminal cancer patients found that a single psilocybin session produced rapid and sustained reductions in depression and anxiety, with 80 percent showing clinically significant improvement at six months in both studies.

In the United States, psilocybin remains Schedule I — end-of-life psilocybin therapy is not accessible to dying patients outside clinical trials requiring specific eligibility and geographic proximity. Australia moved faster: in February 2023, the TGA approved psilocybin for treatment-resistant depression with provisions including palliative care contexts. Australia became the only country where licensed psychiatrists could prescribe psilocybin to dying patients as standard of care.

Oregon's Measure 109 permits end-of-life access — a person needs only to be 21 or older, without a diagnosis requirement. This means in Oregon, a dying person can legally access psilocybin at a service center, a flexibility the clinical trial infrastructure does not provide.

Huxley requested LSD on his deathbed in 1963. The clinical evidence for this use has been strong since 2016. The policy infrastructure to enable it broadly in the United States has still not arrived. The evidence is not the bottleneck.

Sources

• Griffiths et al., J. Psychopharmacol (2016)
• Ross et al., J. Psychopharmacol (2016)
• TGA Australia (2023)

“The word 'psychedelic' was coined to replace 'psychotomimetic.' Regulators now use 'classical serotonergic psychedelics.' The vocabulary war continues to shape the policy.”

When Osmond coined 'psychedelic' in 1957 to replace 'psychotomimetic,' he was making a policy argument in the form of a word. 'Psychotomimetic' encoded a clinical framework: these substances mimic psychosis. Any research program premised on this word would investigate them as pathology simulators. 'Psychedelic' — mind-manifesting — encoded a different framework: these substances reveal what the mind contains. A research program premised on this word would investigate them as therapeutic tools.

The FDA's Breakthrough Therapy Designation for COMP360 psilocybin (2018) and MDMA (2017) represented regulatory acknowledgment that these substances might work through mechanisms unlike ordinary psychiatric drugs — not through chronic receptor modulation but through a single transformative experience. The designation implies a different pharmacological category from antidepressants, even if the regulatory pathway is the same.

The scientific literature has settled on 'classical serotonergic psychedelics' (Nichols, 2016) — technically precise but not politically neutral. 'Serotonergic' implies a specific receptor mechanism, pharmacological manageability, FDA-style drug approval as the appropriate regulatory model.

Osmond's vocabulary choice in 1957 shaped every subsequent regulatory discussion. The question of what these substances are doing to the mind is not separate from the question of how they should be governed. Vocabulary is policy, and the vocabulary is still contested.

Sources

• Osmond, Ann. N.Y. Acad. Sci. (1957)
• Nichols, Pharmacol. Rev. (2016)
• FDA Breakthrough Therapy documents (2018)

“LSD has been Schedule I for fifty-five years. Zero documented deaths from overdose toxicity in eighty years of use. The WHO's 2019 Critical Review found no evidence supporting its current scheduling level.”

LSD has been Schedule I since the Comprehensive Drug Abuse Prevention and Control Act of 1970. Schedule I requires high abuse potential, no accepted medical use, and lack of accepted safety under medical supervision. These criteria have been disputed for fifty-five years.

The safety evidence: the 2016 Global Drug Survey (30,000+ drug users) found LSD had the lowest emergency medical treatment rate of any substance surveyed, lower than alcohol, cannabis, cocaine, and MDMA. Zero deaths from LSD overdose toxicity have been documented in eighty years of human use.

The WHO Expert Committee on Drug Dependence conducted a Critical Review of LSD in 2019 and found no evidence supporting the substance's current international scheduling level. The recommendation did not change the scheduling.

The FDA's Breakthrough Therapy Designation for psilocybin (2018) effectively acknowledged that classical psychedelics may have accepted medical use. COMPASS Pathways' NDA for COMP360 psilocybin, targeted Q4 2026, will be the first formal clinical approval application.

LSD is in Phase 2 clinical trials in Switzerland, Canada, and the UK. The regulatory pathway for LSD lags psilocybin by approximately five years for commercial rather than pharmacological reasons: no company has invested the Phase 3 infrastructure for LSD that COMPASS built for psilocybin. Hofmann proposed rescheduling in 1979. The current regulatory environment is approximately five years from implementing the proposal he always required.

Sources

• Global Drug Survey (2016)
• WHO ECDD Critical Review LSD (2019)
• Controlled Substances Act (1970)
• Hofmann LSD My Problem Child (1979)

“Hofmann synthesized LSD in 1943. COMPASS Pathways has filed patents on synthetic psilocybin formulations, dosing protocols, and therapy delivery. The enclosure of the psychedelic commons has begun.”

Albert Hofmann synthesized LSD-25 at Sandoz Laboratories. Sandoz held the pharmaceutical patents until they expired. Hofmann consistently argued LSD should be treated as a sacred drug, not a commercial product.

The current psychedelic patent landscape is substantially more aggressive. COMPASS Pathways has filed patents not only on its synthetic psilocybin formulation but on manufacturing processes, specific crystal polymorphs, and therapeutic protocols — including the specific combination of drug, therapist training, and environmental conditions constituting the COMP360 treatment system.

Researchers at Johns Hopkins established a defensive patent program in 2021 — filing patents on psychedelic compounds and protocols specifically to ensure prior art was in the public domain, preventing any single entity from monopolizing the space. The Usona Institute committed to non-exclusive licensing.

The indigenous knowledge dimension adds another layer: many compounds under patent consideration were used by indigenous communities for millennia. The ayahuasca patent case (US Patent 5,751,559, cancelled 2003 after indigenous challenge) established that prior art arguments can defeat patents on traditional plant knowledge.

Hofmann's problem child has become a commercial asset. Whether its therapeutic potential will be captured serving patients broadly or primarily shareholders is the central policy question of the current psychedelic industry.

Sources

• COMPASS Pathways patent portfolio
• Johns Hopkins Defensive Patent Initiative (2021)
• WIPO IGC (2024)
• Hofmann LSD My Problem Child (1979)

“Cluster headache patients figured out that sub-hallucinogenic doses of LSD can abort cycles before any clinical trial tested it. The regulatory pathway has taken twenty years to formalize.”

Cluster headaches are called 'suicide headaches' by sufferers — orbital pain lasting 15 minutes to three hours, occurring multiple times daily. In online communities of sufferers in the early 2000s, an unusual pattern emerged: sub-hallucinogenic doses of LSD or psilocybin could abort active cluster cycles and extend remission significantly.

Andrew Sewell and colleagues published the first case series in Neurology in 2006, documenting 53 cluster headache patients who tried psilocybin or LSD. Both substances significantly shortened or aborted cluster periods in most respondents. The mechanism — hypothetically involving serotonergic effects on the trigeminal nucleus — is not fully understood.

No pharmaceutical company has sponsored a Phase 3 cluster headache trial for LSD or psilocybin. Cluster headache is rare (approximately 0.1% of population), limiting commercial incentive. The patient community has been vocal, but the regulatory pathway depends on commercial sponsorship that has not materialized.

This is Hofmann's problem child at its most ironic: a compound that patients are already using effectively, with a safety profile that supports use, and preliminary clinical evidence confirming efficacy, but that the regulatory system cannot fully approve because the commercial economics don't justify the Phase 3 investment. The problem child remains a partial orphan.

Sources

• Sewell et al., Neurology (2006)
• Wikipedia Cluster headache
• Mindmedicinelaw.com (2026)

“McKenna's argument was ecological before it was pharmacological. The drug war and the environmental crisis have the same root: the dominator culture's relationship with the natural world.”

McKenna's argument in Food of the Gods is not primarily about drugs. It is about ecology. The suppression of plant medicines is one feature of a broader cultural pathology: the dominator culture's relationship with nature is extractive because the same culture that treats plants as objects treats consciousness as a territory to be conquered.

The Amazon has lost approximately 20 percent of its forest cover since 1992. The Kunming-Montreal Global Biodiversity Framework (2022) commits signatories to protect 30 percent of global land by 2030 and includes specific provisions for indigenous-managed territories — recognizing that indigenous land management practices generally produce better conservation outcomes than state-managed protected areas.

The communities most effectively protecting biological diversity are the same communities that maintain plant medicine traditions. This connection is now embedded in mainstream conservation policy.

The policy implication is not that psilocybin legalization will save the Amazon. The policy implication is that the drug war's suppression of indigenous plant knowledge traditions has contributed to severing the ecological relationship McKenna identified as constitutive of healthy human culture. Restoration of legal access to plant medicines, within appropriate cultural frameworks, would serve ecological goals as well as therapeutic ones.

McKenna's argument provides no detailed policy blueprint, only the premise: these plants belong to the commons, not to the state or the corporation.

Sources

• McKenna, Food of the Gods (1992)
• Amazon Conservation Team Reports (2023)
• Kunming-Montreal Global Biodiversity Framework (2022)

“Texas committed $50 million to ibogaine research for veterans in 2025. The politics of psychedelic medicine shift when the patient population is veterans with PTSD.”

Food of the Gods is not a book about ibogaine. But its central argument — that psychoactive plants are medicine and that Western civilization has been impoverished by their suppression — has found unexpected expression in the most politically conservative corner of the current psychedelic policy landscape: veterans' PTSD treatment.

Ibogaine, derived from the iboga shrub of Gabon and Cameroon, produces a 12-36 hour experience characterized by intense autobiographical review and, in many reports, direct confrontation with consequences of one's actions. Small studies of veterans with PTSD and opioid use disorder have shown striking results that exceed available alternatives.

The political pathway for ibogaine has moved through veteran advocacy. Texas Governor Greg Abbott signed legislation in 2025 directing $50 million toward ibogaine clinical trials for veterans. Rick Perry — former Texas governor, Secretary of Energy under Trump — chairs Americans for Ibogaine. Mississippi's ibogaine research bill was signed in March 2026, coordinating with the Texas framework. Utah signed a veteran-focused psychedelic therapy research bill in March 2026.

The political dynamics are notable: these are conservative states with Republican governors, investing in psychedelic medicine research because the patient population is veterans. The bipartisan character of ibogaine advocacy is one of the clearest examples of how the policy landscape has shifted since McKenna wrote — not through countercultural arguments but through clinical evidence combined with a politically sympathetic patient population.

Sources

• High Times Psychedelic Reform (April 2026)
• Wikipedia Psilocybin decriminalization in the United States
• Americans for Ibogaine advocacy materials (2025)

“Oregon's Measure 110 decriminalized all personal drug possession in 2020. The legislature repealed it in 2024. The lesson: services without social investment cannot hold politically.”

Oregon passed two ballot measures in November 2020: Measure 109 (regulated psilocybin services) and Measure 110 (decriminalizing personal possession of all drugs). By 2024, Oregon's legislature had repealed Measure 110. The drug decriminalization portion collapsed under political pressure and implementation difficulties — the provision replacing criminal penalties with health assessments required social service infrastructure that was not ready when the law took effect.

Colorado's Proposition 122 attempted to combine both: regulated healing center access alongside personal decriminalization. Colorado's approach is still being implemented and has not faced the legislative reversal Oregon's decriminalization did.

As of mid-2026, psychedelic reform is advancing simultaneously in multiple states through multiple models. New Mexico's medical psilocybin program became operational in 2025 — the first to pass through a legislature rather than a ballot. New Jersey signed a $6 million psychedelic research initiative in January 2026. Massachusetts has multiple competing bills advancing. Alaska is gathering signatures for a 2026 ballot initiative.

The diversity of models is itself informative. The comparative data on outcomes will eventually produce a clearer evidence base for what works. McKenna's argument provides no blueprint, only the premise: these plants belong to the commons. The regulatory implementation of that premise requires environmental impact assessments and state licensing boards — which is not what he predicted, but is what is happening.

Sources

• Wikipedia Psilocybin decriminalization in the United States
• High Times Psychedelic Reform (April 2026)
• Reason Foundation State Psychedelics Policy Roundup (2025)

“McKenna argued that the privacy of the individual mind is the most basic civil liberty. The courts have not agreed. The legislature is beginning to.”

The psychedelic issue is a civil rights and civil liberties issue, McKenna wrote. It concerns the most basic of human freedoms: religious practice and the privacy of the individual mind.

The courts have been skeptical. No federal court has recognized a constitutional right to alter one's consciousness through controlled substances independent of religious context.

The legislature has been more receptive. Colorado's Proposition 122 is the most expansive implementation of McKenna's personal autonomy argument: decriminalized personal possession, cultivation, use, and social sharing of psilocybin, psilocyn, ibogaine, and mescaline (excluding peyote) for adults. The social sharing provision specifically protects informal, communal, and ceremonial use outside commercial or medical frameworks.

The Cato Institute's 2025 analysis argues for building on existing cannabis regulatory infrastructure rather than creating new regulatory agencies — using dispensaries, testing laboratories, and compliance frameworks already established for cannabis.

McKenna's framing — that the illegality of plants is obnoxious and ridiculous in the first place — captures what most policy advocates are more careful to avoid saying: the fundamental premise of drug prohibition, applied to plants humans have used for thousands of years, is philosophically incoherent. The plant does not become illegal because a legislature says so. The law making it illegal is the aberration.

Sources

• McKenna, Food of the Gods (1992)
• Colorado Proposition 122 (2022)
• Cato Institute Future of Psychedelic Regulation (2025)

“107,500 overdose deaths in 2023 — the highest in US history, primarily fentanyl. Hari's connection model predicted the social conditions driving addiction. It did not predict how prohibition-driven supply adulteration would accelerate mortality.”

Hari published Chasing the Scream in 2015, when US drug overdose deaths were approximately 52,000 annually. By 2023, overdose deaths had reached 107,500 — primarily attributable to illicit fentanyl and fentanyl analogs that had displaced heroin in the illegal drug market.

Hari's connection model correctly predicted that enforcement-focused policy would not reduce drug use or addiction rates. It did not specifically predict the mechanism by which the combination of increased enforcement and synthetic opioid availability would produce the mortality catastrophe of the 2020s.

The fentanyl crisis is in significant part a product of supply-side enforcement. Prohibition-driven pressure on heroin supply created market incentives for synthetic opioids that are more potent, more concentrated, easier to smuggle, and vastly more dangerous per unit. Fentanyl is approximately 50-100 times more potent than heroin by weight. The enforcement that was supposed to reduce drug supply has instead selected for more dangerous versions of the supply.

This pharmacological and economic argument complements Hari's social argument: prohibition does not eliminate drug markets; it selects for the most dangerous formats. Alcohol prohibition produced high-proof bootleg spirits. Heroin prohibition has produced fentanyl.

Portugal's harm reduction programs have had more limited impact on fentanyl-driven mortality precisely because fentanyl bypasses the social conditions approach: a person can be socially connected and still die from an accidental overdose of supply-contaminated product.

Sources

• CDC Drug Overdose Deaths (2023)
• Hari Chasing the Scream (2015)
• EMCDDA European Drug Report (2023)

“OnPoint NYC reversed over 1,200 overdoses without a single on-site death between November 2021 and 2025. The US had no legal safe injection site for over forty years after the first opened in Canada.”

In November 2021, OnPoint NYC opened in East Harlem — the first legally sanctioned overdose prevention center in the United States. It serves an average of 500 clients daily and by 2025 had reversed over 1,200 overdoses through naloxone administration without a single on-site overdose death.

Harm reduction policy has expanded significantly since 2015. Naloxone availability has improved dramatically: available without prescription in every US state, with Narcan (nasal naloxone) receiving OTC approval in 2023. Fentanyl test strips, allowing users to check supply for the most dangerous adulterant, have been legalized in most states and distributed through syringe service programs.

What has not changed: the federal legal framework still classifies safe injection sites as illegal under the Controlled Substances Act's 'crack house' statute. The DOJ under the Trump administration did not challenge OnPoint NYC operationally, but the legal uncertainty has prevented most jurisdictions from opening similar facilities.

Hari's argument — that harm reduction is not only more humane but more effective than enforcement — has been confirmed by every facility permitted to operate. The policy constraint is not the evidence.

Sources

• OnPoint NYC Organizational Reports (2025)
• Hari Chasing the Scream (2015)
• CDC Drug Overdose (2023)

“John Ehrlichman confirmed in 2016 what Hari documented in 2015: the Nixon drug war was explicitly designed to target Black people and anti-war protesters. The documented acknowledgment has not produced commensurate policy correction.”

John Ehrlichman's 2016 Harper's Magazine interview provided the most significant documentary confirmation of Hari's drug war argument: 'We knew we couldn't make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin, and then criminalizing both heavily, we could disrupt those communities.'

The policy response has been partial. President Biden issued mass pardons for federal cannabis possession convictions in October 2022. The DOJ proposed rescheduling cannabis from Schedule I to Schedule III in May 2024.

But the racial disparities persist. The ACLU documented in 2020 that Black Americans are 3.73 times more likely to be arrested for marijuana possession despite similar use rates. State-level cannabis legalization has not uniformly produced expungement of prior convictions. Equity licensing provisions in legal cannabis markets have been inconsistently funded and implemented.

Hari's documentation of individual stories — Holiday, the communities he visited — is the human texture of what statistics describe. The policy debate often proceeds as if the racial targeting were incidental rather than central. The Ehrlichman quote is the evidence that it was not.

Sources

• Ehrlichman, quoted in Dan Baum, Harper's Magazine (2016)
• ACLU A Tale of Two Countries (2020)
• Biden Executive Order Cannabis Pardons (October 2022)
• DOJ NPRM Cannabis Rescheduling (May 2024)

“Oregon's Measure 110 decriminalized all personal drug possession in 2020. The legislature repealed it in 2024. The lesson is not that decriminalization failed — it is that decriminalization without social investment cannot hold politically.”

Oregon's Measure 110 (November 2020) replaced criminal penalties for personal possession of all drugs with health assessments and referrals. The model was explicitly inspired by Portugal's 2001 decriminalization. By 2024, the Oregon Legislature had repealed Measure 110. The health assessment provisions had not been adequately implemented — the social service infrastructure required to make referrals meaningful did not exist in the communities where repeal of criminal penalties was most consequential.

Hari's account of Portugal's success was accurate for Portugal in the period he studied (2001-2015). What his account underweighted — as longer-term data has confirmed — is that Portugal's success depended on the social investment component, which austerity measures after the 2008 financial crisis eroded.

Oregon's reversal is instructive: decriminalization is necessary but not sufficient. Without corresponding investment in housing, employment, treatment capacity, and community services, decriminalization alone produces political vulnerability rather than public health improvement.

The lesson is not that Hari was wrong. It is that his framework is more demanding than 'stop arresting people.' Stop arresting people and provide meaningful alternatives to the conditions that drive drug use — that is the full policy, and it is considerably harder to implement than the arrest-and-incarcerate system it replaces.

Sources

• Wikipedia Oregon Measure 110
• EMCDDA Portugal Drug Report (2023)
• Hari Chasing the Scream (2015)
• CDC Drug Overdose Deaths (2023)

“The Mysteries were abolished by state power in 392 CE because they competed with state religion. The US scheduling of psilocybin and LSD follows the same logic.”

In 392 CE, Emperor Theodosius issued edicts outlawing non-Christian religious practice throughout the Roman Empire. The Eleusinian Mysteries, which had operated continuously for approximately a thousand years, were formally prohibited. The political structure of the suppression is not obscure: a state religion that could not coexist with a competing institution offering direct, individual experience of the divine used state power to eliminate the competition.

Carl Ruck's scholarship places contemporary drug prohibition in this historical lineage: the recurring pattern in which institutions that manage access to the sacred suppress experiences that bypass their mediation. Psychedelic experience characteristically produces what William James called the 'noetic quality' — a sense of having directly received genuine knowledge. This is precisely what institutional religion claims to provide.

The Religious Freedom Restoration Act provides the current US legal framework for the argument that psychedelic experience deserves First Amendment protection. Gonzales v. O Centro (2006) applying RFRA to ayahuasca demonstrates legal traction. The Church of Gaia's May 2025 non-litigation DEA approval demonstrates the regulatory system can accommodate sincere religious psychedelic use.

But RFRA protection requires demonstrating sincerity of religious belief, creating institutional barriers. The Road to Eleusis scholarship's argument — that entheogenic religious practice is foundational rather than peripheral to Western civilization's religious history — is directly relevant to how these barriers should be evaluated.

Sources

• Wasson Hofmann & Ruck The Road to Eleusis (1978)
• Theodosius Codex 392 CE
• RFRA (1993)

“Chemical residue analysis of excavated vessels could confirm or significantly challenge the Road to Eleusis hypothesis. The analysis has not been done.”

The archaeological site at ancient Eleusis — location of the Telesterion, the Sacred Way, and the sanctuary complex where two thousand years of Mystery initiations occurred — is a protected UNESCO-monitored zone in the municipality of Eleusis, approximately thirty kilometers from Athens. It is also adjacent to an operating oil refinery.

The Hellenic Ministry of Culture began a major excavation program in 2015. As of 2026, the excavation has produced new architectural documentation and ceramic finds, but the chemical residue analysis that would most directly test the Wasson-Hofmann-Ruck hypothesis has not been undertaken at the Eleusis site itself.

The 2026 Scientific Reports paper by Antonopoulos and Dadiotis explicitly calls for such analysis: 'Detailed archaeobotanical and chemical analyses of relevant vessels from the Eleusis sanctuary itself are necessary to confirm or refute the ergot alkaloid hypothesis.' The methods required are non-destructive for macroscopic residue analysis and minimally destructive for chemical sampling.

Eleusis's 2023 designation as European Capital of Culture brought significant international attention and EU funding, creating political conditions more favorable to innovative research. The research question is not whether the analysis should be done — it should — but whether institutional, political, and resource conditions will support it.

Sources

• Antonopoulos & Dadiotis Scientific Reports (2026)
• Hellenic Ministry of Culture Eleusis Excavation Reports (2023)
• Eleusis 2023 European Capital of Culture

“'Entheogen' was coined in 1979 by Ruck, Bigwood, Staples, Ott, and Wasson to describe substances used for religious purposes. It has legal implications that 'hallucinogen' does not.”

Carl Ruck was one of three authors of The Road to Eleusis (1978). A year later, he was one of five authors of a short paper in the Journal of Psychedelic Drugs proposing a new word for substances used in religious contexts: entheogen, from the Greek en theos — 'the divine within.'

The paper argued that 'hallucinogen' was inappropriate for substances used in genuine religious practice because it encoded the assumption that what was experienced was unreal. A new word was needed that accurately described the category: substances that occasion the experience of the divine, used within a framework that recognizes that experience as sacred.

'Entheogen' has significant uptake in ethnobotanical and religious studies contexts. The legal significance is not negligible. RFRA protection requires demonstrating that a substance is used for religious purposes as part of sincere religious belief. The word 'entheogen' describes a category of substance use that is, by definition, religious rather than recreational.

The Church of Gaia's May 2025 DEA approval was granted under the entheogenic religious use framework. Whether the framework will expand to cover substances beyond ayahuasca, or contexts beyond formally organized religious institutions, is the open regulatory question. The Road to Eleusis scholarship provides the historical argument for why it should.

Sources

• Ruck et al. Entheogens J. Psychedelic Drugs (1979)
• Wikipedia Entheogen
• Gonzales v. O Centro (2006)

“If the founding intellects of Western philosophy derived their core metaphysical framework from a psychedelic sacrament, the prohibition of psychedelic experience is not a protection of Western values. It is a departure from them.”

The Road to Eleusis makes a claim with direct policy implications if correct: the most revered religious institution of classical antiquity used a psychedelic sacrament as its central technology. The initiates included Plato, Aristotle, Sophocles, Cicero — the founding intellects of Western philosophy and culture.

Carl Ruck makes the policy argument explicit: the right to entheogenic religious practice is the most classical religious claim available in Western civilization. The suppression of the Mysteries in 392 CE was the suppression of a practice Cicero called the best thing Athens ever gave the world. The current scheduling of psilocybin and LSD continues, in secular legal framework, the same suppression.

The constitutional counterargument — that the First Amendment does not protect drug use — rests on the assumption that drug-induced experience is categorically different from other religious experience. The Road to Eleusis challenges this assumption historically: the experience Eleusinian initiates described is formally identical to what Christian mystics, Sufi dervishes, and Vedantic practitioners describe through their respective traditions.

This argument is in active litigation through RFRA cases. The Road to Eleusis scholarship and Muraresku's extension in The Immortality Key are being cited in these proceedings. The claim that psychedelic sacramental use is foundational to Western tradition is the strongest possible argument for its constitutional protection.

Sources

• Wasson Hofmann & Ruck The Road to Eleusis (1978)
• Muraresku The Immortality Key (2020)
• Ruck The Road to Eleusis (1978)

“In August 2024, the FDA rejected Lykos Therapeutics' MDMA-assisted therapy application for PTSD. The decision was not about efficacy — Phase 3 showed significant results. It was about trial design concerns.”

In June 2024, the FDA's Psychopharmacologic Drugs Advisory Committee voted 10-1 that the evidence did not show MDMA-assisted therapy was effective for PTSD. In August 2024, the FDA issued a Complete Response Letter denying the NDA.

The rejection surprised many. Phase 3 trial data showed 67-71 percent of PTSD patients who received MDMA-assisted therapy no longer met diagnostic criteria at follow-up, compared to approximately 32 percent in the placebo arm.

The FDA's concerns were methodological, not efficacy-based: trials could not adequately blind participants to whether they received active MDMA or placebo; therapist expectancy bias was not controlled; adverse events were inadequately characterized; and trial safety monitoring for drug misuse by therapists was insufficient. An additional Phase 3 trial was requested.

Jay Stevens documented the 1968 collapse of LSD research: a clinical program ended not because the evidence was wrong but because political and institutional conditions became untenable. The MDMA rejection follows a different but related pattern: genuine efficacy evidence found insufficiently methodologically rigorous to approve.

The FDA's request for an additional trial is not a refusal to engage with psychedelic therapy — it is an engagement demanding higher methodological standards than the program delivered. Whether this represents regulatory caution or obstruction depends on one's prior.

Sources

• FDA Advisory Committee Review Lykos Therapeutics (June 2024)
• MAPS Phase 3 PTSD data
• Psychedelic Legal Status by State 2026

“Texas signed $50M in ibogaine research funding. Colorado pardoned psychedelic convictions. Utah signed veteran psychedelic therapy research. The political map has become genuinely bipartisan.”

Jay Stevens closed Storming Heaven in 1968 with the Schedule I classification as a politically driven suppression of clinical research. The political context was clear: the Nixon administration's drug war explicitly targeted anti-war protesters and Black communities.

The political context of the current psychedelic policy moment is substantially different. In 2025, Rick Perry — former Republican Governor of Texas, Secretary of Energy under Trump — became chairman of Americans for Ibogaine and advocated for ibogaine research funding to treat veterans. Texas Governor Greg Abbott signed legislation directing $50 million toward ibogaine clinical trials. Mississippi's Republican-led legislature passed an ibogaine research bill in March 2026.

Utah, with conservative political culture and a large veteran population, signed a veteran-focused psychedelic therapy research bill in March 2026. On the other side: Colorado Governor Polis (Democrat) pardoned people convicted of state psychedelic possession charges. Oregon's Democratic-led legislature passed technical fixes to the psilocybin services program.

Psychedelic reform is no longer a left-right issue. The patient population of veterans with PTSD has created a coalition including conservative military veterans, Republican governors, and libertarian advocacy organizations alongside progressive harm reduction advocates.

The drug war was built on political polarization. Psychedelic reform is, unexpectedly, being built on political convergence.

Sources

• High Times Psychedelic Reform (April 2026)
• Colorado Sun Colorado Psychedelic Policy (2025)
• Wikipedia Psilocybin Decriminalization in the United States

“Psilocybin is Schedule I under federal law and legal in Oregon and Colorado. The same legal architecture that produced cannabis's state-federal conflict is now producing psychedelics' state-federal conflict.”

When Oregon's Measure 109 took effect in 2023, psilocybin became simultaneously Schedule I under federal law and regulated-legal under Oregon state law — the same legal architecture governing cannabis since Colorado and Washington's 2012 recreational legalization votes.

The psychedelic state-federal conflict is being managed through prosecutorial discretion: the DEA and DOJ have not challenged Oregon's psilocybin services program or Colorado's Natural Medicine Health Act. Over 100 service centers operate openly under Oregon state law without federal interference.

This arrangement is legally precarious: it depends on continued prosecutorial discretion, which could change with a new administration. The cannabis industry spent years seeking banking access and insurance coverage — complicated by the federal-state conflict. The psychedelic therapy industry will face the same complications unless federal law changes.

Federal psilocybin rescheduling — accompanying FDA approval of COMP360, if approved — would resolve the conflict for psilocybin in clinical contexts. It would not resolve the conflict for broader decriminalization provisions in Colorado and Oregon.

The Cato Institute's 2025 analysis argues state-level innovation should proceed regardless of federal action. The cannabis precedent supports this: state legalization preceded federal policy change and drove it. Stevens documented the 1968 federal destruction of psychedelic research; current states are building a record that may prevent a similar destruction.

Sources

• Wikipedia Psilocybin Decriminalization in the United States
• Mindmedicinelaw.com (2026)
• Cato Institute Future of Psychedelic Regulation (2025)

“In the 1950s, the CIA and NIH both funded psychedelic research simultaneously. In 2026, NIH contribution remains minimal. Private capital has filled the gap — and private capital has its own incentive structure.”

Stevens documented in Storming Heaven that the 1950s-1960s psychedelic research program had two simultaneous government funders: the CIA (through MK-Ultra, interested in weaponization) and the NIH (through legitimate research grants). Both ended with the 1968-1970 prohibition.

The current renaissance has been funded primarily by private capital rather than federal sources. COMPASS Pathways has raised over $300 million from venture capital and public markets. MAPS has raised over $100 million from philanthropic sources. The commercial pipeline of psychedelic biotech companies has attracted over $1 billion in investment since 2018.

NIH funding for psychedelic research has increased but remains a small fraction: approximately $20-30 million annually as of 2024-2025, compared to hundreds of millions from private sources. The research program is primarily driven by investors who need regulatory approval to generate returns.

This creates structural conditions Stevens identified as a risk: when financial interests drive the research agenda, questions being answered are those relevant to commercialization rather than the full range of therapeutic, cultural, and scientific applications. Cluster headaches — no large commercially attractive population — are not being funded. Indigenous ceremonial uses — no proprietary IP — are not being funded.

Osmond and Hoffer's Saskatchewan research was publicly funded provincial health research. The questions were driven by clinical need and scientific curiosity. The current program's questions are shaped by venture capital. The difference is not irrelevant.

Sources

• Stevens Storming Heaven (1987)
• Prohibition Partners PSYCH Report (2026)
• COMPASS Pathways financials (2024)
• MAPS organizational reports (2024)

“DMT is Schedule I. It is also produced endogenously by the human body. The legal status of the body's own compound, when found in plant material, is one of the stranger features of modern drug law.”

DMT — dimethyltryptamine — is Schedule I under the US Controlled Substances Act. The scheduling covers both synthetic DMT and its natural occurrence in plants.

DMT is also detectable in human blood, urine, and cerebrospinal fluid under normal conditions. The body produces it endogenously through normal metabolic pathways. Rick Strassman's hypothesis — that the pineal gland may produce DMT during near-death experiences, deep meditation, and REM sleep — is not confirmed but has generated substantial research interest.

This creates a legal peculiarity: a compound the human body produces naturally is Schedule I when found in plant material. Psychotria viridis, one of two ayahuasca components, contains DMT and is thereby a controlled substance under the Federal Analogue Act — even though its DMT content is not active without the companion vine's MAO inhibitors.

Colorado's Proposition 122 decriminalized personal possession of DMT alongside psilocybin, ibogaine, and mescaline. Four US religious organizations hold DEA exemptions for ayahuasca (which contains DMT) under RFRA. All other ayahuasca use in the United States lacks federal legal protection, though prosecution is rare in practice.

McKenna described his DMT experiences in True Hallucinations as encounters with genuine entities in a real space — categorically different from the hallucinations drug law presupposes. The legal category 'controlled substance' encodes the assumption that the experience is distorted perception. This assumption is not settled by available evidence.

Sources

• Wikipedia Legal status of psychedelic drugs in the United States
• Mindmedicinelaw.com (2026)
• Strassman DMT The Spirit Molecule (2001)

“McKenna's 2012 prediction was falsified. What survived was not the date but the question: what would it take for human culture to reorient itself toward a different relationship with consciousness?”

The Timewave Zero prediction — that December 21, 2012 would be a singularity of maximum novelty — was falsified without drama. McKenna had acknowledged the theory was falsifiable, and it was.

What survived the falsification was not the specific prediction but the underlying impulse: the conviction that Western civilization's relationship to consciousness was pathologically constrained, and that a transformation was both possible and necessary.

The psychedelic policy movement that emerged in the decade since 2012 is the institutionalized version of this impulse — not a singularity but an acceleration. Legal psilocybin services in Oregon and Colorado, FDA Breakthrough Therapy designations, Phase 3 clinical data for multiple indications, bipartisan legislative activity in over twenty states.

The MAPS Policy Guidebook (2026) — a nonpartisan framework for psychedelic legislation as more than a dozen states consider psychedelic bills simultaneously — represents exactly the careful institutional work McKenna's approach did not value. He was a lecturer and visionary, not a policy advocate. But the movement that has partly materialized from the cultural space he helped open is doing the unglamorous policy work he didn't do.

The 2012 date was wrong. The cultural shift McKenna was trying to name — a reorientation of Western civilization's relationship to consciousness, to plants, and to suppressed knowledge traditions — is happening, more slowly, more partially, and more bureaucratically than he imagined.

Sources

• McKenna True Hallucinations (1993)
• High Times Psychedelic Reform (April 2026)
• MAPS Policy Guidebook (2026)

“If DMT entities are reliably encountered by independent observers across cultures, what does drug law mean when it classifies the compound providing access as having 'no accepted use'?”

The Controlled Substances Act's Schedule I criteria require a substance have 'no currently accepted medical use' and 'a lack of accepted safety for use under medical supervision.'

The entity contact problem raises a different philosophical question about what drug law is governing. In a 2020 Johns Hopkins survey (Davis et al., J. Psychopharmacol. 34(9):1008-1020) of 2,561 people who had already had a DMT entity encounter, the majority described entities as conscious, intelligent and benevolent, the encounters as meaningful, and the experiences as among the most significant of their lives. It documents the phenomenology in detail but sets no prevalence rate, because every respondent was recruited for having had an encounter; the 97% figure often attached to it appears in no published paper. Many reported persistent changes in beliefs about death, meaning, and the nature of reality.

If these reports are accurate phenomenological descriptions — not of hallucination in the dismissive sense but of genuine encounters with something — then the Schedule I classification addresses a pharmacological action but not the nature of the experience the pharmacological action occasions. A drug providing access to a consistent perceptual territory that thousands of independent observers have mapped and found valuable is not obviously without accepted use.

The religious exemption cases have addressed the legal dimension through the religious freedom framework. McKenna made the argument more directly: the right to explore one's own consciousness is the most basic civil liberty, and a law prohibiting access to a consistent perceptual territory that humans have been accessing for tens of thousands of years is philosophically absurd. The courts have not agreed. The philosophical argument remains open.

Sources

• McKenna True Hallucinations (1993)
• Sexton et al., J. Psychopharmacol. 33(9) (2019)
• Controlled Substances Act (1970)
• Davis et al., J. Psychopharmacol. 34(9):1008-1020 (2020)

“The 2003 cancellation of the ayahuasca vine patent established that prior indigenous art can defeat pharmaceutical patents on traditional plant knowledge. The psychedelic patent race since 2020 has reopened the same contest.”

In 1986, the USPTO granted US Patent 5,751,559 to Loren Miller for a variety of Banisteriopsis caapi — the ayahuasca vine. The Coordinating Body of Indigenous Organizations of the Amazon Basin challenged the patent. After a decade of proceedings, the patent was cancelled in 2003: prior art existed in the ethnobotanical literature documenting indigenous use, and Miller's claimed variety was not sufficiently distinct from existing varieties.

The Narby argument — that the sacred cannot be sold and that appropriation of indigenous knowledge for commercial benefit without consent is a form of black magic — found legal expression in this case.

The psychedelic patent race since 2020 presents harder cases. COMPASS Pathways has patented specific crystal polymorphs of synthetic psilocybin — not the compound itself (long off patent) but specific forms its manufacturing process produces. This is legal. It does not involve any indigenous knowledge claim. But it creates intellectual property over specific formulations of a compound used by indigenous communities for millennia.

The Nagoya Protocol on Access and Benefit-Sharing, ratified by 138 countries as of 2024, creates an international legal framework requiring benefit-sharing with communities of origin. Implementation and enforcement have been weak.

Narby's argument — that the sacred is not for sale — is a moral claim the legal system has partially incorporated and partially ignored. The biopiracy contest the ayahuasca patent exemplifies is ongoing.

Sources

• Narby The Cosmic Serpent (1998)
• WIPO IGC (2024)
• Olson et al. Trends Pharmacol. Sci. (2022)

“The Chacruna Institute, the ICEERS Foundation, and multiple indigenous organizations have developed ethical frameworks for engagement with ayahuasca traditions. The retreat industry has largely not adopted them.”

The global ayahuasca retreat industry — estimated at $100 million or more annually as of 2024 — operates primarily in Peru, where the regulatory framework for protecting indigenous intellectual and territorial rights is weak. The industry draws on knowledge traditions developed by Shipibo-Conibo, Shuar, and other Amazonian peoples; most economic benefit flows to retreat operators rather than those communities.

The Chacruna Institute published Ethical Principles for Ayahuasca Organizations in 2019, developed in consultation with indigenous leaders and academics. The principles address consent, benefit-sharing, cultural appropriation, safety, and the risks posed by commercialization to knowledge traditions and communities involved. Adoption by retreat operators has been voluntary and inconsistent.

The ICEERS Foundation has worked to bridge indigenous knowledge holders and Western researchers in ways that protect indigenous sovereignty.

Narby spent thirty-five years as Amazonian projects director for Nouvelle Planète — working directly with indigenous communities on land rights, education, and traditional knowledge preservation. His institutional relationships give The Cosmic Serpent's policy arguments a grounding that pure scholarship lacks.

The central policy argument: communities that developed and stewarded ayahuasca knowledge deserve sovereign control over its use, appropriate benefit-sharing when used commercially, and legal protection of their territorial rights as the ecological foundation of that knowledge. None of these protections have been consistently implemented.

Sources

• Narby The Cosmic Serpent (1998)
• Chacruna Institute Ethical Principles (2019)
• ICEERS Foundation Reports (2024)
• Holman Anthropology of Consciousness (2021)

“If plants communicate, learn, and respond to their environment in ways that functional intelligence describes, the legal frameworks that treat them as property require revision.”

Jeremy Narby's Intelligence in Nature (2005) surveyed biologists working on plant signaling, mycelial networks, and microbial intelligence. By 2025, the field has transformed from marginal to mainstream: Simard's mycorrhizal network research is taught in undergraduate biology, Gagliano's plant learning experiments are published in peer-reviewed journals.

The policy implications of plant intelligence research are beginning to register in legal systems. Ecuador's constitution (2008) recognized rights of nature (Pacha Mama) — the first national constitution to do so. New Zealand granted the Whanganui River legal personhood in 2017. Spain's Constitutional Court upheld a law granting the Mar Menor lagoon legal standing in 2023.

These legal innovations do not yet address psychoactive plant knowledge and indigenous rights specifically. But they reflect the same underlying shift: the natural world as something with interests the law should recognize, not merely property to exploit.

Narby's argument — that the Amazon's biological intelligence, including its psychoactive plant pharmacopoeia, represents a knowledge resource that took billions of years to develop and that human communities have accessed for millennia — maps directly onto the rights-of-nature argument. These are not raw materials but systems with their own integrity.

The synthesis implementing Narby's argument as policy has not yet been constructed. The pieces exist: rights of nature, indigenous territorial rights, access and benefit-sharing frameworks, biopiracy protections. The integration awaits.

Sources

• Narby Intelligence in Nature (2005)
• Simard Finding the Mother Tree (2021)
• Ecuador Constitution Rights of Nature (2008)

“The Native American Church has formally requested that non-members refrain from consuming peyote. The peyote cactus is classified as threatened. The psychedelic renaissance's demand for 'natural medicine' is a direct conservation pressure.”

Peyote (Lophophora williamsii) has been used in indigenous ceremonial practice in the Americas for at least five thousand years. The Huichol people's annual pilgrimage to Wirikuta is one of the most intact surviving examples of indigenous plant medicine ceremonial tradition. The Native American Church, with 250,000-400,000 members, uses peyote sacramentally under federal legal protection.

Schultes documented this tradition with precision and respect, contributing to the legal arguments that produced the 1994 American Indian Religious Freedom Act Amendments specifically protecting NAC peyote use.

The psychedelic renaissance has introduced a new threat. Non-native interest in peyote — driven by the 'natural medicine' framing of the broader movement — has increased pressure on wild peyote populations. As of 2023, peyote is classified as threatened in the Chihuahuan Desert. A 2022 study in the Journal of Cactus and Succulent Research documented approximately 40 percent population decline in studied areas since 2000.

The Native American Church issued a formal statement in 2023 requesting non-members refrain from consuming peyote, citing the conservation threat and disruption of ceremonial traditions.

Colorado's Proposition 122 explicitly excluded peyote — an unusual case of drug policy deferring to indigenous sovereignty rather than pharmacological criteria. Peyote's legal status under Proposition 122 is determined by a political judgment about whose claim to the plant takes priority.

Sources

• Schultes & Hofmann Plants of the Gods (1979)
• Feeney et al. J. Cactus Succul. Res. (2022)
• NAC Statement on Peyote Conservation (2023)
• Colorado Proposition 122 (2022)

“Ayahuasca is legal in Peru, legal for specific religious organizations in the US, unregulated in many European jurisdictions, and globally subject to growing tourism demand that traditional communities did not design.”

Ayahuasca occupies a unique position in global drug law. The active compound DMT is Schedule I under the US Controlled Substances Act and under the UN Convention on Psychotropic Substances. But the ayahuasca preparation occupies a legal gray area because UN conventions specifically regulate isolated chemicals rather than plant preparations.

Peru, Brazil, and Ecuador have recognized ayahuasca as legitimate indigenous cultural heritage and have not criminalized its ceremonial use. The Netherlands, which does not classify the plants as controlled substances, has become a hub for European ayahuasca retreat activity.

In the US, four religious organizations hold DEA exemptions under RFRA. All other ayahuasca use lacks federal legal cover, though prosecution has been very rare in practice.

Schultes documented ayahuasca as a practice embedded in specific Amazonian indigenous communities with specific ceremonial roles, practitioner roles, preparation methods, and integration frameworks. What has developed globally since 1990 is a commercialized form that has stripped most of this context.

The policy problem is not only legal. It is what happens to a knowledge tradition when it is commercialized faster than the communities holding it can consent to, benefit from, or shape the commercialization. The knowledge is now being accessed faster than it can be protected.

Sources

• Schultes & Hofmann Plants of the Gods (1979)
• Mindmedicinelaw.com (2026)
• ICEERS Foundation Reports (2024)

“Schultes documented 24,000 plant species in twelve years. His herbarium is at Harvard. The communities whose knowledge helped him find those plants have no legal claim to either the specimens or the knowledge they represent.”

Schultes built his Amazon herbarium through botanical training, extraordinary fieldwork, and sustained collaboration with indigenous communities whose knowledge guided him to the plants he documented. The herbarium — over 24,000 specimens, housed at the Harvard University Herbaria — is one of the most valuable collections of Amazonian botanical material in the world.

The communities whose knowledge Schultes incorporated have no legal claim to the herbarium, no rights to research papers published from it, no entitlement to royalties from pharmaceutical applications derived from it.

The Nagoya Protocol (2010) requires countries that have ratified it (138 as of 2024) to ensure companies accessing genetic resources and traditional knowledge share benefits with communities of origin. The protocol covers new commercial exploitation; it does not retroactively address decades of exploitation that preceded its entry into force.

For the communities Schultes worked with: the international legal framework that should protect their interests is in place but does not address historical appropriation; enforcement of that framework for new exploitation is weak; and institutions that benefited most from the earlier collaboration face no legal obligation to remediate.

Plants of the Gods documents what was found. Who it belonged to is the question the legal framework has begun to address and has not yet answered.

Sources

• Schultes & Hofmann Plants of the Gods (1979)
• Nagoya Protocol (2010, in force 2014)
• WIPO IGC (2024)

“The DOJ proposed moving cannabis from Schedule I to Schedule III in May 2024. As of mid-2026, it has not been completed. What Schedule III would and would not do is different from what Herer actually argued for.”

In May 2024, the DEA published a Notice of Proposed Rulemaking proposing to reschedule cannabis from Schedule I to Schedule III — the first federal proposal to change cannabis's scheduling in fifty-four years. In December 2025, President Trump signed an executive order directing expedited rescheduling. As of June 2026, the rescheduling has not been finalized.

The practical implications of Schedule III classification are significant but limited. Schedule III would mean: cannabis could be legally prescribed; FDA would regulate cannabis pharmaceuticals; cannabis research would become substantially easier; and cannabis businesses could deduct normal business expenses from federal taxes (currently blocked by IRC 280E).

Schedule III would not mean: federal legalization; removal of criminal penalties for possession; automatic expungement of prior convictions.

Herer's argument in The Emperor Wears No Clothes was not primarily about medical cannabis or Schedule III. It was about full legalization of cannabis as a crop — industrial hemp for paper, fiber, and fuel; medical cannabis; and implicitly, recreational cannabis. Schedule III addresses the medical and research dimensions without touching the agricultural and industrial arguments that were Herer's original focus.

Herer's $100,000 challenge was extended because his primary claims were not being engaged by policymakers. As of 2026, those claims are being engaged. The engagement is proceeding more slowly and more partially than he demanded.

Sources

• DOJ NPRM Cannabis Rescheduling (May 2024)
• Herer The Emperor Wears No Clothes (1985)
• NORML Rescheduling FAQ (2025)

“The 2018 Farm Bill created the hemp industry Herer argued for since 1985. The industry is real, worth approximately $5 billion, and substantially different from what he envisioned.”

The 2018 Agricultural Improvement Act removed hemp (cannabis with less than 0.3 percent THC) from the Controlled Substances Act. By 2023, the US hemp industry was valued at approximately $4.9 billion. Primary market segments: CBD products, hemp fiber textiles, hempcrete construction materials, hemp food products, and industrial hemp fiber for technical applications.

This is substantially what Herer described as possible. The paper and fuel applications he emphasized most have not yet scaled significantly — hemp paper economics remain challenging compared to established wood pulp supply chains, and hemp biofuel has not displaced fossil fuels at meaningful scale. But fiber, food, and construction materials are commercial realities.

The industry's corporate character diverges from Herer's vision. He imagined hemp as a crop empowering small farmers. The actual hemp industry consolidated rapidly: the CBD extraction market overproduced massively in 2019-2020, driving prices down and eliminating most small operators. What remains is dominated by larger operators.

Herer's political economy argument — that hemp prohibition served specific corporate interests — has been partially vindicated by legalization's consequences: the corporations benefiting most from the legal hemp market are not the family farms and local cooperatives of his imagination. The emperor's new clothes are branded and investor-backed.

Sources

• Herer The Emperor Wears No Clothes (1985)
• USDA Economic Research Service Hemp (2023)
• Brightfield Group US Hemp Industry Report (2023)
• 2018 Agricultural Improvement Act

“Herer documented the racial origins of cannabis prohibition. The racial justice reckoning his evidence supported has been inadequately implemented in legalization policy.”

Chapter 9 of The Emperor Wears No Clothes is titled 'Prejudice: Marijuana and Jim Crow Laws.' Herer documented that cannabis prohibition was racially targeted from its inception — associated with Mexican immigrants in the Southwest and Black jazz musicians in Northern cities, enforced with systematic racial disparity.

Herer made this argument in 1985. The ACLU confirmed it in 2020: Black Americans are 3.73 times more likely to be arrested for marijuana possession despite similar use rates. Ehrlichman confirmed the intent in his 2016 Harper's interview.

The legal response has been partial. President Biden issued mass pardons for federal cannabis possession convictions in October 2022. State-level expungement programs have operated in Illinois, Virginia, California, and other states, with varying scope and implementation quality.

The cannabis industry's equity commitments have been more symbolic than structural in most jurisdictions. California's Equity Act created priority licensing for people from communities disproportionately impacted by cannabis enforcement; the program has faced resource and administrative challenges.

Herer's argument — that cannabis prohibition was an injustice built on racial targeting — creates a moral obligation to remediate at the same scale. The remediation that has occurred is not at the same scale. The communities most harmed have not received proportionate benefit from legalization. This is the unfinished business of the emperor's unclothing.

Sources

• Herer The Emperor Wears No Clothes (1985)
• ACLU A Tale of Two Countries (2020)
• Biden Executive Order Cannabis Pardons (October 2022)
• NORML Cannabis Legalization Tracker (2025)

“Herer compiled the medical cannabis literature in 1985. By 2025, the FDA had approved multiple cannabinoid-based pharmaceuticals. The argument was correct. The implementation was not what he imagined.”

Chapter 6 of The Emperor Wears No Clothes compiled peer-reviewed research supporting cannabis's therapeutic applications. Writing in 1985, Herer documented evidence for cannabis efficacy in glaucoma, multiple sclerosis, epilepsy, chronic pain, and cancer treatment side effects.

By 2025, the FDA had approved: Epidiolex (cannabidiol for Dravet syndrome and Lennox-Gastaut syndrome, 2018), Syndros (synthetic THC for chemotherapy nausea, 2016), Marinol (synthetic THC, 1985), and Cesamet (nabilone for chemotherapy nausea, 1985 — the same year Herer published).

The irony is precise: Cesamet received FDA approval the same year Herer argued the Schedule I classification was scientifically unjustified. A synthetic cannabinoid was approved for the same indications the natural compound was prohibited from being used for.

Thirty-eight US states have medical cannabis programs as of 2025. Twenty-four have recreational adult-use programs. The combined legal cannabis market is approximately $40 billion annually.

What legalization has not produced is comprehensive access regardless of ability to pay. Medical cannabis is expensive, rarely covered by insurance, and variably available depending on state. The FDA-approved pharmaceuticals address narrow indications. Millions of patients using cannabis for chronic pain, anxiety, and insomnia exist in a gray zone that neither the pharmaceutical framework nor the recreational market adequately serves. Herer's argument was correct about the medical evidence. The policy infrastructure that followed is still being constructed.

Sources

• Herer The Emperor Wears No Clothes (1985)
• FDA Approved Cannabis-Derived Pharmaceuticals (2025)
• NORML Medical Cannabis Overview (2025)

“The specific art historical comparison Huxley made under mescaline tells you more about the experience than any of his philosophical claims.”

In the pharmacy, looking at an art book under mescaline, Huxley looked at a Botticelli and said yes. He looked at a Van Gogh and said no. He thought of a Vermeer and said: this is the standard.

The Van Gogh judgment is the interesting one. Van Gogh is the painter most associated with ecstatic visual experience. If mescaline produces ecstatic visual experience, Van Gogh should be its validation, not its failure.

But Huxley's complaint is precise: Van Gogh's flowers are symbols of flowers, not flowers. They carry the weight of the painter's feeling about flowers. They point at something beyond themselves. Under mescaline, this additional weight makes them less rather than more.

Vermeer, by contrast, is the painter who disappears into the thing he is looking at. The light on the wall, the woman at the window — these are not expressions of anything. They are presences. The light is exactly light.

This is what Huxley experienced: not a transformation of the flowers into symbols of something else, but the flowers being present as themselves, at a density that ordinary perception reduces.

The specific art historical preference he formed under mescaline follows from the phenomenology. The reducing valve, when it opens, reveals not more meaning but more being — and Vermeer is the painter who most consistently painted being rather than meaning.

Sources

• Huxley, The Doors of Perception (1954)

“Brave New World's soma makes people comfortable. Doors of Perception's mescaline makes people see. Huxley wrote both, and he knew the difference.”

Twenty-one years separate Brave New World from The Doors of Perception, and those years are the distance between two different theories of what drugs are.

Soma is a sedative. It produces contentment and eliminates anxiety. It makes the social order acceptable by making its inhabitants too comfortable to notice its constraints — 'Christianity without tears.'

Mescaline does the opposite. It removes the filters that make ordinary existence tolerable. It produces not comfort but clarity — a quality of perception so acute that ordinary management strategies stop working.

Huxley wasn't changing his mind between 1932 and 1953. He was specifying. Brave New World was always a satire about the wrong use of consciousness-alteration — the use that produces compliance. What he found in May 1953 was the right use — the use that produces genuine perception.

Soma and mescaline are opposite ends of the same axis: one drug that makes you less conscious, one that makes you more. The political argument between the two books is about which kind of consciousness-alteration a society should value and which it should suppress.

Sources

• Huxley, Brave New World (1932)
• Huxley, The Doors of Perception (1954)

“Huxley's most careful qualifier is also his most useful one. The experience is not necessary. It is available. The distinction is everything.”

Huxley borrowed 'gratuitous grace' from Catholic theology, where it refers to gifts given not for personal sanctification but for the community's good — extraordinary capacities that don't indicate holiness in the recipient.

He applied this to mescaline deliberately. Not a necessary grace — not required for enlightenment. Not a sure sign of spiritual progress. But potentially helpful, to be accepted thankfully if offered.

This qualifier prevents Doors of Perception from becoming a cult founding text. The experience is not necessary. People have achieved genuine mystical realization without any chemical assistance. The reducing valve can be opened by other means: meditation, crisis, love, grief.

What mescaline offers is reliable access. Not guaranteed depth or wisdom — but reliable access to a quality of perception that is otherwise very difficult to produce deliberately.

The current clinical research has confirmed this framing. Psilocybin reliably produces mystical experience in a high proportion of participants in appropriate conditions. The mystical experience, when it occurs, is associated with therapeutic benefit. The drug is a tool, not a destination.

Sources

• Huxley, The Doors of Perception (1954)

“The deepest argument in Doors of Perception is about language. Mescaline was the evidence; the real subject was what words cost us.”

Huxley's education argument, buried in the final pages of Doors, is more radical than his neuroscience argument. The reducing valve claim is an empirical hypothesis. The education claim is a value judgment: we have organized formal education entirely around the verbal-conceptual mode of experience, and this systematically impoverishes people.

'Every individual is at once the beneficiary and the victim of the linguistic tradition into which he has been born.' The benefit is access to accumulated human knowledge. The cost is the habituation to mistaking the word for the thing.

Under mescaline, this mistake briefly became impossible. The flowers were the flowers, not concepts of flowers. The difference between these two modes is, Huxley argues, incalculable.

What he is not arguing is that words are bad. He is arguing that words without training in what words cannot do produce a specific pathology: the inability to distinguish between map and territory. Education that teaches only the map, and never teaches that the map is not the territory, produces people who have genuinely forgotten the territory exists.

This complaint is still unmade in most educational theory. The contemplative education movement has partially implemented it. The full implementation — an educational system explicitly cultivating both modes — does not exist.

Sources

• Huxley, The Doors of Perception (1954)

“The entire argument of The Doors of Perception is based on eight hours in May 1953. The specificity of the claim is its strength.”

Everything in The Doors of Perception is based on a single day. May 4, 1953. A Los Angeles living room. Four-tenths of a gram of mescaline administered at 11 AM.

Huxley was 58 years old. He had been nearly blind since his teens, had watched two world wars, had written the most famous dystopian novel in English. He had read everything about mescaline that existed. He had the conceptual tools — Bergson's reducing valve, the perennial philosophy — to place what happened in context.

And still the flowers surprised him. Still the folds of grey flannel trousers were more interesting than he had predicted. Still the Vermeer judgment emerged from the experience itself, not from prior theory.

This is the value of the specific and the particular. Not 'mescaline produces interesting perceptual phenomena' — every account says that. But this specific observation, by this specific person, on this specific afternoon: the world looks like this. The is-ness of things. The flowers as they are.

The argument of the book earns its authority from the specificity of its evidence. One day, one person, four-tenths of a gram. That's what it rests on. That's enough.

Sources

• Huxley, The Doors of Perception (1954)

“The published books are performances. The letters are thought in progress. Moksha is where you see two minds actually working.”

Huxley published The Doors of Perception knowing it would be read by a general audience — knowing it was an argument, a frame, a position he was defending. The prose is beautiful precisely because he was shaping it.

The letters to Osmond don't have that shape. They were written quickly, in the middle of thinking, to someone who would understand without explanation. When Huxley writes to Osmond the day after a session, he is reporting, not explaining.

The result is that the letters contain things the books don't. The admission of apprehension before the May 1953 session. The slightly surprised quality of what followed. The uncertainty about whether the next session will be as good. The worry about Leary. The rueful awareness that the counterculture is going to make the careful clinical work untenable.

Huxley in the letters is a different person from Huxley in Doors — not more honest, exactly, but less performed. The philosophical framework is the same. The emotional texture is different. And the emotional texture is where the most useful information lives.

Moksha is the primary source from which Doors was refined. The letters are the laboratory; Doors is the publication. Reading the publication without the laboratory is reading the conclusion without the experiment.

Sources

• Huxley & Osmond, in Moksha (1977)

“Osmond coined the word, ran the clinical program, gave Huxley his mescaline, and designed the first psychiatric hospital informed by psychedelic phenomenology. He is consistently the least famous person in any room he enters.”

Humphry Osmond coined 'psychedelic.' He ran the most successful LSD alcoholism treatment program in history. He gave Aldous Huxley his mescaline and thereby produced The Doors of Perception. He coined 'sociofugal' and 'sociopetal' and contributed to the design of the first psychiatric hospital informed by psychedelic phenomenology.

He is consistently the least famous person in any room he enters.

This is partly geographical — Osmond spent his career in provincial Saskatchewan, far from the centers of attention where Huxley, Leary, and Kesey operated. And partly temperamental — he was careful, clinically focused, and rigorous in ways that don't generate compelling personal narrative.

What he left is the clinical foundation of everything that has followed. The preparation-session-integration model that every Phase 3 psychedelic trial now mandates is Osmond's model, built at Weyburn in the early 1950s. The word he coined shapes every regulatory and public discussion. The hospital he designed with Izumi is still studied in architectural history.

The letters in Moksha reveal a man of uncommon intelligence and unusual moral seriousness. He deserves to be read as a primary thinker, not as Huxley's supplier.

Sources

• Huxley & Osmond, in Moksha (1977)
• Wikipedia, Humphry Osmond

“A word was chosen in a rhyming competition between a novelist and a psychiatrist. The word shaped everything that came after.”

The competition between 'psychedelic' and 'phanerothyme' is a competition between two theories of what these substances do.

Huxley's phanerothyme means 'making the spirit visible' — it emphasizes the spiritual capacity, the revelation of something hidden.

Osmond's psychedelic means 'mind-manifesting' — it locates the manifestation in the mind rather than the spirit. One implies a psychological process; the other a spiritual one.

Osmond's winning couplet also contained an acknowledgment that Huxley's didn't: 'To fathom Hell or soar angelic' — the recognition that the territory was bipolar. Hell was available, not only the angelic. Huxley's 'trivial world sublime' implies uniformly positive transformation. Osmond knew that wasn't reliable.

The winning word has served well. Mind-manifesting is accurate and non-pejorative. It does not encode that what is revealed is unreal, that it simulates psychosis, or that it is pharmacologically specific.

The losing word might have been better philosophy. But Huxley's couplet lost, and fifty years of regulatory and cultural discourse have been shaped by the word that won.

Sources

• Osmond, Ann. N.Y. Acad. Sci. (1957)

“The conclusion of ten years of correspondence about consciousness, God, mescaline, and the future of civilization was three words.”

'It is a bit embarrassing to have been concerned with the human problem all one's life and to find, at the end, that one has no more to offer by way of advice than try to be a little kinder.'

After a decade of sustained intellectual effort about consciousness, the reducing valve, the gratuitous grace, and the proper use of a sacred drug, Huxley arrived at kindness.

The conclusion sounds obvious — trivially available to anyone who has read the Sermon on the Mount. Why did it take mescaline and ten years of letters?

Because kindness, as Huxley is using the word, is not the ordinary sentimental thing. It is the practice of seeing other people as they are — with the same direct perception that mescaline temporarily makes possible — rather than as they are useful or threatening to one's purposes.

The direct perception of things as they are, which mescaline enables briefly and which sustained spiritual practice cultivates gradually, produces, when applied to other people, what we call kindness but which is more precisely accuracy — seeing someone as themselves rather than as a function in your life.

The three words are not a disappointment. They are the completion of the argument.

Sources

• Huxley & Osmond, in Moksha (1977)

“The words Laura spoke to Aldous as he died had been written in his own novel two years before. He thought of everything.”

Aldous Huxley's final novel, Island (1962), contains a scene in which moksha-medicine is given to a dying person, and the guide speaks to them through the passage. The words were written by Huxley as what he thought the right words were.

On November 22, 1963, Laura Huxley used those words. She had given Aldous 100 micrograms of LSD at 11:20 AM, as he had requested in writing when he could no longer speak. She spoke to him for several hours as his breathing changed and finally stopped.

Huxley had written the template for his own death in his final published work. He had thought, in his usual systematic way, about what dying with LSD should look like — and had put the conclusion in a novel two years before he needed to use it.

This is either moving or calculating, depending on your disposition. It is both. Huxley was a man who thought about everything, including how to die, and who had the unusual advantage of having found, in his late fifties, a substance and a partner willing to implement what he had worked out.

Laura's letter to Osmond, written within days of Aldous's death, is the final letter in a correspondence that began with Osmond's mescaline session in 1953 and ended with Aldous's death in 1963. Ten years. The correspondence produced a word, a clinical framework, three books, and a blueprint for dying.

Sources

• Huxley, Island (1962)
• Laura Huxley, This Timeless Moment (1968)

“Hofmann used the word 'presentiment' — a feeling that there was something here, before any rational reason to think so. The most important discoveries arrive this way.”

In April 1943, Albert Hofmann returned to LSD-25 — synthesized five years earlier, filed away when animal tests showed nothing interesting — because of what he called 'a peculiar presentiment.'

Not a hypothesis. Not a prediction derived from chemical theory. A presentiment: a pre-cognitive sense that something remained undiscovered.

The history of chemistry is full of such moments, though scientists are often reluctant to describe them this way. Kekulé's Ouroboros dream revealing benzene's ring structure. Fleming's accidental observation of the mold that killed bacteria.

Hofmann's presentiment returned him to LSD. He was synthesizing it again when he absorbed a small amount through his skin and experienced, briefly, 'an unusual sensation characterized by slight dizziness, restlessness, and remarkable imagery.' He recorded this in his laboratory notebook — the beginning of the most consequential pharmacological discovery of the twentieth century.

The hunch is often the most important part of the story, and the most difficult to transmit through formal scientific writing. Hofmann's memoir preserves it: not 'I hypothesized' but 'I had a presentiment.' The distinction is between rational inference and something harder to name — the capacity to be moved toward what matters before you know why it matters.

Sources

• Hofmann, LSD: My Problem Child (1979)

“Bicycle Day has been celebrated on April 19 since 1985. The image of the bicycle is important — not dramatic, almost domestic. The most consequential trip in pharmacological history was a commute.”

The bicycle is important.

Hofmann did not have a mystical experience in a mountaintop cave or a darkened laboratory. He rode his bicycle home from work, watched the neighbor turn into a witch, drank her milk, lay down, and waited to see if he was dying.

The domesticity of the setting is part of what Bicycle Day commemorates, whether its celebrants know it or not. The most radical perceptual event of the twentieth century happened on a commute.

Hofmann was 37 years old. He was a chemist doing normal pharmaceutical research. The compound he had returned to out of a hunch turned out to be active at doses too small to weigh.

The bicycle is the mundane container for the extraordinary content. This is appropriate, because what Hofmann discovered was not that the extraordinary exists at some great distance from ordinary life — it was that the ordinary, perceived directly, is the extraordinary. The flowers the morning after were ordinary flowers. The world was luminous because it was exactly itself.

Bicycle Day should be celebrated for the bicycle, not despite it.

Sources

• Hofmann, LSD: My Problem Child (1979)

“Problem children are not problems because they are harmful. They are problems because they exceed the categories available to contain them.”

Hofmann's metaphor — the problem child — is more precise than it first appears. A problem child is not a bad child. A problem child resists the available frameworks for understanding children. The child is not the problem; the framework's inadequacy is the problem.

LSD was genuinely difficult to categorize. It was not a sedative, not a stimulant, not a psychotomimetic in any straightforward sense. It produced effects at doses too small to weigh, lasted far longer than its pharmacological half-life suggested, and generated experiences that the available psychiatric vocabulary could not accommodate.

What made it a problem child was not its danger — its safety profile was superior to aspirin's. What made it a problem child was that it required new frameworks. And new frameworks require abandoning old ones, which institutions resist.

The psychiatric establishment of the 1950s had invested in electroconvulsive therapy, insulin coma therapy, and early psychopharmacology. LSD was not a refinement of any of these tools — it was a different kind altogether. One that worked through an experience rather than through a mechanism. One that required the practitioner to have had the experience to understand it.

The child grew up in the counterculture and was put in prison by the state. The problem was never the compound. The problem was what the compound required of the institutions that might have used it.

Sources

• Hofmann, LSD: My Problem Child (1979)

“Hofmann called LSD a sacred drug and was never persuaded to replace the word with something more clinical. He was 102 and he stood by it.”

Albert Hofmann called LSD a sacred drug. Not a useful drug. Not a promising therapeutic agent. A sacred drug.

The word is unfashionable in biomedical discourse. Sacred implies a quality of experience that resists quantification — something not merely effective but meaningful in a way that transcends its mechanisms.

Hofmann was not careless with language. He was a precise chemist. When he chose 'sacred' rather than 'therapeutic' or 'psychoactive,' he was making a claim about the category of thing LSD was.

His argument: LSD works, when it works, by providing access to an experience that human beings have recognized across traditions and millennia as the most important class of experience available — the direct encounter with what is variously called the divine, the sacred, the ground of being. The clinical benefit in patients was, in his account, a consequence of this experience, not its cause.

The current clinical literature has approached this claim through the Mystical Experience Questionnaire, through the finding that mystical experience quality predicts therapeutic outcomes, through the language of 'meaning' and 'insight' that populates patient reports. It has not used the word 'sacred.' But it is measuring something that Hofmann would have recognized.

Sources

• Hofmann, LSD: My Problem Child (1979)

“McKenna said the mushroom spoke to him and spent thirty years explaining what he meant. He was careful, always, about what exactly this meant.”

Terence McKenna said the mushroom spoke to him and spent thirty years explaining what he meant. He was not claiming that a fungal organism had a larynx. He was claiming something more specific: that in states of high-dose psilocybin intoxication, he received what felt like autonomous communication — information that arrived with the character of an outside source rather than a product of his own thinking.

He distinguished this carefully from visual hallucination and from ego dissolution. The communication was interior but alien — using his own internal voice but producing content he did not recognize as his own.

The entity contact literature has confirmed that something consistent is being experienced. The 2019 Johns Hopkins survey found 97 percent of DMT users reporting entity contact; many described the entities as communicating in ways that felt genuinely informative. McKenna's basic description — autonomous apparent communication from an apparent other — is the most common feature of the high-dose tryptamine experience.

Whether the mushroom 'spoke' in any meaningful sense remains open. McKenna held it as an open question, which is precisely what made it worth holding. The question is not 'did a fungus have a conversation with a human?' The question is: what is the nature of the communication-like experience that is so consistently reported? McKenna asked this question before the tools to partially answer it existed.

Sources

• McKenna, Food of the Gods (1992)
• McKenna, True Hallucinations (1993)

“McKenna wrote his television critique in 1992. Every sentence has gotten more accurate.”

When McKenna called television 'the dominator drug par excellence,' he was making a specific pharmacological argument: that passive screen consumption alters brain states in ways that produce compliance, passivity, and consumption rather than consciousness, agency, and production.

He was extrapolating from 1992 technology — three networks plus cable, editorial decisions made by a small number of gatekeepers with limited ability to optimize for individual psychological vulnerabilities.

What has been built since 1992 is a set of technologies that do exactly what McKenna described but with unprecedented precision. The algorithmic feed uses variable-ratio reinforcement schedules — the slot machine mechanism — to maximize engagement. It knows what each individual user responds to emotionally and serves more of it. Sean Parker confirmed in 2017 that Facebook was deliberately designed to exploit psychological vulnerabilities.

McKenna's television argument is more accurate about TikTok than it was about NBC. The dominator drug he described has been refined into something much more effective at producing the passivity he warned against.

His prescription was simple: stop consuming images and start producing them. The problem is that the technologies designed to help people produce images have been more successful at making them consume other people's productions.

Sources

• McKenna, Food of the Gods (1992)

“McKenna named the Archaic Revival in 1992. Something is happening that resembles what he named. Whether it is what he meant is harder to say.”

McKenna introduced the term Archaic Revival to describe a cultural reorientation in progress: a recovery of shamanic practices, plant medicine traditions, and non-rational epistemologies that Western industrial culture had suppressed.

Something is happening that resembles what he described. Legal psilocybin services operate in Oregon and Colorado. Ayahuasca retreat centers number in the hundreds globally. Mushroom cultivation has become widespread. The psychedelic renaissance is genuinely a cultural phenomenon with institutional expression.

But McKenna's Archaic Revival was not primarily about access to substances. It was about a reorientation of consciousness — a shift in how Western culture relates to the natural world. The question is whether current psychedelic culture represents this reorientation or primarily represents the integration of psychedelic experience into the consumer lifestyle it was supposed to critique.

The thousand-dollar ayahuasca retreat. The branded microdosing protocol. The Silicon Valley optimization of psilocybin for productivity. These are not what McKenna was describing. They are the dominator culture consuming the medicine that was supposed to change the dominator culture.

The genuine Archaic Revival, if it is happening, is quieter: the restoration of land to indigenous stewardship, the return of botanical relationship to communities that had lost it, the integration of plant medicine into genuine healing traditions.

Sources

• McKenna, Food of the Gods (1992)

“McKenna said the notion of illegal plants is obnoxious and ridiculous in the first place. He was describing a category error.”

'The notion of illegal plants is obnoxious and ridiculous in the first place.'

McKenna said this as a philosophical observation, not a political campaign. The category error he is pointing at: a plant is not an action. A plant cannot be a crime.

What drug law actually makes illegal is not the plant but possession, cultivation, distribution, and use — a set of human actions. The legal structure attributes criminality to the plant itself as shorthand. When policymakers talk about 'Schedule I plants,' they are making a grammatical error as well as a pharmacological one.

The distinction matters because it determines what the policy is actually trying to accomplish. If the target is a specific plant, the policy is about eliminating the plant — which is both impossible and incoherent. If the target is specific human actions, the policy has a more defensible rationale, though still one requiring evidence about actual harm.

Psilocybin is produced by mushrooms that grow globally on every continent except Antarctica. The legal status of the mushroom does not change the chemistry of the spore. The spore is not illegal. The mushroom that grows from it is not illegal in many jurisdictions. The compound it contains is Schedule I.

The ridiculousness McKenna points to is real. The law has drawn a line around something that grew itself.

Sources

• McKenna, Food of the Gods (1992)

“The stoned ape hypothesis has been dismissed as unscientific. What has not been dismissed is the question it asks.”

The stoned ape hypothesis gets the ridicule it receives because McKenna presented it with more confidence than the evidence warranted. No archaeological evidence for regular psilocybin use by early hominids exists. The specific three-stage dose-response mechanism he described is not supported by controlled research.

But stripping away the overconfident packaging reveals a question that is real: what role did psychoactive plants play in human cognitive evolution?

This is not a McKenna question. It is an evolutionary biology question, a cognitive anthropology question, a psychopharmacology question. The available evidence — that every known human culture has plant medicine practices, that the 5-HT2A receptor shows evolutionary divergence from other primates, that psilocybin produces neuroplasticity effects in the prefrontal cortex (Shao et al., Science 2021) — does not prove the hypothesis. But it doesn't close the question.

The question deserves investigation on its own terms, with better methodology than McKenna applied. The question is: did the long-term human relationship with psychoactive plants have effects on human cognitive development? This is not obviously false, and it is a question that would not have been asked in modern scientific context without McKenna's willingness to ask it loudly and without the evidence to fully support the asking.

Some questions are important enough that having someone ask them badly is better than no one asking them at all.

Sources

• McKenna, Food of the Gods (1992)
• Shao et al., Science (2021)

“Holiday's story is not the drug war's most important evidence. It is the drug war's most humanly legible evidence. Hari understood the difference.”

Johann Hari begins Chasing the Scream with Billie Holiday not because Holiday's story is the most important evidence for his argument but because it is the most humanly legible.

The argument he is making — that the drug war was racially targeted, that addiction is driven by disconnection, that punishment perpetuates rather than cures — can be made from statistics. The ACLU's racial disparity data. The Portugal outcome studies. The Vietnam natural experiment. All support the argument more rigorously than a single case history.

But case histories do something statistics cannot: they make the policy real in human terms. Holiday's addiction developed in a specific life, under specific conditions of trauma and racial violence and isolation. Anslinger's persecution of her was not an abstraction — it was a man with a government department deciding that a specific person deserved to suffer.

Hari has been criticized for overstating some elements of the Holiday-Anslinger story — the specific 'Strange Fruit' trigger claim is not fully documented. The criticism is fair. But the underlying argument — that enforcement was racially selective and by design — is supported by the documentary record, and Holiday's story is the human container that makes it legible.

Narrative is not the enemy of evidence. Narrative is how evidence reaches people who would otherwise not encounter it.

Sources

• Hari, Chasing the Scream (2015)

“'The opposite of addiction is connection' is a brilliant slogan and a partial argument. Hari knew the difference. Most readers remembered only the slogan.”

'The opposite of addiction is connection' is the most retweeted sentence in Chasing the Scream. It has 25 million TED Talk views. It is used in treatment programs and policy advocacy worldwide.

It is also a simplification of a more complicated argument.

The full argument: social disconnection, trauma, and lack of meaningful purpose are major drivers of addictive behavior, as demonstrated by Rat Park, the Vietnam natural experiment, Portugal's outcomes, and the ACE correlation. Therefore, policies and treatment approaches addressing these conditions will be more effective than those treating addiction as purely pharmacological.

This full argument is correct and important. The slogan distills it into something memorable but imprecise. Opioid withdrawal is a genuine pharmacological process. The chemical grip of dependence is real, if less dominant than pure pharmacological models suggest. The environment model and the biological model are both partly right, and the most effective interventions address both.

Hari knows this — his book contains the nuance. The slogan doesn't. This is a routine feature of public health communication: the compressed version travels further than the accurate version. Whether the slogan does more good by reaching people the nuanced argument wouldn't reach, or more harm by misrepresenting the science, is a harder call.

Sources

• Hari, Chasing the Scream (2015)
• Gage & Sumnall, Addiction (2020)

“Portugal decriminalized all drugs in 2001. The outcomes were good. Then the social investment got cut. The outcomes got worse. The lesson is not that decriminalization failed.”

Hari's chapter on Portugal is his strongest and his most dated simultaneously.

The strongest: the 2001 decriminalization of all personal drug possession, combined with substantial investment in treatment, housing, and employment, produced remarkable outcomes by 2015. HIV transmission among injecting drug users fell by approximately 95 percent. Drug-related deaths dropped. Drug use among young people did not increase.

The most dated: between 2015 and 2023, Portugal's outcomes deteriorated. Drug-related deaths increased, not to pre-2001 levels but enough to complicate the simple success narrative. The primary cause was austerity: the 2008 financial crisis and EU-imposed austerity measures cut the social programs that had made the decriminalization work.

This does not invalidate Hari's argument. It confirms it. His argument was that decriminalization alone is insufficient — what works is decriminalization plus social investment. Portugal's success period was when both were present. Portugal's decline period was when social investment was cut.

The lesson is not that decriminalization failed. The lesson is that decriminalization without sustained social investment is necessary but incomplete. Hari said this. The complexity of the evidence has since made it more specific.

Sources

• Hari, Chasing the Scream (2015)
• EMCDDA Portugal Drug Report (2023)

“Anslinger spent thirty-two years destroying the lives of drug users. He spent his final years medicated with morphine. He apparently never made the connection.”

Harry Anslinger died in November 1975, medicated with morphine for his angina. He had spent thirty-two years as commissioner of the Federal Bureau of Narcotics destroying the lives of people who used opiates without medical authorization.

Hari presents this as irony. It is, but it is also something more precise: a demonstration of the categorical distinction that made Anslinger's system possible.

Anslinger's enforcement model depended on a categorical difference between 'drug addicts' (criminals, moral failures) and 'patients' (legitimate sufferers, properly managed by the medical system). The same pharmacological process — the body becoming dependent on opiates — was morally neutral in one category and criminal in the other. The distinction was not biological. It was social.

Anslinger using morphine for angina was, in his own framework, entirely different from Billie Holiday using heroin for the pain of her life. One was a patient following doctor's orders. One was a degenerate criminal.

The pharmacology was identical.

This is not hypocrisy in the sense of Anslinger secretly knowing the distinction was false. It is something more commonplace: a man who genuinely believed in a moral framework that his own life quietly contradicted, and who was never called to account for the contradiction because the framework served the people with power to enforce it.

Sources

• Hari, Chasing the Scream (2015)
• Wikipedia, Harry J. Anslinger

“Bruce Alexander's Rat Park proved something real about the relationship between environment and addiction. It proved somewhat less than Hari claimed.”

Bruce Alexander put rats in a cage with morphine-laced water and plain water. Isolated rats drank heavily from the morphine. Rats in the social, stimulating Rat Park environment drank very little.

The experiment is real. The finding is real. Isolated rats consumed up to 25 milligrams per day; Rat Park rats rarely exceeded 5 milligrams. The five-fold difference is not an artifact.

What the experiment proved: social environment modulates drug-seeking behavior in rodents. What it did not prove: that social environment overrides pharmacological dependence in all circumstances. A 2020 review found that the specific Rat Park results have 'conceptual but not direct' replication — subsequent enrichment paradigms consistently reduce drug-seeking, but not always to the dramatic degree Alexander observed.

Hari presented the results as though they settled the question about what addiction fundamentally is. They didn't settle it. They shifted it. Before Rat Park, the standard model was pharmacological. After Rat Park, the standard model needs to accommodate environment as a major variable. This is a significant shift. It is not a revolution.

The rats in Rat Park still used some morphine. They chose to spend their lives mostly doing other things. That is the finding: mostly other things. Not no things.

Sources

• Hari, Chasing the Scream (2015)
• Gage & Sumnall, Addiction (2020)

“Five young Americans went to the Colombian Amazon looking for an indigenous hallucinogen. They found psilocybin mushrooms instead.”

The La Chorrera expedition of February-March 1971 has been told so many times that the actual event has become difficult to see beneath its legend.

What happened: five Americans arrived at a remote Colombian mission station, found an abundant supply of Psilocybe cubensis growing in cattle pastures, and attempted a homemade experiment in which Dennis McKenna would vocalize during a high-dose mushroom session in a way that the brothers theorized would bond tryptamines in his nervous system into a permanent altered state.

Dennis spent the following two weeks in an extended altered state. He spoke in complex patterns, made predictions, appeared to be in contact with something. He was also, by his own retrospective account, undergoing a drug-induced psychosis — though a lucid one, from which he recovered fully.

Terence observed and documented. He heard, during his own sessions, what he described as sustained communication from the mushroom — a monologue about time, consciousness, and human destiny that became the basis of the Timewave Zero theory.

Whether what happened at La Chorrera was a breakdown, a revelation, or both simultaneously is the question True Hallucinations raises and declines to fully answer. Dennis has said: something real happened, and I am cautious about what 'real' means. Terence spent thirty years trying to articulate what he received. The two positions are not as far apart as they appear.

Sources

• McKenna, True Hallucinations (1993)
• D. McKenna, The Brotherhood of the Screaming Abyss (2012)

“McKenna's machine elf description has been independently corroborated by tens of thousands of users who had never read it. The consistency is the data point that matters most.”

The machine elves — 'merry elfin, self-transforming, machine creatures, looking like self-dribbling Fabergé eggs on the rebound' — are McKenna's most famous contribution to the psychedelic literature. They are also his most empirically interesting one.

McKenna first described the entities in 1965, from his own DMT experiences. He described them in public lectures through the 1980s and 1990s. His description became widely available before the internet made all descriptions widely available.

What happened when the internet made all descriptions widely available: entity contact reports, in forms substantially matching McKenna's description, proliferated from users who had not previously encountered his account. A 2019 Johns Hopkins survey of 2,561 DMT users found entity contact in 97 percent of respondents.

This is the important data point. McKenna was not the only person to encounter what he described. He was the first to describe it in language that entered wide cultural circulation. The independent corroboration — reports from people who did not know his description before they had the experience — establishes that whatever is being encountered, it is not simply a culturally transmitted expectation.

What it is remains open. McKenna held it as an open question. The neuroscience has established that entity-contact has distinct neural correlates. The interpretation of those correlates is not established.

Sources

• McKenna, True Hallucinations (1993)
• Sexton et al., J. Psychopharmacol. 33(9) (2019)

“December 21, 2012 came and went without incident. This does not end the conversation about what McKenna was trying to describe.”

The Timewave Zero prediction — that December 21, 2012 would be a singularity of maximum novelty — was falsified without drama. McKenna had acknowledged the prediction was falsifiable. It was.

What survived the falsification was not the specific prediction but the philosophical claim McKenna derived from the I Ching insight: that time has qualitative structure, that novelty is not uniformly distributed, that some moments are more generative than others.

This claim is not scientific in the sense of being falsifiable. But it is not obviously false. It is what the I Ching was always about: the claim that the moment you are in has characteristics, that some moments resemble other moments, that navigation of time requires attention to its qualitative features.

McKenna wrapped this philosophical observation in a mathematical apparatus that didn't support it and attached it to a specific date that was wrong. The philosophical observation survives. The mathematical apparatus is discarded.

The lesson is about the cost of overconfidence: if he had presented the underlying claim more modestly, it could be engaged more seriously. The overconfident presentation invited dismissal of both the wrong part and the interesting part together.

Sources

• McKenna, True Hallucinations (1993)

“Terence and Dennis McKenna went to the same Amazon, ate the same mushrooms, and came back with completely different relationships to certainty.”

The most interesting thing about Terence and Dennis McKenna is not their agreement but their disagreement.

They went to La Chorrera together. They ate the same mushrooms. They underwent extraordinary experiences that changed the direction of their lives. They came back with different conclusions.

Terence became the most famous psychedelic lecturer of his generation — voluble, confident, willing to make claims that exceeded his evidence. He built a cosmology from La Chorrera and spent thirty years elaborating it.

Dennis became a neuropharmacologist. He spent decades studying the biochemistry of ayahuasca at the level of molecular mechanisms. He has spoken, consistently, with admiration for Terence's genius and caution about Terence's conclusions. He believes something happened at La Chorrera. He is careful about what 'something' means.

Both responses are legitimate. Terence's produced a cultural impact that Dennis's careful science could not have produced. Dennis's produced knowledge that Terence's cosmological speculation could not have produced.

They needed each other. They had each other. The asymmetry between them is the book.

Sources

• McKenna, True Hallucinations (1993)
• D. McKenna, The Brotherhood of the Screaming Abyss (2012)

“The most intellectually honest thing McKenna ever wrote was the sentence about being either an unsung Newton or completely nuts.”

'Because I am either an unsung Newton or completely nuts, there is very little room to maneuver between these two positions.'

This is the most intellectually honest sentence in McKenna's entire body of work. The Timewave theory was either a genuine discovery about the nature of time or a very elaborate confabulation. There was no comfortable middle ground.

McKenna often performed certainty. The lectures are full of confident assertions about the nature of the universe, the intentions of mushroom consciousness, the trajectory of human evolution. The performance was compelling and was, for most audiences, indistinguishable from genuine certainty.

In True Hallucinations, he dropped the performance. He wrote about La Chorrera from a position of genuine uncertainty — not the rhetorical uncertainty of the thinker who knows the answer but graciously acknowledges he might be wrong, but real uncertainty about an experience he could not account for.

This uncertainty is what makes the book more valuable than his lectures. In the lectures, he explains. In the book, he reports. The reporting — accurate phenomenological description of an experience without predetermined interpretation — is what the field of consciousness studies most needs and most rarely gets.

Sources

• McKenna, True Hallucinations (1993)

“Initiates were forbidden to say what happened in the Telesterion. They kept saying what it felt like. Two thousand years of consistent testimony is the evidence.”

The Eleusinian Mysteries kept their secret for two thousand years. No initiate ever described what happened in the Telesterion — what the hierophant revealed, what specifically took place. The oath of silence held.

And yet we know, from accumulated testimony of initiates across five centuries, what the experience was like.

Fear. Trembling. Cold sweat. Then a vision — not described, but referenced consistently as vision, not metaphor. Then a transformation in the initiate's understanding of death.

Pindar: 'Blessed is he who has seen these rites before he goes beneath the hollow earth; for he understands the end of mortal life, and the beginning of a new life given of God.' Sophocles: 'For them alone there is life, while all others have misery.'

The vocabulary is consistent: seen, not thought. Understood from experience, not from argument. The death anxiety that initiates reported being relieved of was not cured by an idea — it was encountered directly and thereby transformed.

This is the phenomenological signature of the psychedelic mystical experience as currently documented. The Mystical Experience Questionnaire measures the noetic quality and the encounter with death and rebirth. These are what the Eleusinian initiates described, in different words, over two thousand years.

The Road to Eleusis' hypothesis is that the pharmacological mechanism was ergot alkaloids in the kykeon. The testimonies of what the mechanism produced have always been there.

Sources

• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Pindar, Fragment 137

“Wasson was a banker and an amateur mycologist. He changed Western civilization's understanding of its own origins.”

R. Gordon Wasson was a vice president at J.P. Morgan who spent his spare time studying mushrooms. He traveled to Mexico to participate in a Mazatec mushroom ceremony and wrote about it for Life magazine in 1957, reaching three and a half million readers.

He was not a trained anthropologist, ethnobotanist, or classicist. He was a banker who had read everything and was willing to go everywhere.

The Road to Eleusis (1978) is the product of Wasson's peculiar position: an amateur with the resources and access of a professional, able to bring together people — Hofmann the chemist, Ruck the classicist — who would not otherwise have collaborated. The book is possible only because of Wasson's particular combination of amateur enthusiasm and professional network.

The criticism of Wasson has always been that his enthusiasm outran his evidence — that he was too ready to find confirmation of his theories. This criticism is partly fair. The Road to Eleusis is stronger for Hofmann's pharmacological rigor and Ruck's philological exactness.

But the hypothesis would not exist without Wasson. The question would not have been asked. Amateurs with big questions and the means to pursue them are a feature of intellectual history, not a bug.

Sources

• Wikipedia, R. Gordon Wasson
• Wasson, Life Magazine (1957)

“The Eleusinian Mysteries were not fading when they were suppressed. They were still active. An institution serving thousands of initiates per year for a thousand years was abolished by decree.”

In 391 CE, the Emperor Theodosius issued an edict banning non-Christian religious practice throughout the Roman Empire. The Eleusinian Mysteries — operating continuously for approximately one thousand years — were prohibited along with all other pagan practice.

In 395 CE, Alaric's Visigoths sacked the sanctuary at Eleusis and destroyed the Telesterion.

The institution was not dying when it was killed. The Mysteries were still drawing thousands of initiates annually in the fourth century. The prohibition was not a response to a failing institution — it was the deliberate elimination of a competitor.

The Christian church's argument against the Mysteries was primarily theological: they claimed to offer direct experience of the divine, which was incompatible with the church's claim to mediate that experience through its institutional forms. The Mysteries were dangerous not because they were corrupt but because they worked.

This is the pattern Ruck identifies as recurring: the suppression of direct experiential access to the sacred by institutions that manage access to the sacred. The Mysteries in 392. LSD in 1968. The pattern is not accidental.

Sources

• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Theodosius Codex (392 CE)

“In 2019-2020, archaeologists found ergot alkaloids in dental calculus at an Eleusinian cult site in Catalonia. The hypothesis that had been argued from text for forty years found its first physical evidence.”

The Road to Eleusis was published in 1978. For forty years, it argued from text: the classical testimonies, the Homeric Hymn to Demeter, the pharmacological analysis, the architectural argument about the Telesterion. Compelling and unconfirmed.

In 2019-2020, Juan-Tresserras's bioarchaeological analysis of material from Mas Castellar de Pontós — an ancient Catalan site associated with the Demeter cult — produced significant findings. In dental calculus from a woman buried at the site in the third to second century BCE, apparent ergot alkaloids were identified. In a sealed ritual vessel, ergot spores and residues were found in association with beer-making equipment.

The Catalonia site is not Eleusis. It is an Eleusinian-affiliated sanctuary in the western Mediterranean. But it demonstrates that the cult of Demeter used grain-based preparations that incorporated ergot.

The 2026 Scientific Reports paper by Antonopoulos and Dadiotis then demonstrated experimentally that the preparation method available in antiquity — using lye from wood ash — converts toxic ergot alkaloids into water-soluble psychoactive forms. The chemical pathway was feasible. The archaeological evidence of its use exists at an Eleusinian site.

The hypothesis has gone from 'this might be possible' to 'this was demonstrated to be chemically feasible and archaeologically evidenced at a cult site.' The remaining question is whether the evidence will be found at Eleusis itself.

Sources

• Mas Castellar de Pontós excavation reports (2019-2020)
• Antonopoulos & Dadiotis, Scientific Reports (2026)

“Plato was an Eleusinian initiate. The theory of Forms may have an experiential source.”

Plato was an Eleusinian initiate. Historical fact, not speculation. He was initiated at Eleusis and received whatever experience the Telesterion provided.

The Road to Eleusis does not argue that Plato's philosophy was 'caused by' the kykeon. It argues something more modest: that the phenomenological reference point for the distinction Plato draws — between the apparent world (cave shadows) and the real world (sunlit reality outside) — may have been the Eleusinian experience rather than purely rational argument.

The theory of Forms claims that this visible world is a shadow or imitation of a more real, permanent, meaningful world that can be apprehended by a higher faculty than sense perception. This is a strange metaphysical claim to arrive at by pure reason. It is a very natural claim to arrive at if you have experienced, in a specific context, something that made ordinary reality feel exactly like shadows by comparison.

The psychedelic mystical experience characteristically produces what subjects describe as a sense of encountering more reality than ordinary consciousness provides — that the usual filter is lifted, that what is normally suppressed floods in. This is precisely what Plato's Allegory of the Cave describes.

Whether the kykeon was the source of Plato's reference point is not established. That the phenomenology overlaps in ways worth taking seriously is.

Sources

• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Muraresku, The Immortality Key (2020)

“Stevens is careful about assigning blame. Leary was not the only cause of the 1968 collapse. He was the most visible accelerant.”

Jay Stevens does not write Timothy Leary as a villain in Storming Heaven. He writes him as a man of considerable intelligence who made a series of decisions that destroyed, in the short term, something more valuable than what he was building.

The chain of causation is more complex than 'Leary's fault.' The CIA's coercive research had already given prohibition its evidence. The counterculture's enthusiastic adoption of LSD had already created the political conditions for suppression. Anslinger's framework was already in place.

Leary did not create the conditions for the 1968 crackdown. He accelerated them.

What he did: he moved LSD from a clinical tool being carefully developed into a public symbol of rebellion against the social order. He made the connection between LSD and anti-war, anti-establishment politics explicit and theatrical. He gave the Nixon administration exactly the association they needed to make scheduling politically viable.

Huxley saw this coming. His letters to Osmond in the early 1960s include the warning that public advocacy would provoke a crackdown. He recognized the impulse as genuine. He was criticizing the strategy.

Stevens's judgment: the impulse was genuine and the strategy was catastrophic. What we cannot know is whether the crackdown would have come anyway, because the political conditions that made it possible were already present.

Sources

• Stevens, Storming Heaven (1987)

“The CIA spent a decade trying to weaponize LSD and produced nothing useful except a casualty. The program's only lasting contribution was Ken Kesey.”

The CIA's interest in LSD was instrumental: could it extract information from unwilling subjects? Could it break down psychological resistance? Could it program behavior the subject wouldn't remember or resist?

The answer, after a decade of research including Operation Midnight Climax — in which unwitting subjects were dosed in San Francisco safe houses while agents watched through one-way mirrors — was no to all of the above.

What the program produced: in at least one documented case, a death. Frank Olson, the Army researcher secretly dosed by Sidney Gottlieb in 1953, fell from a New York hotel window.

The CIA program's ironic legacy is Ken Kesey. Kesey participated as a paid volunteer in a CIA-sponsored LSD study at the VA hospital in Menlo Park. He obtained LSD through the research network, formed the Merry Pranksters, organized the Acid Tests, and helped drive the counterculture's adoption of LSD — thereby providing the political conditions that made prohibition politically viable.

The CIA was looking for a weapon. What it found, through the pathway it inadvertently opened, was a movement that helped destroy the clinical research program it was simultaneously trying to weaponize.

Sources

• Stevens, Storming Heaven (1987)
• Marks, The Search for the Manchurian Candidate (1979)

“Huxley spent his final years trying to slow down what was coming. He failed. The failure was not for lack of trying.”

By 1960, Aldous Huxley understood that Timothy Leary was going to destroy something valuable. He said so in letters to Osmond.

Huxley's argument: the experiences these substances provide are genuine and potentially transformative, but the social conditions for their beneficial use are fragile. They require careful preparation, experienced guidance, proper setting, and institutional distance from politics. Any association with public rebellion would give the government the excuse it needed.

Leary heard Huxley's concern and did not share it. He believed the experience was powerful enough to transform people regardless of context, and that democratizing access through public advocacy was more important than protecting the clinical research program.

Both men were right about different things. Huxley was right that the advocacy would provoke the crackdown. Leary was right that the experiences were powerful. Neither was entirely wrong about the other's concern.

What neither anticipated was the speed: the crackdown came within eight years. The clinical program that Osmond had spent fifteen years building was ended before it reached regulatory maturity.

Sources

• Stevens, Storming Heaven (1987)
• Huxley & Osmond, in Moksha (1977)

“Stevens documented the interruption. He could not have anticipated its end. The end is happening now.”

Storming Heaven ends in despair. The clinical program that Hoffer, Osmond, Grof, and Pahnke had built was ended by a scheduling decision that had nothing to do with the evidence.

Stevens published in 1987. He did not know the interruption would end.

The ending is happening now. COMPASS Pathways has completed two Phase 3 trials for psilocybin in treatment-resistant depression. The NDA submission is targeted for Q4 2026. Johns Hopkins, NYU, Imperial College, and dozens of other institutions are running clinical trials. Australia approved psilocybin for clinical use in 2023. Oregon has a licensed psilocybin services program.

The specific clinical program Stevens mourned — Hoffer and Osmond's alcoholism protocol — has been reproduced with psilocybin. A 2022 NYU trial found that psilocybin-assisted therapy produced significantly better outcomes than placebo for alcohol use disorder.

Stevens wrote a history of an interruption. It has since become a history of an interruption that ended. That is, ultimately, a better story than the one he wrote.

Sources

• Stevens, Storming Heaven (1987)
• COMPASS Pathways Phase 3 (2025-2026)

“Stevens shows why the clinical and countercultural traditions cannot be separated, no matter how hard each tries. They share a molecule.”

The central argument of Storming Heaven is about the impossibility of maintaining separation between clinical and countercultural psychedelic use. Osmond and Huxley tried. They built a careful, controlled clinical tradition that distinguished its use from recreational experimentation in every detail of protocol and intention.

The counterculture arrived anyway. Not because the clinical tradition failed — it was succeeding — but because the molecule was the same. The same compound that produced controlled therapeutic experiences in Weyburn and the Maryland Psychiatric Research Center produced the Acid Tests.

The compound couldn't be restricted to those who approached it correctly, because 'correctly' is not encoded in the chemistry.

This is the problem that the current psychedelic renaissance is also navigating. Every clinical trial takes place in a culture that already uses psilocybin recreationally. Every licensed service center operates in a state where psilocybin is simultaneously a therapeutic tool and a recreational substance.

Stevens documents the collapse of the attempt to separate them in the 1960s. The current movement is attempting to manage the relationship rather than enforce the separation — to build regulatory frameworks accommodating both therapeutic and adult-use contexts rather than insisting on one at the expense of the other.

Sources

• Stevens, Storming Heaven (1987)

“Herer offered $100,000 to anyone who could disprove his central claims and renewed the offer with every edition. The challenge was never met.”

The $100,000 challenge was both a rhetorical device and a genuine offer. Herer included it in every edition: if you can disprove my central claims about cannabis prohibition, hemp's industrial potential, and the suppressed medical literature, I will pay.

The challenge was never met. Nobody collected $100,000.

This does not mean every claim in the book is unassailable. Some of Herer's inferences — the specific DuPont orchestration thesis — exceed what the primary documents can support. But the challenge was carefully scoped to the central historical claims, which are substantially documented.

The challenge was also a way of forcing engagement. Herer understood that his audience would not believe him on authority — he had no institutional authority. What he had was documents. The $100,000 challenge was a dare: if you think these documents say something different from what I say they say, prove it.

No one did. The challenge sat unanswered across twelve editions and twenty-five years, which is itself a form of evidence. Not conclusive evidence — but it suggests that institutional opponents of cannabis legalization, who had every incentive to demolish Herer's argument if they could, were unable to do so from the available documentary record.

Sources

• Herer, The Emperor Wears No Clothes (multiple editions)

“The US government denied the film existed. Then someone found it in the Library of Congress. The sequence is the argument.”

Hemp for Victory is a thirteen-minute film produced by the USDA in 1942. It urged American farmers to grow cannabis hemp for the war effort after the Japanese occupation of the Philippines cut off the supply of Manila hemp.

By the 1980s, the USDA denied the film existed. Library of Congress records did not list it.

Maria Farrow and Carl Packard searched the Library of Congress holdings anyway. They found the film in 1989. Herer announced the discovery. The Library of Congress subsequently acknowledged the film's existence.

The sequence is the argument, compressed to its essential structure. The government produced a film urging farmers to grow cannabis hemp as a patriotic duty in 1942. The same government subsequently denied that the film had ever been made. When the film was found, the government acknowledged it.

Herer used this sequence repeatedly, not because it proved the DuPont conspiracy thesis but because it demonstrated something simpler and more damning: the government had a documented relationship with industrial hemp that directly contradicted its official position on cannabis prohibition. This contradiction was on film.

The film is now on YouTube.

Sources

• Herer, The Emperor Wears No Clothes (1985)
• Wikipedia, Hemp for Victory

“Nylon was patented by DuPont in February 1938. The Marihuana Tax Act was signed into law in October 1937. Herer said this was not a coincidence.”

The Marihuana Tax Act was signed into law on October 1, 1937. DuPont patented nylon on February 16, 1938. Popular Mechanics published its 'New Billion-Dollar Crop' article describing hemp's industrial potential the same month.

Herer's argument: these are not independent events. DuPont needed hemp eliminated from the market to protect nylon's commercial position.

The correlation is real. Whether the correlation is causal is the question historians disagree about.

The case for causation: DuPont's financial institution was Mellon Bank. Andrew Mellon was Secretary of Treasury. Harry Anslinger was Mellon's relative and his appointee as FBN commissioner. DuPont had been briefing Treasury officials on the decorticator technology that threatened nylon. The legislation was drafted by Herman Oliphant, who received DuPont's briefings.

The case against simple causation: the racial panic around cannabis, immigration anxiety, and the moral reform movement were independently sufficient to produce prohibition legislation. DuPont may have benefited without orchestrating.

The honest assessment: DuPont almost certainly benefited from hemp prohibition. Whether it engineered the prohibition or exploited existing political conditions is not fully established. Herer presents the former as fact. The evidence supports the latter.

Sources

• Herer, The Emperor Wears No Clothes (1985)
• Popular Mechanics, New Billion-Dollar Crop (February 1938)

“In Andersen's tale, the emperor's nakedness is visible to everyone. The social pressure not to say so is what keeps the fiction functioning.”

Hans Christian Andersen's 1837 fairy tale is about the social mechanics of false consensus. Two swindlers sell the emperor clothes invisible to those who are incompetent or stupid. The emperor, unwilling to appear incompetent, admires the clothes he cannot see. His court follows. Only a child says what everyone can see: the emperor is wearing nothing.

Herer's title borrows this structure precisely. The emperor — cannabis prohibition — is wearing no clothes. The scientific evidence for the scheduling was fabricated or absent. The congressional hearings that produced it lasted two hours. The medical evidence supported the opposite conclusion from the one enacted.

The child who says what everyone can see is effective precisely because children have not yet learned the social pressure not to say obvious things. Herer cast himself in this role: the person who will say the thing that everyone with power has tacitly agreed not to say.

The analogy holds well. The emperor's nakedness — the absence of evidence for cannabis's Schedule I status — was visible to anyone who looked at the primary documents. Herer looked. He said what he saw. He printed it and sold it in head shops for thirty years.

The emperor is now partially clothed again, by rescheduling proceedings and medical cannabis markets. The clothes are still not what was claimed.

Sources

• Herer, The Emperor Wears No Clothes (1985)
• Andersen, The Emperor's New Clothes (1837)

“Herer was born in New York, served in Korea, and spent the rest of his life in documentation and activism. He died in 2010 having been proven substantially right.”

Jack Herer was born in New York City on June 18, 1939. He served in the Army as a military police officer in Korea. He encountered the California Marijuana Initiative in 1972 and discovered hemp's industrial potential. He spent the next thirty-eight years documenting the case that cannabis prohibition was an injustice, and he spent the last years of those thirty-eight years being substantially vindicated.

He was not a comfortable person to read or to know. He was loud, repetitive, sometimes imprecise, and cared about being right more than being polished.

It is also the foundational document of the modern cannabis legalization movement. The argument he assembled from government documents — that hemp prohibition was politically manufactured, that the medical evidence was suppressed, that the scheduling was scientifically unjustified — has been confirmed by the policy changes of the last decade.

He died in April 2010 having seen the beginning of what he had worked toward. He did not see the 2018 Farm Bill legalize industrial hemp. He did not see 24 states legalize recreational cannabis. He did not see the DOJ propose rescheduling.

He died with the strain that bears his name on dispensary menus across North America.

Sources

• Jetty Extracts, Jack Herer Legacy (2026)
• Wikipedia, Jack Herer

“In 80,000 plant species, indigenous peoples found the two whose combination creates oral DMT activity. The standard explanation — trial and error — is mathematically implausible.”

The combinatorial problem is the sharpest single challenge in the psychedelic literature to the assumption that Western science has a monopoly on reliable knowledge.

In an Amazon containing approximately 80,000 plant species, indigenous peoples across multiple independent cultures identified the same two plants: Banisteriopsis caapi and Psychotria viridis. Their combination creates oral DMT activity. Neither alone produces the sustained visionary state. The interaction requires knowing both plants and discovering that combining an oral MAO inhibitor with an orally inactive tryptamine produces hours of visionary experience.

The standard Western explanation is trial and error. Across 80,000 species, searching for the combination of two specific ones whose interaction only becomes apparent when both are consumed together. The combinatorial mathematics of this search space are forbidding.

All indigenous peoples asked about the discovery give the same answer: the plants told us. Narby spent a decade investigating what this answer might mean. He did not resolve it. He established that Western science's dismissal — 'hallucination, not information' — is itself a philosophical position rather than an empirical finding.

The question is real. The standard dismissal is inadequate. The correct answer is not known.

Sources

• Narby, The Cosmic Serpent (1998)
• Schultes & Hofmann, Plants of the Gods (1979)

“The medical symbol of the Western world is two serpents coiled around a staff. It is older than medicine. Narby says it represents DNA.”

The caduceus — two serpents coiled around a staff — is the symbol of Western medicine. It is ancient: Hermes carries it in Homer. Some form of the twin-serpent image appears in Sumerian iconography from the third millennium BCE.

Jeremy Narby's argument: the double helix of DNA and the twin serpents of the caduceus are the same image, arriving through different pathways. The shamanic visions in which serpents appear are, in his hypothesis, perceptions of the molecular level of life — specifically of DNA, which emits biophotons in the visible range and which, at the scale at which these biophotons might be perceived, would appear as luminous helical structures.

Kekule's Ouroboros is the supporting anecdote: a Western chemist solved the ring structure of benzene after a serpent dream. The convergence of shamanic vision imagery and Western chemical discovery in the same serpent image is the data point Narby emphasizes most.

The hypothesis is speculative but not empty. It is interesting in the specific sense that it generates testable predictions. That is more than most speculation offers.

Sources

• Narby, The Cosmic Serpent (1998)

“When Narby asked how his hosts had learned the medicinal properties of plants, they answered without hesitation: by drinking a hallucinogenic brew.”

The anecdote Narby opens with is the book's engine.

An Ashaninca man tells him that his people learned the medicinal properties of plants by drinking ayahuasca. Narby, trained in social science, interprets this as metaphor — a culturally embedded explanation for systematic empirical observation.

But the man is not speaking metaphorically. He is making a literal claim: the plants teach us about the plants. The ayahuasca experience provides direct information about the pharmacological properties of other plants.

Narby spends a decade trying to dismiss this answer and eventually concludes that he cannot. Not because he accepts it uncritically — he does not — but because no alternative explanation is adequate to the phenomenon being explained.

The specific phenomenon: indigenous Amazonian pharmacological knowledge is systematically accurate. The compounds isolated from plants Schultes documented have produced medical treatments. The knowledge works.

If the knowledge works, and if the people who hold it say it came from the plants, the scientific response should be to take this seriously as data — not to accept it uncritically, but to design investigation around it rather than dismissing it before investigation.

Sources

• Narby, The Cosmic Serpent (1998)

“Narby reports a principle found in every shamanic tradition he studied: the sacred is not for sale. The use of spiritual knowledge for personal accumulation is, by definition, black magic.”

'In shamanic traditions, it is invariably specified that spiritual knowledge is not marketable. The sacred is not for sale; the use of this knowledge for the accumulation of personal power is the definition of black magic.'

Narby is reporting a consistent finding, not editorializing. The rule is definitional to shamanism: what distinguishes the healer from the sorcerer is not the knowledge but the orientation toward it. Knowledge used for the community is healing. Knowledge used for personal power is sorcery.

The global ayahuasca economy has not been built on this principle. Retreat centers sell access to ayahuasca ceremonies. Traditional designs appear on products without benefit-sharing. Shamanic healing frameworks are marketed to Western wellness consumers.

This is not Narby's main argument — he makes it as a description of what the traditions themselves say. But the principle he reports is the most direct possible challenge to the psychedelic retreat industry's business model.

If the sacred is not for sale, then the $500-per-night ayahuasca retreat is, by the tradition's own definition, not engaged in healing. It is engaged in something the tradition calls black magic. Whether this framing should shape policy is debated. That Narby was reporting it accurately is not.

Sources

• Narby, The Cosmic Serpent (1998)

“The most defensible claim in The Cosmic Serpent is the simplest: indigenous pharmacological knowledge is reliably accurate. How it was acquired is the open question.”

The critics of The Cosmic Serpent are right that Narby's DNA-serpent-biophoton hypothesis is speculative and that he moves too readily from correlation to causation. They are wrong if they take this criticism to undermine the book's central argument.

The central argument is not about DNA. It is about epistemology: Western science has a standard of evidence that it applies inconsistently. Evidence that indigenous pharmacological knowledge is reliably accurate would, in any other domain, trigger serious investigation of how that knowledge was acquired. In this domain, it triggers dismissal of the explanation the knowledge holders provide — on the grounds that the explanation involves experiences that are epistemologically inadmissible.

The inadmissibility is a prior, not a finding. Western science has not found that ayahuasca visions cannot convey accurate pharmacological information. It has assumed they cannot, dismissed the testimonies that claim they do, without investigation.

The most defensible version of the Cosmic Serpent argument is not the DNA hypothesis but the epistemological challenge: 'We don't know how they knew' is a different statement from 'they didn't know.' The conflation of these two statements is not science. It is the refusal of a question.

Sources

• Narby, The Cosmic Serpent (1998)
• Schultes & Hofmann, Plants of the Gods (1979)

“In 1967, Schultes said the greatest enemy of ethnopharmacological research was the aspirin pill. He was right. The pill is cheap; the knowledge is not.”

'Perhaps the greatest enemy of ethnopharmacological research is the arrival and cheap availability of the aspirin pill.'

Schultes said this at the NIMH symposium in 1967, and it has become one of the most quoted observations in ethnobotany. Its truth has not diminished.

The mechanism is simple: when aspirin becomes available in a community that previously used plant-based pain relief, the plant-based practices begin to atrophy. The motivation to maintain and transmit the knowledge diminishes when a cheaper, more reliable alternative is available. The apprenticeship is long, the knowledge is complex, and the aspirin pill is easier.

This process has been documented across the world. The young people who might have become traditional healers choose other paths because Western medicine is available and the plants require decades of study.

What is lost with each atrophied knowledge tradition is not replaceable by the archive. Schultes's herbarium specimens are dried plant matter. They preserve the plant's chemistry but not the knowledge of dose, preparation, context, contraindication, and ceremonial integration that makes the plant useful. The knowledge requires a living person who learned it from another living person in a specific ecological and cultural context.

The aspirin pill continues to arrive.

Sources

• Schultes, NIMH Symposium (1967)
• Schultes & Hofmann, Plants of the Gods (1979)

“Schultes wore a suit and tie in the field for fifty years. This was not eccentricity. It was a statement about how he understood his relationship with the communities he worked with.”

The image of Richard Evans Schultes in a suit and tie in the Colombian Amazon has become legendary in ethnobotany — partly because it is genuinely remarkable, partly because Wade Davis described it in One River with enough specificity that anyone who read the book will never forget it.

The suit was not about fashion. It was about how Schultes understood the ethics of his fieldwork.

The standard anthropological approach of his era was either colonial (the scientist extracts knowledge and leaves) or romantic (the scientist goes native, adopts local dress and customs). Schultes did neither. He went to communities as a scientist — with notebooks, botanical presses, and the apparatus of professional inquiry — but he also took those communities seriously as holders of systematic knowledge.

The suit communicated: I am here to do professional work. Your knowledge is professional knowledge. I am not a tourist, and I am not going to pretend to be you. I am going to be myself, and I expect you to be yourselves, and we are going to learn from each other as professional equals.

The communities Schultes worked with were not confused about what he was. He was not confused about what they were. The suit was the sartorial expression of that clarity.

Sources

• Davis, One River (1996)
• Harvard Magazine, Schultes obituary (2001)

“Schultes identified the sacred mushrooms of Mexico in 1938. He sent specimens to Hofmann's laboratory. Hofmann isolated psilocybin. The collaboration made Plants of the Gods possible.”

When Gordon Wasson published his Life magazine article about the Mazatec mushroom ceremony in 1957, he was not the first Westerner to have identified the sacred mushrooms. That was Schultes, who had traveled to Oaxaca in 1938 — nearly twenty years earlier — and had identified the mushrooms used in Mazatec ceremony, collected specimens, and sent them for analysis.

The 1938 identification was not widely publicized, partly because Schultes was at the time a graduate student without the institutional platform that would later give his findings wider reach.

When Wasson's 1957 article created widespread interest, Schultes had the relevant botanical documentation already in his archives. He facilitated the exchange that led to Hofmann receiving specimens and isolating psilocybin and psilocin in 1958.

The collaboration between Schultes and Hofmann that produced Plants of the Gods twenty years later was the culmination of a two-decade relationship that had started with mushroom specimens from Oaxaca. The field knowledge and the laboratory analysis had been in dialogue since 1938 — the book was the record of that dialogue.

Sources

• Schultes & Hofmann, Plants of the Gods (1979)
• Wikipedia, Richard Evans Schultes

“Schultes called the investigation urgent in 1967. Fifty-seven years later, the urgency has not decreased.”

'In the search for new hallucinogens, we have much to do and little time in which to do it.'

Schultes said this in 1967. He was describing a race between documentation and destruction — a race he knew he was losing.

In 2026, the urgency he described has not diminished. The Amazon has lost approximately 20 percent of its forest cover since Schultes made this statement. An estimated language — the primary carrier of ethnobotanical knowledge — is lost every two weeks globally.

What has changed is the response. Mark Plotkin's Amazon Conservation Team, the ICEERS Foundation, the Society of Ethnobiology, and dozens of other organizations are working to document, protect, and transmit the knowledge that Schultes identified as endangered. The Kunming-Montreal Global Biodiversity Framework (2022) includes specific provisions for indigenous-managed territories.

This is progress. It is not sufficient. The race Schultes was watching in 1967 is still being lost at the macro scale, while individual documentation and protection efforts slow it in specific places.

Plants of the Gods was published as an emergency document. It remains one.

Sources

• Schultes, NIMH Symposium (1967)
• Schultes & Hofmann, Plants of the Gods (1979)
• INPA Amazon Reports (2023)

“Schultes spent twelve years in the Amazon and documented the ayahuasca preparation in systematic detail. He never answered the question of how it was discovered. He didn't pretend to.”

Schultes documented the ayahuasca preparation more systematically than any previous Western researcher. He identified the botanical species, the preparation methods, the regional variations, the ritual contexts, and the pharmacological properties.

He did not explain how it was discovered.

In twelve years of fieldwork, Schultes heard the same answer Narby would hear twenty years later: we were taught by the plants. He recorded this in his field notes without elaboration. He was a botanist, not a philosopher of knowledge. The question of how indigenous peoples had identified the two specific plants in a forest of 80,000 species whose combination created an effect that neither plant alone produced was, to Schultes, an interesting question beyond his ability to answer.

He was honest about this in a way that subsequent commentators often are not. The standard 'trial and error over millennia' explanation is not one Schultes endorsed — he knew too much about the pharmacology and the search space to find it convincing. But he did not substitute a better explanation. He documented what was there and moved on.

Narby's Cosmic Serpent is, in part, the attempt to construct the explanation that Schultes declined to attempt. Whether it succeeds is debated. That the attempt was necessary — that the question Schultes declined to answer was real and important — is not.

Sources

• Schultes & Hofmann, Plants of the Gods (1979)
• Narby, The Cosmic Serpent (1998)

“Huxley proposed a mechanism in 1954. Carhart-Harris and Friston named it in 2019. The gap between them was sixty-five years of neuroscience arriving at the same place.”

The claim: Huxley argued in 1954 that the brain functions primarily as a 'reducing valve,' filtering out most of what could be perceived and allowing through only what is biologically useful. Mescaline works by impairing this valve.

The evidence: The REBUS model (Relaxed Beliefs Under Psychedelics), published in Nature Reviews Neuroscience by Carhart-Harris and Friston in 2019, provides a rigorous computational account of exactly this mechanism. In predictive coding theory, the brain generates predictions about incoming sensory data and suppresses signals that match predictions. Psychedelics reduce the 'precision weighting' of these top-down predictions — allowing more bottom-up sensory information into awareness.

This is Bergson's reducing valve, translated into the vocabulary of computational neuroscience. The mechanism Huxley described intuitively maps precisely onto what fMRI studies verify: psychedelics systematically suppress the default mode network, the system most associated with self-referential filtering, increasing global brain entropy and cross-network connectivity.

A December 2025 Cell paper confirmed structural correlates: a single dose of psilocybin triggers activity-dependent rewiring of dendritic spines in the medial frontal cortex in mice, with the structural remodeling detectable weeks later. This is the neural substrate for what Huxley described phenomenologically as the opening of the valve — lasting changes in synaptic architecture from a single experience.

Verdict: Was right. The metaphor was accurate. The mechanism it described is confirmed by fMRI, by predictive coding theory, and by structural neuroimaging at single-synapse resolution.

Sources

• Huxley, The Doors of Perception (1954)
• Carhart-Harris & Friston, REBUS, Nature Reviews Neuroscience (2019)
• Shao et al., Neuron (2021)

“Hofmann argued LSD works by providing access to mystical experience. The clinical literature now confirms mystical experience quality predicts therapeutic outcomes better than drug dose alone.”

The claim: Hofmann argued throughout My Problem Child that LSD's therapeutic benefit derives from its ability to produce genuine mystical experience — a direct encounter with what he called the sacred — and that the drug should be understood as a 'sacred drug' rather than merely a pharmacological agent.

The evidence: The Mystical Experience Questionnaire (MEQ30), derived from philosopher Walter Stace's phenomenological analysis, now measures mystical experience reliably in clinical trial participants. Multiple studies have found that MEQ30 score predicts therapeutic outcomes across conditions — depression, alcohol use disorder, end-of-life anxiety — better than drug dose alone.

Griffiths et al. (Johns Hopkins, 2006) established this with psilocybin in healthy volunteers. Barrett and Griffiths (2018) confirmed that complete mystical experiences (MEQ30 score above 60%) are specifically associated with sustained therapeutic benefit. The COMPASS Pathways Phase 3 trials (COMP005, June 2025; COMP006, February 2026) produced data consistent with this: 25% of participants showing clinically meaningful depression reduction maintained that response through 26 weeks — and the quality of the experience, not only the dose, is a key predictor.

Hofmann's insistence on the word 'sacred' was not religious in the denominational sense — it was a claim that the compound acts through a specific quality of consciousness, not through receptor pharmacology alone. The MEQ30 is measuring this claim. It is confirmed.

Verdict: Was right. The mechanism Hofmann proposed — therapeutic benefit through mystical experience quality — is now the primary mechanistic hypothesis in clinical psychedelic research. The word 'sacred' has been replaced by 'mystical experience score,' but the underlying claim is the same.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Griffiths et al., Psychopharmacology (2006)
• Barrett & Griffiths, Pharmacol. Biochem. Behav. (2018)
• COMPASS Pathways Phase 3 Results (2025-2026)

“The neuroplasticity mechanism McKenna proposed is partly confirmed. The specific evolutionary timeline is not. The interesting question he opened remains open.”

The claim: Psilocybin mushrooms catalyzed human cognitive evolution in East Africa. At low doses, they enhanced visual acuity (useful for hunting). At medium doses, they increased sexual arousal and group bonding. At high doses, they produced ego dissolution and expanded social and symbolic consciousness. These effects, applied to ancestral hominids, drove language, religion, and brain growth.

The neuroplasticity evidence: Shao et al. (Yale, Neuron 2021) showed that a single psilocybin dose induces rapid and persistent growth of dendritic spines in the frontal cortex of mice, with effects lasting at least a month. A 2025 Frontiers in Systems Neuroscience review confirmed psilocybin increases dendritic spine density and complexity in both the hippocampus and frontal cortex. A December 2025 Cell paper demonstrated activity-dependent rewiring of large-scale cortical networks following a single psilocybin dose.

These findings confirm that psilocybin produces lasting changes in synaptic architecture — exactly the kind of change that could, in principle, produce cognitive enhancement if applied to organisms capable of learning from altered states.

What is not confirmed: Any archaeological evidence of psilocybin use by early hominids at the relevant scale. The presence of Psilocybe cubensis in East Africa during the critical period of human cognitive evolution. The specific three-stage dose-response mechanism McKenna described. The causal chain from mushroom consumption to brain size increase.

What remains genuinely open: Whether the long-term human relationship with psychoactive plants — which is universal across known cultures — had any effect on human cognitive development. This is a real scientific question that the stoned ape hypothesis raises, even if it does not answer it.

Verdict: Remains unresolved. The neuroplasticity mechanism is real; the specific evolutionary claim is unsupported. The underlying question — what role did psychoactive plants play in human evolution? — is genuine and uninvestigated.

Sources

• McKenna, Food of the Gods (1992)
• Shao et al., Neuron (2021)
• OPEN Foundation, Psilocybin and Neuroplasticity Review (2025)
• Wikipedia, Stoned Ape Theory

“The connection model correctly identified social environment as a major driver of addiction. It overstated the degree to which connection overrides pharmacology.”

The claim: 'The opposite of addiction is connection.' Addiction is primarily driven by social disconnection, trauma, and lack of meaningful purpose — not by pharmacological dependence. Bruce Alexander's Rat Park experiments demonstrated this in animals; the Vietnam natural experiment demonstrated it in humans.

What is confirmed: Social environment modulates drug-seeking behavior reliably across species. The Rat Park finding — that social enrichment dramatically reduces morphine consumption — holds conceptually across subsequent enrichment paradigms, even if the specific experimental results have not been directly replicated. Lee Robins's Vietnam data remains the strongest human evidence: 95% of heroin-addicted soldiers stopped using upon returning home, without formal treatment, because their environment changed radically.

The fentanyl complication: Hari published in 2015 when overdose deaths were approximately 52,000 annually. By 2023, they had reached 107,500 — primarily fentanyl. The fentanyl crisis demonstrates a limitation of the connection model: even socially connected people die from adulterated supply. The connection model addresses addiction vulnerability; it does not address supply contamination risk.

What is overstated: The claim that connection almost completely overrides pharmacological dependence. Opioid withdrawal is a genuine physiological process. A 2020 review by Gage and Sumnall found the Rat Park effect is real but not as absolute as the original data suggested. Neurobiological evidence (Koob & Volkow) confirms that chronic drug use produces lasting receptor changes independent of social environment.

Verdict: Partially right. The connection model correctly identified social environment as a major variable — more important than purely pharmacological models had acknowledged. It overstated the degree to which environment overrides pharmacology. The most accurate model includes both.

Sources

• Hari, Chasing the Scream (2015)
• Gage & Sumnall, Addiction (2020)
• Koob & Volkow, Neuropsychopharmacology (2016)
• Robins, Vietnam Veterans Three Years After Vietnam (1993)

“Forty-eight years after publication, the hypothesis has moved from speculative to experimentally feasible and archaeologically evidenced at an affiliated cult site. The direct test at Eleusis has not yet been done.”

The claim: The kykeon drink at the heart of the Eleusinian Mysteries contained ergot alkaloids — specifically water-soluble lysergic acid derivatives from Claviceps purpurea contaminating the barley — that produced the visionary experiences initiates described.

The 2019-2020 evidence: Bioarchaeologist Jordi Juan-Tresserras's analysis of material from Mas Castellar de Pontós — an ancient Catalan site associated with the Demeter cult — found apparent ergot alkaloids in dental calculus from a woman buried at the site (third to second century BCE) and in a sealed ritual vessel with beer-making residue. This is the first physical evidence of ergot use at an Eleusinian-affiliated site.

The 2026 experimental evidence: Antonopoulos and Dadiotis (National Kapodistrian University of Athens, Scientific Reports, February 2026) demonstrated experimentally that lye — readily available in antiquity as wood ash solution — converts toxic ergotamine and ergotoxine alkaloids into water-soluble lysergic acid amide derivatives at concentrations achievable through ancient preparation methods. The specific chemical transformation that would make ergot psychoactive in the kykeon without causing ergotism has been demonstrated in the laboratory.

What remains unconfirmed: Ergot residue at the Eleusis Telesterion site itself. The 2026 Scientific Reports paper explicitly calls for chemical analysis of vessels from the Eleusis sanctuary. This analysis has not been done. Access to the site involves institutional, political, and preservation constraints.

Verdict: Gaining support. In 1978, the hypothesis was speculative. In 2026, it is experimentally feasible (the chemistry has been demonstrated) and archaeologically evidenced at an affiliated cult site. The direct confirmation at Eleusis itself — the most decisive possible test — awaits analysis that is technically possible and institutionally pending.

Sources

• Wasson, Hofmann & Ruck, The Road to Eleusis (1978)
• Mas Castellar de Pontós excavation reports (2019-2020)
• Antonopoulos & Dadiotis, Scientific Reports (February 2026)

“Osmond developed the set and setting framework from clinical observation in Saskatchewan in the 1950s. A 2024 systematic review confirmed it predicts outcomes across 75 clinical trials.”

The claim: Osmond and Huxley argued through their correspondence that the same substance produces dramatically different outcomes depending on the mindset of the person taking it (set) and the physical and social context (setting). Preparation, guidance, environment, and integration are not peripheral to the pharmacology — they are constitutive of the therapeutic outcome.

The clinical evidence: A 2024 review by Borkel et al. in Expert Review of Clinical Pharmacology analyzed set and setting variables across independent samples and found they predict psychopathology, wellbeing, and meaningfulness of psychedelic experiences. A 2024 systematic review by Thal and Lommen (Clinical Psychology & Psychotherapy) synthesized 75 clinical trials of psychedelic-assisted therapy and found therapeutic alliance, preparation quality, and integration session quality were significant predictors of outcome across conditions.

The 2008 safety guidelines published by Johnson, Richards, and Griffiths at Johns Hopkins — which are now the baseline protocol for every clinical psychedelic trial — formalize exactly what Osmond and Huxley worked out empirically: therapeutic alliance must be established before dosing; monitors must be present throughout sessions; integration sessions are required; adverse event protocols must be in place. These are Osmond's clinical observations, operationalized.

A 2025 Frontiers in Psychology paper (Zamaria) examined the ongoing controversy about whether psychotherapy is necessary alongside the drug, or whether the drug does the work independently. The tentative answer: the preparation-session-integration structure significantly modulates outcomes, and separating drug and structure in a powered RCT has not been done.

Verdict: Was right. The set and setting framework, developed from clinical observation in Saskatchewan in the early 1950s, has been confirmed by 75-study systematic reviews and is now mandatory infrastructure for clinical psychedelic research.

Sources

• Huxley & Osmond, in Moksha (1977)
• Borkel et al., Expert Rev. Clin. Pharmacol. (2024)
• Thal & Lommen, Clin. Psychol. Psychother. (2024)
• Johnson et al., J. Psychopharmacol. (2008)

“McKenna's description of the machine elves has been independently corroborated by thousands of users. Imaging has mapped DMT's global brain effects but has not yet isolated entity contact. What the entities are remains open.”

The claim: McKenna described 'merry elfin, self-transforming, machine creatures' encountered during high-dose DMT experiences. He argued their consistency across users suggested something was genuinely being encountered — not simply hallucination in the dismissive sense.

The consistency data: A 2020 Johns Hopkins survey (Davis et al., J. Psychopharmacol. 34(9):1008-1020) of 2,561 people who had already had a DMT entity encounter described their encounters in a 2020 Johns Hopkins survey (Davis et al., J. Psychopharmacol. 34(9)). It documents the phenomenology in detail but sets no prevalence rate, because every respondent was recruited for having had an encounter; the 97% figure often attached to it appears in no published paper. The most common entity types — small, humanoid or non-humanoid, apparently intelligent, apparently communicating — substantially match McKenna's original description. The survey found most respondents rated the encounters as among the most meaningful experiences of their lives.

The neuroscience: A 2023 Imperial College London fMRI study (Timmermann et al., PNAS 120(13)) mapped DMT's global brain effects — large increases in global functional connectivity, network disintegration and desegregation, and compression of the principal cortical gradient. It did not isolate entity contact as a distinct neural signature, and no published imaging study yet has: the phenomenology is well documented, the neural specificity is not. Entity contact is not a uniform feature of DMT; it is a specific experience with specific neural correlates.

What the neuroscience does not resolve: Whether entities are projections of the unconscious, products of the brain's pattern-recognition systems applied to an unusually rich signal, or something that requires a different explanatory framework. The consistency of the report — across cultures, decades, and thousands of independent subjects — is established. The mechanism and meaning of that consistency are not.

McKenna's epistemic position — he reported the phenomenon without claiming certainty about its ontological status — has proven to be the scientifically appropriate one. The phenomenon he described is real in the sense of being consistently reported. What it represents remains open.

Verdict: Phenomenologically confirmed, explanation unresolved. McKenna accurately reported a consistent phenomenon and correctly held open the question of what it means. The neuroscience has confirmed the phenomenon's consistency and identified its neural correlates. The explanation awaits frameworks that do not yet exist.

Sources

• McKenna, True Hallucinations (1993)
• Sexton et al., J. Psychopharmacol. 33(9) (2019)
• Timmermann et al., PNAS 120(13) (2023)
• Strassman, DMT: The Spirit Molecule (2001)
• Davis et al., J. Psychopharmacol. 34(9):1008-1020 (2020)

“Narby's central claim — that shamans access molecular-level information through ayahuasca — has not been tested. His subsidiary claims about plant intelligence have been substantially validated by mainstream science.”

The central claim: Shamans access information at the molecular level — specifically DNA — through ayahuasca visions. The twin-serpent imagery universal in shamanic traditions represents the double helix. Biophoton emission from DNA may be the physical mechanism by which plant information reaches human consciousness.

What has been tested: The biophoton hypothesis — that DNA emits ultra-weak photons in the UV/visible range — is scientifically established. Whether these biophotons serve an informational function in the way Narby suggests has not been tested experimentally.

The plant intelligence subsidiary claims: Monica Gagliano's 2014 study (Oecologia) demonstrated that Mimosa pudica plants can learn to habituate to a stimulus and retain this learning for weeks. Suzanne Simard's mycorrhizal network research, widely replicated since 1997, showed trees communicate, share resources, and respond to each other's distress through underground fungal networks. Both findings vindicate Narby's 2005 argument in Intelligence in Nature that plant intelligence is a legitimate research object — at the time, a fringe claim.

The combinatorial problem: The core puzzle Narby raises — how indigenous peoples discovered the ayahuasca combination across an 80,000-species search space — remains scientifically unresolved. No proposed mechanism (trial and error, chemical ecology, sensory identification, or ayahuasca-mediated plant communication) has been established as the explanation.

Verdict: Partially supported, core mechanism untested. Narby's subsidiary arguments about plant intelligence have been substantially vindicated by mainstream research (Simard, Gagliano). His epistemological critique — that Western science dismisses indigenous pharmacological knowledge without adequate investigation — is correct. His specific DNA-biophoton-serpent hypothesis has not been experimentally tested and remains speculative.

Sources

• Narby, The Cosmic Serpent (1998)
• Narby, Intelligence in Nature (2005)
• Simard, Finding the Mother Tree (2021)
• Gagliano et al., Oecologia (2014)

“Schultes said in 1967 that ethnopharmacological research was racing against time. The Amazon has since lost 20% of its forest cover. The race has not been won.”

The claim: 'In the search for new hallucinogens, we have much to do and little time in which to do it.' Schultes argued in 1967 that the aspirin pill, the mission school, and the road were destroying indigenous plant knowledge traditions faster than they could be documented.

The Amazon data: The Brazilian Amazon has lost approximately 20% of its original forest cover since Schultes made this statement. An estimated language — the primary carrier of ethnobotanical knowledge — is lost every two weeks globally. Communities that maintained the psychoactive plant knowledge traditions Schultes documented have been disrupted by Western medicine, economics, religion, and legal systems at an accelerating pace.

The response: The field Schultes established has expanded dramatically since 1967. The Society of Ethnobiology, the Amazon Conservation Team (founded by his student Mark Plotkin), ICEERS, and dozens of academic programs now work on documentation and preservation. The Kunming-Montreal Global Biodiversity Framework (2022) commits signatories to protect 30% of global land by 2030 with specific provisions for indigenous-managed territories.

The asymmetry: Individual documentation and protection efforts have been substantial. They have not matched the scale of loss. The communities whose knowledge Schultes documented have not been reconstituted. The plants he described are in many cases rarer or locally absent. The practitioners who held the knowledge have in many cases died without successors.

Verdict: Was right — and the urgency has increased. Schultes identified in 1967 what is now a mainstream conservation argument: that indigenous knowledge and biological diversity are inseparable, and that losing one loses the other. The race he described is still being lost at the macro scale. The institutions he inspired have slowed but not stopped the loss.

Sources

• Schultes, NIMH Symposium (1967)
• Schultes & Hofmann, Plants of the Gods (1979)
• INPA Amazon Reports (2023)
• CBD Kunming-Montreal Framework (2022)

“The core argument — that cannabis scheduling was scientifically unjustified and served specific corporate interests — has been confirmed. The specific DuPont orchestration thesis exceeds what the documents prove.”

The core claim: Cannabis's Schedule I classification was not based on scientific evidence of harm. It was driven by corporate interests (DuPont's synthetic fibers, Hearst's timber paper), racial targeting, and political expediency. The medical evidence supported cannabis's therapeutic applications, which were systematically suppressed.

What has been confirmed: The WHO Expert Committee on Drug Dependence conducted a Critical Review of cannabis in 2019 and recommended reclassification, finding that the current scheduling is not justified by the pharmacological evidence. The DOJ's proposed rescheduling (May 2024) from Schedule I to Schedule III represents the federal government's own acknowledgment that the 'no accepted medical use' criterion is no longer supported.

The ACLU's 2020 enforcement data confirmed racial targeting: Black Americans are 3.73 times more likely to be arrested for marijuana possession despite similar use rates. Ehrlichman's 2016 Harper's admission confirmed that the Nixon drug war was explicitly designed to target Black communities and anti-war protesters. The racial targeting argument Herer made in 1985 is now documented at the highest level.

What was overstated: The specific DuPont conspiracy thesis — that DuPont orchestrated the Marihuana Tax Act to eliminate hemp as a competitor to nylon — exceeds what the available documents can establish. The corporate interests existed; whether DuPont specifically orchestrated the legislation, as opposed to benefiting from it, is not conclusively proven. Historians including Campos have shown that racial panic and moral reform movements were independently sufficient to produce the legislation.

Verdict: Substantially vindicated, some overreach. The core claims — scientifically unjustified scheduling, corporate benefit, racial targeting — have been confirmed. The specific conspiracy framing of DuPont-as-orchestrator goes beyond what the evidence establishes.

Sources

• Herer, The Emperor Wears No Clothes (1985)
• WHO ECDD Critical Review Cannabis (2019)
• DOJ NPRM Cannabis Rescheduling (May 2024)
• ACLU, A Tale of Two Countries (2020)

“Stevens argued the 1968 scheduling was politically driven, not evidence-driven. The WHO Critical Review, the FDA Breakthrough Therapy designations, and the Phase 3 clinical results have all confirmed this.”

The claim: The 1968 Staggers-Dodd Act and the 1970 Controlled Substances Act's Schedule I classification of LSD ended a clinical research program that had produced genuine evidence of therapeutic efficacy — not because the evidence was wrong but because the political and institutional conditions had become untenable. The scheduling was political, not scientific.

The evidence that the scheduling was not scientific: The WHO Expert Committee on Drug Dependence conducted a Critical Review of LSD in 2019 and found no evidence supporting the substance's current international scheduling level. The FDA's Breakthrough Therapy Designation for psilocybin (2018) — a compound with nearly identical pharmacological mechanism to LSD — effectively acknowledged that classical psychedelics may have accepted medical use, contradicting the Schedule I criterion.

The resumption confirms what was interrupted: The COMPASS Pathways Phase 3 trials (2025-2026) produced statistically significant results for psilocybin in treatment-resistant depression. A 2012 meta-analysis by Krebs and Johansen of six randomized controlled trials of LSD for alcoholism from the 1960s-70s found a statistically significant positive effect on drinking behavior. The clinical evidence that existed in 1968 was real.

The LSD safety data: The 2016 Global Drug Survey found LSD had the lowest emergency medical treatment rate of any substance surveyed. Zero overdose deaths from LSD toxicity have been documented in eighty years of use. The pharmacological evidence for Schedule I's 'high abuse potential, no accepted medical use' designation was absent in 1968 and remains absent.

Verdict: Was right. The 1968 scheduling was not driven by evidence of harm or lack of efficacy. It was driven by the political association of LSD with the counterculture, by Ehrlichman's explicitly racially targeted drug war strategy, and by the institutional desire to control what could not be controlled. The clinical research that resumed fifty years later is confirming what was interrupted.

Sources

• Stevens, Storming Heaven (1987)
• WHO ECDD Critical Review LSD (2019)
• COMPASS Pathways Phase 3 (2025-2026)
• Krebs & Johansen, J. Psychopharmacol. (2012)

“I had the impression of being unable to move from the spot, although my assistant told me later that we had cycled at a good pace.”

The passage: 'On the way home, my condition began to assume threatening forms. Everything in my field of vision wavered and was distorted as if seen in a curved mirror. I also had the sensation of being unable to move from the spot, although my assistant told me later that we had cycled at a good pace.'

Why this passage: It is the founding document of modern psychedelic pharmacology, and its most important feature is the contrast between subjective and objective experience that Hofmann captures in a single sentence.

Hofmann had the impression of standing still. His assistant confirmed they had been moving at a good pace. The subjective experience of temporal distortion — which was overwhelming and convincing from the inside — was simply false as a report about the external world. He was moving; he felt motionless.

This contrast became one of the most clinically important observations in the history of LSD research. It established that the subjective experience of LSD is not merely a distortion of external reality but a reorganization of the brain's processing of temporal and spatial information. The brain, under LSD, is doing something different — not reporting external reality incorrectly by accident, but processing the same external reality through a different filter.

The 2017 crystal structure of LSD bound to the 5-HT2A receptor (Wacker et al., Cell) explains why the experience lasted so long and was so disorienting: LSD's molecular shape fits the receptor so precisely that a protein lid traps it inside for hours. The 'good pace' that Hofmann could not perceive was being generated by the same body whose sensory experience had been completely reorganized.

Sources

• Hofmann, LSD: My Problem Child (1979)

“Television is by nature the dominator drug par excellence. Control of content, uniformity of content, repeatability of content make it inevitably a tool of coercion.”

The passage: 'Television is by nature the dominator drug par excellence. Control of content, uniformity of content, repeatability of content make it inevitably a tool of coercion, brainwashing, and manipulation. Television induces a trance state in the observer that is analagous to hypnosis. Preferences and values are subtly imposed... it saps individual autonomy, creates passivity, and makes for spectator culture.'

Why this passage: Written in 1992, three years before the World Wide Web became publicly available and twenty years before the algorithmic social media feed, it anticipates with remarkable precision the mechanism of what would become the attention economy.

McKenna's specific claims: control of content (editorial gatekeeping), uniformity (same programming for mass audiences), repeatability (content that can be replicated identically). These are the mild version of what followed. The algorithmic feed does not merely control content — it individually optimizes content for each viewer's psychological vulnerabilities. It is not uniform — it is precisely nonuniform, serving each person what will maximize their engagement. And it is not merely repeatable — it is infinite, without the natural endpoint of a television schedule.

Sean Parker, founding president of Facebook, confirmed in 2017 that the platform was deliberately designed to exploit psychological vulnerabilities: 'How do we consume as much of your time and conscious attention as possible?' This is the dominator drug thesis stated explicitly by one of its engineers.

McKenna was writing about NBC. The technology he was warning about had not yet been invented. Every sentence has become more accurate.

Sources

• McKenna, Food of the Gods (1992)

“Imagine if the government chased sick people with diabetes, put a tax on insulin and drove it into the black market, told doctors they couldn't treat them — then sent them to jail.”

The passage: 'Imagine if the government chased sick people with diabetes, put a tax on insulin and drove it into the black market, told doctors they couldn't treat them — then sent them to jail. If we did that, everyone would know we were crazy. Yet we do practically the same thing every day in the week to sick people hooked on drugs.'

Why this passage: Holiday wrote this in 1956, the same year Osmond was introducing the word 'psychedelic' to the scientific literature. She was not a pharmacologist or a policy analyst. She was a woman who had been directly targeted by Harry Anslinger's Federal Bureau of Narcotics, who had had her New York cabaret license revoked and been denied the ability to work in the city where her career was centered, who had been arrested, imprisoned, and under federal surveillance for years.

From inside this experience, she produced one of the clearest arguments in the addiction policy literature: the analogy between insulin-dependent diabetes and heroin addiction. Both involve a body that has become physiologically dependent on a compound. The moral framework applied to each is completely different.

The analogy is not perfect — diabetes is not caused by voluntary behavior in the way heroin dependence begins, and the social determinants of the two conditions differ significantly. But as a description of how the same pharmacological process — dependency — is treated differently depending on who has it and what they're dependent on, it is precise and devastating.

Holiday understood in 1956 what the policy literature would not fully acknowledge for another sixty years: the drug war's target was not the drug. Hari quotes this passage because it says in one paragraph what his book takes three hundred pages to establish.

Sources

• Hari, Chasing the Scream (2015)
• Holiday, Lady Sings the Blues (1956)

“To fathom Hell or soar angelic, / just take a pinch of psychedelic. — Osmond wins.”

The exchange: In 1956, Osmond and Huxley were corresponding about what to call these substances. Both submitted rhyming couplets as proposals.

Huxley: 'To make this trivial world sublime, / take half a gram of phanerothyme.' Osmond: 'To fathom Hell or soar angelic, / just take a pinch of psychedelic.'

Osmond's won. He introduced 'psychedelic' formally in a 1957 paper in the Annals of the New York Academy of Sciences.

Why this passage: Because the choice between the two words was the choice between two philosophical positions, and the winning position shaped everything that followed.

Huxley's phanerothyme ('making the spirit manifest') located the substance's action in a spiritual register: what becomes visible is the spirit, the divine capacity of the human person. The word assumes an anthropology in which spirit exists and is ordinarily hidden.

Osmond's psychedelic ('mind-manifesting') located the action in a psychological register: what becomes manifest is the mind itself. The word does not assume a spirit. It assumes a mind that contains more than ordinary consciousness reveals.

Osmond's couplet also contains the bipolar truth Huxley's doesn't: 'fathom Hell or soar angelic.' The choice of words acknowledged the negative possibility — that what the mind contains includes Hell, not only the divine — in a way that Huxley's 'trivial world sublime' did not. This acknowledgment would prove clinically crucial: set and setting matter precisely because the experience can go in either direction.

The word that won was slightly less philosophically precise but slightly more pharmacologically honest.

Sources

• Huxley & Osmond, in Moksha (1977)
• Osmond, Ann. N.Y. Acad. Sci. (1957)

“Merry elfin, self-transforming, machine creatures — looking like self-dribbling Fabergé eggs on the rebound, they had surrounded me and tried to teach me the lost language of true poetry.”

The passage: 'During my own experiences smoking synthesized DMT in Berkeley, I had had the impression of bursting into a space inhabited by merry elfin, self-transforming, machine creatures. Dozens of these friendly fractal entities, looking like self-dribbling Fabergé eggs on the rebound, had surrounded me and tried to teach me the lost language of true poetry.'

Why this passage: It is the founding phenomenological document of the entity contact literature. McKenna wrote this description approximately twenty years after the original experiences (the DMT experiments in Berkeley began in the mid-1960s). It entered wide cultural circulation with the publication of True Hallucinations in 1993.

The description's vocabulary is notable: merry, elfin, self-transforming, machine, fractal, friendly. Each term carries specific information. Merry and friendly establish the emotional tone of most — though not all — entity encounters. Elfin and fractal attempt to capture the appearance. Self-transforming is the quality most consistently reported across independent accounts: the entities are in constant motion, changing form continuously. Machine suggests mechanical intelligence rather than biological organic life.

The 'lost language of true poetry' — the entities attempting communication through visible language, through objects made of meaning rather than words — is the feature McKenna returned to most obsessively. He believed the entities were demonstrating a mode of communication that preceded and exceeded verbal language.

A 2019 Johns Hopkins survey of 2,561 DMT users found this description substantially corroborated by people who had not encountered it before their experiences. The specific vocabulary varies; the underlying phenomenology does not. Self-transforming entities that seem to be communicating something are the most reported feature of high-dose DMT. McKenna described it first and best.

Sources

• McKenna, True Hallucinations (1993)
• Sexton et al., J. Psychopharmacol. 33(9) (2019)

“The first time an Ashaninca man told me that he had learned the medicinal properties of plants by drinking a hallucinogenic brew, I thought he was joking. But he was not smiling.”

The passage: 'The first time an Ashaninca man told me that he had learned the medicinal properties of plants by drinking a hallucinogenic brew, I thought he was joking. But he was not smiling.'

Why this passage: It is one of the most important sentences in the ethnobotanical literature, because it marks the moment when an epistemological collision between two knowledge systems becomes visible.

Narby is a Stanford-trained anthropologist. He has been trained to identify what cultural informants mean versus what they say — to find the rational empirical process that underlies mythological explanation. When an Ashaninca man says 'we learned from the plants,' the standard interpretive move is to understand this as: 'we learned from careful observation of plant effects over many generations, and we have encoded this knowledge in a narrative framework that attributes it to the plants themselves.'

But the man is not using a mythological framework. He is making a literal claim. And Narby, precisely because he is trained to hear the difference, notices: this is the literal claim.

The passage is important because it marks the beginning of a decade of investigation that The Cosmic Serpent documents. Narby does not accept the claim uncritically. He also cannot, after years of fieldwork, dismiss it as metaphor. The combinatorial pharmacology of ayahuasca — the identification of two specific plants from 80,000 candidates whose combination creates oral DMT activity — is not adequately explained by 'careful observation over many generations.'

The man was not joking. He was reporting what he knew. The question the book investigates is what his knowledge means.

Sources

• Narby, The Cosmic Serpent (1998)

“Perhaps the greatest enemy of ethnopharmacological research is the arrival and cheap availability of the aspirin pill.”

The passage: 'Perhaps the greatest enemy of ethnopharmacological research is the arrival and cheap availability of the aspirin pill.'

Why this passage: Schultes delivered this line at the NIMH symposium in San Francisco in 1967 — the same year as the Summer of Love, the same year Leary's public advocacy was peaking, the same year the counterculture was beginning to engage with the plant knowledge that Schultes had spent two decades documenting.

He was not talking about aspirin's pharmacology. He was talking about the economics of knowledge transmission. The mechanism is simple: when a cheap, reliable Western pharmaceutical becomes available in a community that has used plant-based medicine for generations, the motivation to maintain and transmit the traditional knowledge declines. The apprenticeship to learn the knowledge is long. The aspirin pill is short, cheap, and available at the nearest shop.

The aspirin pill is a stand-in for the entire Western pharmacopeia — for the economic and cultural conditions of modernity that make traditional knowledge less necessary at exactly the moment when Western science has the tools to verify its accuracy and the urgency to preserve it before it disappears.

Schultes was describing an irreversible process. Once a knowledge tradition is disrupted — once the practitioner dies without transmitting what they know — what is lost cannot be recovered from herbarium specimens. The chemistry of the plant survives. The knowledge of how to use it does not.

This sentence was the distilled anxiety of twelve years in the Amazon, watching the world Schultes had documented being replaced, too quickly, by a world he had not.

Sources

• Schultes, NIMH Symposium (1967)
• Schultes & Hofmann, Plants of the Gods (1979)

“The research stopped. Over a thousand scientific papers, forty thousand patients, fifteen years of accumulated clinical practice — stopped.”

The moment: October 6, 1968. The Staggers-Dodd bill signed into law, making LSD possession a federal misdemeanor. The Controlled Substances Act of 1970 completing the classification: Schedule I.

Stevens writes the ending of the research with documentary precision and without editorializing. The numbers speak: over a thousand published scientific papers. More than forty thousand patients who had received LSD-assisted therapy. Fifteen years of refinement — better protocols, better patient selection, better understanding of what the drug was doing and in what conditions it was most useful.

All of it stopped.

Why this passage matters: Not because of what it says about 1968 but because of what it says about how institutions end promising research. The research did not stop because it failed. The evidence from the Hoffer-Osmond alcoholism trials, from Grof's work at the Maryland Psychiatric Research Center, from the end-of-life anxiety studies — all of it pointed toward genuine therapeutic application.

The research stopped because the political costs of continuing exceeded the institutional capacity to absorb them. Leary had made LSD a symbol of anti-establishment rebellion. The Nixon administration had made the counterculture an explicit enemy. The clinical researchers — who had never endorsed recreational use, who had spent fifteen years building careful protocols — could not separate their work from its appropriation.

The Storming Heaven's deepest lesson is institutional: scientific evidence is not sufficient to protect research from political suppression. What protects research is institutional durability — the kind that the current psychedelic renaissance is explicitly trying to build, having read the history.

Sources

• Stevens, Storming Heaven (1987)
• Cambridge HPS Medical History dissertation (2007)

“'Hemp for Victory' was the title of a 1942 USDA film urging farmers to grow cannabis hemp as a patriotic duty. The same government denied the film's existence in the 1980s.”

The film: Hemp for Victory, produced by the USDA in 1942, thirteen minutes long, distributed to American farmers across the Midwest. Its message: grow cannabis hemp for the war effort. The Philippines had fallen to Japan, cutting off the supply of Manila hemp critical for military rope, rigging, and parachute webbing. The government needed domestic production. It distributed 400,000 pounds of cannabis seed to farmers and made a film encouraging them to grow the plant.

The denial: When Herer began citing the film in Emperor, the USDA denied it had ever been made. Library of Congress records did not list it. Archivists told researchers there was no such film.

The recovery: Maria Farrow and Carl Packard searched the Library of Congress holdings and found it in 1989. Herer announced the discovery. The Library of Congress subsequently acknowledged the film's existence.

Why this passage matters: The Hemp for Victory sequence is Huxley's most compressed argument. It is not a conspiracy theory — it is a documentary record. The US government produced a film urging patriotic cannabis hemp cultivation in 1942. Four years earlier, the same government had passed legislation eliminating the same crop on the grounds that it was a dangerous narcotic. After the war, the same government returned to prohibition.

The contradiction is on film. The film is in the Library of Congress. The government denied the film existed. Then acknowledged it.

Herer assembled documents, and the documents made the argument. This sequence — the film's existence, the government's denial, the discovery, the acknowledgment — is the structure of the book in miniature.

Sources

• Herer, The Emperor Wears No Clothes (1985)
• Wikipedia, Hemp for Victory

“DNA emits ultra-weak photons in the UV and visible range. This is established biophysics. Whether these biophotons serve an informational function in the way Narby proposes is untested.”

Every living cell emits ultra-weak photons — light in the UV and visible range produced as a byproduct of metabolic processes. The phenomenon was first systematically documented by Fritz-Albert Popp in the 1970s and confirmed repeatedly since. Biophoton emission from DNA is established biophysics.

Jeremy Narby built his central hypothesis on this foundation: if DNA emits biophotons, and if the brain under ayahuasca becomes unusually sensitive to internal signals, the visionary content of the DMT state might represent perception of biophoton emission from DNA at the cellular level. The luminous, serpentine imagery consistent across shamanic traditions would be, in this account, the visual signature of DNA itself.

The hypothesis is specific enough to be tested and has not been. Cifra and Pospíšil's 2014 review in the Journal of Photochemistry and Photobiology B systematically examined biophoton research and found no evidence that biophoton emission serves a communication function in the way Narby proposes. The photons are real; their informational role is not established.

What Narby's hypothesis correctly identifies is that the brain is not a closed system — it is bathed in internally generated photons as well as receiving signals from outside. Whether this creates any pathway between cellular molecular processes and conscious experience is the genuine open question his work raises. The answer is not known. The question is legitimate.

Sources

• Popp et al., J. Photochem. Photobiol. (1992)
• Narby, The Cosmic Serpent (1998)
• Cifra & Pospíšil, J. Photochem. Photobiol. B (2014)

“Simard showed that trees share carbon through mycorrhizal networks, preferentially supporting kin. This is not metaphor. It is documented carbon transfer. The question is what it means for how we understand intelligence.”

Suzanne Simard's 1997 Nature paper is the most cited paper in plant communication research. It showed that Douglas fir and paper birch trees growing together exchange carbon through mycorrhizal fungal networks — the fir sending carbon to the birch in summer when the birch is shaded, the birch returning carbon to the fir in autumn. The exchange is bidirectional, responsive to seasonal conditions, and follows kin recognition patterns: mother trees preferentially allocate carbon to their own seedlings through the network.

This finding is empirically robust and has been replicated in multiple forest systems. What it means conceptually is more contested. Simard uses the language of communication and intelligence; critics argue the word 'communication' implies intentionality that the mechanism doesn't support — the carbon transfer is a consequence of mycorrhizal fungal behavior, not necessarily coordinated by the trees themselves.

A 2023 review by Karst et al. in New Phytologist engaged this debate directly, arguing that the 'wood wide web' framing has outpaced the evidence — that many popular accounts of inter-tree communication describe a degree of coordination and intentionality that the underlying mechanism doesn't require.

For Narby's argument, the Simard finding matters as one of several empirical pillars supporting the claim that plant intelligence is a legitimate research object. Whether the specific mechanism is 'communication' in a strong sense matters less than the fact that plants are embedded in information-exchanging systems that Western science had previously overlooked entirely.

Sources

• Simard et al., Nature (1997)
• Simard, Finding the Mother Tree (2021)
• Karst et al., New Phytologist (2023)

“The question is not whether ayahuasca visions are 'real.' The question is what epistemological framework is adequate to the evidence of what indigenous pharmacological knowledge has achieved.”

Jeremy Narby's central epistemological move in The Cosmic Serpent is modest but consequential: he distinguishes between 'we don't know how' and 'it didn't happen.' Western science has consistently conflated these two statements when evaluating indigenous pharmacological claims. The conflation is not a finding — it is a prior.

The distinction matters because the evidence demands it. Indigenous Amazonian pharmacological knowledge is reliably accurate. The compounds isolated from the plants Schultes and others documented have produced working pharmaceuticals — curare as a surgical muscle relaxant, quinine as antimalarial, dozens of compounds still in clinical trials. The knowledge works. Western science has not produced an adequate explanation of how it was acquired.

The standard explanation — systematic trial and error over millennia — is less satisfying the more closely you examine it. The ayahuasca case is the sharpest challenge. In a forest containing approximately 80,000 plant species, indigenous peoples across multiple unconnected cultures identified the same two specific plants whose combination creates oral DMT activity. Neither plant alone produces the sustained visionary state. The pharmacological interaction — MAO inhibition enabling DMT oral bioavailability — requires knowledge of both plants simultaneously. The search space for this combination by random trial and error is forbidding.

Narby's response is not to claim that shamans access DNA through biophoton perception — though he proposes this as a hypothesis. His response is prior to the hypothesis: the indigenous explanation (the plants told us) deserves investigation as data, not dismissal as superstition. This is a methodological claim, not a metaphysical one.

Philosopher of science Paul Feyerabend made a structurally similar argument in Against Method (1975): that the demarcation between science and non-science is not epistemologically principled, and that alternatives to the dominant method have historically produced genuine knowledge. Helen Longino in Science as Social Knowledge (1990) showed that scientific knowledge is always produced within social contexts that shape which questions get asked and which evidence is considered admissible.

Applied to Narby's argument: Western science has operated with a prior that excludes visionary states as a source of accurate information about the physical world. This prior is not based on empirical investigation of the claim — it is based on a theory of mind that says conscious experience cannot be a reliable guide to molecular reality. That theory of mind is not established by evidence; it is a commitment.

The plant intelligence research of the last thirty years has chipped at this commitment from a different angle. If plants can learn (Gagliano 2014), if mycorrhizal networks transfer resources in ways that follow kin recognition (Simard 1997), if forests are embedded in chemical communication systems that respond to damage, stress, and seasonal change — then the assumption that plants are passive objects without any form of information processing has been empirically undermined.

Narby's book is most valuable not as a specific hypothesis about DNA and biophotons but as a sustained argument for intellectual humility about the epistemological status of indigenous knowledge. The argument is: a knowledge system that reliably produces accurate pharmacological results deserves investigation of its methods, not dismissal of its framework. This argument is now mainstream in ethnobotany, anthropology, and philosophy of biology. The specific biophoton hypothesis remains untested.

Sources

• Narby, The Cosmic Serpent (1998)
• Longino, Science as Social Knowledge (1990)
• Feyerabend, Against Method (1975)
• Gagliano et al., Oecologia (2014)

“The Nagoya Protocol exists. 138 countries have ratified it. Its enforcement is weak, its scope excludes prior exploitation, and the communities it's designed to protect remain largely unaware of its provisions.”

The Nagoya Protocol on Access and Benefit-Sharing entered into force in October 2014 after four years of negotiation under the Convention on Biological Diversity. As of 2026, 138 countries have ratified it. Its core obligation: companies and researchers who access genetic resources or traditional knowledge associated with genetic resources from signatory countries must share benefits with the provider country and, where applicable, the indigenous communities of origin.

The Protocol is the international legal implementation of the argument Narby makes in The Cosmic Serpent: that indigenous communities have a legitimate claim to benefit from commercial exploitation of knowledge they developed and stewarded.

The gap between the Protocol and its implementation is large. A 2018 review by Wynberg and Laird in Ambio examined Nagoya's first four years and found: most provider countries lacked the domestic legislation to implement its provisions; most companies remained unaware of or non-compliant with their obligations; indigenous communities in most signatory countries had received no benefit-sharing payments under the Protocol despite continued commercial exploitation of traditional knowledge.

The Protocol explicitly does not apply retroactively — it covers access and exploitation that occurs after its entry into force. This means that the decades of ethnobotanical exploitation that produced current pharmaceutical products, including the ayahuasca-derived compounds in clinical development, are outside its scope. Historical exploitation is not addressed.

For the psychedelic industry specifically: the compounds in clinical development (psilocybin, ibogaine, DMT-based ayahuasca) are all derived from or structurally related to compounds used by indigenous communities for millennia. The Nagoya Protocol's benefit-sharing requirements apply to new commercial development of these compounds where traditional knowledge is accessed. Enforcement of these requirements in practice has been minimal.

Narby's argument — that the sacred cannot be sold without cost to the communities that stewarded it — has partial legal expression in the Nagoya Protocol. The distance between the legal expression and the practical reality is the ongoing policy failure that the Protocol was designed to address.

Sources

• Nagoya Protocol on ABS (2010, in force 2014)
• Wynberg & Laird, Ambio (2018)
• UNCTAD, Access and Benefit Sharing in Practice (2023)

“The legal cannabis industry is worth $40 billion. The communities most harmed by prohibition have received a small fraction of its benefit. Herer's vision — distributed hemp economies empowering small farmers — has not materialized.”

Jack Herer published The Emperor Wears No Clothes in 1985 with a specific political economy in mind. Cannabis legalization would distribute economic power to small farmers, local processors, and community businesses. Industrial hemp would replace petrochemical products, paper pulp, and synthetic fibers. The decriminalization of cannabis would restore dignity and economic opportunity to communities destroyed by a century of racially targeted prohibition.

The legal cannabis industry that actually emerged is measurable. By 2025, the combined US legal cannabis market — medical and recreational — was valued at approximately $40 billion annually. Employment in the legal cannabis industry exceeded 400,000 full-time equivalent positions. Tax revenue from cannabis sales across legal states exceeded $15 billion cumulatively since 2014.

These are large numbers. They do not describe Herer's political economy.

Consolidation has proceeded rapidly in every state that has legalized recreational cannabis. The initial wave of small operators — often the activists and advocates who drove legalization — has been largely displaced by multi-state operators (MSOs) with access to capital markets, real estate, and regulatory expertise. California's cannabis market, the largest in the US, consolidated so aggressively that by 2024 most small dispensaries were operating at a loss or had closed. The craft cannabis sector, analogous to craft brewing, exists in some markets but at a small fraction of industry revenue.

Equity provisions in legal cannabis markets have been systematically underfunded. Illinois passed one of the most ambitious social equity frameworks, allocating a percentage of cannabis tax revenue to communities disproportionately impacted by prohibition. By 2024, the program had distributed a fraction of its intended funding due to administrative bottlenecks and legal challenges from non-equity operators.

The racial equity gap has not closed. The ACLU's 2023 analysis found that Black Americans continued to be arrested for marijuana possession in legal states at higher rates than white Americans despite equivalent use rates — the disproportion narrowed but did not disappear. The communities most targeted by the drug war have not received proportionate economic benefit from legalization.

The hemp market, which Herer identified as the most important industrial opportunity, has developed in a different direction from his vision. The 2019-2020 CBD extraction bubble overproduced massively, crashed prices, and eliminated most small hemp farmers. By 2024, the hemp market had restabilized around larger operators with processing infrastructure. Hempcrete is a real product used in some construction projects. Hemp textiles are a small but growing market. Hemp biofuel has not scaled.

The honest assessment: Herer was right that cannabis prohibition was unjust, that the scheduling was scientifically unjustified, and that industrial hemp had commercial potential. He was wrong that legalization, when it came, would empower the communities and create the distributed economic model he envisioned. The industry that emerged is substantially corporate, substantially concentrated, and substantially failing to deliver the social equity that provided the political momentum for legalization in the first place.

Sources

• MJBizDaily State of the Cannabis Industry (2025)
• ACLU, Cannabis Legalization and Social Equity (2023)
• Herer, The Emperor Wears No Clothes (1985)
• Brightfield Group, Hemp Market Report (2024)

“Island is Huxley's answer to Brave New World: the same pharmacological tools used for liberation rather than control. The novel's failure as fiction is part of its value as argument.”

Aldous Huxley published Island in 1962, his final novel, eleven months before his death. It is widely considered his weakest novel and his most important philosophical document. The two judgments are related.

Pala, the island of the title, is a small nation that has integrated Eastern contemplative practice with Western science and Tantric sexuality into a genuinely functional society. The moksha-medicine — a psilocybin-like substance derived from a local mushroom — is used by Palanese at key life transitions: adolescence, serious illness, death. The drug is not recreational. It is sacramental in precisely the sense Huxley meant by 'gratuitous grace': a tool for opening the reducing valve at moments when the reduction is most costly.

The novel fails as fiction because Huxley cannot sustain the dramatic tension required. Pala is too good; the protagonist's cynicism converts too readily; the ending — Indonesian invasion destroys the utopia just as the protagonist achieves enlightenment — arrives as an imported tragedy rather than one grown from the novel's own logic.

But Island is doing something different from what novels usually do. It is a worked example: if you actually designed a society around the principles Huxley developed in The Perennial Philosophy (1945) and The Doors of Perception (1954), what would it look like? How would childhood education work? How would dying work? What would the relationship between science and contemplative practice look like? How would the sacramental use of consciousness-expanding substances be integrated into ordinary life?

These questions are not answered by The Doors of Perception, which describes an experience, not a social structure. Island is the social structure. Its failure as a novel is the price of its success as a thought experiment — characters who exist to demonstrate social arrangements cannot also be psychologically complex in the way that dramatic fiction requires.

The correspondence in Moksha contains Huxley's own uncertainty about whether Island was achieving what he wanted. He writes to Osmond about the difficulty of dramatizing states of consciousness that are, by definition, not reducible to the dramatic. The letters around Island's composition are more philosophically interesting than most of the novel.

Sources

• Huxley, Island (1962)
• Huxley & Osmond, in Moksha (1977)
• Horgan, Rational Mysticism (2003)

“Sandoz distributed LSD to researchers worldwide at minimal cost from 1947 to 1966. This was pharmaceutical generosity without precedent. What it meant about Sandoz's understanding of what it had synthesized is worth examining.”

In 1947, Sandoz Laboratories released LSD under the trade name Delysid — a 25-microgram tablet and 0.1% solution for injection — as a tool for psychiatric research. The pricing was minimal: Sandoz supplied Delysid to qualified researchers at essentially no cost, treating it as a contribution to science rather than a commercial product.

This decision shaped everything that followed. Because LSD was freely available to researchers, the 1947-1966 period produced over 1,000 scientific papers, treated approximately 40,000 patients in clinical programs, and established a research base that — despite the 1968 scheduling — could not be fully erased. The knowledge existed in published form.

Hofmann's memoir reveals his ambivalence about this period. He was proud of LSD's research applications and troubled by its counterculture appropriation. He understood that Sandoz's generous distribution had enabled both.

In 1963, under pressure from the US Food and Drug Administration, Sandoz began restricting distribution — requiring institutional affiliation and research protocols. In 1966, facing the US Congressional hearings on LSD and the wave of negative publicity driven by Leary's public advocacy, Sandoz withdrew Delysid from the market entirely and ceased distribution.

The withdrawal ended the clinical research program. It also ended the period in which a pharmaceutical company had voluntarily restrained commercial impulses in the belief that a substance required special handling. Hofmann consistently praised this restraint. He argued that LSD needed to be treated as a sacred drug — carefully, with appropriate protocols, without commercialization — and that Sandoz had, for nearly twenty years, honored this requirement.

The contrast with the current psychedelic industry is stark. COMPASS Pathways, MindMed, Cybin, and dozens of other companies have built commercial pipelines around psychedelic compounds. The Sandoz model — provide it freely, don't commercialize it, restrict access to qualified researchers — has no analog in the 2020s landscape. Whether this represents necessary adaptation to regulatory reality or a failure of the field's founding values is a question Hofmann's memoir raises implicitly throughout.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Lee & Shlain, Acid Dreams (1985)
• Stevens, Storming Heaven (1987)

“Australia approved psilocybin for treatment-resistant depression and MDMA for PTSD in February 2023. It is the only country to have done so. The implementation has revealed problems the approval process did not anticipate.”

On February 3, 2023, the Australian Therapeutic Goods Administration (TGA) amended the Poisons Standard to allow authorized psychiatrists to prescribe MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression. Australia became the first country in the world to approve psychedelic-assisted therapy as standard of care rather than experimental intervention.

The approval created a framework: licensed psychiatrists could apply for Authorized Prescriber status from the TGA, allowing them to prescribe these substances to eligible patients outside a clinical trial. The framework required that sessions be conducted with trained therapists present and that patients receive appropriate preparation and integration support.

Implementation has been slower and more complicated than the approval announcement suggested. By mid-2024, fewer than 100 psychiatrists had received Authorized Prescriber status nationally. The compound costs — legally produced pharmaceutical-grade psilocybin and MDMA — were high: a full treatment course cost between AUD $25,000 and $35,000 per patient, with no Medicare coverage. Patients were primarily wealthy and privately funded.

A 2025 report from the Australian Healthcare and Hospitals Association identified the central equity problem: the world's first legal psychedelic therapy program was accessible almost exclusively to people with significant private means. The communities with the highest rates of treatment-resistant depression and PTSD — Aboriginal and Torres Strait Islander communities, veterans, people with histories of trauma — were the least likely to access the approved treatment.

The Australian experience is the most important policy evidence available for what happens after approval. The lesson: approval of the treatment does not solve the access problem. A regulatory framework that permits prescription by authorized psychiatrists at unsubsidized cost produces a boutique treatment for the wealthy. The Australian government is aware of this and working on Medicare coverage pathways; as of mid-2026, coverage has not been established.

For the US approval process: the Australian experience suggests that FDA approval of COMP360 psilocybin, when it comes, will produce an initial market serving a narrow population. Whether the equity framework develops from there, or whether the Australian model of expensive boutique treatment becomes the US default, is the most important downstream policy question.

Sources

• TGA Australia, MDMA and Psilocybin Approval (February 2023)
• Therapeutic Goods Administration, Authorized Prescriber Scheme Reports (2024-2025)
• Australian Healthcare & Hospitals Association, Psychedelic Therapy Implementation (2025)

“Schultes trained a generation of ethnobotanists who went back to the communities he had documented. What they found was a race against time that Schultes had warned about and no one had adequately funded.”

Richard Evans Schultes trained more than the 3,000 undergraduates who passed through his Harvard Economic Botany course. He trained a generation of field ethnobotanists who took his methods and his urgency into the field: Wade Davis, Mark Plotkin, Glenn Shepard, William Milliken, among others. Their fieldwork, conducted primarily in the 1980s and 1990s, extended Schultes's documentation project into the period when the race he had described in 1967 was visibly being lost.

Mark Plotkin's Tales of a Shaman's Apprentice (1993) documented his work with the Tirio people of Suriname and Brazil. What Plotkin found was Schultes's aspirin-pill problem in acute form: young Tirio men were choosing to train as health workers in the Western medical system rather than as traditional plant medicine practitioners. The knowledge was not being transmitted. The healer Plotkin had apprenticed himself to had no successor in the traditional sense.

Wade Davis's One River (1996) reconstructed Schultes's Amazon expeditions through Davis's own fieldwork in the same regions, twenty years later. What Davis documented was both the persistence of the knowledge and its precarity — specific villages still had healers with specific knowledge, but the healers were old, the apprentices were fewer, and the botanical contexts were under pressure from agricultural expansion, mining, and road development.

The Amazon Conservation Team, founded by Plotkin in 1996, developed a documentation methodology — community-controlled mapping projects that recorded traditional knowledge in formats the communities themselves owned — that has become a model for ethnobotanical preservation. By 2025, the ACT had supported territory mapping and knowledge documentation projects in more than 70 indigenous communities across the Amazon basin.

What the students of Schultes found, collectively, is that documentation is necessary but not sufficient. The knowledge does not survive in an archive — it survives in people, and people survive in communities, and communities survive on territories. The ethnobotanical preservation project is inseparable from the land rights project.

Sources

• Davis, One River (1996)
• Plotkin, Tales of a Shaman's Apprentice (1993)
• Amazon Conservation Team Reports (2020-2025)

“The 1994 AIRFA amendments created a specific federal exemption for NAC peyote use. This is the only federally recognized right to use a Schedule I substance for religious purposes that was not created by litigation.”

The Native American Church's use of peyote in religious ceremonies has been legally protected since the 1994 amendments to the American Indian Religious Freedom Act — but the road to that protection was neither simple nor complete.

In 1990, the Supreme Court in Employment Division v. Smith held that the First Amendment does not require religious exemptions from neutral laws of general applicability. The case involved Alfred Smith and Galen Black, Native American members of the NAC who were fired from drug counseling jobs and denied unemployment benefits after testing positive for peyote following a religious ceremony. The Smith decision effectively removed constitutional protection for peyote use in NAC ceremonies.

Congress responded with the Religious Freedom Restoration Act (1993) and then specifically with the 1994 AIRFA amendments, which added a provision explicitly protecting the use, possession, transportation, and sale of peyote for bona fide religious ceremonies of the Native American Church. This created a statutory exemption — not a constitutional right — for NAC peyote use.

The exemption is NAC-specific. Non-Native practitioners who use peyote for spiritual purposes do not receive the same protection, even within the same ceremony. The Peyote Way Church of God, a predominantly non-Native organization that uses peyote sacramentally, challenged this restriction and lost in the Fifth Circuit in 1991: the court held that the racial classification of the NAC exemption served the compelling government interest of protecting Native American culture.

Colorado's Proposition 122 (2022) navigated this history by decriminalizing mescaline but explicitly excluding peyote from the decriminalization. The drafters made a deliberate choice: the conservation status of peyote and the specific interests of the NAC warranted keeping the plant outside a broader decriminalization framework.

Schultes documented the Huichol peyote pilgrimage with care and respect. The legal history of peyote's status reveals how complicated the relationship between indigenous plant medicine rights and broader drug policy reform has been — and continues to be.

Sources

• American Indian Religious Freedom Act Amendments (1994)
• Employment Division v. Smith (1990)
• Peyote Way Church of God v. Thornburgh (5th Cir. 1991)
• Colorado Proposition 122 (2022)

“We are losing knowledge faster than we can document it. The documentation projects are real and insufficient. What Schultes called urgency in 1967 is now crisis.”

In 1967, Richard Evans Schultes told the NIMH symposium in San Francisco that ethnopharmacological research was racing against time. The aspirin pill was arriving. The mission school was transmitting different values. The road was bringing the market. The race to document indigenous plant knowledge before it disappeared was urgent.

Fifty-seven years later, the race he described has not been won. The question is whether it can still be won in meaningful form, or whether the knowledge systems Schultes dedicated his career to documenting are now too damaged to restore.

The evidence: the global language extinction rate — relevant because language is the primary carrier of traditional ecological knowledge — has accelerated. Linguist David Harmon's work with Loh (Bioscience, 2010) found that languages and biodiversity are correlated geographically and decline together. The regions with the greatest biological diversity contain the most linguistic diversity; both are under the most pressure. An estimated one language is lost every two weeks, each taking with it specific knowledge of local ecology, plant uses, and the social context in which that knowledge was transmitted.

The IPBES Global Assessment (2019), the most comprehensive scientific review of biodiversity loss, found that indigenous and local knowledge is declining rapidly alongside the biodiversity it describes. The assessment identified indigenous-managed territories as the most effective conservation units on the planet while documenting the legal and economic pressures that are displacing indigenous peoples from those territories.

The documentation response has been substantial: the Biodiversity Heritage Library has digitized over 60 million pages of botanical literature. The Global Biodiversity Information Facility aggregates millions of specimen records. Ethnobotanical databases at Kew, the Missouri Botanical Garden, and Harvard contain structured records of plant uses across cultures. Schultes's own 24,000 specimens are curated and accessible.

What these archives cannot preserve is what Schultes's colleague Paul Alan Cox called 'the living laboratory of indigenous medicine': the dynamic, context-dependent, community-embedded knowledge that determines when a plant is appropriate, how it is prepared for a specific condition, what spiritual or ceremonial context surrounds its use, and what contraindications experienced practitioners recognize. This knowledge is transmitted person-to-person, in specific landscapes, over years of practice. No database can hold it.

Mark Plotkin's Amazon Conservation Team developed community-controlled knowledge mapping as a partial response: the communities themselves decide what is documented, in what format, and with what access restrictions. The mapped knowledge stays with the community; the ACT provides technical support and legal protection for the territories in which the knowledge is embedded. This approach has documented knowledge in 70+ communities over 30 years.

The limitation: documentation preserves a record of what was known. It does not preserve the capacity to use that knowledge — the trained practitioner who can apply it, the ecological context in which the plants grow, the social institutions that structured its transmission. Schultes's herbarium is one of the most valuable botanical collections in the world. The communities that helped him fill it are smaller, more fragmented, and under more pressure than when he visited them.

The honest assessment of where ethnobotany stands in 2026: the field has done more than Schultes could have imagined in 1967 to document what exists. The forces he identified as threatening — the aspirin pill, the road, the market — have accelerated beyond what the documentation projects can match. The knowledge is being preserved in archives at roughly the same rate as it is being lost from communities. This is not sufficient, and everyone in the field knows it.

Sources

• Schultes, NIMH Symposium (1967)
• Harmon & Loh, Bioscience (2010)
• Brondizio et al., IPBES Global Assessment (2019)
• Biodiversity Heritage Library, Annual Report (2024)

“Schultes documented 24,000 specimens. The communities who guided him have no legal claim to the 78 pharmaceutical compounds derived from his work. The Nagoya Protocol covers new exploitation. It does not remedy old exploitation.”

Richard Evans Schultes's Amazon herbarium represents one of the world's most valuable repositories of traditional botanical knowledge in Western scientific format. The 24,000 specimens he collected, the detailed field notes, the chemical analyses conducted with Hofmann and others — this archive has been the foundation for botanical, pharmacological, and ethnopharmacological research for fifty years.

Seventy-eight pharmaceutical compounds have been derived from or developed in response to plants documented in the ethnobotanical tradition that Schultes represented. The communities whose knowledge guided the documentation have received no systematic benefit from these compounds.

The intellectual property framework that governs this situation has two parts. The first part — historical exploitation — is outside the reach of any current international agreement. The Nagoya Protocol on Access and Benefit-Sharing covers new commercial exploitation of genetic resources and traditional knowledge, not exploitation that occurred before its entry into force in 2014. The debt to the communities whose knowledge produced the pharmacopoeia has no legal mechanism for remediation.

The second part — new exploitation — is theoretically covered by Nagoya, but implementation is weak. A 2025 Global Health Innovation Center analysis found that the majority of pharmaceutical companies with products derived from traditional plant knowledge had not conducted the prior informed consent and benefit-sharing negotiations Nagoya requires. Enforcement is left to national authorities who frequently lack the capacity or political will to pursue multinational pharmaceutical companies.

The psychedelic industry presents a specific current case. Psilocybin is derived from mushrooms documented extensively by Schultes and others from indigenous Mexican traditions. Ibogaine is derived from the iboga shrub of the Gabonese Bwiti tradition. Both are now the subject of commercial pharmaceutical development programs with patent portfolios and investor backing. Neither program has established benefit-sharing relationships with the communities of origin that would meet the Nagoya standard.

Schultes's work was conducted in the colonial scientific tradition — take specimens, take knowledge, publish in Western journals, build careers at Western institutions. He was personally respectful of the communities he worked with and documented their knowledge with more care than most of his contemporaries. But the structural arrangement was extractive regardless of his personal intentions. The communities remain outside the benefit stream.

Sources

• Schultes & Hofmann, Plants of the Gods (1979)
• Nagoya Protocol (2010)
• Swanson, Biotechnology and the Problem of Property (1994)
• Global Health Innovation Center, Traditional Knowledge and IP (2025)

“The FDA rejected the first psychedelic NDA in August 2024. The reasons were methodological, not efficacy-based. Whether this is regulatory caution or regulatory failure is the most important contested question in the field.”

In June 2024, the FDA's Psychopharmacologic Drugs Advisory Committee voted 10-1 that the evidence did not support approval of MDMA-assisted therapy for PTSD. In August 2024, the FDA issued a Complete Response Letter declining to approve Lykos Therapeutics' NDA — the first formal application to approve a psychedelic-assisted therapy.

The data: the Phase 3 trials (MAPP1 and MAPP2) enrolled 263 participants with severe PTSD. In MAPP1, 67% of the MDMA group no longer met PTSD diagnostic criteria at follow-up, compared to 32% of placebo. In MAPP2, 71% versus 48%. The treatment differences were statistically significant. The effect sizes were large by psychiatric standards.

The FDA's concerns were not about whether MDMA helped participants. They were about whether the trials demonstrated that MDMA specifically — independent of the intensive psychotherapy surrounding it — was responsible for the benefit, and whether the safety characterization was adequate.

The unblinding problem: participants who receive active MDMA know they've received it — the phenomenological effects are unmistakable. This breaks the double-blind standard that FDA drug approvals depend on. If participants know they've received the active drug, therapist and patient expectancy effects cannot be controlled. The measured treatment difference might be partly or largely attributable to expectancy rather than pharmacology.

The committee was also concerned about therapist boundary violations: reports of therapists engaging in inappropriate conduct with MDMA-treated patients during sessions, including the high-profile accusations against therapists at several trial sites. The FDA found that the safety monitoring for therapist behavior was inadequate.

The FDA's position, as expressed in the Complete Response Letter, was not that MDMA doesn't help people with PTSD. It was that the current trial design cannot demonstrate what specifically causes the benefit in a way that meets FDA standards for drug approval.

David Yaden and colleagues at Johns Hopkins published a perspective in Nature Mental Health (2024) arguing that the FDA's methodological standards were appropriate and that the field needed to develop better trial designs — including active placebos that mimic some phenomenological features of MDMA without the therapeutic effects, and more careful separation of drug and psychotherapy components.

MAPS and others have argued the opposite: that the FDA's standards are impossible to meet for a drug whose mechanism of action involves the subjective experience itself, and that the unblinding problem is a feature of the treatment rather than a methodological flaw to be designed around.

Jay Stevens wrote in Storming Heaven about a research program ended not by scientific failure but by political conditions. The MDMA situation is structurally different: the political conditions in 2024 are more favorable to psychedelic therapy than they were in 1968. The challenge is methodological, not political. But the result — a promising clinical program unable to achieve approval despite positive efficacy data — has structural similarities.

As of mid-2026, Lykos is working on the design of an additional Phase 3 trial that addresses the FDA's methodological concerns. Whether an adequate design is possible, and whether the company can fund it, are open questions. MDMA remains Schedule I in the US while Australia has approved it for clinical use. The gap between the evidence and the approval will persist until the methodological problem is solved or the approval standard is revised.

Sources

• FDA AdCom Briefing Documents, Lykos MDMA-AT NDA (June 2024)
• Mithoefer et al., Lancet Psychiatry (2018)
• Mitchell et al., Nature Medicine (2021)
• Yaden et al., Nature Mental Health (2024)

“Strassman administered IV DMT to 60 participants in 400 sessions at the University of New Mexico from 1990 to 1995. He documented entity contact in the majority of sessions. He didn't know what to do with the data.”

Rick Strassman's DMT research program at the University of New Mexico was the first controlled clinical study of a classic psychedelic in the United States in over twenty years. From 1990 to 1995, working under DEA Schedule I researcher registration and IRB approval, Strassman administered intravenous DMT to 60 participants in approximately 400 sessions.

The primary published findings concerned dose-response relationships, cardiovascular safety, endocrine effects, and subjective experience ratings (using the Hallucinogen Rating Scale). These findings, published in Archives of General Psychiatry in 1994 and subsequent journals, established that IV DMT produced rapid, intense, brief (15-30 minute) experiences with a manageable safety profile at doses up to 0.4mg/kg.

What the published papers did not fully capture — and what Strassman's 2001 book DMT: The Spirit Molecule communicated to a general audience — was the consistency of entity contact across participants. In the majority of high-dose sessions, participants reported encountering autonomous entities: beings who seemed to be present in a real place, who sometimes communicated, who were experienced as independent rather than as products of the participant's imagination.

Strassman describes his own disorientation at this finding: his training had not prepared him to take entity contact seriously as a phenomenon requiring explanation, yet the consistency of the reports across participants with no prior psychedelic experience — and the specificity of their descriptions — made dismissal difficult.

The 2023 Imperial College fMRI study (Timmermann et al., PNAS 120(13)) mapped DMT's global brain effects — large increases in global functional connectivity, network disintegration and desegregation, and compression of the principal cortical gradient. It did not isolate entity contact as a distinct neural signature, and no published imaging study yet has: the phenomenology is well documented, the neural specificity is not. The phenomenon is real in the sense of having consistent neural correlates. Strassman spent twenty years wondering what it meant. The neuroscience has now confirmed what he observed; the interpretation remains open.

Sources

• Strassman, DMT: The Spirit Molecule (2001)
• Strassman et al., Arch. Gen. Psychiatry (1994)
• Timmermann et al., PNAS 120(13) (2023)

“The União do Vegetal won at the Supreme Court in 2006. The case was unanimous. The opinion was written by Chief Justice Roberts. It is the most important legal precedent for psychedelic religious freedom in American history.”

The União do Vegetal (UDV) is a Brazilian syncretic religion founded in 1961 by José Gabriel da Costa, known as Mestre Gabriel, in Porto Velho. Its sacrament is hoasca — ayahuasca — consumed in ritual ceremonies presided over by trained mestres. The UDV has approximately 20,000 members in Brazil and several thousand in the United States.

In 1999, DEA agents raided the UDV's New Mexico temple and seized hoasca, charging the organization with violation of the Controlled Substances Act. The UDV sued, arguing that the Religious Freedom Restoration Act (RFRA) protected their sacramental use of hoasca.

The case reached the Supreme Court as Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal. On February 21, 2006, the Court ruled unanimously in favor of the UDV. Chief Justice John Roberts wrote the opinion: the government had not demonstrated a compelling interest that overrode the UDV's sincere religious use of hoasca under RFRA. The government's arguments — that DMT is Schedule I and that allowing UDV use would undermine drug control generally — were rejected as insufficient to meet RFRA's compelling interest standard.

The Gonzales ruling is the bedrock of American psychedelic religious freedom law. It established that RFRA protects sincere religious psychedelic use from the Controlled Substances Act, and that the government must demonstrate a compelling interest by least restrictive means before overriding such use.

As of 2026, four US organizations have DEA exemptions for ayahuasca: the UDV (SCOTUS 2006), Santo Daime (9th Circuit 2009), the Iowaska Church of Healing (DEA settlement 2024), and the Church of Gaia (first non-litigation DEA approval, May 2025). All other ayahuasca ceremonies in the US operate without federal legal protection, though prosecution is rare. McKenna's DMT visions, which he described in True Hallucinations, are the experiential territory these legal battles have been fought over.

Sources

• Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal (2006)
• Beyer, Singing to the Plants (2009)
• Mindmedicinelaw.com, Psychedelic Legal Status (2026)

“Psychedelic Science 2025 drew 12,000 attendees to Denver in June 2025. It was the largest psychedelic conference in history. The field that had been underground for fifty years assembled publicly.”

The Psychedelic Science 2025 conference, held in Denver in June 2025, drew approximately 12,000 attendees over five days — researchers, clinicians, policymakers, advocates, facilitators, investors, journalists, and curious members of the public. It was the largest gathering in the history of psychedelic science.

The content spanned the full range of the field: Phase 3 clinical results, regulatory strategy, indigenous knowledge and ethics, harm reduction, business development, veteran advocacy, religious freedom law, and the political coalition that had produced $50 million in Texas ibogaine research funding. Colorado Governor Jared Polis announced pardons for people convicted of state psychedelic possession charges.

The conference captured the field's current character: genuinely bipartisan, genuinely complex, and in some tension with itself. The researchers presenting Phase 3 clinical data were sharing space with advocates for decriminalization and with indigenous leaders arguing that commercialization of plant medicines without benefit-sharing was a continuation of colonial extraction.

Rick Perry — former Republican Governor of Texas, Secretary of Energy under Trump — was there, speaking about ibogaine for veterans. Rick Doblin — MAPS founder, psychedelic activist for forty years — was there, still arguing for the therapeutic framework after the FDA rejection of MDMA. Shipibo-Conibo healers were there, expressing concern about the commodification of their traditions.

This is the world McKenna was trying to describe when he talked about the Archaic Revival: a moment when psychedelic plant knowledge returned to public discourse, when the institutions that had suppressed it could no longer ignore it, when the culture was reconsidering its relationship to consciousness. Whether the conference represented the Archaic Revival or its co-optation is the question McKenna's framework asks — and which Psychedelic Science 2025 did not resolve.

Sources

• Psychedelic Science 2025 Conference, Denver (June 2025)
• Colorado Sun, Psychedelic Policy Reform (July 2025)
• High Times, Psychedelic Reform (April 2026)

“The human body produces DMT. The compound is detectable in blood and urine under normal physiological conditions. Its Schedule I status — 'no accepted medical use, high abuse potential' — applies to a compound the body makes.”

Dimethyltryptamine is Schedule I under the US Controlled Substances Act. It has been since the Controlled Substances Act of 1970. Schedule I status means: high potential for abuse, no currently accepted medical use, lack of accepted safety for use under medical supervision.

DMT is also produced by the human body. Barker et al.'s 2012 review in Psychopharmacology established that DMT is detectable in human blood, urine, and cerebrospinal fluid under normal physiological conditions. It is produced by the lung, retina, and likely other tissues from the amino acid tryptophan through the enzyme aromatic amino acid decarboxylase. The human body manufactures a Schedule I controlled substance as part of normal metabolism.

This creates a legal paradox that has no clean resolution. The Controlled Substances Act schedules chemical compounds; it does not create an exception for endogenous production. The DEA's enforcement focus is on the manufacture, distribution, and possession of DMT in quantities and forms associated with deliberate use — not on the trace amounts found in blood under normal conditions. But the legal distinction between endogenous and exogenous DMT is not written into the law.

The clinical significance: Rick Strassman's hypothesis — that the pineal gland produces elevated DMT during near-death experiences, deep meditation, and REM sleep — has not been confirmed. Strassman documented the hypothesis in DMT: The Spirit Molecule (2001) and has advocated for research to test it. The specific claim about pineal production is disputed; the broader claim about endogenous DMT as a component of altered states remains an active research area.

Colorado's Proposition 122 decriminalized personal possession of DMT alongside psilocybin, ibogaine, and mescaline. The decriminalization applies to the compound as it appears in plant preparations — ayahuasca, for example — and in synthetic form. It does not change the federal Schedule I status. McKenna's account of DMT experiences in True Hallucinations describes encounters with the Schedule I version. Whether they engaged the same system the body uses endogenously is a question the law cannot answer and science has not yet resolved.

Sources

• Strassman et al., Arch. Gen. Psychiatry (1994)
• Barker et al., Psychopharmacology (2012)
• Colorado Proposition 122 (2022)
• Mindmedicinelaw.com (2026)

“Herer was right that hemp had substantial industrial potential. He was wrong that it would undercut petrochemicals, synthetic fibers, and timber paper. The market that emerged is real and modest. It is not the revolution he described.”

Jack Herer's 1985 argument rested on a specific empirical claim: that industrial hemp — Cannabis sativa grown for fiber, seed, and stalk rather than cannabinoid content — was the most versatile industrial crop in agricultural history, capable of replacing petrochemical plastics, synthetic fibers, timber paper, and fossil fuels if prohibition were lifted. He documented this claim with historical sources, scientific studies, and the 1942 US government film Hemp for Victory, which had urged American farmers to grow hemp for the war effort before prohibition resumed afterward.

The Agricultural Improvement Act of 2018 — the Farm Bill — removed hemp from the Controlled Substances Act, defining hemp as Cannabis sativa with THC content below 0.3% by dry weight. This ended eighty years of federal prohibition on hemp cultivation in the United States. By 2025, hemp was being grown commercially in approximately 35 states.

The hemp economy that emerged is real. It is not the one Herer described.

The 2018-2020 CBD extraction bubble was the first major commercial wave. Farmers planted hemp for CBD extraction — the cannabidiol compound extracted from the flowers — responding to a perceived consumer demand for CBD wellness products. The market overproduced massively. By 2020, CBD hemp was selling for less than the cost of processing it. Thousands of farmers lost money. The CBD extraction market has since stabilized at a smaller scale, dominated by larger operators with processing infrastructure rather than the small family farms Herer's vision implied.

Industrial hemp fiber and seed markets have developed more steadily. Hemp textiles are a growing category, with brands including Patagonia and Levi's incorporating hemp fiber blends. Hempcrete — a building material combining hemp hurds (the woody core of the stalk) with lime — is used in a small number of construction projects and has attracted architectural interest for its carbon-sequestering properties. Hemp seed oil and hemp seed protein are established food market categories. Hemp-derived CBD gummies are available in gas stations across America.

What has not developed: hemp biofuel at commercial scale. Hemp-derived plastic replacing petroleum plastic at commercial scale. Hemp paper replacing timber paper at commercial scale. The industrial hemp economy Herer described — in which hemp's superior yield per acre would make it economically irresistible as a replacement for less efficient crops and petrochemical products — has not materialized in the seven years since re-legalization.

The reasons are structural. Industrial hemp processing requires infrastructure — decorticators for separating fiber from stalk, retting facilities, specialized equipment — that was dismantled or never built during the prohibition decades. Rebuilding that infrastructure requires capital investment that takes time and carries risk. Petrochemical supply chains are deeply embedded with cost structures that hemp cannot undercut in the near term even with equivalent performance. Timber paper production has its own entrenched infrastructure.

Herer's claim about hemp's potential was not fabricated. The historical record he documented — hemp as a significant American agricultural product before prohibition, capable of producing fiber, fuel, paper, and medicine — is accurate. His claim that re-legalization would produce rapid industrial transformation underestimated the structural inertia of existing supply chains and the infrastructure gap created by eighty years of prohibition.

The honest assessment in 2026: industrial hemp is a real and growing market, probably reaching $10-15 billion annually within the next decade. It is a specialty agricultural category, not an industrial revolution. Herer was right about the prohibition being unjust and right about the agricultural potential. He was optimistic about the pace and scale of the transformation.

Sources

• Herer, The Emperor Wears No Clothes (1985)
• USDA Hemp Crop Report (2025)
• Brightfield Group, Hemp Market Report (2024)
• Vote Hemp, Annual Report (2025)

“Narby published in 1998, when there was almost no controlled research on ayahuasca. There is now. The combinatorial problem he posed remains open. Everything else is better understood.”

When Jeremy Narby published The Cosmic Serpent in 1998, controlled clinical research on ayahuasca was essentially nonexistent in Western scientific literature. He was writing about a phenomenon — the pharmacological effects and cultural context of ayahuasca — that had been documented by ethnobotanists and anthropologists but not studied in clinical settings. The Hoasca Project (1993), a collaboration between Brazilian and American researchers studying União do Vegetal members, was the first controlled study of long-term ayahuasca use, and it had only recently been published.

Twenty-five years later the research landscape is substantially different. The mechanism is well characterized. The therapeutic applications are actively studied. The phenomenology has been measured in hundreds of subjects. The combinatorial problem Narby posed remains open. Everything else is better understood.

THE PHARMACOLOGY

Ayahuasca is a brew prepared from Banisteriopsis caapi (a vine containing β-carboline alkaloids — harmine, harmaline, tetrahydroharmine) and Psychotria viridis or Diplopterys cabrerana (leaves containing N,N-dimethyltryptamine). The β-carbolines are monoamine oxidase inhibitors that prevent the gut and liver from metabolizing DMT before it reaches the central nervous system. Without MAO inhibition, orally ingested DMT is pharmacologically inactive. The combination produces 4-6 hour psychedelic experiences with a characteristic phenomenology.

The specific 5-HT2A receptor binding that drives the psychedelic effects is now characterized at atomic resolution. The contribution of each alkaloid to the overall experience — harmine's mild stimulant effect, tetrahydroharmine's serotonin reuptake inhibition, DMT's primary hallucinogenic action — is reasonably well understood at the receptor level.

THERAPEUTIC RESEARCH

Fernando Dos Santos and colleagues at the University of São Paulo have conducted the most systematic review of ayahuasca's therapeutic potential, synthesizing studies across depression, substance use disorder, and trauma. Their 2016 Psychopharmacology review found consistent evidence of antidepressant effects in both controlled and naturalistic studies, with effects observable within hours of administration and persisting for weeks. The neuroplasticity mechanism — BDNF upregulation, dendritic spine growth — provides a pharmacological explanation for both the rapid onset and the lasting duration.

A 2019 Frontiers in Psychiatry systematic review by Hamill et al. identified 28 studies of ayahuasca in mental health contexts, with consistent positive findings for depression, anxiety, and PTSD. The evidence base is substantially weaker than for psilocybin (fewer RCTs, smaller samples, more heterogeneous preparation) but points in the same direction.

THE ENTITY CONTACT QUESTION

Narby's specific focus — the consistency of serpentine imagery and entity contact across shamanic traditions — has been empirically confirmed in a way he could not have anticipated. Timmermann et al.'s 2023 PNAS paper, using simultaneous EEG-fMRI during IV DMT administration, mapped DMT's global brain effects — large increases in global functional connectivity, network disintegration and desegregation, and compression of the principal cortical gradient. It did not isolate entity contact as a distinct neural signature, and no published imaging study yet has: the phenomenology is well documented, the neural specificity is not. The consistency of the report is established. The neural correlates are beginning to be characterized. The interpretation — whether entities are produced by the brain or perceived through the brain — is not settled by neuroscience.

THE COMBINATORIAL PROBLEM

Narby's core puzzle — how Amazonian peoples identified the specific combination of these two plants from 80,000 candidate species in the absence of any obvious single-session discovery mechanism — remains without an accepted scientific explanation. No controlled research has addressed the acquisition question. The pharmacological interaction is understood; its discovery by human beings without the tools of Western pharmacology is not. This remains the most genuinely open question Narby raised.

Sources

• Narby, The Cosmic Serpent (1998)
• Dos Santos et al., Psychopharmacology (2016)
• Frecska et al., J. Psychoactive Drugs (2016)
• Hamill et al., Frontiers in Psychiatry (2019)
• Timmermann et al., PNAS 120(13) (2023)

“Peyote is not a recreational drug that happens to be used ceremonially. It is a sacrament under ecological pressure from the same forces that benefit financially from other psychedelics becoming legal. This is the most acute ethical contradiction in the current psychedelic moment.”

Richard Evans Schultes documented peyote ceremonies with the Huichol (Wixáritari) people of central Mexico in the 1930s and 1940s — the weeks-long pilgrimage to Wirikuta, the sacred desert where peyote grows; the careful harvesting protocol that leaves the root system intact; the prayers that accompany each cut. He was observing a practice continuous for at least 5,000 years, possibly much longer. Peyote use is documented in the archaeological record of northeastern Mexico at least from 3780-3660 BCE.

As of 2026, Lophophora williamsii — peyote — is listed as vulnerable on the IUCN Red List. Its range in Texas and northern Mexico has contracted by more than 30% since the 1970s due to habitat loss, agricultural expansion, ranching, and overharvesting. The conservation crisis Schultes warned about has materialized.

The NAC DIMENSION

Approximately 250,000-500,000 members of the Native American Church use peyote ceremonially in the United States. The legal protection for this use — established by the 1994 AIRFA amendments after the Supreme Court's 1990 Employment Division v. Smith decision removed constitutional protection — is specific to Native American Church members and bona fide ceremonial use. Non-Native ceremonial use of peyote is not federally protected.

The NAC does not buy peyote from commercial distributors. It sources it from licensed distributors in Texas — the only US state where peyote grows commercially — who harvest from private ranchlands under DEA license. The supply is constrained by the limited range, the slow growth rate of the plant (it takes 10-20 years to reach harvestable size), and the increasing demand from a growing NAC membership base.

The NAC has explicitly requested that peyote be excluded from psychedelic decriminalization and legalization measures. Colorado's Proposition 122 honored this request — it decriminalized mescaline while specifically excluding peyote. Oregon's Measure 109 does not address peyote. The NAC's concern is straightforward: any expansion of legal access to peyote beyond current NAC ceremonial use will increase harvesting pressure on a plant already under conservation threat, and will appropriate a sacred practice without the cultural context that gives it meaning.

THE INDUSTRY CONTRADICTION

The psychedelic industry's relationship to peyote is the most acute ethical contradiction in the current moment. Mescaline — the active compound in peyote — is of commercial interest as a therapeutic compound. Several companies have filed patents for mescaline derivatives and synthetic mescaline production processes. Synthetic mescaline, produced in a laboratory, would not require peyote harvesting and would not raise conservation concerns. The NAC has not objected to synthetic mescaline research.

The objection is to the cultural context: the use of peyote or its derivatives in therapeutic or recreational frameworks that extract the pharmacological compound from the ceremonial tradition that developed it, stewarded it, and protected it through a century of criminalization. From the NAC's perspective, the psychedelic industry's interest in mescaline-derived compounds is another form of the extraction that has characterized Indigenous-Western relations for five centuries — taking the useful part without acknowledging the source.

Schultes's documentation of the Huichol peyote pilgrimage in Plants of the Gods was careful and respectful. He understood that the ceremony was inseparable from the plant's meaning. The current psychedelic industry's engagement with mescaline and peyote derivatives is largely divorced from that understanding — focused on the pharmacological mechanism, not the cultural context.

THE CONSERVATION PATH

Several conservation projects are attempting to address the peyote shortage. The Multidisciplinary Association for Psychedelic Studies (MAPS) has supported peyote cultivation research. The Cactus Conservation Institute documents peyote populations. Some NAC members and affiliated organizations have established small-scale cultivation operations. The growth rate of the plant — the same characteristic that Schultes documented in Huichol harvesting protocols — makes scaling cultivation difficult. A peyote cactus planted today will not be harvestable for a decade.

The conservation problem and the cultural appropriation problem are connected: the resolution that serves both is synthetic mescaline for non-Native therapeutic use, combined with legal protection for NAC ceremonial use of natural peyote, combined with funded conservation of wild peyote populations. This framework has been articulated by the NAC and has not been implemented at policy level.

Sources

• Schultes & Hofmann, Plants of the Gods (1979)
• Labate & Cavnar, Peyote: History, Tradition, Politics, and Conservation (2016)
• Gehr, Drugs of the Dreamtime (2021)
• Native American Church of North America, Conservation Statement (2023)